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Statement of conjoint work 
 
Work presented in this thesis draws on three publications of which I was first author. 
Methods to calculate costs of telehealth and telecare interventions are presented in Chapter 4 
and results reported in Chapter 5. These drew on work reported in the following: 
 
Henderson, Catherine, Jennifer Beecham, and Martin Knapp (2013) "The costs of telecare 
and telehealth" in Lesley Curtis, eds. Unit Costs of Health and Social Care 2013. Canterbury: 
Personal Social Services Research Unit. 
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(6):794-800. doi: https://doi.org/10.1093/ageing/afu067. 
 
I have indicated the Unit Costs publication as the source of a boxed description of the 
methods of costing the intervention (in Box 4.1 Costing the telehealth and telecare 
interventions), although the text presented there is not a direct quotation. 
 
Methods and results of the multilevel analyses (presented in Chapter 4 and Chapter 6) were 
not presented in the above publications.  
 
The methods and results of the cost-effectiveness analyses (presented in Chapter 4 and 
Chapters 7 and 8) draw on work initially presented in the BMJ and Age Ageing publications 
listed above. However the multiple imputations and cost-effectiveness analyses presented in 
the thesis are new.  
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Abstract 
 
In the English health and social care system, budgets are now constrained more than ever, 
while an increasing proportion of the population is expected to require care. There is an 
urgent need to find new ways to enable people with long-term illness and disability to live 
well, within the national budget. Policymakers have embraced new assistive technologies 
such as telecare and telehealth as a means to achieve this goal. Evidence that telehealth is 
cost-effective is emerging but remains limited; evidence on the impacts of telecare is still 
more limited. In this thesis I investigate the effectiveness of two advanced assistive 
technologies, telehealth and telecare, in improving or maintaining health-related quality of 
life and other psychological outcomes, given the costs of providing these interventions.  
 
I deploy cost-effectiveness methods to analyse questionnaire data from two large-scale 
randomised controlled trials of telecare and telehealth in England. Drawing on provider data 
collected during the evaluation, I describe the inputs to production of the telehealth and 
telecare interventions and calculate their unit costs. I describe the health and social care costs 
of telehealth and telecare participants and explore participant characteristics associated with 
cost variations.  
 
The results of cost-effectiveness analyses of telehealth and telecare indicate that these 
technological interventions did not produce the hoped-for improvements in self-reported 
quality of life and other psychosocial outcomes, nor reduce the overall estimated annual costs 
of health and social care. Policymakers and practitioners would benefit from better evidence 
on the mechanisms by which telecare and telehealth ‘work’, and for whom, to direct future 
investments of resources into these technologies.  
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Chapter 1  
 
 
Introduction 
 
In this thesis I examine the costs and outcomes of two interventions. One intervention, 
“telehealth” falls largely within the ambit of the National Health Service; the other, “telecare” 
has been traditionally a service funded and/or provided by local authorities. Both 
interventions can be described as “advanced assistive technologies”. Along with related 
innovations such as mobile health and telemedicine, telehealth and telecare have attracted 
substantial interest from governmental and non-governmental actors within the health and 
social care systems of the UK. Telehealth and telecare technologies promise new ways for 
health and social services to assist people with long-term and chronic conditions to take 
charge of their care and their lives. These technologies also promise to reduce unwanted 
contact with health services, such as hospital stays, and to reduce reliance on social services 
such as domiciliary and residential care. They hold the potential to address the twin 
governmental preoccupations of containing costs and meeting public expectations about 
health and care services. The relationships between the service use, costs and benefits 
associated with telehealth and telecare therefore merit close examination. 
 
1.1 Background 
Expenditure on health and social care has risen steadily over recent years.1 Furthermore it is 
likely, if not inevitable, that expenditure on health and social care will continue to rise at a 
faster rate than today if it is to keep pace with growing need. In this chapter I begin by 
exploring the potential extent of future expenditure and drivers of this expenditure. I then 
move to a discussion of the important role that advanced assistive technologies may play in 
managing future pressures on health and social care.  
The age profile of the UK population is changing. The population 85 years and over is 
set to double from 1.6 million in 2016 to 3.2 million in 2041 (Office for National Statistics 
                                                          
1 Social care spending has experienced periods of decline but grown overall since 2010 in cash terms (Cromarty 
2017). 
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2016, Barlow et al. 2012). The potential for compression of morbidity in western countries is 
debatable. The UK cannot count on an increase in disability-free life expectancy to counteract 
the impact of projected increases in life expectancy on demand for health and social care 
services (Howse 2006). Despite gains in life expectancy, years lived free of ill health and 
disability have not kept pace. Between 1990 and 2016, life expectancy in the UK increased 
from 78.47 to 82.86 years for women and 72.85 to 78.92 years for men (GBD 2016 DALYs 
and Hale Collaborators 2017). Healthy life expectancy in 2016, on the other hand, was 
estimated to be 70.97 years for women and 69.11 years for men. Jagger et al. (2016) suggest 
that there has been an expansion of morbidity in England (comparing 1991 and 2011 survey 
data) in terms of mild physical disability, a smaller proportion of life expectancy at age 65 
being spent without a disability than previously. Guzman-Castillo et al. (2017) forecast that 
between 2015 and 2025, life expectancy will increase (by 1.7 years) but also a 65-year-old 
individual will live a quarter of his or her remaining life with a disability. Also, while the 
prevalence of disability in the older population is projected to decline, the numbers of older 
people are growing. The numbers of older people with a disability will increase by an extra 
560,000 people in 2025 compared to a decade earlier, to a total of 2.81 million (Guzman-
Castillo et al. 2017). These figures suggest that for many, it will be important to find ways to 
cope with ill health or disability in later life.  
 
1.2 The Health and Long-Term Care System in the UK, Long-Term Conditions and 
Rising Future Expenditure 
The National Health Service in the UK is funded by general taxation. The English NHS is 
overseen at a national level by the Secretary of State for Health; oversight in the other 
countries of the UK is devolved to ministers in the regional parliaments. Most NHS services 
in the UK are free at the point of access (Cylus et al. 2015). Long-term care consists of 
services such as home-based personal care, day- and other community-based care facilities 
and residential and nursing home care. Local authorities (‘councils’) in the UK are funded to 
provide care services from a mixture of general and local taxation. In England, councils are 
responsible under the Care Act 2014 (HM Government 2014) for ensuring that residents have 
access to information about care and to a range of care and support services; they are also 
responsible for enabling residents to receive care services to mitigate or delay the impacts of 
their needs (Department of Health 2016). This type of care and support is commonly known 
as ‘social care’. Local authority-funded care and support services in England are mostly 
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means-tested (but assistive devices and small-scale home adaptations are provided free of 
charge).  
The terms ‘social care’ and ‘long-term care’ cover very similar ground; however, long-term 
care can encompass services such as long-stay hospital care, rehabilitation and intermediate 
care that are funded at least in part by the NHS (and sometimes jointly with local authorities). 
In this thesis I will use the term ‘social care’ as synonymous with paid care funded by local 
authorities directly or indirectly (for instance through grant-funding voluntary organisations 
to provide services). I will for the most part concentrate on the English health and care 
system. 
Long-term or chronic conditions can be life-changing. These are incurable conditions that 
must be controlled over long periods of time (Department of Health 2012b). The management 
of those with long-term or chronic conditions is increasingly under the spotlight, given that, 
as the population ages, such conditions may be expected to rise. Department of Health 
estimates suggest that treatment costs of those with long-term conditions (LTC) make up 69 
per cent of all health and social care spending in England, and that the numbers of those with 
at least one LTC will rise from three million to eighteen million by 2025 (Department of 
Health 2008b). Consequently the volume of treatment and care for those with chronic 
conditions is likely to rise in the future. Thus, purely from a cost-containment perspective, 
there is pressure on governments to seek ways to prevent or reduce the impact of chronic 
conditions on health and care services. In terms of the size of expenditure to be contained, a 
much higher proportion of GDP goes towards the NHS than to long-term social care services 
(7.3 per cent vs. 1 per cent in 2016/17 (Office for Budget Responsibility 2017)). 
 
1.2.1 Health Care Expenditure 
Projections of health expenditure typically incorporate assumptions about demographic, 
organisational and economic factors (health planning, financing, productivity and prices), 
consumer behaviour and income and also medical technological innovation (Astolfi, 
Lorenzoni, and Oderkirk 2012). While some technological innovations will decrease the costs 
of treatment, in many cases the technologies are high-cost. The diffusion of new medical 
technologies has been seen as a driver of dramatic rises in health expenditure within OECD 
countries over the past forty years (Cutler 2002, Appleby 2013). Demographic change 
accounts for a relatively small amount of rising health spending compared to technological 
progress and increases in national income levels (OECD 2010).  
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Health expenditure as a proportion of GDP in England has risen steadily over recent 
years. Spending rose by 36.6 per cent between 1997 and 2002 (The King's Fund 2005). There 
were annual real spending increases in the order of 5.1 per cent over the period from 1994 to 
2011 (Appleby, Crawford, and Emmerson 2009). Estimates of future health spending vary: 
the Office for Budget Responsibility (OBR) projects UK-wide health expenditure as a 
proportion of GDP rising steeply from 6.9 per cent in 2021/2 to 12.6 per cent in 2066/67 
(Office for Budget Responsibility 2017). The OECD has estimated a similar rise from 6.5 per 
cent in 2010 to 12.4 per cent in 2060; however with stronger government policies to contain 
costs, there could be a more modest rise of 8.5 per cent (OECD 2013). In the economic 
climate of recent years, it appears that NHS funding might be squeezed a little more than 
might have been expected in the previous decade. Projections carried out by the King’s Fund 
and the Institute for Fiscal Studies (Appleby, Crawford, and Emmerson 2009) suggest that 
spending on the English NHS would need to increase by about 1.1 per cent a year to maintain 
service quality in light of demographic changes, yet the NHS faced the possibility of a gap of 
about £4 billion opening up between expenditure required to maintain quality in the NHS and 
the available budget2 by 2017. Recent OBR figures suggest that UK-wide health spending as 
a proportion of GDP is expected to fall in the short-term, from 7.2 per cent of GDP in 
2015/16 to 6.8 per cent in 2019/20: this equates to a rise of 0.5 per cent annually in real terms 
over this period (Office for Budget Responsibility 2016).  
 
1.2.2 Social Care Expenditure 
The system of care provision for disabled older people is, and has been under, a great deal of 
strain for a number of years. Recent reviews by the regulator of social care3 have identified a 
number of problems in current patterns of provision, one being a lack of choice and flexibility 
in the way the state meets people’s needs (Commission for Social Care Inspection 2009), 
another being inequities in access to publicly-funded care (Commission for Social Care 
Inspection 2008). Concerns have been raised over the past decade that the threat of unmet 
need in the population of older disabled people is increasing, due to the funding constraints 
and the progressive tightening of eligibility criteria used by local authorities when they assess 
                                                          
2 The authors calculated the gap between projected expenditure under the their ‘tepid’ spending scenario and the 
‘fully engaged’ Wanless projections (Wanless 2002), a scenario involving dramatic improvement in health 
outcomes, high levels of public engagement in health, high confidence in the NHS, high life expectancy, a high 
level of responsiveness in the NHS and more efficient use of resources. 
3 The current Care Quality Commission, which superseded the Commission for Social Care Inspection. 
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older people for care (Commission for Social Care Inspection 2008). Forder (2007) estimated 
that some 15 per cent of those who appear to have low level needs for help do not receive it, 
through formal or informal channels. An Age UK report found that the numbers in need but 
not receiving social care support in England had increased by 383,900 between 2010 and 
2016, rising to as many as 1.2 million people (Age UK 2016, Cromarty 2017). Recent 
research has found that more than half of people aged 65 and over in England had unmet 
needs (drawing on the Care Act 2014 definition of qualifying need)4.  
In addition to the current pressures on the system, future demand for care is likely to 
increase, whereas it is uncertain that there will be a corresponding rise in the supply of 
informal care (Pickard et al. 2007). The majority of disabled older people receive help and 
support from relatives, such as spouses and children (Pickard et al. 2007). Projections suggest 
that as the population of those 65 years and over increases, the number of disabled older 
people likely to be in receipt of at least 20 hours of care a week from their (adult) children 
will almost double, from 665,000 in 2005 to 1,270,000 in 2041 (Pickard 2008). If the ratio of 
numbers of adult caregivers to parents receiving care remains constant, the gap between 
provision and receipt of intense care is likely to rise very substantially, supply exceeding 
demand in the near future. Any change in the level of supply of informal care is likely to have 
an impact on demand for formal care. In the UK, availability of informal care traditionally 
has been considered along with other criteria in local authority decision-making on providing 
funding for care (Comas-Herrera, Wittenberg, and Pickard 2010). The oldest-old (85 years 
and over) being the fastest growing segment of the older population (Office for National 
Statistics 2014, 2009) and the segment mostly likely to receive formal care (Pickard et al. 
2007, Comas-Herrera, Wittenberg, and Pickard 2010) only adds to the demand pressures 
upon both formal care providers and adult children providing care over the coming years. 
Changes in living circumstances of older people, from communal to solo living may decrease 
the availability of assistance when there is no co-resident carer on hand (Falkingham et al. 
2010). 
Personal Social Services Research Unit (PSSRU) projections estimate that 
expenditure on social care and disability benefits for older people could increase from 1.2 per 
cent of GDP in 2005 to 2 per cent in 2041, assuming that current funding systems and 
                                                          
4 Depending on the survey examined – English Longitudinal Study of Ageing or Health Survey for England - 58 
per cent or 73 per cent had unmet needs respectively (Dunatchik et al. 2016, Ipsos MORI 2017). 
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patterns of care do not change (Wittenberg et al. 2008). The OBR on the other hand projects 
slower rises, such that 2 per cent of GDP will be spent on long-term care in 2066-67 (Office 
for Budget Responsibility 2015). 
Savings targets imposed by central government in recent years have intensified budget 
pressures on English local authorities. The 2010 Spending Review (decreasing the settlement 
to local authorities by 27 per cent) was estimated to have resulted in a social care funding 
‘gap’ in 2014/155 between available funding and anticipated expenditure of around £267 
million (Appleby and Humphries 2010). In the first half of this decade, the National Audit 
Office found that local authorities had made deep cuts to their budgets, reducing their 
spending on adult social care by 8 per cent, or £1.4 billion from 2010 to 2013. English 
councils’ expenditure on social care for people aged 65 and over fell by 9 per cent over this 
period, while numbers in receipt of council-funded care declined from 1.1 million to 0.85 
million (The King's Fund 2016). The Local Government Association recently estimated that 
the funding ‘gap’ would reach £1.3 billion by 2020 (Local Government Association 2016). 
Several central government policies have added to cost pressures on local authorities’ social 
care budgets. The introduction of the National Living Wage for workers aged 25 and over in 
2016 increased the labour costs of social care, as many workers are on low wages. Changes in 
the scope of the Deprivation of Liberty Safeguards following a Supreme Court ruling and the 
winding up of the Independent Living Fund increased the number of assessments to be 
carried out by the local authority workforce (Local Government Association 2015, Cromarty 
2017). 
  
1.2.3 Policy Responses 
The English Department of Health has long recognised that its share of the national budget 
cannot grow at the same pace as health and care costs will grow as a share of GDP. As long 
term conditions’ “cost and prevalence continues to grow, doing more of the same is not an 
option if NHS and social services are to be sustainable in the future” (Department of Health 
2012b, p.4). As well as the need for cost containment, there are compelling quality of life 
arguments for tackling long-term conditions (Department of Health 2005d). Evidence 
suggests that people do not consistently receive the information and advice they need to be 
able to manage their conditions (Blendon et al. 2003, Department of Health 2005b). The 
                                                          
5 The projections assume that there will be a 4% real annual growth in the budget for social care needed due to 
demographic pressures and unit cost rises, and that existing eligibility criteria will continue to apply. 
  
23 
 
government has taken note of the personal and human cost of long-term health conditions 
over recent years and responded with initiatives such as community matrons, case-finding, 
expert patient groups and increased funding for the assessment and treatment of such 
conditions (Department of Health 2005d). At the same time, those in need of assistance with 
activities of daily living, for instance people with disabilities and long-term conditions, have 
not always been well served by the lack of choice and flexibility in the help provided by local 
authorities (Patmore and McNulty 2005, Williams et al. 2008, Commission for Social Care 
Inspection 2009). The last Labour government acknowledged calls for a system of assistance 
tailored to the individual’s needs and wishes. It advocated a personalisation agenda to allow 
those with chronic long-term conditions and disabilities to direct their own care, through 
initiatives such as the individual budgets programme (Department of Health 2008a) and 
personal health budgets (Department of Health 2010a). Social care strategy under the 
Coalition government continued to promote this agenda. “A Vision for Adult Social Care: 
Capable Communities and Active Citizens” (Department of Health 2010b) emphasised 
prevention, allowing people to maintain their independence through initiatives such as re-
ablement, the involvement of ‘the Big Society’, promoting plurality of provision and 
personalisation, along with partnership, high quality care and support services and the use of 
advanced assistive technologies. More recently, integrated personal commissioning has been 
introduced for people who have chronic needs for support (including adults with multiple 
long term physical or mental health conditions and people with frailty). This model was 
intended to provide people with access to integrated health and social care funding for 
personalised support packages (Bate 2017, NHS England 2017). 
 
1.3 Advanced Assistive Technologies: The Route to a Sustainable Health and Care 
System? 
The previous discussion has established that the landscape is one of rapid technological and 
demographic change creating pressures for higher expenditure over the long-term. Yet budget 
constraints threaten to undermine the quality of health and social care in the short-term as 
well as in the longer term. There are good reasons for central and local government, health 
and social care providers, interest groups and those in industry to seek new ways of managing 
long-term conditions and disability in order to mitigate these important drivers of future 
expenditure. In the first decade of this century, there was a growing interest in the potential of 
advanced assistive technologies (AAT) such as telemedicine, telehealth and telecare. 
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Proponents of AAT have given cost savings as one rationale for advocating their introduction 
and widespread implementation (Department of Health 2005a) and maintaining or improving 
quality as another (Department of Health 2005a, 2010b).  
Hopes to improve the evidence base for making the best use of public funding for 
assistive technologies and for shaping the growing market for AAT underlay the decision to 
fund the £31 million Whole System Demonstrator (WSD) programme, the largest-scale trial 
of telehealth and telecare to be carried out in the UK (Department of Health 2007, 2010b). At 
the outset of the study, research evidence on telehealth was growing but had many gaps, 
particularly in terms of good-quality cost-effectiveness studies. The research evidence for 
telecare had a much weaker base than in the case of telehealth. This formed the context in 
which I began working on my thesis, with the aim of contributing to the economic evidence 
for the two technologies.  
 
1.3.4 The Role of Economic Evaluation in Health and Social Care Decision-making  
Policymakers in the UK, as elsewhere, must balance fiscal constraints and rising demand for 
health and social care services. Because public resources are scarce, decision makers face 
choices as to which services should be funded, at the expense of funding some other service. 
In other words, each service has an opportunity cost. Because there are often several credible 
alternatives that could be funded, some framework or organising principle is required for 
decision makers to allocate resources in an efficient and equitable way (Brazier 2007, 
Drummond et al. 2015). Economic evaluation provides such a framework, being a 
“comparative analysis of alternative courses of action in terms of both their costs and 
consequences” (Drummond et al. 2015, p.4). There are several approaches to economic 
evaluation. In cost-effectiveness analysis (CEA), alternative treatments with the same 
objective are compared in terms of outcomes measured in ‘natural’ units (for instance, 
changes in blood pressure readings) and the results presented as cost per unit. The objective 
of the treatment is unquestioningly presented as worthwhile. The approach has limitations: 
interventions differing in more than a single outcome cannot be compared simultaneously: so 
for instance. as a monetary value cannot easily be attributed to each outcome, the net benefit 
of the different interventions cannot be established (Brazier 2007). In cost utility analysis 
(CUA), a comparison of costs can be made across a broader range of alternative health 
programmes with the benefits measured using an indicator of “utility”, usually in terms of a 
measure of quality adjusted life years (QALY) (Brazier 2007, Drummond et al. 2015). The 
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QALY combines a measure of length of life with a measure of health related quality of life 
(HRQoL) on one scale. This has the advantage of allowing the comparison of interventions 
with more than one outcome, allowing comparison of interventions with different outcomes 
and allowing comparison of interventions for different conditions with different outcomes 
(Brazier 2007).6  
In England, the National Institute for Health and Care Excellence (NICE)7 was 
founded to appraise new and existing health technologies in terms of clinical and cost-
effectiveness, develop clinical guidelines and promote clinical audit (Rawlins 1999). NICE 
has adopted the ‘reference case’ as part of a process of the appraisal process. “A reference 
case goes beyond recommendations of good practice for economic evaluation, and attempts 
to standardize the scientific value judgements required in the conduct of economic 
evaluation, thereby improving quality and comparability of results” (Gray and Wilkinson 
2016, p.112). Cost per QALY (an incremental cost-effectiveness ratio, or ICER) features 
prominently in the NICE decision framework (Gray and Wilkinson 2016); the ICER 
threshold, above which a technology could be considered not to represent value for money, 
has been set at between £20,000 to £30,000 per QALY since 2001 (McCabe, Claxton, and 
Culyer 2008, National Institute for Clinical Excellence 2004). Thus in England the 
consideration of cost-effectiveness is an important aspect of the technology appraisal process.  
 
1.3.5 The production of welfare 
The production of welfare (PoW) approach offers a framework useful for evaluating the 
economic consequences of interventions taking place across health and social care (Davies 
and Knapp 1981, Knapp 1984). This approach has been refined in studies of a number of 
social care services and service innovations. Essentially, welfare is seen as a function of the 
relationship between outputs, in terms of quality of life and three kinds of inputs. Outputs 
“include all those consequences that so directly reflect aspects of welfare that they are valued 
in their own right” (Davies and Knapp 1981, p. 5). These can be further categorised as final 
                                                          
6 There are other approaches to economic evaluation. In cost-benefit analysis, costs and consequences are valued 
in money terms so that if the benefits exceed the costs then the intervention is worth implementing (Brazier 
2007); cost consequence analyses present the results of a number of relevant analyses rather than just the one 
summary CEA; and cost-minimisation seeks to establish the "least-cost alternative", if the outcomes of the 
treatment are the same (Brazier 2007, Drummond et al. 2015).  
 
7 NICE has had one acronym but several titles since its inception in 1999: National Institute for Clinical 
Excellence (1999 to 2005); National Institute for Health and Clinical Excellence (2005 to 2013); National 
Institute for Health and Care Excellence (from 2013). 
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and intermediate outputs, final outputs being for instance, improved mobility and functioning 
or more social engagement, intermediate outputs being the services given such as the number 
of home care hours or day centre places (Knapp 1984). Inputs encompass both ‘resource 
inputs’– labour and capital – but also ‘non-resource’ inputs – intangible factors that are 
within the control of the producer, such as ‘atmosphere’ or ‘friendly staff members’ in a care 
home, and ‘quasi-inputs’, that are outside of the service producer’s control, for instance, the 
personal characteristics of older people using home care services or entering a care home. 
Resource inputs influence the extent of achievement of the aims of care; but such influences 
are mediated by non-resource inputs (Knapp 1984).   
 
Figure 1.1 The production of welfare (adapted from Davies & Knapp (Davies and Knapp 
1981) and  Knapp (Knapp 1984)) 
 
 
 The model is illustrated in Figure 1.1. Thus “outputs are determined by the levels 
and modes of combination of the resource and non-resource inputs (which are mainly under 
the control of the administrator or policymaker[...], given the exogenously determined values 
of the quasi-inputs” (Davies and Knapp 1981, p. 8). A further component of the model is 
cost, this being a way of reflecting the resource inputs within the production relation (Knapp 
1984). 
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 I have adopted standard methods of cost-effectiveness and been guided by the 
PoW approach throughout the thesis. 
 
1.4 Research Questions 
The main question to be addressed within the thesis is:  
What are the costs and benefits of introducing telehealth and telecare in England? 
This leads to the following sub-questions: 
1. What are the patterns of service use for people with and without telecare or telehealth 
support? 
2. What are the total and component (service-specific) costs per person of the 
support/treatment received, and  
3. What patient/user characteristics are associated with cost variations? 
4. Are telecare and telehealth cost-effective compared to standard support/treatment? 
Put another way, are these two instances of advanced assistive technologies efficient ways to 
improve or maintain the outcomes of health and social care, given the costs of that provision? 
I address these questions in the chapters that follow.  
 
1.5 Overview of the Thesis 
In chapter 2, I describe the context within which my research takes place, setting out some 
definitions of the technologies and introducing some important sub-classifications of the 
terms ‘telecare’ and ‘telehealth’. I discuss potential areas of overlap between these terms and 
closely associated technologies. I briefly review the conceptual literature to ask what the 
mechanisms are whereby the technologies ‘work’, focusing on service use and costs as 
outcomes.  
In chapter 3, I begin the thesis by reviewing the evidence on telehealth and telecare, 
asking: what do we know about the effectiveness and cost consequences of implementing 
these technologies? I summarise the evidence base available on the effectiveness of telehealth 
and telecare, reviewing what is known about their impacts on preventing disease and 
disability and promoting independence. I concentrate on the literature in the years running up 
to the publication of results of the Whole Systems Demonstrator (WSD) Trials and 
Questionnaire Studies. I conclude the chapter with an in-depth discussion of the evidence 
base for costs and cost-effectiveness of these technologies, identifying gaps in the literature. I 
examine whether the technologies are reducing or increasing costs to the health and social 
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care system, and also whether on balance the evidence base on costs and benefits has been 
interpreted as suggesting cost-effectiveness. 
In chapter 4, I describe the methodologies employed in the empirical chapters. I give 
an overview of the methodologies employed in the WSD Trials and Questionnaire Studies, 
the source of the data for the analyses in this thesis. I explain how I estimated costs of health 
and social care; and describe in detail how I estimated the costs of the telecare and telehealth 
interventions. The chapter covers the methods employed to investigate subgroup variations in 
costs in the study samples, including imputation of missing data. I finish by describing the 
methods used to carry out the economic evaluations.  
In chapter 5, the first empirical chapter, I set the scene by describing the participants 
of the WSD Telehealth/Telecare Questionnaire Studies in terms of their socio-demographic 
characteristics, health and social care service use, and costs, split by experimental group. The 
unit costs of the interventions are also described. This provides necessary background 
information on the sample and addresses sub-question (1) and addresses sub-question (2).  
In chapter 6, moving onto the more analytical investigations of the data, I address sub-
question (3) in each of the telecare and telehealth questionnaire samples. These are subgroup 
analyses, examining cost variations of people in terms of socio-demographic and needs-
related characteristics in the telecare and telehealth questionnaire study samples. The analysis 
of the telehealth sample data focuses on the role of three long-term conditions, diabetes, 
chronic obstructive pulmonary disease (COPD) and heart failure; the analysis of the telecare 
sample data concentrates on the impact of living arrangements (living with others and living 
alone).  
In chapters 7 and 8, I present the results of the cost-effectiveness analyses of the 
telehealth and telecare interventions. In chapter 7, I address research question (3) by looking 
at the Telehealth Questionnaire study sample, discussing salient points from chapter 6, and 
presenting the results of the statistical models of the QALYs, and other quality of life and 
psychological outcomes, associated incremental cost-effectiveness ratios (ICERs), net-benefit 
lines and cost-effectiveness acceptability curves. I discuss the results in terms of the 
implications for policy and practice, and discuss limitations and future directions for research. 
In chapter 8, I address research question (3) by examining cost-effectiveness of telecare. I 
present the main findings. I also discuss a subgroup analysis of cost-effectiveness in terms of 
people living with others and living alone.  
In the final chapter, I review the aims of the thesis and the research questions I sought 
to answer. I discuss the findings of the empirical chapters, setting them in the context of the 
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conceptual and empirical literature. I summarise the limitations of the work carried out. I 
draw out the implications of the findings and make recommendations for policy and for 
further research.  
 
1.6 My Contribution to the Study Research Effort and Relationship with the PhD 
I was involved, under the supervision of Martin Knapp, in planning the economic evaluation 
component of the WSD study since the inception of the project in 2008. I was responsible for 
designing the cost-effectiveness analyses. Because of the enormous scale of the study, it 
would not have been practical for me to collect the quantitative data personally. The 
evaluation questionnaires, including those needed for the economic evaluation, were 
administered by interviewers from a company specialising in research interviewing. For this 
reason administering the questionnaires did not form part of my planned fieldwork, although 
I carried out all the subsequent cleaning and processing of the data collected through the cost 
collection instruments. I worked within a team of researchers assembled across a number of 
other institutions, whose objective was to investigate both outcomes and costs. We worked 
together to discuss and interpret the emerging results. I was first author of three published 
papers (Henderson, Beecham, and Knapp 2013, Henderson et al. 2014, Henderson et al. 
2013) on the costs and cost-effectiveness of the interventions, based on data from the 
questionnaire studies; I was co-author on five others (Steventon et al. 2012, Steventon et al. 
2013, Hirani et al. 2013, Cartwright et al. 2013, Bower et al. 2011). All data were collected 
between 2008 and 2010. All the statistical analyses carried out for this thesis are my own 
work, with the guidance of my supervisors. While the cost-effectiveness analyses were 
presented in the published papers noted above, the analyses presented here feature new work. 
All errors are my own. 
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Chapter 2  
 
 
Telehealth and Telecare: The Context 
 
2.1 Introduction 
The purpose of the thesis is to investigate whether telecare and telehealth, as defined within 
the Whole Systems Demonstrator evaluation, were cost-effective interventions. It is 
necessary to understand something of the nature of these interventions and where they lie in 
the assistive technology landscape, prior to considering cost-effectiveness. In this chapter, I 
discuss assistive technology broadly, setting out some definitions of the technologies as they 
are understood in the UK and internationally. I introduce some important sub-classifications 
of the terms ‘telecare’ and ‘telehealth’, in order to set the material characteristics of these 
technologies into context. I set out the systems-level context and address supply-side and 
demand-side perspectives on the purpose and function of the technologies. I briefly review 
the conceptual literature to ask what are the mechanisms whereby the technologies ‘work’.  
 
2.2 Telehealth and Telecare are Assistive Technologies 
The term ‘assistive technology’ can cover a broad range of different technologies, from low-
tech (ramps, rails, bath equipment) to advanced, or high-tech (telemedicine via video-link, 
health ‘apps’, robotics). Kubitschke and Cullen (2010) carried out a wide-ranging survey of 
information and communications technology (ICT) that could be used to address the needs 
and challenges created by ageing. Their map relating different kinds of ICT to these needs is 
reproduced in Figure 2.1. The diagram illustrates how a need may be addressed by more than 
one technological domain: for instance, aspects of depression-related needs might be 
addressed by both telehealth and telecare. These technologies may therefore cross service 
boundaries, both offering opportunities and creating tensions between services in the process. 
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Figure 2.1 The spectrum of needs and technology reproduced from Kubitschke and Cullen 
(2010) 
 
2.2.1 An Array of Telehealth and Telecare Terminology 
It should be noted that there is a variety of terminology used within the literature on telecare 
and telehealth, depending on the discipline and nationalities of the authors. Both technologies 
have been described variously as types of ‘telemonitoring’ and aspects of ‘remote care’ 
(Barlow et al. 2012). Researchers reviewing the literature have not always differentiated 
telecare ‘telemonitoring’ from telehealth ‘telemonitoring’, rather viewing the two as variants 
of technology with similar purposes.  
Telecare has been characterised as a form of “health smart homes and home-based 
consumer health technologies that support aging in place” (Reeder et al. 2013) or “assisted 
living technologies (ALTs) that specifically enable older people to 'age in place'” (Graybill, 
McMeekin, and Wildman 2014),  as well as “ADL telemonitoring” (Gokalp and Clarke 2013) 
and “gerontechnology” (Piau et al. 2014). 
Telecare in the UK was once used to describe any preventative or supportive 
technology, but as medical applications for telecare were introduced, these have tended to be 
labelled telehealth (Doughty et al. 2008). This can be confusing, both for those seeking to 
understand the evidence base for AT, and for commissioners considering the purchase of 
AAT services (Doughty et al. 2008). 
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While telehealth and telecare can be viewed as elements of a common ‘remote care’ 
approach, the technologies are more often treated as separate domains of care. Section 2.2.2 
covers definitions and classifications within telehealth and Section 2.3, within telecare.  
 
2.2.2 Definitions of Telehealth 
The term ‘telehealth’ as employed in the literature covers several distinct areas of clinical 
activity. There are ‘telehealth’ activities that could be characterised as telemedicine or 
distance medicine, where health care professionals use telecommunications to deliver health 
care through, for instance, joint teleconsultations (Currell et al. 2000). Then there are 
activities that are delivered by health care professionals to patients directly, which might 
involve ‘telephone support’ (or ‘coaching’) or might involve ‘telemonitoring’. Telephone 
support involves the use of a simple or ‘plain old’ telephone system by health care providers 
to deliver support to patients or carers; and transmission of vital signs data does not occur 
over that system (Polisena, Tran, et al. 2009, Inglis et al. 2010).  Telemonitoring can involve  
vital signs being monitored in real-time, for instance via video-link (also known as 
synchronous monitoring), or monitored using store-and-forward systems, where data such as 
video clips or sound files are submitted by the patient and transmitted to the health 
professional for later assessment (asynchronous monitoring) (Polisena, Tran, et al. 2009, 
Bergmo 2009). This non-invasive vital signs data are usually delivered by newer 
telecommunications technologies such as broadband or wireless data transfer (Inglis et al. 
2010).  
Telehealth as ‘telemonitoring’ can be classified into four generations (Anker, Koehler, 
and Abraham 2011, Cartwright et al. 2013):  
First generation or ‘non-reactive data collection and analysis systems’: measurements 
are transferred to healthcare providers by store-and-forward systems asynchronously. 
Healthcare providers cannot respond in real time.  
Second generation or ‘non-immediate analytical or decision-making structure’ 
systems: measurements are transferred in real time; the system processes and analyses the 
data provided by the patient. Healthcare providers are available to respond in real time, but 
their responses may be delayed if the systems are not running continuously out-of-hours.  
Third generation or ‘remote patient management systems’: in addition to real-time 
processing and analysis of patient data, the monitoring centre is led by physicians and carried 
out by specialist nurses. 
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Fourth generation or ‘fully integrated remote management systems’: in addition to the 
features of third generation telehealth, patient data may be collected by non-invasive and also 
invasive (implanted) devices. The system is monitored by physicians.  
 
2.3 Definitions of Telecare 
The Telecare Aware website gives an expansive definition of Telecare:  
…from simple personal alarms (AKA pendant/panic/medical/social 
alarms, PERS, and so on) through to smart homes that focus on alerts for 
risk including, for example: falls; smoke; changes in daily activity 
patterns and 'wandering'. Telecare may also be used to confirm that 
someone is safe and to prompt them to take medication. The alert 
generates an appropriate response to the situation allowing someone to 
live more independently and confidently in their own home for longer. 
(Telecare Aware) 
  
As illustrated in this quotation, telecare can be an umbrella term for rather different services 
such as “pendant alarms” and “smart homes”. Differences in the type and sophistication of 
telecare equipment and systems can also be classified in terms of ‘generations’ of telecare 
technology (Kubitschke and Cullen 2010). There appears to be some consensus in the 
literature that there are three generations.  
First-generation: This form of telecare consists of a telephone unit and a pendant 
alarm with a button for summoning help; a monitoring centre receives the alert and identifies 
the user and can contact the user via the telephone unit; there is a protocol in place to alert the 
appropriate nominated responder (a paid or unpaid carer). The terms ‘social alarm’ and 
‘community alarm’ and ‘personal emergency response system’ (PERS) are used 
synonymously to describe this generation of telecare (Kubitschke and Cullen 2010). 
Second-generation: Here, automatic, passive alarm/sensor systems are added to the 
telephone unit; alarms/sensors can be triggered automatically and send an alert to the 
monitoring centre (Kubitschke and Cullen 2010). 
Third-generation: These automatic, passive alarms/sensors in the home provide data 
that can be viewed by paid or unpaid carers to monitor the user’s well-being and evaluate the 
user’s care needs (Kubitschke and Cullen 2010). ‘Lifestyle monitoring’ is another term used 
to describe this generation of telecare. This involves the home installation of sensors “to 
monitor behaviour in order to gain an understanding of ‘normal’ activity so that any unusual 
changes over time can be recognised and responded to” (Brownsell et al. 2011, p.185).  
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2.3.1 Smart homes  
Telecare also can be seen as fitting into a part of a broader concept, that of smart homes, “an 
innovative concept that integrates technology within residences in order to maintain and even 
enhance functional health, security, safety and quality of life of their residents” (Demiris and 
Hensel 2008, p. 35). Balta-Ozkan et al. (2013) give a broader definition: “A smart home is a 
residence equipped with a high-tech network, linking sensors and domestic devices, 
appliances, and features that can be remotely monitored, accessed or controlled, and provide 
services that respond to the needs of its inhabitants.” Martin, Kelly et al. (2008) have created 
a useful hierarchy of smart homes, adapted from Aldrich (Aldrich 2003). At the most basic 
level, smart home environments can contain stand-alone “intelligent objects” for 
environmental control and monitoring; or at a greater level of sophistication, these objects 
can be networked within the home. In the more technologically complex “ubiquitous home”, 
these networks extend beyond the home. The data are collected automatically by the 
technology without the resident having to initiate this process. The information thus 
accumulated can be used for care assessment and planning processes. Beyond this level, 
“learning homes” gather information on activity patterns, which can be compiled, so that the 
occupant’s future needs can be anticipated and the technology adjusted in accordance; while 
“attentive homes” build on these systems to continuously record activity to the same end. 
It might seem that ‘telecare’, ‘smart homes’ and ‘lifestyle monitoring’ descriptors are 
interchangeable; however there can be important differences between these technologies. 
Unobtrusive technology works behind the scenes to collect information for some proactive 
future use in ‘learning’ and ‘attentive’ smart homes, ‘third-generation telecare’ systems and 
‘lifestyle monitoring’. This continuous data-gathering aspect is absent from first- and second-
generation telecare systems. In practice, however, the boundaries between the labels 
‘telecare’ and ‘smart homes’ are sufficiently blurred that interventions that could be classified 
as second-generation telecare according to Kubitschke and Cullen (2010) are described 
elsewhere in the literature as examples of smart home technology (cf. Peek, Aarts, and 
Wouters 2015) (and see also Chapter 3, section 3.5).  
  
  
35 
 
2.3.2 Functional classifications of telecare and similar technologies 
Several classifications of home-based remote care technologies have been proposed (Box 
2.1). Demiris and Hensel (2008) suggest that health-related ‘smart home’ technologies could 
be categorised in terms of six functions: physiological monitoring; functional monitoring and 
emergency detection; safety monitoring and assistance; cognitive and sensory assistance; and 
social interaction monitoring and assistance. Categorisations by Doughty and Steele (2009) 
include  similar functions; Brownsell, Blackburn, and Hawley (2008) list packages including 
specialist monitoring of people with specific conditions such as epilepsy, and lifestyle 
monitoring (see Section 2.3). 
 
Box 2.1 Categorisations of smart home and telecare technologies 
 
2.4 Markets for Telehealth and Telecare in the UK  
Kubitschke and Cullen (2010) estimated the number of potential first-generation telecare 
users across the European (EU27) market to be in the vicinity of 2.6 to 12.8 million users in 
Six categories of smart-home technologies (Demiris and Hensel (2008), p. 34) 
Technologies that collect and analyse data for: 
 Physiological monitoring – measuring vital signs (e.g. blood pressure);  
 Functional monitoring/emergency detection and response – measuring activity levels, 
motion, ADLs, and critical events such as falls;  
 Safety monitoring and assistance – detecting environmental hazards and providing safety 
assistance e.g. automatic lighting, location technologies;  
 Security monitoring and assistance – detecting human threats e.g. intruder alarms;  
 Social interaction monitoring and assistance – tracking phone calls, visitors, e.g. video 
technologies to communicate with relatives, participate in groups online;  
 Cognitive and sensory assistance – automated reminders; sensory devices for sight, touch 
e.g. water temperature sensors. 
 
Categories of stand-alone telecare devices (Doughty and Steele (2008), p. 41) 
 Safety – e.g. bath thermometers 
 Security – e.g. timed lights 
 Communication – picture phones 
 Reminders – pill dispensers 
 Safe walking – GPS trackers 
 
Four types of telecare package (Brownsell, Blackburn, and Hawley (2008), p. 9) 
 Security package – includes intruder alarm, flood and temperature detection, CCTV of 
entrance 
 Falls package – fall detectors and lights on sensors 
 Specialist devices – epilepsy bed monitors, vibrating pillow alerts, front door alarms 
 Lifestyle reassurance (third generation system) – bed occupancy detectors, movement 
detectors, electrical usage 
  
36 
 
2009; the number of potential users with a long-term condition of heart disease was estimated 
to be somewhere between 9.4 million and 13.9 million, and the number of potential users 
with diabetes between 3.8 and 5.4 million. The authors also reported that the UK and Ireland 
had the highest levels of first-generation telecare market penetration in Europe in 2010, 
estimated at 14-16% of people of 65 years and over; in contrast, only approximately 1% of 
older people had taken up second-generation telecare. 
The number of telehealth users in Great Britain was about 350,000 in 2010 according 
to Barlow et al. (2012). Estimates of the number of telecare users (whether first- or second-
generation) in England vary substantially, depending on the source. According to a report by 
Deloitte Centre for Health Solutions (2012), the actual number of users in England in 2010 
was 1.6 million. On the other hand, based on data obtained via Freedom of Information Act 
2000 requests from 121 (of 152) English councils, Corbett-Nolan and Bullivant (2012) 
reported that there were only 204,809 telecare users in 2009/10 and 241,582 in 2011/12. Over 
the 2011/12 financial year, councils spent a total of £50 million on telecare (an average of 
£500,529 per council). In terms of the proportion of the older population using some form of 
telecare, the figure appears to be low. Nyman and Victor’s (2014) analysis of the English 
Longitudinal Study of Ageing (ELSA) dataset (Marmot et al. 2008) found that only 6% of 
adults 65 years and over reported the use of a personal call alarm (180 of a sample of 3091).8 
Using ELSA data (wave 4) and drawing on a more expansive definition of telecare, Lloyd 
(2012b) reports that 2% (375,000) of individuals 50 and over in England used mobile 
personal alarms9 while 4% (720,000) had an alerting device.10  
Market analyses and projections have predicted considerable scope for growth in 
uptake of tele-technologies. Barlow et al. (2012) suggested the existence of substantial 
untapped demand for "preventative remote care” in the UK: if the technology was expanded 
to cater for not only the most intensive users of health services but targeted at a broader pool 
of occasional health service users, this could open up a market of as much as 1.4 million 
people. In a similar vein, Lloyd (2012a, b) predicted a potential market of as many as 
4,175,000 users in England if the service was broadened to include the younger-old (people 
                                                          
8 ‘Personal call alarms’ were defined as alarms that are used to call for assistance after falls (Nyman and Victor 
2014). 
9 ‘Mobile personal alarms’ were defined as alarms to call for assistance after falls, excluding other types e.g. 
attack alarms. 
10 These ‘alerting devices fixed to the home’ were defined as devices such as pendant alarms. The authors 
further define these devices as being fixed to the home, and also that they could be used in the event of a fall but 
the term could refer to a broader range of devices. 
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aged 60 and over) at ‘low-risk’ as well as the current population of telecare users, who tend to 
be older and frailer people at ‘high-risk’.  
Globally the market for telehealth and telecare was £1.7 billion in 2015 (Monitor 
Deloitte 2015). This market has grown significantly over the past decade. In the UK, the total 
market for telecare and telehealth brought in revenues of £141.7 million in 2010 (Deloitte 
Centre for Health Solutions 2012). By 2014, the market for telehealth alone in the UK was 
£90 million;11 and the telecare market was worth £246 million (Monitor Deloitte 2015). The 
telehealth market in the UK was predicted to grow strongly between 2014 and 2018, at a 
compound annual growth rate (CAGR) of 13% to £148 million; but the telecare market was 
expected to grow more slowly at a CAGR of 4% to £292 million over the same period 
(Monitor Deloitte 2015).  
Although the technologies are relatively new, they already face disruption from 
further smartphone-based developments such as mHealth (mobile applications that monitor 
vital signs) and ‘connected homes’ and ‘internet of things’ (IoT) applications (aimed at the 
general public to monitor aspects of the home environment such as temperature and security). 
A more privatised telecare market is emerging, manifested by increased co-payments, 
bundling of monitoring and response services and devices through a managed service, and 
increasing numbers of private payers (Monitor Deloitte 2015).  
 
2.5 Supply and Supplier Perspectives 
From the point of view of industry, there have been a number of barriers to the expansion of 
the market for telehealth and telecare. A number of these spring from the demand-side. Many 
health and social care markets in the UK feature public payers with strong purchasing power: 
the markets for telecare and telehealth are no exception to this general picture. The vast 
majority of UK telecare sales are to councils, only about a tenth being privately purchased; 
while telehealth services are typically commissioned by NHS organisations. Health and social 
care organisations’ budget constraints can limit their flexibility and attitude to risk, 
hampering innovation (Barlow et al. 2012). Health providers’ fondness for pilot projects has 
limited the growth of the telehealth market (Monitor Deloitte 2015, Barlow et al. 2012). For 
instance, parallel services have to be set up for a typically small number of pilot patients as a 
temporary arrangement, but this offers limited lessons for delivering the technologies at scale 
(Barlow et al. 2012). Lack of commissioning expertise with the technologies and short-term 
                                                          
11 Their definition of telehealth was more inclusive as it included teleconsultation. 
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thinking can hamper successful procurement; for example, health service commissioners 
have tended to think of telehealth as merely a set of devices rather than a potentially 
transformative model of care requiring both expert software support and organisational 
learning (Barlow et al. 2012). The funding model does not encourage NHS commissioners to 
invest in new technologies as the funding is based on patient admissions, procedures or visits 
(Deloitte Centre for Health Solutions 2012). The telehealth and telecare manufacturing sector 
is relatively small in the UK. In 2015, around 20 companies were involved in manufacturing 
telehealth and/or telecare equipment (Monitor Deloitte 2015). About a quarter (23 per cent) 
had annual revenues of £1 million to £10 million (Monitor Deloitte 2015). Barlow et al. 
(2012) note that companies supplying telehealth and telecare technology have been relatively 
small-scale, typically employing about 40 people; according to Monitor Deloitte (2015), only 
12 per cent of companies in this sector had more than 50 employees. 
As it typically requires multiple stakeholders to produce remote care, the business 
model needs to allow for partnerships. As Barlow et al. (2012) say, 
The key features of a successful business model are an identified market, 
a value chain to create and distribute the offer, an understanding of the 
value chain’s cost structure and profit potential, and understanding of the 
roles of different suppliers in the value chain, and finally – for private 
sector companies – a competitive strategy to gain and hold advantage over 
rivals. In remote care in the UK, these features are only partially 
developed. (p. 13) 
In addition, there can be problems related to the technologies themselves. Some of the 
rapid development of devices was induced by suppliers looking to expand their share of the 
market, creating complexity for purchasers; also a lack of interoperability locked purchasers 
into ordering most of their equipment from one supplier (Barlow et al. 2012). At the 
beginning of the current decade, purchasers were hesitant to invest in telehealth because the 
devices were perceived to be expensive. Yet while costs of newer devices were falling, they 
could still “end up sitting on a shelf” (Deloitte Centre for Health Solutions 2012 p.15). There 
was a large number of purchasers (Primary Care Trusts (PCTs), and post-2013, Clinical 
Commissioning Groups (CCGs)) whose budgets for telehealth varied substantially. Clinician 
buy-in or resistance was a problem, such that a number of CCGs reported problems with 
clinical take-up and with supply chains, resulting in some CCGs deciding to cease 
commissioning telecare and telehealth (Monitor Deloitte 2015).  
On the telecare side, incentives were not well aligned, in that local authority 
purchasers could question allocating their limited funds to telecare services, only to achieve 
reductions in hospital admissions and other benefits accruing to the health system. Because 
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telecare has been a feature of the social care system for many years, opportunities for market 
expansion have become rather limited (Monitor Deloitte 2015). Despite this apparent near-
saturation of the telecare market, there has been significant variation in numbers of telecare 
users between local authorities (Corbett-Nolan and Bullivant 2012).  
It is evident that demand-side factors such as public payers’ willingness and ability to 
pay the costs of the technologies are of great importance in determining the future success of 
the market for telehealth and telecare. The Department of Health (DH) entered into a 
concordat with the telehealth and telecare industry to show the extent of governmental 
commitment to promoting the uptake of telehealth and telecare (Department of Health 
2012a). The DH simultaneously launched a five-year campaign (called 3millionlives) aimed 
at enabling 3 million people with social care need and long-term conditions to access these 
technologies.  
 
2.6 Demand and Demand-side Perspectives 
While the role of public payers is clearly important to the growth of the telehealth and 
telecare market and to the success of private-sector suppliers of the technologies, the role of 
other demand-side factors deserves consideration. These include consumers’ preferences as 
to material aspects of the technologies; their attitudes towards the substitutability and 
complementarity of the technologies with other services; and their willingness and ability to 
pay for the technologies. The academic literature that touches on consumer preferences for 
telehealth and telecare encompasses disciplines such as health care research, sociology, 
gerontology, political science, engineering and computer science.  
Research into stakeholders of telecare and telehealth by Greenhalgh et al. (2012) 
identified four discourses. In the modernist discourse, technology was a rational solution to a 
demographic problem. To age well was to use technologies proficiently; contact with paid 
carers was seen as a needless waste. By and large, the modernist discourse reflected the UK 
policymaking position. The change-management discourse portrayed the technologies as 
societally useful but challenging to implement and in need of project management; the 
humanist vision portrayed the lived reality, with technology having meanings that could be 
positive or could be stigmatising; the political economy discourse portrayed technology as 
potentially an agent of social control. Stakeholders’ discourses and agendas were found not to 
be in alignment, with no single ‘organising vision’. As a consequence, the authors predicted 
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that there could be a considerable gap between the cheerleaders for the technologies and 
actual take-up. 
A complication in considering where demand-side issues begin and end lies in the co-
productive aspect of telehealth and telecare services. These services are rarely produced by 
only one organisation or within one sector. Telehealth services require the involvement of a 
health care practitioner (usually an NHS employee) as well as telemonitoring software and 
vital-sign monitoring equipment supplied by private sector companies. Telecare services are 
delivered by monitoring call centres typically run by local authority or voluntary sector staff 
(although purely private sector call centres do exist), using telecare call-handing software and 
monitoring equipment from private sector suppliers. Thus, while not ‘suppliers’, 
telemonitoring clinicians and telecare call centre providers are producers of these services. In 
the case of telehealth, clinicians (whether or not directly involved in telemonitoring) have an 
important demand-side role, with the power to influence commissioners’ purchasing 
decisions and patients’ attitudes towards this new technology. In the following discussion, 
these actors are considered as consumers rather than suppliers.  
 
2.6.1 Adoption and Acceptance of Telehealth and Telecare: Stakeholder Perspectives 
A number of studies have investigated factors influencing the acceptance of and resistance to 
health and care technologies. Clinicians’ resistance to telehealth has been remarked on within 
the policy and academic literature (Standing et al. 2016). Health professionals’ predisposing 
attitudes – whether scepticism about the evidence base, or fears of duplication – can influence 
their engagement in the use of telehealth. Tensions are likely to arise between the goals of 
policymakers and clinicians because of the nature of the telehealth intervention: the 
introduction of new technologies, new systems of information management and new clinical 
protocols and processes could potentially increase the clinical workload. Clinicians may see 
telehealth as a threat to their traditional work roles. Also they may fear that patients will 
become over-reliant on and have unrealistic expectations of telemonitoring (Salisbury et al. 
2015, Morton et al. 2017, Segar et al. 2013, Vassilev et al. 2015).  
Some of the literature on adoption and acceptance of tele-technologies documents 
results of consulting stakeholders in the process of designing or market-testing new 
telemonitoring products; some of it reports stakeholder perspectives as part of research 
intended to inform system-level introduction of these technologies. The bulk of adoption 
research focuses on the prospective or pre-implementation stage (Peek et al. 2014). 
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Stakeholders in the adoption process include prospective users, carers and designers, as well 
as professional caregivers. In this literature, the concerns of potential users and carers about 
telemonitoring turn on the safety, reliability and costs of technology and threats to privacy 
and autonomy (Bentley et al. 2016, Cook et al. 2017, Milligan, Roberts, and Mort 2011, 
Peek, Aarts, and Wouters 2015, Percival and Hanson 2006, Powell et al. 2010, Rahimpour et 
al. 2008) . Nonetheless, there is also evidence that potential users can be receptive to the 
potential usefulness of new technologies (Williams, Victor, and McCrindle 2013), indeed 
they may be more receptive than clinicians (Standing et al. 2016).  
In the case of telecare, there is an apparent disconnect between prospective users’ 
receptiveness to these technologies and actual use. While older people may consider these 
technologies potentially useful, they may also think that they are for other, more disabled 
people than themselves (Bentley et al. 2016, Peek, Aarts, and Wouters 2015). Carers in 
Powell et al.’s study (2010) similarly saw new technologies as likely to be used increasingly 
in the future, and potentially helping them to be able to care at a distance, yet also envisaged 
them as being for ‘other people’ than themselves. Consumer acceptance and use of telecare is 
also influenced by the design of the devices; for instance, people do not want to wear devices 
that might mark them out as vulnerable (Williams, Victor, and McCrindle 2013). Prospective 
users’ involvement at the design stage could be greater: older people do wish to be involved 
in the design of and choice of telecare devices and services (Peek, Aarts, and Wouters 2015). 
This is problematic, according to some assessments (Roberts, Mort, and Milligan 2012, 
Milligan, Roberts, and Mort 2011), because telecare is subject to a strong ‘technological 
push’ from industry, not responding to the actual needs of potential users, a situation that 
could lead users to experience disempowerment.  
An individual’s level of social care need may influence the choice to seek out and use 
telecare technologies. Nyman and Victor (2014) found from their analyses of ELSA data 
(wave 3) that having difficulty with activities of daily living and being in an older age 
category predicted personal call alarm use in people of 65 years and older.12 Their findings 
also differed by household composition, in that people aged 75 to 84 years who were living 
with others were more likely to report using an alarm than those aged 65-74 years who were 
living with others; yet those living alone aged 85 years and older were more likely than those 
living alone aged 65-74 years to report using an alarm. This perhaps suggests that people 
living alone have to be much frailer before contemplating the use of these devices. Lloyd 
                                                          
12 Their analyses controlled for other characteristics such as wealth, functional ability and quality of life scores. 
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(2012b) examined ELSA data (wave 4), finding that telecare users13 were in poorer health 
than non-users, more likely to have difficulties with mobility and activities of daily living 
(ADL) than non-users. Users were also more likely to report particular reasons for difficulty 
in walking such as difficulty with balance, dizziness, fear of falling or fatigue than non-users. 
Users also had lower scores on memory and executive function measures than non-users. An 
Australian study by De San Miguel et al. (2015) compared people who had purchased a 
personal emergency alarm with people who had enquired about but decided not to purchase 
an alarm. Purchasers were older than non-purchasers and more functionally dependent in 
activities of daily living. These statistics appear to support Peek, Aarts, and Wouters (2015) 
surmise that there is a limit to the number of older people who see a need for telecare 
services, beyond those who are already disabled and in a position to consider that telecare 
will be a useful way to mitigate frailty and disability. Golant’s (2017) model, discussed 
below, offers a more formal framework covering similar territory.  
 
2.6.2 Models of Health Information Technology Adoption and Implementation 
There is a substantial body of conceptual literature on consumer acceptance and adoption of 
new information technologies. These include the Technology Acceptance Model (Davis, 
Bagozzi, and Warshaw 1989, Davis 1989), the Unified Theory of Acceptance and Use of 
Technology models (Venkatesh, Morris, Davis, & Davis, 2003; Venkatesh, Thong, & Xu, 
2012) and the Value-based Adoption Model  (Kim, Chan, and Gupta 2007). It is beyond the 
scope of this chapter to present more than a brief explanation of these generic models.  
Technology Acceptance Model (TAM): The model examines acceptance in the 
organisational context. The concepts of perceived usefulness (the belief that the technology 
will improve job performance) and perceived ease of use (the degree of effort believed to be 
needed to master the system of technology) are key to acceptance behaviours. Perceived ease 
of use influences perceived usefulness; perceptions of both ease of use and usefulness 
influence the attitude to using a technology, which in turn influences behaviour. Perceptions 
of usefulness also directly influence acceptance behaviours. External factors (e.g. quality of 
the system) can affect perceptions of usefulness and ease of use.  
Unified Theory of Acceptance and Use of Technology (UTAUT): Venkatesh et al. 
(2003) built on models of technology acceptance in the organisational context to construct the 
UTAUT. The model has four constructs that determine acceptance: performance expectancy 
                                                          
13 Users of mobile personal alarm and alerting devices. 
  
43 
 
(belief that the system will assist job performance, effort expectancy (ease of using the 
system), social influence (belief that others think the prospective user should use the system) 
and facilitating conditions (the belief that the system has the infrastructure - organisationally 
and technically – to support the system). Individual characteristics (age, gender, voluntariness 
of use and experience) are moderators of some relationships between these determinants and 
behavioural intentions. Behavioural intentions and facilitating conditions both directly 
influence use of the technology, moderated by age and experience.   
Unified Theory of Acceptance and Use of Technology 2 (UTAUT2): This was 
adapted from UTAUT to suit a consumer context, with three additional constructs to that 
model: hedonic motivation (pleasure derived from the technology), price value (trade-off 
between potential benefits and costs) and habit (prior use). The model posits complex 
relationships between the consumer’s intention to accept and use technology. For instance, 
individual characteristics (age, gender and experience of use) moderate the relationship 
between hedonic motivation and behavioural intention. 
Value-based Adoption Model (VAM): The VAM seeks to explain adoption of more 
recent ICT such as mobile internet by consumers. In this model, building on consumer choice 
theories, there is a benefit component and a sacrifice component to the consumer’s perception 
of the value of the product. Benefit consists of two concepts: usefulness and enjoyment; 
sacrifice consists of the concepts of technicality (quality of service) and perceived fees (the 
consumer’s subjective assessment of the service price). These four concepts influence the 
perceived value of the technology which in turn influences the consumer’s intention to adopt 
the technology. 
The models discussed above are generically applicable to acceptance of ICT by 
workers and/or consumers and not specific to health information technologies (IT). I next 
discuss models of acceptance and adoption of health IT, beginning with a model of consumer 
acceptance with particular relevance to telehealth and telecare.  
Golant (2017) proposes a model of smart technology adoption by older people 
seeking to age in place (here, ‘smart’ technologies include telecare and telehealth but also 
ICT). The model builds on previous models such as TAM, UTAUT and UTAUT2, and 
incorporates theories from other disciplines such as marketing and social psychology. Older 
people may have unmet needs related to ageing (including disability and chronic ill health). 
In this situation, an individual will examine a set of coping options that include ‘assimilative’ 
coping strategies such as: adoption of smart technologies; traditional solutions such as paid 
and unpaid assistance with ADL, ‘low-tech’ adaptive equipment and relocation to other 
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housing; or a mixture of the smart technology and traditional solutions. The person may 
alternatively adopt ‘accommodative’ coping strategies that involve taking no action (for 
instance, denying or accommodating mentally to the problem). In the model, the smart-
technology adoption decision is positively influenced by the degree of perceived stress of 
having unmet needs, which influences the extent to which the person will take into account 
external information (e.g. from media, relatives, professionals) and past personal experiences. 
Both perceived stress and personal resilience impact upon adoption indirectly to influence an 
individual’s overall appraisal of the ‘efficaciousness’ (usefulness), usability and ‘collateral 
damages’ (unintended consequences of technology such as loss of identity) of the technology. 
As a result, “when older people feel more stressed because of their unmet needs, they will be 
more motivated to attend to and evaluate information about their possible coping solutions.” 
Older individuals facing the need to decide on a coping option will not adopt the smart 
technology option unless they appraise that option as better than ‘traditional’ options in terms 
of efficaciousness, usability and (lack of) collateral damages.  
 Golant’s model chimes with themes identified in the smart home and telecare 
stakeholder research discussed in the previous section (2.6.1). Barriers to take-up may arise 
for complicated reasons, not least that older people may see telecare technologies as not all 
that useful to their own situations. "Many older adults have the desire to age in place, and 
many older adults also believe that smart home technology can contribute to independent 
living, yet these conditions often do not translate into a willingness to accept smart home 
technology" (Peek, Aarts, and Wouters 2015, p.4).  
Health information technology must be not only accepted by consumers (users and 
front-line professionals) but implemented by a variety of stakeholders. Greenhalgh et al. 
(2017) propose a new framework for examining technology implementation in terms of 
“Nonadoption, abandonment, spread, scale-up, and sustainability of patient-facing health and 
care technologies” (NASSS). The framework was devised to appraise the likelihood of 
success of new health- or social care-related IT systems (e.g. ICT, smartphone apps, telecare 
and telehealth) at the individual level (non-adoption/abandonment) and the organisational 
level (failure to scale-up, spread or sustain the new system). NASSS consists of six domains: 
type of condition; technology; the value proposition; system adopting the technology; wider 
institutional context; adaptation between domains over time.  The domains contain sub-
questions, the answers to which are graded into three classifications (simple, complicated, 
complex). For instance, the key features of the technology (in the technology domain) could 
be ‘simple’ or off-the-shelf, ‘complicated’ because not properly developed, or ‘complex’ 
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because of serious dependability issues. Applying the technology implementation framework 
to real-world case studies, the authors found that adoption could fail because a technology 
might be thought to be complicated (having several components but predictable to 
implement) when it was in fact complex (constantly changing during implementation). Or a 
technology could be built for ‘textbook’ conditions that did not fit individuals well; it could 
be under-developed or unreliable; workers could find the data unhelpful and choose not to 
use it; its value could be unclear to users; the organisation was unable to find a commercial 
partner; there could be regulatory hurdles; it could be unadaptable for the local health and 
social care system. In particular, technology systems that were ‘complex’ across several 
NASSS domains were very difficult to bring into mainstream use. 
 
2.6.3 How Do Telehealth and Telecare ‘Work’? 
The previous discussion has covered some definitions of telehealth and telecare, markets for 
these technologies and the supply-side and demand-side factors that have influenced their 
development. A further question relevant to setting the context of the economic evaluation of 
these technologies concerns their ‘active ingredients’. How do these technologies work to 
produce outcomes of interests to patients, practitioners and policymakers? Health 
telemonitoring technologies purportedly play a role in the management of long-term 
conditions: I explore this first. I then examine the question of the role of telecare in fostering 
independence and improving quality of life outcomes. 
 
2.6.4 Long-term Conditions, Self-management and Telehealth 
To consider what role telehealth could play in the management of chronic conditions requires 
a little background on disease management. In the health policy literature, perhaps the best-
known approach to disease management is the Chronic Care Model (CCM), an evidence-
based framework for quality improvement and condition management involving system-level 
redesign (Wagner et al. 2001, Wagner, Austin, and Von Korff 1996). According to the model, 
effective self-management support linked to community resources are essential components 
of good chronic disease care, made possible by appropriate health care organization, delivery 
system design, decision supports and clinical information systems. In this model,  
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High-quality chronic illness care is characterized by productive 
interactions between practice team and patients that consistently provide 
the assessments, support for self-management, optimization of therapy, 
and follow-up associated with good outcomes. (Wagner et al. 2001, p. 68)  
  
The 2005 White Paper Our Health, Our Care, Our Say (Department of Health 2006) 
summarised the elements of current disease management in lay terms: 
At the moment, half the people with long-term conditions are not aware 
of support or treatment options and do not have a clear plan that lays out 
what they can do for themselves to manage their condition better. If 
people have a clear understanding of their condition and what they can 
do, they are more likely to take control themselves. (p. 8) 
 
Self-management support – ‘helping people to help themselves to manage their condition’ – 
is strongly emphasised in Our Health, Our Care, Our Say and subsequent documents 
(Department of Health 2008b, 2012b). To unpack terms widely deployed in the disease-
management literature, ‘self-care’, ‘self-management’ and ‘self-management support’ all 
refer to aspects of the practice of involving the patient in managing a chronic condition 
(Rijken et al. 2008). In self-care, the emphasis is on lay experiences of managing health 
problems in the context of everyday living (Rijken et al. 2008); in self-management, patients 
take on managing their conditions between their usual appointments with health care 
practitioners; in self-management support, patients and practitioners collaborate to treat the 
condition. Support includes joint goal setting and treatment planning, problem solving around 
barriers to self-management, information provision and efforts to enhance patient confidence 
(Wagner et al. 2001, Rijken et al. 2008). Patients who are active participants in their care can 
engage in more productive interactions with their health care providers (Wagner et al. 2001). 
In the extensive conceptual literature on the self-management of chronic conditions, a 
number of theories (such as rational choice; self-regulation models (Petrie and Weinman 
1997); and the stress coping model (Ridder and Schreurs 1996, Lazarus and Folkman 1984) 
describe how behaviours are related to psychological and social factors. These approaches 
form a starting point for health care practitioners seeking to effectively support patients in 
self-management (Rijken et al. 2008). Depending on the theoretical underpinning, the choice 
of support strategy could differ. For instance rational choice theory assumes that people make 
decisions on the basis of welfare-maximisation: the decision to modify one’s behaviour will 
depend on whether the resultant benefits are assessed to be greater than the costs (Rijken et 
al. 2008). Strategies suggested by this theory include providing financial incentives to change 
patient behaviour and education about potential consequences of the illness and availability 
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of information about treatments. In the self-regulation model, behaviours are shaped by 
illness representations (which are beliefs about the illness including its aetiology and the 
possibility of influencing the outcome of the illness). Thus the behaviours of patients with 
chronic conditions may be changed by changing their illness representations (Weinman and 
Petrie 1997, Rijken et al. 2008).  
Strategies to support people in managing their long-term conditions depend on several 
aspects of the person: knowledge of the illness, beliefs about the illness, the individual’s 
attitudes towards healthy or unhealthy behaviours, levels of confidence, personal motivation 
and the characteristics of the individual’s social networks (Rijken et al. 2008). UK health 
policymakers have asserted that telehealth technology has the potential to facilitate chronic 
disease management and also to facilitate self-management and self-management support 
(Department of Health 2006, 2008b). How might this work? As Salisbury et al. (2015) 
contend, theories to explain the workings of telehealth to achieve the goals of chronic 
conditions management have been largely lacking. The Chronic Care Model, for example, 
“does not in itself provide a model for the design of telehealth interventions” (p. 4). Salisbury 
et al. (2015) propose a conceptual model specific to telehealth (TElehealth in CHronic 
Disease, “TECH”). The model describes the means by which telehealth works to achieve 
beneficial outcomes for patients. This consists of 5 components: effective chronic disease 
management (promoting self-management, optimising treatment and care coordination); 
partnership between telehealth, primary care and other health care providers; contextual 
factors (characteristics of patients, wider health and social care system); and engagement of 
patients and primary care providers. The model posits that contextual factors and engagement 
moderate the relationship between managing the chronic condition and outcomes (health 
outcomes, costs, patient access to care and experience), while telehealth services delivered in 
partnership with other health providers will also produce beneficial patient outcomes. The 
model puts telehealth in a facilitating position between condition management and desired 
outcomes.  
Gee et al. (2015) propose a role for eHealth (including telehealth but also mobile 
health and electronic health records) in the Chronic Care Model (CCM). They suggest that 
the “eCCM” would require the introduction of eHealth education (training patients to use 
eHealth tools, and health care practitioners to implement the tools and educate patients in 
their use); and the addition of a “complete feedback loop” (CFL). The CFL is a five-stage 
cycle whereby health data are transmitted, data are interpreted on the basis of clinical 
information (e.g. guidelines), addressing specific patient needs, providing timely and specific 
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feedback to patients and regular repeating of the loop. This feedback loop will contribute to 
the productive patient-physician interaction (Wagner et al. 2001) and will be needed to enable 
eHealth technologies to promote better outcomes in people with long-term conditions. For 
example, CFL is important to patient-provider communications, in that the time it takes for a 
clinician to respond to a patient-initiated eHealth communication is likely to have an impact 
on a patient’s satisfaction with the eHealth system.  
There is some qualitative evidence on the nature of the relationship between self-
management and the kinds of outcomes that policymakers desire of telehealth (for instance, 
better disease control, better quality of life). Vassilev et al. (2015) conducted a realist 
synthesis to identify three mechanisms by which telehealth interventions ‘work’ to produce 
successful outcomes: these were relationships, fit and visibility. They refined these initial 
concepts by interrogating the qualitative evidence base on the use of telehealth in specific 
long-term conditions. Their findings reflect the mediating function that telehealth plays in 
self-management. Relationships provide telehealth users with support 
(professional/clinical/social) for behavioural change. For instance, telehealth can elicit 
practitioner feedback, thereby reinforcing positive changes in behaviour. The extent to which 
a telehealth intervention can be integrated within everyday life (its ‘fit’), determines patients’ 
likelihood of continued use. The patient’s ability to use the technology can facilitate his/her 
ability to benefit from telehealth. This suggests that simple technologies that fit in with 
existing technologies (e.g. messaging systems giving reminders or health behaviour prompts) 
will be easier to use and thus more effective than unfamiliar technologies. In particular, 
visibility, “how telehealth care makes an illness or condition apparent to the self and others” 
(p. 23) is a mediator between self-management tasks and the patient’s motivation and 
understanding of the condition. How the technology reveals the condition to the patient is in 
some way related to the patient’s capacity to manage that condition. Feedback on these 
visible signs by professionals and peers can improve engagement with self-management 
activities. 
There is some evidence that telehealth can be effective even in the absence of clinical 
involvement, particularly if the intervention is visibly tailored to the person’s needs (Vassilev 
et al. 2015). Morton et al. (2017) conducted a meta-ethnographic review of patient and 
practitioner experiences of “self-management digital interventions” (including telehealth) for 
chronic physical health conditions. They noted that patients reported experiencing increased 
motivation to change their behaviour, on the basis of vital signs readings alone when using 
“stand-alone telemonitoring systems” (monitoring systems where patients send vital signs to 
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practitioners for feedback or health advice but which have no explicit educational or 
behavioural change support elements).  
The above discussion suggests that telehealth could have more than one ‘active 
ingredient’. The intervention could effect positive outcomes by presenting vital signs in such 
a way as to make the condition manifest to the patient, even without the involvement of a 
clinician. Also telehealth may facilitate positive patient-clinician interactions through a 
continuous feedback loop related to the patient’s specific needs. On the other hand, it is worth 
asking whether telehealth really needs to facilitate self-management in order to be effective. 
Morton et al. (2017) cite Schermer’s (2009) assertion that telemonitoring systems usually 
facilitate a “compliant self-management” by patients – following the instructions of their 
health care practitioners. This would suggest that telehealth does not necessarily require 
much engagement on the part of the patient beyond following clinical advice; however, as 
Schermer (2009) suggests, a “concordant” approach is also possible, integrating clinical 
instructions with patients’ own understandings of their illness to plan treatment. Morton et al. 
(2017) observe that practitioners may face problems helping patients with self-management 
goals, if these conflict with clinical guidelines. 
There is little quantitative evidence on the nature of the links between telehealth, self-
management and desired outcomes. Hanlon et al. (2017) drew on the PRISMS taxonomy of 
self-management support (Pearce et al. 2016) to identify 5 components14 as deliverable 
through telehealth. These are patient education and information provision; telehealth-
facilitated clinical review; adherence support; psychological support; and lifestyle 
interventions. The authors examined systematic reviews of the telehealth literature to identify 
the reported impact of these self-management components, finding that reporting was of 
variable quality and that there was “little explicit evidence of the mediating role for self-
management in telehealth interventions”. It was not possible to establish whether telehealth 
could be used to support self-management. They recommended that further telehealth 
research should be based more explicitly on self-management theory. 
 
                                                          
14  The PRISMS taxonomy has four overarching dimensions (mode of delivery, personnel delivering support; 
targeting and intensity, intervention’s frequency and duration) and 14 components delivered to individuals 
directly, including: information about the condition and resources, agreeing clinical action plans, training in 
communication with clinicians, training for self-management and psychological strategies (Pearce et al. 2016). 
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2.6.5 Independence, Risk and Telecare 
Industry and policy literature has emphasised the ‘preventive’ role of telecare in delaying 
dependence and promoting ‘independence’ and a better quality of life (Telecare Aware) 
(Department of Health Change Agent Team 2005, Department of Health 2005a, 2008c, 
2015). Yet the policy message on telecare appears to take a shortcut between introducing the 
instrument and the desired outcome without suggesting any mechanism through which 
change in outcomes is to be effected. Several papers have addressed the problems that ensue 
from taking an over-simplistic policy line. Glasby, Lynch, and Robinson (2018) conducted a 
case study of telecare delivery in one English local authority. The national-level policy 
narrative – that telecare fosters independence and improves users’ quality of life while saving 
money – was espoused by local social services managers and front-line workers, becoming a 
familiar storyline about ‘better outcomes’. However, telecare service users’ and social 
services managers’ perceptions of independence differed. Managers equated ‘independence’ 
with the reduction of dependence on the state for assistance. Service users painted a more 
complex picture, for instance some had feelings of isolation as contact with council workers 
was reduced. Others aspired to ‘independence’ in the sense of being free to make their own 
decisions, even if this led to taking risks.  
Aceros, Pols, and Domènech (2015) examined conflicts that arise from twin 
governmental policies of ‘ageing in place’ and ‘active ageing’. The former seeks to keep 
older people in their homes; the latter to help older people to remain fit and active 
participants in their social networks and wider communities. Telecare’s allure is as a 
mechanism to implement both policies at once, yet the policies are not in alignment. ‘Active’ 
older people may want to go out for leisure activities and to socialise, potentially putting 
themselves at risk for falls; ‘ageing in place’ can imply a much more restrictive regime, 
where older people are encouraged to stay put and stay safe rather than venture out and put 
themselves at risk. The authors suggest that the technology shapes “a particular type of user: 
a place-bound subject who, due to his or her age, is in need of constant alertness at home” 
(Aceros, Pols, and Domènech 2015 p.109). In a similar vein, Peek, Aarts, and Wouters 
(2015) observe that policymakers tend to focus on independence as ‘being able to look after 
yourself’ but other modes of independence (Sixsmith 1986) are in play in the use of smart 
home technology: self-direction and ‘not being obligated to someone else’. As an example of 
this last, an older person might decide not to activate a pendant alarm to avoid disrupting the 
lives of relatives. If the technology encroaches on a person’s sense of self-direction, it may 
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not be acceptable. All three modes of independence may come into play in response to these 
technologies – perceptions of usefulness alongside fears of loss of self-direction and of being 
a burden. Technologies designed to assist older people to age in place appear to arouse 
feelings of ambivalence in this group. Telecare can signify frailty and encroaching 
dependence and at the same time be perceived as a potentially useful means of warding off 
dependence (Aceros, Pols, and Domènech 2015, Bentley et al. 2016). 
There is a dearth of conceptual literature addressing how telecare might act to 
promote ‘independence’ and, importantly, what is the association between a ‘sense of 
independence’ and other outcomes of interest to individuals and policymakers alike, such as 
self-perceived quality of life. Theoretical models of the technologies aimed at supporting 
‘ageing in place’ are needed to guide future studies examining the relationship of these 
technologies and potential outcomes (Reeder et al. 2013). 
 There is a modest literature on the way that individuals choose to use or not use 
PERS in managing their lifestyles (Agboola et al. 2017, De San Miguel et al. 2015, De San 
Miguel et al. 2017b, Fallis et al. 2008, Williams, Victor, and McCrindle 2013). This literature 
is exploratory or descriptive rather than model-building; much of it focuses on compliance 
and patterns of use. McKenna et al. (2015) point out that the role of risk, the unpredictability 
associated with risk, and the decision-making around how to manage that risk are key factors 
in the use of these alarm systems. Users of PERS typically fail to use their devices during 
high-risk activities (using bathrooms, moving around at night) (De San Miguel and Lewin 
2008). In a study by De San Miguel et al. (2017a), only a third of personal emergency alarm 
users reported using the alarm during an emergency, a quarter choosing to use the telephone 
to call relatives or medical assistance.  
From the point of view of enhancing autonomy, one question we could ask is whether 
first-generation telecare offers greater scope for active decision (cf. McKenna et al. 2015, 
Hawley-Hague et al. 2014), which could reinforce an individual’s sense of autonomy, than do 
later-generation technologies. While PERS users may choose to activate the alarm or not, in 
second-generation telecare, sensors may go off automatically, with consequences out of the 
control of the user. As discussed earlier in section 2.6, older people can be deeply concerned 
about the technology encroaching on their privacy and autonomy. In particular, Milligan’s 
study uncovered “significant reservations about telecare systems whose primary purpose is 
active monitoring or surveillance and which does not rely on the older person to activate 
them” (Milligan, Roberts, and Mort 2011 p. 353). The important difference between first and 
subsequent generations of telecare – the addition of automatic monitoring to the (first-
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generation) alarm-activation function – poses a further problem for locating conceptual 
frameworks that would be relevant in linking second-generation telecare to outcomes such as 
quality of life. Any lessons from the PERS evidence may have limited applicability to 
second-generation telecare. 
To summarise, there is a gap in the telecare research literature in terms of theoretical 
frameworks linking telecare to final outcomes.  
 
2.6.6  How Similar and How Different Are Telehealth and Telecare Interventions? 
This thesis concerns two technologies that are often mentioned together in policy 
documents. While the empirical chapters examine the costs and cost-effectiveness of the 
technology separately, it is worth considering how much these technologies have in common. 
Telehealth and telecare share certain features: both can offer “remote care” – technologically-
enabled monitoring by agents outside the home. The two technologies nonetheless differ in 
important ways. Telehealth is by and large provided by the NHS, and the monitoring, 
software and equipment are therefore free at the point of access. Telecare is delivered by a 
combination of local authority and voluntary sector providers and users can be charged for 
the service. Telehealth appears to require a more active role on the part of the user than 
telecare; for instance, the telehealth user can examine information extracted from vital signs 
monitors (oximeters, glucometers etc.) to manage the long-term condition. In contrast, there 
is no requirement for day-to-day active input from the telecare user. In this sense, telehealth 
is a technology that could actively promote the autonomy and decision-making capacity of 
the user and there is some evidence that it does so (see section 2.6.4). In the case of telecare 
and in particular second-generation telecare, as discussed in section 2.6.5, the picture is more 
complicated.  
On the other hand, differences in the intensity of ‘use’ of the technologies may in 
practice be quite minimal. For instance, it is possible for little interaction to occur between 
the monitor and the monitored in either case. For instance, if the long-term condition is 
stable, with little day-to-day change in vital signs, then depending on the model of telehealth 
monitoring, the patient might be largely unaware of being monitored. If telecare sensors 
remain untriggered, the user can also largely remain unaware of being monitored. 
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2.7 Summary  
In this chapter, I set out to define telehealth and telecare and explain the terminology 
used to describe these technologies. Assessing the evidence base for the technologies is made 
more difficult by the variety of different labels used, depending on the country and discipline 
producing the research. Different kinds of ‘telemonitoring’ are not always well delineated in 
the literature, with telehealth and telecare being described in some reviews as two variants of 
‘ageing-in-place’ technologies.    
I described the markets for remote technologies such as telehealth and telecare. These 
have been growing, despite demand-side barriers (e.g. budget constraints to health and social 
care financing, lack of commissioning expertise, consumer resistance) and supply-side issues 
(e.g. poor interoperability, small-scale production methods). The market for telehealth in 
particular has experienced strong growth; however, m-Health may make inroads into the 
demand for telephone and internet-based telehealth products.    
The addition of telehealth to self-management support is a recent development but 
some frameworks have been proposed to understand how telehealth relates to the outcomes 
of self-management. Conceptual frameworks linking telecare technology to final outcomes 
such as quality of life are lacking. 
One purpose of this chapter was to describe literature on how telehealth and telecare 
‘work’. In the next chapter, I consider the evidence on whether the technologies work.    
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Chapter 3  
 
 
Evidence for Effectiveness and Cost-effectiveness of Telehealth and Telecare 
 
3.1 Introduction 
In this chapter, I examine the evidence base on effectiveness and cost-effectiveness of 
telehealth and telecare, the technologies that were to be implemented in the Whole Systems 
Demonstrators trials. The literature reviewed here focuses in large part on the literature 
available prior to 2013, because after this point, the evidence base contained the findings of 
the WSD studies (as those publications began to emerge in mid-2012). Relevant publications 
from more recent years are discussed in Chapter 9.  
The chapter begins with an overview of the methods employed to search the 
knowledge base and continues with an exploration of the pre-2013 evidence on the 
effectiveness of the technologies, reviewing what was known up to that point about the 
effectiveness of the technologies in terms of preventing disease and disability and promoting 
better quality of life and other psychosocial outcomes. The chapter finishes with an in-depth 
discussion of the evidence base for costs and cost-effectiveness of these technologies, asking 
whether they are reducing or increasing costs to the public purse.  
 
3.2 Methods 
3.2.1 Scope 
The terminology used to describe telehealth and telecare varies considerably depending on 
research discipline and country setting. This poses challenges to identifying literature relevant 
to telehealth and telecare. In selecting studies to be considered in this chapter, I used the 
WSD Telehealth Trial intervention and population as a guide. As described in Chapter 4, 
section 4.1, the trial population consisted of individuals with the long-term conditions COPD, 
heart failure or diabetes. The intervention involved the remote exchange of data between a 
patient and health care professional to assist in diagnosing and managing a health care 
condition (Chapter 4, section 4.2), where the patient was transmitting vital signs data using 
(non-implanted) devices based in the home (Chapter 5, section 5.7). The definition of 
telehealth was operationalised for this chapter as telemonitoring (TM) and/or telephone 
support (TS) for long-term respiratory, cardiac and diabetic conditions. I defined the 
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following activities as not within the scope of this review: health-professional-to-health-
professional communication (distance medicine), technologically-enabled programmes 
without interaction/data exchange between patients and health professionals (e.g. online 
health education, peer-to-peer support), monitoring of invasive/implanted devices or of 
electrode-mediated devices (e.g. cardiac telemetry), smartphone-mediated health applications 
(m-health) or telehealth for patients within hospital/clinic settings (e.g. teleradiology). The 
intervention and population examined in the WSD Telecare Trial served as a guide to 
defining telecare for the selection of studies. The intervention involved the remote, automatic 
and passive monitoring of lifestyle changes and emergencies in order to manage the risks of 
independent living; the population consisted of community-dwelling individuals with social 
care needs (Chapter 4, sections 4.1 and 4.2).  I considered any first-, second- or third-
generation telecare interventions to be within the scope of the review rather than limit the 
pool of evidence for consideration any further, given the anticipated sparsity of studies on 
telecare.  
 
3.2.2 Search Strategy 
Over the course of writing the thesis, I assembled evidence on the effectiveness and cost-
effectiveness of telehealth and telecare from a combination of sources. Initial searches were 
conducted in April 2011 via EBSCOhost in CINAHL Plus with Full Text and in May 2011 in 
PubMed, using search concepts for telehealth and telecare, including keywords for telecare, 
remote monitoring, home telecare, telemedicine, teleconferencing, teleconsultation, telephone 
support and telephone monitoring. Searches in PubMed also included keywords for costs and 
effectiveness. I undertook further searches on these concepts in March 2014 via EBSCOhost 
simultaneously on several databases: CINAHL Plus with Full Text; EconLit; MEDLINE; 
PsycARTICLES; and PsycINFO. The keywords for telehealth and telecare that had been used 
in the April 2011 search were combined with the text string ‘systematic review’ in a search 
where results were limited to publication in 2008 (the first year of the trial) to 2014 and to 
peer-reviewed journals. Additional searches of the same databases were then carried out on 
combinations of keywords related to costs and telehealth trials and to trials of technologies 
related to telecare, including assistive technology and smart homes. Searches on 
combinations of keywords for costs, telehealth, telemonitoring and telecare were also carried 
out in Cochrane Library and Google Scholar with results limited to publication in 2008 and 
thereafter. Papers that were published after 2013 located in these searches were collected for 
  
56 
 
use in the discussion in Chapter 9. Results were compiled in EndNote and Mendeley 
databases. These compilations of references were frequently updated over the next three 
years through alerts from academic publishers based on the ‘telehealth’ and ‘telecare’ 
keywords, from intermittent searches on those keywords in Mendeley’s literature catalogue, 
in PubMed and Web of Science from EndNote and in Google Scholar. 
 
3.2.3 Selection Criteria 
Having defined the scope of the telehealth and telecare activities to be considered, I also 
developed other criteria to choose whether to include papers for discussion in this chapter. In 
adopting further selection criteria, I necessarily balanced questions of relevance to the WSD 
trial populations with the availability of evidence. I included single studies where these were 
more recent than the last available systematic review. In the case of the telehealth literature, I 
focused on systematic reviews and single studies comparatively examining clinical outcomes 
(including service use and costs) in adult populations with one or more conditions related to 
the long-term conditions examined in the WSD Telehealth trial (COPD, diabetes and heart 
failure). I therefore excluded systematic reviews and studies that were focused exclusively on 
children, or on adult populations with other than diabetic, cardiac or respiratory conditions. I 
also excluded systematic reviews that only examined out-of-scope activities (e.g. web-based 
health education interventions, m-health, teleradiology, telemetry) and systematic reviews 
that included telemonitoring of invasive devices/implants. Single studies and systematic 
reviews of studies of experimental and quasi-experimental design were considered. 
Systematic reviews of economic evaluations of telehealth and telecare for any condition were 
considered.  
 
3.2.4 Procedure 
The quality of papers and systematic reviews was appraised in terms of the clarity of research 
aims and questions, the methods employed (e.g. selection criteria, study design and sample 
size; in the case of systematic reviews, evidence of having summarised and considered 
included studies, evidence of having considered the quality of studies in terms of study 
design and sample size) and the extent to which the conclusions reflected the evidence that 
had been presented. I summarised papers qualitatively, in more or less depth depending on 
my assessment of study quality, and grouped the results of the review into sections, 
separately presenting evidence on effectiveness, service use and costs, and cost-effectiveness. 
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3.3 Telehealth Effectiveness: Clinical and Health Related Outcomes 
Reviews of the literature on telehealth have identified some weaknesses in the evidence base 
in relation to clinical and health-related quality of life (HRQoL) outcomes, but nevertheless 
there is a rapidly growing body of evidence on the subject, much of it based on studies 
carried out in the USA. Whereas a pre-2005 study of telemedicine publications judged good 
quality studies to be scarce (Hailey 2004), more recent systematic reviews have noted 
promising findings, particularly with regard to clinical, or surrogate outcomes, for some 
populations of telehealth users. Systematic reviews of telephone support (TS) and 
telemonitoring (TM) have been carried for a variety of populations: those with cardiac 
conditions, hypertension or congestive heart failure (Inglis et al. 2010), diabetes (Polisena, 
Tran, et al. 2009), respiratory disorders (Polisena et al. 2010a, Jaana, Paré, and Sicotte 2009) 
and depression (Garcia-Lizana and Munoz-Mayorga 2010) among others. Most have 
reviewed the literature on resource use and costs associated with the interventions. The 
following sub-sections cover the evidence base on effectiveness, in terms of clinical and 
health-related quality of life outcomes.  
  
3.3.5 Cardiac Conditions 
Evidence on the effectiveness of telephone-based technologies is perhaps most robust in the 
area of congestive heart failure (CHF). Polisena et al. (2010b) carried out a systematic review 
of telemonitoring studies involving adults and children with CHF, locating 11 randomised 
controlled trials (RCTs) and 10 observational studies (total N=3082). The review included 
RCTs and prospective observational studies and rated these for quality; meta-analyses were 
conducted on studies rated as of fair-to-good, good or high quality. A meta-analysis of 
mortality from all causes (data from 6 studies, N=1304) found that mortality was reduced in 
telemonitoring (TM) vs. usual care (UC) (the relative risk of death was 0.64, 95 per cent CI 
0.48 to 0.85). 13 studies with quality ratings ranging from high to poor-to-fair reported 
various measures of HrQoL and satisfaction (condition specific and generic): seven found no 
differences between TM and UC and five reported better outcomes. The authors 
acknowledged the diversity of QOL and satisfaction measures used.  They concluded that TM 
was "generally clinically effective” (Polisena et al. 2010b, p.75) but recommended more 
high-quality research into the clinical outcomes of TM in this population. The Inglis et al. 
(2010) systematic review of structured non-invasive home-based telephone support (TS) and 
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telemonitoring (TM) for CHF gave detailed descriptions of methods followed and of 
characteristics of included studies, presented risk of bias assessments and where possible 
carried out meta-analyses (fixed effects models). All included studies were RCTs. The meta-
analyses indicated that the risk of all-cause mortality in patients with heart failure receiving 
either TS (pooled over 15 studies) or TM (pooled over 11 studies) was reduced, by 12 per 
cent (a non-significant positive effect) and 34 per cent (a significant positive effect) 
respectively, in comparison to those in usual care (UC). In terms of health-related quality of 
life (HRQoL) and satisfaction outcomes, six of nine TS studies reported improvements; of 
seven TM studies reporting these measures, three noted significant improvements. The 
reviewers concluded that both TS and TM interventions could improve quality of life.  
There is also some evidence on other cardiac conditions, namely hypertension. A 
systematic review by Clark et al. (2010) examined nurse-led telephone monitoring (TM), 
community monitoring and clinics. The review included only RCTs, provided detailed 
summaries of all included studies, and assessed for risk of bias. The reviewers conducted a 
meta-analysis (applying a random-effects model) of three studies that they had rated as good-
quality, finding that there were no significant differences between pooled TM treatment and 
usual care groups for either systolic blood pressure (BP) or diastolic BP. On the other hand, 
pooled data from three studies (one of which was rated by the reviewers as being of good 
quality) showed a significantly higher achievement of study BP targets with TM, with a 
relative risk of 1.24 (95 per cent CI 1.08 to 1.43). 
Two trials reported in 2010 were not covered by these systematic reviews. Chaudhry 
et al. (2010) report a large-scale US-based RCT of patients with a recent hospital admission 
for heart failure randomised to “automated telemonitoring” or usual care (826 in TM and 827 
in UC). The “automated telemonitoring” intervention involved daily calls into the system to 
complete automated questionnaires about general and HF-related health symptoms. TM did 
not reduce the risk of the combined 180-day endpoint of readmission (for any reason) or 
death (of any cause). In a US-based RCT (Datta et al. 2010), patients with a hypertension 
diagnosis using a Veterans Administration primary care clinic were randomised to a 
telephone-based nurse-administered patient education behavioural intervention to assist 
hypertensive patients to attain and maintain blood pressure control (N=294) or to usual care 
(N=294). Intervention patients received a telephone call from a nurse every 2 months for 24 
months. Nurses provided educational and behavioural information, feedback on recent blood 
pressure values and medication and appointment reminders. Intervention patients experienced 
improvement in blood pressure control (from 40.1 per cent to 54.4 per cent); control patients 
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experienced a smaller improvement (from 38.2 per cent to 43.9 per cent), a non-significant 
difference between groups of 10.5 per cent (p=0.17). 
 
3.3.6 Diabetes 
Polisena et al. (2009) carried out a systematic review of the impact of home telehealth, either 
TM or TS, for people with diabetes. The authors clearly described review objectives and 
methods and provided details of characteristics of the 26 included studies and rated these for 
quality. Both RCTs and prospective observational studies were included. Data on HbA1c 
were meta-analysed: pooling results of twelve RCTs, the reviewers found that TM improved 
control of diabetes as measured by HbAc115: the HbA1c levels in the TM group were 
significantly lower than in the UC group, with a weighted mean difference of -0.22 (95 per 
cent CI -0.35 to -0.08). The evidence on HRQoL and patient satisfaction was more mixed. 
Eleven studies measured HRQoL or patient satisfaction using a number of instruments. In 
four studies, telehealth (TM/TS) was better than usual care, for instance in terms of reliability 
and ease of use. No differences between groups were found in four telehealth studies in terms 
of satisfaction or HRQoL. The authors considered that participants in the TM and TS 
intervention groups had HRQoL outcomes that were similar to, or less good than, the UC 
groups. Limitations were acknowledged in terms of the number and variable quality of 
available studies for some outcomes. The authors concluded that, notwithstanding these 
limitations, home telehealth interventions were clinically effective.  
 
3.3.7 COPD 
Polisena et al. (2010a) carried out a systematic review of literature on the use of home-based 
TH for patients with chronic obstructive pulmonary disease (COPD). The reviewers included 
nine studies (RCTs and prospective observational designs), quality-rated the included studies 
and carried out meta-analyses (random-effects models). The authors examined papers 
reporting studies of both TM and TS. There were fewer studies involving the COPD 
population than were available for the systematic reviews of diabetes or cardiac conditions 
described above. The quality of the studies as rated in the review ranged from high to low; 
sample sizes ranged from 18 to 240. A meta-analysis found a higher mortality rate in TS 
patients compared to usual care (relative risk 1.21 (95 per cent CI 0.84, 1.75)), based on three 
                                                          
15 This is a measure of the control of diabetes. 
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studies. The review listed four studies reporting quality of life and satisfaction, finding 
improved outcomes in the telehealth relative to the usual care groups in two studies and no 
difference between groups in outcomes in the other two. Having acknowledged the small 
number of available studies and variations in their quality, they concluded that “home 
telehealth is generally clinically effective” (Polisena et al. 2010a, p.127).  
A systematic review by Jaana, Paré, and Sicotte (2009) identified 23 studies on 
telemonitoring (TM) of people with respiratory conditions (including COPD and asthma) 
where monitoring consisted of various technologies such as short messaging services, internet 
monitoring and electronic diaries. The reviewers presented characteristics of included studies 
and rated these for strength of evidence (using a rating system based on the type of study 
design): 13 studies were rated as being of fair to poor quality; most relied on small samples 
(ranging from 5 to 300) and 13 had no control group. Most of the clinical effects reported 
involved disease markers and respiratory symptoms rather than HrQOL. The reviewers 
summarised the psychological effects of TM as positive in most of the included studies. The 
review noted improvements in some clinical indicators such as disease control, to be 
interpreted with caution given small sample sizes, unsystematic and uncontrolled designs in 
the reviewed studies.  
  
3.3.8 Reviews across Chronic Conditions 
One systematic review (Barlow et al. 2007) surveyed the evidence on a broader range of 
telephone or internet-based interventions, categorised as ‘vital signs monitoring’ (TM), 
‘information and support’ (TS) and ‘safety and security’ (telecare, as defined in section 2.1). 
The reviewers included RCTs and observational studies as a means of ensuring quality and 
did not formally score studies on quality. The authors found that the evidence on TM was 
inconsistent: three studies involving populations with diabetes reported improvements in 
clinical measures but in five studies, there was no difference in blood glucose control 
between groups. The authors concluded from an examination of the systems’ outcomes 
across fifteen studies that the automated transmission of clinical readings was as effective as 
usual care. Studies of telephone information and support (TS) found improved clinical 
outcomes in those with depression (six studies), heart disease (three studies), diabetes (seven 
studies), asthma (one study), COPD (one study) and frail older people (one study). Another 
two studies found no improvements for people with diabetes clinically; and one found no 
improvement in HRQoL. The reviewers concluded that the evidence on the clinical impact of 
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vital signs monitoring was equivocal. They noted that while most studies they had reviewed 
were of randomised design, in many cases these were based on small samples.  
A study by Pare et al. (2010) examined peer-reviewed articles reporting the results of  
studies involving people with a diagnosis of diabetes, asthma, heart failure or hypertension 
receiving TH or TM. 45 percent (28/62) of the studies were US-based. The review used a 
strength of evidence-rating system based on the type of study design. The authors found a 
trend towards better glycaemic control in patients with diabetes. There were improvements in 
peak expiratory flows, reductions in related symptoms and improvements in self-reported 
QOL in asthma patients. For patients with hypertension, there were reductions in systolic 
and/or diastolic blood pressure. However, the findings of studies of TH or TM in heart failure 
patients were equivocal; no reductions in mortality or hospitalisations were reported. The 
authors observed that in diabetes, asthma and hypertension patients, TM allowed more 
frequent follow-ups, enabling early detection of deterioration in patient health.  
A large-scale trial of care coordination through case management and disease 
management (Brown et al. 2007) included a number of projects using home telemonitoring 
but concluded that “few programs had statistically detectable effects on patients’ behavior or 
use of Medicare services” (Brown et al. 2007, p. xviii).  
 
3.4 Telecare Effectiveness: Clinical and Health Related Outcomes 
Whereas there is demonstrably a mounting evidence base from controlled trials and 
observational studies for telehealth applications, the same cannot be said for telecare. It was 
difficult to find empirical literature on the relationship between the impacts (for users) and 
characteristics of telecare systems. Reeder et al. (2013) make a useful point about the 
evidence base for ‘health smart homes’ (HSH) and ‘home-based consumer health 
technologies’ (HCH) (terms which encompass second-generation telecare):  
HSH/HCH research has been conducted in both health services and 
technology disciplines and scientific findings have been published in 
different literature repositories that do not always overlap in their 
indexing […]This fragmentation of reported evidence represents a 
knowledge gap concerning what research has been done and 
communication barriers for knowledge translation to relevant 
stakeholders. (Reeder et al. 2013, p.566-7) 
 
In the Barlow et al. (2007) review, the authors identified no RCTs or observational studies on 
the monitoring of safety and security reporting individual level outcomes that met their 
quality criteria; the authors concluded that the evidence base for the effectiveness of home 
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safety systems (telecare) was insufficient. One systematic review of smart home 
technologies, including telecare (Martin et al. 2008), found no studies of sufficient quality for 
inclusion. The reviewers considered studies of social alarms, electronic assistive devices, 
telecare platforms, environmental control systems, automated home environments and 
"ubiquitous" homes. Of 62 papers they excluded fourteen as actually being about 
telemedicine; most of the papers were only discussions or editorials.  
One of the papers retrieved but excluded from the Martin et al. (2008) review (by 
Vincent et al. (2006)) does address the effectiveness of a home telesurveillance scheme in 
older people and is worth noting, given the dearth of relevant studies, although the study 
sample size was small (n=38), had an uncontrolled before-after design and measured 
outcomes over a short period, of six months. The intervention equipment consisted of a big-
button telephone and call transmitter with emergency button worn as pendant/bracelet. The 
telephone had a programmable voice reminder feature. The monitoring was conducted by a 
telesurveillance call centre operated by nurses rather than unqualified call operators. The 
authors found that there was no significant improvement in HRQoL (SF-12) after six months 
of using the service.  
A systematic review of health smart homes (HSH) and home-based consumer health 
(HCH) technologies to support ageing in place by Reeder et al. (2013) covered the literature 
from 1980 to 2011. Searches were conducted in databases of health care and also informatics 
publications. The search uncovered 31 publications from Europe, North America and Asia. 
The review covered technologies to support older people (60 years and older) in residential 
settings that supported, or prevented threats to, independence and collected data for 
monitoring health or communication. HSH were residential settings with embedded 
technologies for passive monitoring; HCH were health technologies used by older people in 
their homes. Strength of evidence was assessed by classification into four categories covering 
stage of technological readiness (from validity and feasibility testing through to larger-scale 
evaluation and implementation stages), sample size and study design. The review uncovered 
only 3 studies that were evaluations on a larger scale than 10 people, all of which had 
methodological weakness such as unequal dropout between comparator groups, non-
randomised comparators or historical controls. The authors cited a paper by Tomita et al. 
(2007) reporting an RCT which found that a smart home technology intervention group 
(N=46) maintained their physical and cognitive status while controls (N=67) declined in 
these measures over 2 years. Almost half of intervention participants chose not to use some of 
the smart home technology, because of problems with usability. The reviewers identified a 
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study by Brownsell, Blackburn, and Hawley (2008), which compared participants receiving a 
mix of second and third generation telecare technologies (N=24) to non-equivalent controls in 
similar housing (N=28). Intervention participants spent more time outside the home than 
controls and felt safer during the day and night than controls. The reviewers cited a paper by 
Kelly (2005) (a historical controlled study, N=1700) which reported that a home safety 
(second-generation) telecare package reduced hospital admissions, hospital lengths of stay 
and nursing home lengths of stay.  
A systematic review of telecare outcomes for carers (Davies, Rixon, and Newman 
2013) identified very few papers reporting relevant quantitative analyses. Only seven studies 
fulfilled the criteria for inclusion, of which just two had been peer reviewed, the others being 
unpublished work or reports. Telecare was defined as “the continuous, automatic and remote 
monitoring of real‐time emergencies and lifestyle changes over time in order to manage the 
risks associated with independent living”(Davies, Rixon, and Newman 2013 p.584, citing 
Telecare Aware website (accessed 14th May 2013)). The included evaluations were from US, 
UK and Norway. Four studies had sample sizes of less than 30, others had sample sizes of 
between 100 and 300. The equipment used in evaluations were mostly passive sensors to 
monitor activity, e.g. bed sensors; or response to emergencies, e.g. flood detectors; or 
assistive devices (stand-alone), e.g. calendar clocks. Davies, Rixon, and Newman (2013) find 
some evidence of positive impacts on carer well-being in terms of reductions in stress and 
strain but not QOL, burden or impact in terms of time; however their conclusions were 
tentative as all the studies reported in the review were methodologically weak. 
Despite the prevalence of pendant alarms or PERS, there is very little hard evidence 
on the outcomes of these systems (De san Miguel 2017). de Miguel Diez et al. (2008) 
reported the results of a retrospective survey of 1476 users of a first-generation telecare 
service (PERS) in Western Australia. Respondents reported positive impacts such as greater 
sense of security, being less anxious about having a fall and more confidence in carrying out 
ADLs. Lee et al. (2008) randomised older people 70 years and over discharged from the 
emergency department after a fall to PERS (N=43) or standard discharge planning (N=43). 
Outcomes measured were fear of falling and anxiety, emergency department visits, hospital 
admissions and lengths of stay. The study found no differences between PERS and standard 
discharge planning groups after 60 days in terms of reductions in anxiety or fear of falling; 
nor in subsequent visits to the emergency department, numbers of admissions or lengths of 
stay. 
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There is some evidence on the effects of more advanced versions of telecare. A recent 
systematic review of “lifestyle monitoring” found just 4 papers reporting trials with over 20 
participants, and 21 papers on trials involving fewer than 20 participants (Brownsell et al. 
2011). The authors concluded that, given the small number of papers available on lifestyle 
monitoring, much remains to be understood on how such systems can be made effective. A 
systematic review of smart home projects (Demiris and Hensel 2008) (see also Chapter 2 on 
smart homes) located 114 publications reporting 21 projects from Europe, the US and Asia. 
The authors were not able to locate evidence on health outcomes or impacts on delaying 
admission to nursing homes. Most studies were at the stage of examining feasibility issues or 
had very limited sample sizes.  
 
3.5 Telehealth- and Telecare-Related Use of Health and Social Services Resources, Costs 
and Cost-Effectiveness 
It is important to consider whether AATs represent a useful and effective route for delivering 
health care. It is equally important to investigate whether AATs represent the best use of the 
available public funds. A relatively small proportion of telehealth evaluations have 
considered the relationship between the outcomes of the interventions and the costs 
associated with implementing the interventions (Whitten et al. 2002, Bensink, Hailey, and 
Wootton 2006). Bensink, Hailey, and Wootton (2006) found that less than a fifth of published 
studies on home telehealth gave economic data “judged sufficient for economic strength of 
evidence evaluation” (pp. 12-13). The information on the costs and cost-effectiveness of 
interventions featuring home telehealth is also scarcer than that on their effectiveness (Barlow 
et al. 2007). On the other hand, a number of recent systematic reviews were able to locate 
data on health service use, particularly in terms of either numbers of hospitalisations or 
numbers of bed-days. The evidence on the costs and cost-effectiveness of telehealth and 
telecare are reviewed in the following sections.  
 
3.6 Telehealth: Resource Use and Costs 
3.6.1 Cardiac Conditions 
The Inglis et al. (2010) review of TS and TM for heart failure conditions identified a number 
of studies reporting hospitalisations and lengths of stay, but a smaller number of studies 
reporting the costs of the intervention and/direct service costs. The risk of all-cause 
hospitalisation in TS (pooled over 11 studies) significantly reduced risk of all-cause 
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hospitalisation by 10 per cent; the risk was non-significantly reduced by 6 per cent by TM 
(pooled over 8 studies). CHF-related hospitalisations were reduced significantly by 23 per 
cent in TS (pooled over 13 studies); and also in the TM studies, by 24 per cent (pooled over 4 
studies). There was less evidence on length of stay (LOS): of six TS studies, only one study 
reported a significant reduction in LOS; in one TM study there was large decrease in the 
number of days but in another the trend towards a shorter stay did not reach significance. 
Twelve studies of TS or TM included information on health service costs. Nine reported cost 
reductions in hospital service use; three studies reported no reductions or an increase in health 
service costs. The reviewers reported that where studies identified decreases in resource use 
and costs, the range of savings was 35 per cent to 86 per cent. Five studies involving TS 
provided details on reductions in service costs. Four of the five were US-based studies. Inglis 
et al. (2010) report cost savings per patient expressed in a variety of ways in different studies: 
for instance as savings on inpatient care and also in terms of cost per QALY gain. Figures on 
reductions in service costs were given in fewer TM than TS studies (in terms of costs of 
readmissions, hospital care, medications). 
Four studies involving TS provided details on the intervention costs according to 
Inglis et al (2010): these were also within a wide range and came from a variety of different 
health systems and countries. The review gave figures from US-based studies of between US 
$23.60/patient (n=34)  (Barth 2001, cited by Inglis et al. (2010)) and US $2177 per patient 
(n=406) (Hebert, Sisk et al 2008, cited by Inglis et al. (2010))  Of European studies covered 
by the review, one industry-funded Dutch study (Balk et al. 2007, Balk et al. 2008) (n=214) 
noted that costs of TM (MOTIVA) for intervention patients increased the total costs for the 
intervention group, but did not give the actual cost of the intervention; and Giordano et al. 
(2009) gave a mean annual cost per patient for TM of 185 EUR +/-39 EUR.  
In Polisena et al. (2010b), a meta-analysis of patients hospitalised (N=891 in 4 
studies) found lower numbers hospitalised in TM than UC (a relative risk of 0.77 (95 per cent 
CI 0.65, 0.90)). Emergency department (ED) visits (in 8 studies) and all-cause bed days of 
care (in 4 studies) were decreased in the TM relative to the UC groups. While two studies 
found outpatient and primary care visits had increased in TM vs. UC, two others found 
outpatient visits reduced in TM vs. UC. The authors concluded that evidence on health care 
utilisation in TM was less than was available on clinical outcomes.  
A study by Chaudhry et al. (2010) (RCT, n=1653) found that automated TM did not 
reduce the risk of hospitalisation for heart failure and there were no differences between 
groups in number of days in hospital. The authors noted that 14 per cent of the TM group 
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never used the automated system and only 55 per cent were still using the system at least 
three times weekly by the end of the study period.  
Datta et al. (2010) (RCT, n=588) describe the service use and costs of a telephone-
based nurse-administered patient education behavioural intervention for hypertensive 
patients. Over 2 years, 27.5 per cent of TS patients had 162 admissions vs. 25.2 per cent of 
control patients who had 150 admissions. The mean length of stay in TS was 9.57 days vs. 
9.72 in UC. TS patients had fewer primary care clinic visits than control patients (4.2 vs. 7.5). 
The groups did not differ in terms of overall costs (including inpatient, outpatient and 
primary care services) over 2 years. The mean annual intervention cost was estimated at 
$112, constituting about 3 per cent of total costs. The same authors reported a cost-
effectiveness analysis using a decision model: ICERs generated by this model were between 
$42,457 to $87,300 per life-year saved (for women and men of normal weight respectively). 
TS was described as "potentially cost-effective" (Datta et al. 2010, p.262). 
 
3.6.2 Diabetes 
The Polisena et al. (2009) systematic review of home telehealth for diabetes identified some 
studies reporting on health service use outcomes. There was evidence of significant 
reductions in proportions hospitalised in TM vs. UC groups in two studies. There was a 
significant reduction in hospitalisations in TM vs. UC groups in one study and significant 
reductions in bed days in three, although these results were limited in that no measures of 
variation were reported. In terms of visits to emergency departments, two observational 
studies reported contradictory results, one with significant reductions in the TM relative to 
the UC group and one with the opposite finding. There were no significant results related to 
proportions of hospitalisations or ED visits in the case of TS. The review’s authors thus found 
some evidence of reductions in hospitalisations and bed days; evidence was limited to one or 
two studies for some types of clinic and primary care use. The authors concluded that, 
although impacts on the use of health services had a limited evidence base, home telehealth 
showed “great potential in some studies” (Polisena, Coyle, et al. 2009, p. 928). 
A US-based RCT (Moreno et al. 2009) examined the costs to Medicare of introducing 
a computer-based monitoring system for patients with Type II diabetes, in tandem with nurse 
case management and guidelines-based recommendations to patients’ primary care 
physicians. The study recruited Medicare beneficiaries in medically underserved areas of 
New York State (US). The study found that costs of TM participants (N=825 in a first cohort 
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and N=243 in a second) were 71 to 116 per cent greater than those of controls (N=800 in the 
first cohort and 248 in the second). The annual costs of the intervention itself were well over 
USD $8000 per patient ($8924 to $8437 depending on the enrolled cohort), which were 
described as “excessive”.  
 
3.6.3 COPD 
Polisena et al. (2010a) reported in their systematic review that home telehealth had reduced 
hospital admission rates (in one study) and numbers of hospitalisations (in eight studies) and 
visits to emergency departments (in four studies), while evidence on the impact of TH on the 
use of other health care services was more limited. The impact on use of hospital bed days 
was quite varied between the six studies reporting this outcome, particularly in regard to TM: 
higher than in UC in one study, and lower in two others. The reviewers concluded that overall 
there were limitations to the evidence on health service use in home telehealth. The 
systematic review by Jaana, Paré, and Sicotte (2009) found no consistent evidence that 
telemonitoring for respiratory conditions reduced health care utilisation (visits to primary 
care or emergency department, hospitalisations and lengths of stay or visits). 
 
3.6.4 Reviews across Chronic Conditions 
The Barlow et al. (2007) review suggested that automated vital signs monitoring could 
decrease utilisation of health services in the case of COPD and CHF, based on the evidence 
of 11 trials, but that the evidence was more mixed in the case of diabetes.   
 
3.7 Telehealth: Economic Evaluations 
Systematic reviews have been carried out on the economic evaluation evidence for telehealth 
(Bergmo 2009, Polisena, Coyle, et al. 2009, Vergara Rojas and Gagnon 2008). Polisena et al. 
(2009) identified 22 studies on economic evaluations of home telehealth on populations with 
CHF, COPD and diabetes. The review included comparative economic evaluation designs 
(cost-effectiveness, cost-utility, cost-minimisation and cost-benefit studies; costs-analyses 
where the intervention was assumed to be as effective as the alternative). Quality was 
assessed using a checklist for economic evaluation, adapted for examining telehealth studies; 
study interventions and comparators and study costs and consequences were summarised in 
some detail. The majority of these economic evaluations (14) were based on RCTs, four on 
case-control studies, four on pre-post study data; twenty-one were cost analyses, one, a cost 
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utility analysis (CUA). All but two of the studies found that home telehealth led to reduced 
costs of health care, from a system or an insurance provider perspective. The authors caution 
that although most studies found home telehealth to be cost-saving, conclusions drawn on 
cost-effectiveness “must be qualified as the quality of the studies in terms of economic 
evaluations was poor" (Polisena, Coyle, et al. 2009, p. 347). They found that the relatively 
few economic evaluations of telehealth for chronic disease management were mostly of poor 
quality; most failed to address perspective, use marginal analysis or carry out sensitivity 
analyses. The studies were characterised by small sample sizes, and lacked information on 
patient characteristics as well as clinical outcomes.  
Vergara Rojas and Gagnon (2008), in a review of cost-effectiveness indicators used in 
telehomecare (telehealth), report similar findings: the great majority of the 23 economic 
analyses they had identified found telehomecare to be cost-effective. However they also 
caution that the studies were “far from providing the basis to make a good decision” (Vergara 
Rojas and Gagnon 2008, p. 902), finding flaws in the methods employed and the 
interpretation of results in many of the papers. The authors acknowledged a limitation of their 
review in that they did not assess the quality of the papers reviewed.  
Bergmo (2009) set out to review telehealth-related economic evaluations in terms of 
their quality and validity, finding 33 economic evaluations covering a number of specialties, 
including six on diabetes, six on cardiology, and a range of others in areas such as 
dermatology and psychiatry. Studies comparing full economic evaluations (excluding costs 
analyses) were included; characteristics and results of all included studies were briefly 
summarised. Among the evaluations were thirteen RCTs, two case control studies, three 
before and after studies, two crossover trials and six decision modelling studies using 
secondary data. There were five cost utility analyses, the rest being cost-effectiveness 
analyses. Twenty-one evaluation papers did not report perspective, but where reported, the 
perspective was more often the health provider (eight studies) than societal (two studies), and 
two studies combined health provider and patient perspectives. A variety of effectiveness 
measures had been used, including process outcomes such as diagnostic accuracy, and 
surrogate measures of outcome, e.g. blood glucose. Seven studies employed the SF36 or 
EQ5D, and two used condition-specific HRQoL instruments. Four reported QALY gain. 
However, only two studies of TM were based on RCTs: one (Mason et al. 2006) (for 
diabetes) reported a cost-per-QALY of £43 400; another (for asthma) (Willems, Joore, 
Hendriks, Wouters, et al. 2007) reported a cost-per-QALY of  €31 035 per QALY gained for 
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adults (the other studies being before-after or decision models) (Willems, Joore, Hendriks, 
van Duurling, et al. 2007).   
In terms of the methods used to calculate costs, all studies had calculated direct health 
care costs, including investment, installation, call costs, personnel costs and other health 
costs. Fewer (eight studies) reported travel costs for personnel while eleven estimated 
patients’ travel costs. However five studies gave little to no cost information, while the author 
found that in half the studies, the methods for costing were unclear. Less than half gave 
details of resources used in their physical units and reported the unit costs or prices they had 
used to value the resources. Three studies calculated marginal costs. In terms of estimation of 
uncertainty of the reported costs, 23 studies had calculated confidence intervals for point 
estimates, three employing non-parametric bootstrapping techniques. Only five reported 
incremental cost-effectiveness ratios (ICER). Less than half reported sensitivity analyses. 
This review prompted the author to conclude that the “evidence base for telemedicine 
decisions is alarmingly scarce” (Bergmo 2009, p.6) and that “few economic evaluations can 
be trusted to provide reliable information for decision making” (Bergmo 2009, p. 8). 
In summary, there were several problems common to most published economic 
evaluations of telehealth: sample sizes were generally small; most evaluations failed to state 
perspective; which costs have been considered and included were not presented transparently; 
there was a lack of information on patient characteristics; and few conducted marginal 
analysis (Bergmo 2009, Polisena, Coyle, et al. 2009, Vergara Rojas and Gagnon 2008). Also, 
costs of older evaluations might not reflect current conditions in a fast-changing market with 
the potential for rapid price decreases. There was a need for those carrying out economic 
evaluations in this field to address issues of local variation, use more diverse populations to 
boost external validity, use a standardised approach, such as an explicit economic evaluation 
framework, to include all relevant costs and to be clear about inclusions and exclusions 
(Bergmo 2009, Polisena, Coyle, et al. 2009). Another issue for policymakers in the UK is 
how generalizable are the widely varying estimates of intervention costs and cost savings 
given in the literature to this health and social care system, particularly as many of these 
studies have been conducted in the US (Vergara Rojas and Gagnon 2008).   
 
3.8  Telecare: Resource Use, Costs and Cost-effectiveness 
If there were concerns about the quality of the economic evidence for telehealth, then they 
applied doubly to telecare, for which virtually no good quality studies of its impacts exist. 
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The more general question of telecare’s efficacy was also not well supported by the evidence 
base. In contrast to the bourgeoning of evaluation literature on telehealth applications over 
recent years, where more randomised controlled trials and observational studies had been 
conducted, the same could not be said for telecare.  
While the quantity of small-scale evaluations is growing, the quality was generally 
poor. In their 2007 review, Barlow et al. (2007) identified no RCTs or observational studies 
on the monitoring of safety and security reporting individual level outcomes that met their 
quality criteria. The review identified just two observational studies of ‘safety and security’, 
or telecare, interventions at ‘systems level’, one of which was case-controlled. That study 
(Woolham 2005) found that a home alert system might help people to stay at home and 
improved function in the ‘intervention’ group. The other observational study compared 170 
people in care homes to the same number of people living in their own homes, finding that 
telecare was associated with fewer hospital admissions and improvement in discharge rates 
and cost savings (West Lothian Council 2004). Vincent et al. (2006) found that the provision 
of a telesurveillance call centre operated by nurses decreased hospitalisations (from twelve to 
ten admissions, in a three month period per client) and use of home care services (from 
eighteen to ten visits, on average in a three month period) at the end of the six month study. 
There was a systematic review with some findings relevant to telecare by Graybill, 
McMeekin, and Wildman (2014), covering literature up to July 2012. The review covered 
economic analyses of assisted living technologies facilitating ageing in place (defined as 
home and environmental adaptations and/or telemedicine). The study populations were 
home-dwelling people 65 years and older with complex co-morbid conditions or functional 
limitations. Quality was assessed using an economic evaluation checklist; intervention 
characteristics and quality ratings were summarised. The reviewers searched two economic 
databases (NHS EED and HEED) for relevant studies and located eight. One concerned (low-
tech) assistive devices (e.g. equipment for daily living, wheelchairs); seven others involved 
telemedicine or tele-rehabilitation interventions. The Vincent et al. (2006) study (also 
reviewed by Barlow et al. (2007)) was reviewed and classified as telemedicine. All eight 
studies were assessed to be of low methodological quality. Thus it seems that up to 2012, no 
economic evaluations of telecare (of any generation) were available within these economic 
databases. While most of the interventions reported in the studies covered by this review 
were not similar to telecare, the nature of the intervention described by Vincent et al. (2006) 
appeared as related to telecare as to telemedicine, in providing a safety surveillance system, 
even if delivered by health rather than social care workers. The authors cite Bowes and 
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McColgan (2006) (not included in the review) as an example of the gap in research evidence 
on costs of ALTs for ageing in place, because that evaluation did not consider the cost of the 
(telecare) intervention. Bowes and McColgan (2006) themselves presented costs and 
outcomes results from their observational study but conducted no formal cost-effectiveness 
analysis. Nonetheless they concluded that the evidence base for the cost-effectiveness of 
home safety systems was insufficient.   
A curious feature of the telecare literature is that there appeared to be as much written 
about the potential for cost savings as on the effectiveness or cost-effectiveness of the 
intervention. In particular, a reduction in service utilisation was discussed in this literature as 
a measure of a satisfactory outcome. Yet there were few peer-reviewed publications that 
provided information on not just cost savings but such basic details as the typical composition 
of a telecare package, the cost of the equipment and of supporting the monitoring service and 
the range of support services available to respond to sensor activations. The cost of a “home 
safety and security package” in England, based on information from telecare pilots in 
England, was estimated in 2005 to be £360 (Department of Health 2005c),while the cost of 
monitoring was estimated to be about £5 per week. Uplifted to 2010 prices, the cost of 
equipment and monitoring might cost approximately £735 in the first year, or using an annual 
equivalent cost for the equipment, it might cost £403 per year, or about £7.70 per week. A 
report on the West Lothian telecare programme (Bowes and McColgan 2006) gives details of 
a cost study based on a sample of 57 older people receiving telecare in both home and new-
build sheltered care settings. This estimated the costs of telecare for people in their own 
homes ("Opening Doors Dispersed") at £7 per week. These costs included the weekly cost of 
the technology, taking battery replacement and depreciation into account, and the support 
costs of the monitoring centre. More recently, the cost of a package of telecare in a Welsh 
local authority, providing a response as well as a monitoring service, was estimated at 
approximately £9 per week (including equipment), with revenue costs of £5.30 per client per 
week (Bayer and Barlow 2010). There was very little empirical information on the cost-
effectiveness of lifestyle monitoring versus standard or usual care (Brownsell et al. 2011). 
Reeder et al. (2013) report that the costs of the smart home intervention in Tomita et al. 
(2007, cited in Reeder et al. (2013)) were less than €304; also that a small-scale study by 
Mahoney, Mahoney, and Liss (2009, cited in Reeder et al. (2013)) of nine family members of 
older people found that five were willing to pay €45 and four were willing to pay €23 per 
month for smart home technology. 
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3.9 Conclusion 
In this chapter I gave an overview of the literature on outcomes, service use, costs and cost-
effectiveness associated with telehealth (including telephone support and telemonitoring) and 
telecare (including smart homes, first-generation/PERS and third-generation telecare). I 
focused on the evidence available prior to the publication of the evidence emerging from the 
WSD research programme in mid-2012. The evidence for clinical outcomes of telehealth 
across the specific conditions of HF, COPD and diabetes, and across chronic conditions, was 
in general promising or at least suggested some equivalence between telemonitoring, 
telephone support and conventional medical management. On the other hand, telehealth 
economic evaluations were of variable quality and many did not adhere to standard economic 
evaluation checklists. It was evident that the quality and quantity of literature on telehealth 
differed from that of telecare. Much of the telecare literature reported small-scale 
investigations of weak methodological quality. The evidence base was somewhat fragmented 
between health indexing and informatics databases.   
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Chapter 4  
 
 
Methods 
 
In this chapter I first describe the context within which my research took place. I set the scene 
by giving an overview of the methodologies employed in the Whole Systems Demonstrator 
trials. The trial and accompanying evaluation required the endeavours of a large number of 
people, and it is not within the scope of the thesis to describe their work in great detail; 
however it would be impossible to understand the context of the economic evaluation without 
knowing something of the trial design. I describe in greater detail the methods used to carry  
out the economic evaluation.  
4.1 The Whole Systems Demonstrator Evaluation: an Overview 
The Whole Systems Demonstrator (WSD) evaluation examined two telemonitoring 
technologies, telehealth and telecare (Bower et al. 2011). The evaluation sought to assess the 
outcomes and costs of the technologies in the context of integrated health and social care and 
support. Evaluators used a range of quantitative and qualitative methods to investigate 
outcomes. There were two pragmatic cluster-randomised controlled trials investigating the 
impact of the interventions in two populations: 
1. Telehealth: individuals with an index long-term condition (chronic obstructive pulmonary 
disease, heart failure or diabetes)  
2. Telecare: individuals with social care needs 
Alongside the quantitative research, qualitative studies examined the experiences of 
professionals involved in implementing the technologies (MacNeill et al. 2014) and of trial 
participants and their carers (Sanders et al. 2012), and an ethnographic study examined the 
organisational challenges to mainstreaming the technologies (Hendy et al. 2012). 
The main trials drew on administrative data to address the question of effectiveness on 
utilisation and costs to the health and social care systems (Steventon et al. 2013, Steventon et 
al. 2012). Two questionnaire sub-studies, involving about half of the trial participant 
population, collected data from participants on self-reported outcomes and use of health and 
social care services (Cartwright et al. 2013, Henderson et al. 2013, Bower et al. 2011).  
The WSD pilots operated in three English local authority areas, geographies covered 
by four Primary Care Trusts. The three sites were chosen to exemplify continuing 
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engagement in ‘whole-systems redesign’ between health and social care. The technologies 
were implemented with the objective of supporting integrated care services and processes 
(Bower et al. 2011).  
The overall design of the WSD evaluation was devised by the principal investigator 
(Professor Stanton Newman) and other lead investigators of the study (Dr Jennifer Dixon, 
Professor Raymond Fitzpatrick, Professor Martin Knapp, Professor Anne Rogers and 
Professor James Barlow, Dr Peter Bower, Dr Helen Doll). I undertook my doctoral research 
in the context of this study. While the overall design of the evaluation was not part of my 
doctoral work, it is important background and its description will help to understand the 
origins, strengths and limitations of the data analysed in subsequent chapters.  
 
4.2 Trial Interventions 
The WSD trial employed the following definitions of telehealth and telecare: 
Telehealth (TH): "the remote exchange of data between a patient and health care 
professional to assist in the diagnosis and management of a health care condition. Examples 
include blood pressure and blood glucose monitoring” (Bower et al. 2011 p. 2). 
Telecare (TC): “Telecare is the remote, automatic and passive monitoring of changes 
in an individual’s condition or lifestyle (including emergencies) in order to manage the risks 
of independent living. Examples include movement sensors, falls sensors, and bed/chair 
occupancy sensors. These technologies are generally provided to patients with social care 
needs” (Bower et al. 2011 p. 2). 
 
4.3 Trial Sample Size, Randomisation Procedures 
The quantitative study design was a pragmatic cluster-randomised controlled trial. The level 
of randomisation was at the general practice level (Figure 4.1). Practices were allocated to 
either the telecare or telehealth intervention, and acted as a control for the other intervention, 
so that those allocated to the telehealth control would be allocated to the telecare intervention 
and vice versa. In this way all participating practices had access to one of the two 
technologies.  
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Figure 4.1 Cluster randomisation design (Newman and Whole System Demonstrator 
Programme Evaluation Team 2014) 
 
The telehealth trial sample size of 3000 was determined so as to power the study to 
detect a relative change of 17.5 per cent in the proportion of participants admitted to hospital 
at 12 months, from 25 per cent at baseline (80 percent (1-Type II error) power and two-sided 
p-value < 0.05 (type 1 error)). A minimisation procedure was put in place in order to allocate 
general practice clusters to the telehealth or telecare intervention or control, while balancing 
characteristics that might be associated with outcomes of the intervention across the trial 
arms. The characteristics considered were: size of practice (small/medium/large), prevalence 
of each of the index long-term conditions (low/medium/high), proportion of white/non-white 
patients (low/medium/high), Index of Multiple Deprivation 2007 (Noble et al. 2008) 
(low/medium/high) and site.  
 
4.4 Trial Eligibility Criteria 
All general practices within participating sites were eligible to join the trials.  
Telehealth trial: Potential participants were deemed eligible for inclusion in the TH 
trial if they met any of the following criteria: they were included in a relevant QOF (Quality 
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Outcomes Framework) register; they had a confirmed diagnosis in either secondary or 
primary care health records (by ICD 10 or GP Read code); a local clinician (e.g. hospital or 
primary care medical practitioner or community matron) confirmed their disease status. 
Telecare trial: Potential participants were eligible for inclusion in the TC trial if they 
met one or more of the following criteria: receiving or considered to need night sitting; 
receiving one or more days of day care or 10 or more hours of home care per week; having 
mobility difficulties; having falls or considered at high risk of falling; having a live-in or 
nearby carer facing difficulty providing support; having cognitive impairment, with a live-in 
or nearby carer (Bower et al. 2011). Potential participants were not excluded for having such 
basic forms of telecare as pendant or other community alarms (i.e. alarms that do not 
remotely collect and automatically send data to monitoring centres), or having items that 
were not part of a telecare package (e.g. smoke or carbon monoxide detectors). 
 
4.5 Cluster and Participant Selection and Recruitment 
General practices in each site were invited to join the trial. Once the practices had consented, 
a process of identification of potential TH and TC participants began. General practice 
registers were used to identify potential TH participants. For the TC trial, Social Services 
records were used to identify potential participants. Identified individuals were sent letters 
requesting their initial consent to share data with the WSD research team. Consenting 
individuals were invited to join the trial. Members of the sites' project teams then made a 
'light-touch' visit to check eligibility for the trial. They also made initial checks on the home 
environment to assess suitability for TH/TC equipment, provided information on the trial and 
took informed consent to participate in the trial and also the nested questionnaire study 
(described below). People with cognitive impairments were eligible to take part in the TH 
trial, as long as family or friends were able to assist them with operating the TH equipment. 
Because the TH systems had an interactional element (for instance users had to respond to 
short questions about their health), the project teams also checked that potential users had the 
English language literacy required (Bower et al. 2011). People who wished to participate 
were visited again to receive a TH/TC needs assessment.  
 
4.6 Trial Data Collection Procedures 
The data collected and analysed for the WSD telecare and telehealth trials was extracted from 
routine data sources and included hospital and primary care service use, mortality, and social 
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services such as residential and nursing home and domiciliary care (Steventon et al. 2013, 
Steventon et al. 2012). A small set of participant characteristics at baseline were derived from 
administrative sources. Index of Multiple Deprivation 2007 scores were assembled by the 
trial team from participants’ postcodes for use in analyses carried out within both the trial and 
questionnaire studies (see below). In addition, an index of the number of comorbidities was 
assembled based on a count of conditions diagnosed in the hospital episode statistics over 
three years prior to the trial. Reasons for withdrawal from the trial were also recorded by the 
trial team. 
 
4.7 Questionnaire Studies 
The questionnaire studies were nested within the parent TH and TC trials. The necessary total 
sample sizes for both questionnaire studies were powered to detect a small effect size of 0.3, 
given an intra-cluster correlation coefficient (ICC) of 0.05, with power of 80 per cent and 
p<0.05 (Newman and Whole System Demonstrator Programme Evaluation Team 2014). A 
required sample size of 550 telecare participants and 550 telehealth participants was 
estimated by inflating the planned numbers by 10 per cent to allow for possible increases 
related to varying-sized clusters. However, in order to reach the power needed for planned 
secondary LTC-specific subgroup analyses in each of the three long-term conditions, the 
Telehealth Questionnaire study aimed to attain a total sample size of 1650 telehealth 
participants (Newman and Whole System Demonstrator Programme Evaluation Team 2014). 
In addition the evaluation programme included a smaller-scale carers’ questionnaire study, 
which will be referred to herein as the ‘carers’ study’. The following sections report the 
methods employed within the questionnaire studies.  
 
4.7.1 Questionnaire Studies: Participant Eligibility, Selection and Recruitment 
Individuals who had been identified as eligible to take part in the telehealth and telecare trials 
were invited to participate in the nested questionnaire studies. Those assenting were 
subsequently contacted by trained interviewers from a market research company, who visited 
to take written consent for the study and administer the study instruments (Newman and 
Whole System Demonstrator Programme Evaluation Team 2014, Bower et al. 2011). People 
who had been assessed as having cognitive impairments prohibiting them from completing 
the outcome measures on their own were ineligible for the questionnaire studies, but eligible 
for the parent trials (Cartwright et al. 2013, Hirani et al. 2013).  
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4.7.2 Questionnaire Studies: Data Collection  
Questionnaire packs containing the Client Service Receipt Inventory (see 4.8.1) and other 
study instruments were administered by interview at baseline and posted to participants at 4- 
and 12-month follow-up. Participants who had not returned their questionnaire at 12 months 
were contacted to arrange an interview. 57 per cent of TH study questionnaires and 52 per 
cent of TC study questionnaires returned were completed by interview. Socio-demographic 
information about participants’ characteristics was collected at baseline and covered age, sex, 
educational attainment and ethnicity. Housing tenure and household living arrangements 
were covered by the CSRI and therefore collected at all three time points.  
 
4.8 Outcomes 
The choice of outcomes and instruments to measure outcomes was made by evaluators of 
both the outcomes and cost-effectiveness research streams, in planning the questionnaire 
study. While I contributed to the choice of instruments used for the economic evaluation, the 
process of adopting the instruments for use in the study was made by the wider evaluation 
team.  
Outcomes considered in the cost-effectiveness analyses reported in the thesis are 
presented in Section 4.16. The effectiveness analyses of the data from the Telehealth and 
Telecare questionnaire studies (Cartwright et al. 2013, Hirani et al. 2013) examined health-
related quality of life, anxiety and depressive symptoms.  
 
4.8.1 Outcome Measures – Instruments 
Both generic and condition-specific health outcomes for participants were measured in the 
studies. Generic health-related quality of life (HRQoL) measures included the EQ-5D 
(Brooks 1996), the SF-12 (Jenkinson et al. 1997) and the ICECAP-O (Coast, Flynn, 
Natarajan, et al. 2008). Psychological outcomes (depression and anxiety), self-care 
behaviours, self-efficacy and social networks were measured, as well as long-term condition-
specific quality of life measures (in the telehealth study only). Further information on all 
generic and condition-specific outcome measures used in the questionnaire studies can be 
found in other publications (Cartwright et al. 2013, Hirani et al. 2013, Newman and Whole 
System Demonstrator Programme Evaluation Team 2014). The following instruments were 
used to measure the outcomes examined in the cost-effectiveness analyses. 
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EQ-5D-3L (EuroQol Group 1990): The EQ-5D-3L is a generic preference-based 
measure of health (Brazier 2007). This 6-item instrument consists of the EQ-5D-3L 
descriptive system, which covers 5 dimensions of health-related quality of life (mobility, self-
care, usual activities, pain/discomfort, anxiety), and a Visual Analogue Scale on which 
participants rate their health at the current time. Each item of the descriptive system in this 
original version of the EQ-5D-3L has three levels (no problem, moderate/some problems, 
severe/unable to perform). The system can be used to create a utility score, a single index 
value for health status. The index (the York A1 tariff) was derived using societal weights: to 
create the weights, 42 health states were valued by a representative sample of the UK 
population using the time-trade off technique and a statistical model created to estimate 
valuations of all 243 possible health states (Dolan et al. 1995, Brooks 1996, Dolan 1997). The 
instrument is suitable for use with older populations (see (Haywood, Garratt, and Fitzpatrick 
2005, Hawton et al. 2011)). The NICE ‘reference case’ specifies the EQ-5D-3L as the 
preferred measure of health-related quality of life (National Institute for Health and Clinical 
Excellence 2008). 
ICECAP-O (Coast, Flynn, Natarajan, et al. 2008, Grewal et al. 2006): The ICECAP-O 
(ICEpop CAPability measure for Older people) is a measure of capability in people aged 65 
years and older. The descriptive system comprises five attributes of well-being: attachment, 
security, role, enjoyment and control. Population values (for people aged 65 years and over) 
for the attribute levels were estimated using best-worst scaling methods to construct a 
capability index. The index is “anchored” at 0, for no capability, and at 1, for full capability. 
The instrument was designed to be used for economic evaluations that span health and social 
care (Coast, Flynn, Sutton, et al. 2008).  
SF-12 (MCS-12 and PCS-12) (Jenkinson et al. 1997): Summary mental health and 
physical functioning scores (Mental Component Summary (MCS-12) and Physical 
Component Summary (PCS-12)) were constructed from the 12-Item Short-Form Health 
Survey (SF-12). Differences of 2 to 2.5 points on the SF-36 summary scores have been 
suggested as clinically meaningful (Ware et al. 2007); larger values for the SF-12 summary 
scores of 2.5 and 10 points have been estimated (Parker et al. 2012).  
SF-6D: 249 health states from the SF-6D descriptive system (derived from the SF-12), 
were valued using standard gamble technique by a sample representative of the UK 
population (the UK tariff) to produce a preference-based index (Brazier and Roberts 2004, 
Brazier 2007). 
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CESD-10 (Andresen et al. 1994): The short form Center for Epidemiologic Studies 
Depression scale (CESD-10) is a 10-item screening instrument for depression symptoms. The 
CESD-10 scale summary score ranges from 0 to 30 (where 0 is the lowest and 30 is the 
highest level of symptomatology). A difference of five points or more has been interpreted as 
clinically meaningful (i.e. showing depressed symptoms) (Steffens et al. 2002). 
Spielberger State-Trait Anxiety Inventory (Brief STAI) (Marteau and Bekker 1992): 
The six-item short form of the instrument measures “state anxiety” (feelings of anxiety at the 
current time) and has been widely used, including for people with diabetes (Park et al. 2008). 
Inventory scores range from 6-24 (where 6 is lowest and 24 is highest).  
CSRI (Beecham and Knapp 2001): The Client Services Receipt Inventory (CSRI) for 
this study collected comprehensive information from participants on their service use in the 
prior three months, living arrangements, employment status and welfare benefits. A carer 
module of the CSRI collected information (for use in the accompanying carers' study) on 
patterns of unpaid care and support provided by family and other carers.   
 
4.9 Economic Evaluation: Choice of Evaluative Approach  
Economic evaluators have, broadly speaking, a choice of two theoretical approaches to guide 
the methodology for assessing the costs and benefits of health care interventions. Cost-utility 
and cost-effectiveness analysis spring from the extra-welfarist or ‘decision-maker’s 
approach’, aimed at maximising health outcomes from a given budget (Brouwer and 
Koopmanschap 2000). Cost-benefit analysis involves measuring health gains and the costs of 
achieving those gains in monetary terms (Pauly 1995): this approach has its roots in welfare 
economics and aims to assess whether a new technology is worth the expenditure from a 
given budget (Buchanan and Wordsworth 2015, Drummond et al. 2015).  
 
4.9.1  Welfare economics, Welfarism and Extra-welfarism 
In welfare economics, individuals maximise their utility (thereby improving their welfare) by 
making choices that suit their own preferences (Drummond et al. 2015). The ‘welfarist’ 
approach dictates that social welfare is a function of individual utility alone (Culyer 1989). If 
there are gains for some individuals without losses for others (a Pareto improvement), welfare 
is improved and efficiency increased (Coast 2009, Brouwer et al. 2008). But there are 
obvious limitations to this approach since it offers no steer for policy makers allocating 
resources to public services, in deciding which group in society will benefit and which will 
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lose out (Drummond et al. 2015, Coast, Smith, and Lorgelly 2008). To allow comparisons 
between individuals, the compensation principle has been proposed: welfare improvement 
can still result if those who gain from the introduction of a new technology are able to 
compensate the losers and still be better off (a potential Pareto improvement) (Coast, Smith, 
and Lorgelly 2008, Drummond et al. 2015). The compensation test being met, resource 
transfers do not actually have to be paid for the innovation to be judged cost-beneficial (Pauly 
1995). Benefit is measured in terms of a person’s maximum willingness to pay for a new 
technology (whether a health or other technology); willingness to pay (in money terms) being 
the maximum amount of other goods/consumption opportunities the person would forgo to 
get that benefit (Drummond et al. 2015, Pauly 1995). If the total willingness to pay of all 
affected individuals outweighs the costs of supplying the technology, then it is welfare-
maximising and therefore efficient (Coast, Smith, and Lorgelly 2008, Brouwer and 
Koopmanschap 2000). Thus those gaining (getting the benefit, or outputs, of the technology) 
could pay compensation to the suppliers of inputs to the technology and still be better off  
(Pauly 1995). Measuring improvement requires the measurement of benefits (gains) and costs 
(losses) in terms of their (monetary) value to individuals. However, in situations where 
markets do not exist or do not function well, as may arise in the case of health services, 
valuing relevant outcomes is not straightforward and must be established by other means, 
typically by establishing how much people are willing to pay for these types of outcomes 
(Drummond et al. 2015).   
There are several possible objections to this approach. Welfare in the welfarist 
approach depends on a measure of individuals’ willingness to pay, which may be influenced 
by ability to pay, so allocation on this basis could be biased towards the better-off (Coast, 
Smith, and Lorgelly 2008). Preferences other than those of the affected individuals could be 
important to society if people perceive inherent merit in providing certain services (Brouwer 
et al. 2008). Importantly, decision making on what constitutes the social good may depend 
upon more than individuals’ welfare alone (Drummond et al. 2015). 
The extra-welfarist (or decision maker’s) approach proposes another way of 
determining the social welfare function. A decision maker delegated to make choices by 
society is provided with information on the valuation of individuals’ preferences, and the 
implications of the decision to choose a particular option. In extra-welfarism, the social 
welfare function may maximise individual characteristics, typically health (Drummond et al. 
2015). Brouwer et al. (2008) have summarised four key features of this approach. Evaluative 
outcome measures frequently involve health gain but others exist, such as well-being and 
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satisfaction with services. Valuation of costs and benefits can be undertaken by not only the 
individuals likely to be affected by the technology but also by representative samples of 
individuals, or societal decision makers. Weighting is often applied to outcomes in extra-
welfarism, for instance to reflect need. Lastly, interpersonal comparisons of evaluative 
outcomes are explicitly of interest in the extra-welfarist framework and the use of measures 
of health can facilitate such comparisons. 
The role of economic evaluation depends on the choice of methodological approach. 
From the welfarist perspective, the role is to determine whether a new technology is worth 
funding on the basis of social welfare maximisation. In the extra-welfarist framework, the 
role is “more modest, claiming to inform social decisions in health rather than prescribing 
social choice. […I]t exposes the policy implications of the social values implicit in existing 
policies and the resources allocated by those who claim some legitimacy to make such 
decisions.” (Drummond et al. 2015, p.37)   
Cost-effectiveness and cost-utility analytic approaches have increasingly dominated 
the practice of economic evaluation of health care programmes since the 1980s. This trend 
emerged as the demand for evaluations increased, the ability to measure health-related quality 
of life outcomes improved, and importantly, as numerous national health technology 
assessment (HTA) agencies (including NICE) adopted the extra-welfarist perspective 
(Buchanan and Wordsworth 2015, Coast, Smith, and Lorgelly 2008). Cost-benefit analytic 
approaches to evaluating health care technologies appear to have fallen out of favour for 
several reasons16. Drummond et al. (2015) suggest that governments have not been keen to 
distribute funding on the basis of preferences that might be skewed by existing inequalities in 
income distribution. Also, in the UK, monetary valuations of health are unpalatable to the 
general public (Coast, Smith, and Lorgelly 2008). The economic evaluation evidence base for 
telehealth described in Chapter 3 (cf. Polisena, Coyle, et al. 2009, Vergara Rojas and Gagnon 
2008, Bergmo 2009) rests on extra-welfarist foundations (the evidence from any formal cost-
effectiveness or cost-benefit analyses of telecare being scant). The choice to take a cost-
effectiveness and extra-welfarist approach to the economic evaluation of telehealth and 
telecare was straightforward in the current HTA context.  
                                                          
16 It has been argued, on the other hand, that other approaches than extra-welfarism (for instance examining 
capabilities) could be taken to evaluate certain kinds of health interventions. For example, interventions that 
cross sectors and government departments (for example such public health interventions as alcohol abuse or 
obesity prevention) may have non-health outcomes that could be measured within a different evaluative 
framework (Buchanan and Wordsworth 2015, Coast, Smith, and Lorgelly 2008).  
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4.10 Economic Evaluation of a Complex Intervention: Methodological Issues 
Evaluators considering the impacts of telemonitoring upon the use of health and social 
services face a number of challenges. The populations using these technologies may be very 
diverse; the technologies to be compared may be offered to populations that differ in terms of 
needs and expectations; the interventions are sensitive to local conditions, constraining 
generalisability and reliability; and furthermore the technologies themselves differ in terms of 
the responses that are required from their users and from the health and social care agencies 
that provide them (Bergmo 2009, Polisena, Coyle, et al. 2009).  
The types of challenges that Bergmo (2009) and Polisena (2009) identify will look 
familiar to evaluators of complex health and social care interventions. As Byford and Sefton 
(2003) suggest, studies of even quite standardised interventions may vary considerably in 
practice, given the skills and preferences of practitioners. A number of additional issues are 
likely to arise in evaluating complex interventions. Users of services may be a heterogeneous 
group. They may be highly involved in the production of care; the more active the user 
involvement, the more complicated the relationship between inputs and outputs. This is also a 
source of increased heterogeneity, with implications for the sample size required and number 
of user-related variables that should be controlled for. Some interventions, particularly social 
care and mental health services, may be deliberately flexible and complicated, tailored to the 
user, and covering several service areas, e.g. housing, day care and health. The goals of the 
intervention may be numerous and complicated. Finally, multiple agencies may be involved 
in delivering the intervention. The authors make an important point that measuring costs can 
be more difficult because the questionnaires may need to be long and broad in focus to try to 
capture a broad range of possible services; however this may limit the accuracy of self-report 
methods. While accuracy might be improved by electronic records, these may be limited to 
the use of services provided by the agency in question, so that the data from records of 
several agencies may be required. Valuation of the relevant costs is challenging as some 
services do not have national applicable unit costs readily available, and these must be 
directly calculated, which in turn requires more recording of more service components. The 
authors recommend that evaluators spend time at the design stage on understanding the 
components of the intervention in order to understand the mechanisms that influence 
outcomes and costs.  
Recent guidance on complex interventions (Craig et al. 2008) makes a number of 
similar observations, defining these interventions as containing multiple interacting 
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components, which can be complex in terms of the numbers of interactions between 
components, the number of required behaviours (on the part of the intervener or the 
recipient), the number of levels of organisation or groups involved, the number of outcomes 
and the extent of flexibility allowed the intervention. The guidance addresses the role of 
economic evaluations, advising researchers to use information about the additional cost of the 
intervention to calculate how much more effective the intervention would need to be to be 
cost-effective (however this does require the existence of such information in the first place). 
They also suggest that the intervention be clearly defined so that relevant resource use can be 
identified; that resource use and outcomes are recorded consistently across time points, as 
cost and effects might differ at different points; that the perspective be identified and 
preferably a societal viewpoint be used; and that using the QALY as the outcome measure 
should be considered. 
 
4.11 Economic Evaluation Methods  
In order to address the question of cost-effectiveness in a trial context, and from a local 
authority or NHS commissioning perspective, it is necessary to gather information on costs to 
health and social services. Johnston, Buxton et al. (1999) suggest that in terms of health 
service costs, there are “direct” costs relating to the intervention itself; costs of illness more 
generally; costs of future use of health services; and trial-specific costs. There are also costs 
outside of the commissioner’s perspective: these include costs to other public agencies 
immediately and in the future; to patients, service users and carers (travel, time lost in 
receiving treatment, productivity losses); and non-resource costs such as transfer payments 
(e.g. benefits). The following sections outline the data collection activities necessary to 
'identify, measure, value and compare the costs and consequences of the alternatives being 
considered', which are the basic tasks of economic evaluation (Drummond et al. 2015, p. 4, 
Drummond et al. 1999, p. 9). 
The cost-effectiveness analyses reported in this thesis took a NHS and local authority 
(LA) perspective. The analyses of costs and cost-effectiveness in the thesis are in the main 
focused on results at 12-month follow-up. The time horizon was limited to the trial period, 
and no discounting of costs or outcomes was undertaken.  
The data from the “short-term”, or 4-month follow-up assessments were of a poorer 
quality and in different sample sizes than those obtained at baseline and long-term follow-up 
assessment points. Whereas all of the baseline and more than half of the 12-month follow-up 
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questionnaires were administered by interviewers, all 4-month follow-up questionnaires were 
administered by post. The sample of participants returning data at this point did not entirely 
overlap with that returning data at 12-month follow-up (see 5.14). An example of the 
problems encountered with the short-term data collection involved a number of respondents 
opting to provide details of services they had used in the 'other' boxes on the CSRI, even 
when the option of reporting use of that particular service had been presented in a previous 
question. Such issues required making intensive scrutiny of individual forms and re-
classifying such “other” services where relevant. I undertook extensive checks and all 
cleaning of the CSRI-generated data. 
 
4.12 Health and Social Care Service Use and Costs 
Health and social care utilisation data were collected from trial participants on the CSRI as 
described in section 4.7.2. Unit costs were then attached to the units of services used to 
calculate per-participant costs. In the next sections, I describe the methods used to locate and 
assign unit costs. I then describe in more detail the methods I followed to calculate the costs 
of the intervention.  
 
4.13 Valuation Strategy for Self-reported Service Use 
Unit costs (in 2009/10 prices) were applied to units of self-reported service use. Unit costs 
applied are summarised in Table 4.1; a table of unit costs with detailed descriptions of their 
sources and calculations or assumptions made is given in Appendix 1. The majority of unit 
costs for social care, primary and community health care were sourced from Personal Social 
Services Research Unit Costs compendium (PSSRU UC) (2010); if unavailable from this 
source, costs were taken from other published sources. For instance, some equipment costs 
were located in the national catalogue and tariff for Simple Aids to Daily Living (Department 
of Health Care Services Efficiency Delivery Programme 2010). Unit costs for hospital 
services (accident and emergency (A&E), inpatient overnight and day case bed-days, and 
outpatient attendances) were taken from the National Schedule of Reference Costs 2009-10 
for NHS Trusts and PCTs Combined (2011).  
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Table 4.1 Unit costs summary 
 
Medications costs were obtained from the NHS Information Centre’s Prescription cost 
analysis (PCA) (Health and Social Care Information Centre 2011). All medications at each 
time point were examined and assigned a medication code. The medication data in the dataset 
were then assigned the corresponding code using a string search method, matching the 
reported name to a stub of between four and eight characters. A look-up table was developed 
including the price per unit, the medication unit (such as milligrams or micrograms) and the 
dosage. Where all information on medication, medication unit and dosage was known, the 
specific unit price from the PCA was matched to the reported medication. Where the 
medication dosage was not known, the medication was matched to an average weighted price 
for the medication and medication unit from the PCA. Where only the name of the 
medication was known, the medication reported was matched to an average weighted price 
for that medication from the PCA. 
In general the assumption was made that costs were borne by health and social care, 
including in cases where participants might make co-payments (e.g. use of services of 
dentists, chiropodists and opticians); however in the case of household adaptations and 
equipment for daily living, costs of those items reported to have been provided by 
participants or their relatives were excluded.  
Cost category  Unit  Unit cost (£, 2009-10) 
A&E  Attendance   103 - 133 
Inpatient care  Attendance  116 - 1657 
Day Hospital care  Bed-day  156 - 1496 
Outpatient appointments and procedures  Attendance  23 - 306 
Community health services/primary care  Visit  Range: 24-192 
Community health services/primary care  Contact  Range: 20.26-86.85 
Community health services/primary care  Minute  Range: 0.95-4 
Community mental health care  Minute  Range: 0.83-4.72 
Community care  Minute  Range: 0.42-0.92 
Equipment  Item  Range: 1.5 - 455 
Adaptations  Item  Range: 0.1-97.5 
Care home respite  Days  Range: 63.72-70.57 
Day care and other day services  Attendance  Range: 36-155.82 
Medications   
Standard 
Quantity Unit  
 Range: 0.01-419.62 
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In the cost-effectiveness analyses, the costs of service use over the three-month 
periods prior to the baseline and 12-month follow-up were calculated and then multiplied by 
four, giving annual equivalent costs for the pre-baseline year and the year over which the 
intervention was delivered.  
 
4.14 Intervention Costs 
In order to estimate ‘direct’ costs associated with any intervention services consumed during 
the trial (‘intervention costs’), I added a stream of work to the planned data collection to 
support the economic evaluation. This was to carry out a series of interviews with those 
responsible for implementing the interventions, in order to be able to describe the 
implementation of the interventions in all three sites (there were telecare and telehealth 
programmes in each site, requiring descriptions of six programmes altogether).  
This work was to describe the interventions, agencies, staffing and other resource 
inputs and understand the activities, production processes and mechanisms that may influence 
costs. Estimating the intervention costs involves four stages (cf. Allen and Beecham 1993, 
Beecham 2000): (i) describing the interventions in terms of their typical resource inputs and 
associated routine activities; (ii) calculating relevant service units; (iii) collecting cost data; 
(iv) calculating a unit cost for the intervention. The elements involved in the estimation of a 
unit cost of a telecare/telehealth package are summarised in Figure 4.2. The arrows show the 
direction of influence: resource inputs influence resource costs and vice versa; the way that 
resource inputs are used in the production process influences not only the quantities of the 
outputs but the scope and quality of the outputs. Finding a relevant service unit is necessary 
to construct a useful and meaningful unit cost, in this case an annual per-person cost of a 
telecare/telehealth package (Box 4.1). 
  
88 
 
Figure 4.2 Elements involved in estimating a unit cost of telehealth/telecare 
 
Box 4.1 Costing the telehealth and telecare interventions  
Source: Henderson, Beecham, and Knapp (2013) 
To develop an understanding of production inputs and processes, information was collected 
using a “bottom-up” approach, involving 19 interviews (by telephone or face-to-face) with 
key informants and drawing on correspondence with three on-site WSD project teams. A 
more “top-down” approach was taken to collecting cost and activity data on the delivery of 
the intervention, whereby a spreadsheet-based pro-forma was used to guide collection from 
the project teams. These bottom-up and top-down data were used to establish a unit cost, the 
direct annual per-person cost of a telecare or telehealth package. Unit costs were calculated 
based on 2009/10 service configurations (when most trial participants were recruited) in order 
to approximate the costs of running the services at the sites’ planned capacity, rather than in 
the 2008/09 start-up phase.  
The aim of the work was to establish the average costs of the interventions across the 
three sites. The ways in which telecare or telehealth services were delivered were determined 
locally and were not prescribed by the trial evaluation team.  
The first step to building a detailed picture of the services in each site was to 
understand the inputs and processes involved in producing the interventions, examining  
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Box 4.1 (continued) 
important features of the delivery systems put in place, in terms of equipment supply, systems 
and infrastructure enabling the appropriate equipment to operate (assessment, installation, 
servers, maintenance), and monitoring and response services interacting with participants 
through the telehealth/telecare technology.  
As a condition of the WSD trials, participants were not to be charged for telehealth or 
telecare equipment or support services. Participants were however expected to have telephone 
lines and power supplies for telecare; in the case of telehealth, participants in one site were 
expected to have a television set. Data transmission by participants was also provided free of 
charge to them. 
Telecare and telehealth equipment 
The sites’ project teams provided data on participants’ telecare/telehealth equipment, and the 
prices that had been paid for the equipment, for the evaluation. Equipment costs were 
calculated for each participant. While most of the equipment was purchased for the trial, 
telehealth base units and most peripherals were rented in one pilot site. In either case, the 
purchased base units were annuitised over 5 years (Department of Health 2001), while costs 
of purchased “peripherals” (alarms, sensors or items attached to the base unit, e.g. blood 
pressure monitors) were annuitised over the same period or over the peripheral’s lifetime if 
this information was available from sites or manufacturers' specifications. One site provided 
equipment rental charge information.  
Telehealth 
Telehealth users received a base unit, that could be either free-standing or a set-top box for a 
television, and ‘peripherals’ appropriate to their long-term condition. The latter consisted of 
cabled or bluetoothed pulse oximeters, blood-pressure cuffs, glucometers and weighing 
scales, which transmitted the observations data to the base unit. While a description of 
clinical processes and behavioural regimens associated with the telehealth intervention was 
not within the scope of this thesis, interested readers will find these details in Cartwright et al. 
(2013).  
Telecare 
Telecare users received equipment consisting of a telecare ‘base unit’ (Tunstall Lifeline 
Connect or Connect+), a pendant alarm and at least one other sensor or device.  
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Box 4.1 (continued) 
Up to 27 types of device were available for use by trial participants, for instance ‘key safes’, 
bed sensors, temperature extremes sensors, and fall detectors; amongst those participating in 
the WSD questionnaire study, participants received between one and 11 items. 
Costs of supporting the delivery of the interventions 
Methods for calculating support costs were similar across both interventions. Support 
personnel were assumed to comprise individuals working to monitor and respond to 
alarms/sensor alerts and to triggers flagged by algorithms in the telehealth software 
programmes; supervisors of these workers; and on-site WSD team managers, trainers and 
back-office staff. The cost calculations excluded posts/parts of posts that involved trial 
evaluation or recruitment. On-costs, administrative, premises and capital overheads of 
directly-provided workers were calculated based on the WSD teams’ information. Where 
sites could not provide details for calculation of administrative overheads, these were 
assumed to be 16 per cent of salary costs (Curtis 2010). Other relevant costs were: server 
maintenance, software licences, and costs of providing free-phone numbers and data 
transmission from base units to servers.  
Installation and maintenance costs were partly variable and partly fixed. One site had 
maintained a detailed breakdown of spending on these activities in 2009/10; these proportions 
of expenditure were applied to costs in the other sites where less detailed information was 
available. Fixed costs were spread over five years, the assumed lifetime of the base units, 
while the variable costs were taken to be incurred within 2009/10. Costs of installers, their 
associated overheads and of storage and transport of equipment were all taken into account. 
For telecare, the split between fixed and variable costs was 65 per cent and 35 per cent 
respectively, and for telehealth 90 per cent and 10 per cent respectively.  
Telecare monitoring services and dedicated response services were provided under 
contract and the assumption made that such contracts covered the providers’ costs. The costs 
of contracts in 2009/10 were divided by the number of trial participants in order to obtain an 
annual per-participant average cost.  
Telehealth monitoring services were calculated either top-down or bottom-up, 
depending on the components of the service. All sites had centralised monitoring call centre 
teams: the costs of these directly provided or contracted central teams were calculated in 
terms of annual expenditure on their staff in 2009/10 (included associated overheads).  
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Box 4.1 (continued) 
However two sites provided some monitoring services through local nursing teams 
(community matrons or specialist nurses): their costs were estimated from the bottom-up, 
counting their time spent in telehealth training and in monitoring the telehealth screen. The 
annual total monitoring costs were calculated by applying the relevant unit costs (based on 
WSD project team information on NHS pay bands and local nursing team staffing 
complements, and including on-costs and capital, indirect and direct overheads) to the total 
estimated monitoring time. This latter was based in turn on the average daily screen-
monitoring time (calculated using data provided by WSD project teams) of two minutes 
(Henderson et al. 2013). The costs of central and local monitoring were aggregated and 
divided by number of study participants monitored over the year, for an average annual per-
participant cost of monitoring.  
Mean annual telehealth and telecare support costs per participant (including 
monitoring, equipment infrastructure, installation and maintenance) were calculated and 
allocated to participants who had received the telehealth/telecare equipment. Because the 
support costs were estimated mostly top-down, these data did not vary between participants 
in the same site, although equipment cost data did vary between individual cases. In addition, 
variations of these total costs were calculated for use in future sensitivity analyses: annual 
costs for telehealth and telecare, excluding staff posts and contracts specifically related to 
WSD project management; and in the case of telecare only, the annual costs of support, 
excluding costs of the dedicated WSD telecare response services. 
  
4.15 Economic Analyses 
4.15.1 Intention-to-Treat and Per-protocol Populations 
Cost-effectiveness analyses were carried out for all randomised participants, adhering to the 
principle of intention-to-treat (ITT). If data for 12 months were available for a participant, 
they were included in the cost-effectiveness analyses (modified intention to treat). The cost-
effectiveness analyses were conducted using baseline and 12-month follow-up data (see 
section 4.11 for an explanation of the issues with the 4-month follow-up data). Participants’ 
data were analysed within the group to which they were originally allocated, within each trial. 
In-depth analyses of cost variations by subgroup of interest in the telehealth and telecare 
samples were both analysed by ITT. The intention-to-treat analysis is important to understand 
what the benefits of changing to a new treatment are generally and not only within those 
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adhering precisely to the intervention (Hollis and Campbell 1999). The per-protocol 
population reflected participants’ de facto allocations (for instance control participants who 
were provided with telehealth/telecare and intervention participants who declined their 
telehealth/telecare equipment but continued to participate in the questionnaire study).  
 
4.15.2 Sample Characteristics at Baseline 
Baseline characteristics of all samples are described for each experimental group in terms of 
means and standard deviations for continuous variables and in terms of percentages and 
number of observations for binary and categorical variables. Between-group raw differences 
are presented. In this thesis, conforming to CONSORT guidelines (Schulz, Altman, and 
Moher 2010, Moher et al. 2010), I have not presented tests for baseline differences in 
characteristics between experimental groups. Differences in the samples due to loss to 
follow-up have been compared within the group to which participants were allocated, and 
tested for differences using clustered t-tests for continuous variables and clustered chi-
squared tests for dichotomous variables (Donner and Klar 2000, Herrin 2012) where 
appropriate, or a z-test of proportions where the variable is not grouped by general practice 
cluster. 
 
4.16 Economic Evaluation Outcome Measures 
4.16.1 Primary Outcomes 
Cost per quality-adjusted life year was adopted as the primary outcome in both telehealth and 
telecare cost-effectiveness analyses. 
Quality-adjusted life years (QALY) were constructed by calculating the utility scores 
derived from the EQ-5D-3L using societal weights (Dolan et al. 1995, Brooks 1996). QALYs 
were calculated taking the 'area under the curve' with linear interpolation between the 
baseline and 12-month follow-up assessment scores.  
 
4.16.2 Secondary Outcomes 
Secondary outcomes examined were: psychological well-being (ICECAP-O), state-trait 
anxiety (Brief STAI), depression symptoms (CESD-10), and summary mental health and 
physical functioning scores (MCS-12) and (PCS-12) (examined in the telecare cost-
effectiveness analyses). The baseline standard deviations of the PCS-12 and MCS-12 
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measures (PCS-12 SD=9.0168 and MCS-12 SD=11.965) were multiplied by the effect size 
(Samsa et al. 1999), which had been set at 0.3 for the study HRQoL instruments as the 
smallest size of effect that was meaningful (Bower et al. 2011), to give differences (rounded 
to integer) of 3 and 4 points respectively. The Brief STAI scores were rescaled to between 0 
and 1, to indicate effectiveness in terms of, respectively, lowest and highest levels of anxiety. 
QALY were also constructed from the SF-6D index and QALYs calculated in the same 
manner as described in Section 4.16.1.  
In the case of telecare, psychological well-being, state-trait anxiety and summary 
mental health and physical status were examined in the cost-effectiveness analyses. For 
telehealth, cost-effectiveness analyses included psychological well-being, state-trait anxiety 
and depression symptoms.  
 
4.17 Descriptive Analyses and Cost Categories 
All descriptive analyses of the Telecare and Telehealth questionnaire study samples are 
presented in Chapter 5. Raw data on service use over the prior three months have been 
summarised, by trial and by experimental group in terms of the numbers and proportions of 
participants that used each service, and in terms of numbers of service units (reporting the 
means and standard errors). Intervention and control group imputed costs over the prior three 
months have been summarised in terms of their means and cluster-adjusted standard errors. 
Raw differences between groups in mean utilisation and mean costs are also presented.  
Descriptive statistics in Chapter 5 have been organised by cost-reporting categories, 
the agency to which costs are assumed to fall and resource use sub-categories, as given in 
Table 4.2. 
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Table 4.2 Cost reporting categories and sub-categories 
 
  
Cost category Agency Resource use 
Hospital services   
 NHS A&E attendance 
 NHS Inpatient bed days 
 NHS Day Hospital attendances 
 NHS Outpatient attendances 
Community health   
 NHS Paramedic  
 NHS Community matron  
 NHS Community or district nurse  
 NHS Practice nurse  
 NHS Night nurse  
 NHS Specialist nurse 
 NHS Physiotherapist or occupational 
therapist   NHS GP (home)  
 NHS Dentist  
 NHS Chiropodist  
 NHS Optician  
Community mental health   
 NHS Psychiatrist visit 
 NHS Mental health nurse visit 
 NHS Medications 
Community social care   
 Local Authority Social worker visit 
 Local Authority Council home help visit 
 Local Authority Private/independent home care/home 
help visit  Local Authority Paid night carer visit 
 Local Authority Meals on Wheels meal 
 Local Authority Laundry (incontinence) service 
 Local Authority Community alarm* 
 Local Authority Long-term care/respite stays 
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*For the participants in receipt of a telecare package (per-protocol allocation), community 
alarm costs were excluded from all follow-up cost calculations to avoid double-counting with 
the cost of the intervention. For examination of variations in social service costs (excluding 
intervention costs) in the telecare sample (Chapter 6), receipt of community alarms was 
excluded from cost calculations. This exclusion was necessary to avoid confounding receipt 
of social services as an indirect result of the intervention with the direct result of allocation to 
the intervention.  
 
4.18 Costs and Cost-effectiveness Analyses 
I used analytical methods appropriate to the cluster-randomised nature of the trial, to avoid 
biasing the standard errors of the regression coefficients (Bartholomew et al. 2008); hence 
preventing errors in inference and inefficient parameter estimates (Manca et al. 2005). My 
approach varied depending on the objectives of the analysis and necessarily balanced the 
requirements of the analysis against the time available for analysis, the capabilities of the 
software packages to which I had access and my ability to use them appropriately.  
 
4.19 Multivariate Analyses of Service Use and Costs Data  
To address research sub-question 3, “what patient/user characteristics are associated with cost 
variations?” I undertook in-depth explorations of variations in the costs of the study 
participants.  
 
4.19.1  Variations in Costs of Telehealth and Telecare: Subgroup Analyses 
In other parts of the thesis, I compare the costs of intervention and control participants. 
However in chapter 6, I drill down beyond the pooled analyses to explore whether:  
Cost category Agency Resource use 
Equipment   
 Local Authority Equipment items 
 NHS Equipment items 
Adaptations   
 Local Authority Adaptations items 
 NHS Adaptations items 
Day care   
 Local Authority Day care and other day services 
 NHS Day care and other day services 
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1) the three-month costs of participants allocated to telehealth or usual care differed 
between baseline and long-term follow-up time points, depending on their index long-
term condition (diabetes, COPD or heart failure); and  
2) the three-month costs of participants allocated to telecare or usual care differed 
between baseline and long-term follow-up time points, depending on their living 
arrangements (living alone or with others). 
Costs were examined at different levels of aggregation: total health and social care costs 
(including and excluding the costs of the intervention), and agency-specific costs. Thus all 
NHS costs were considered (including all items in the following cost categories in Table 4.2: 
hospital, community health and mental health, NHS day services, equipment and 
adaptations). Hospital costs were also examined separately. Social care costs included all 
items in the following cost categories in Table 4.2: community social care (except community 
alarms in the case of the Telecare costs analyses), local authority day services, equipment and 
adaptations.  
In the following sections I first describe the motivation for my choice of modelling 
approach; I then describe the multilevel models and underlying assumptions, specifying 
equations generically to cover both telehealth and telecare analysis strategies (in Chapter 6, I 
set out equations covering the telehealth- and telecare-specific models); lastly I describe the 
dependent and independent variables of interest.  
 
4.19.2 Econometric Modelling Approach 
I adopted a multilevel framework for modelling health and social care costs. This approach 
met the requirements of the cluster-randomised data structure, with the flexibility to reflect 
within-subject differences in three-month costs between the baseline and 12-month follow-
up. In this framework, at the third level, data were clustered by general practice; at the second 
level (subject-level), data were clustered by participant; the first level consisted of cost 
observations at each time point (two observations per participant).  
There are several approaches to the issue of clustering effects, depending on whether 
the clustering unit is of interest to the analyst, or merely a nuisance factor. From either 
perspective, the analysis must take account of clustering in order to avoid downwardly 
biasing the standard errors of model estimates (Bartholomew et al. 2008). Exploring the 
influence of clustering can yield valuable information about the interaction between and 
within clusters simultaneously. The relationship between an outcome of interest and the 
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characteristics of cluster members is not necessarily the same at the cluster level. For 
instance, wards in a hospital may have different outcomes depending on their characteristics, 
while hospital-level outcomes and hospital-level characteristics may also be related, but not 
in the same way. Perhaps some hospitals are more likely to have lower infection rates 
because of other hospital-level characteristics (e.g. leadership, staff relations, geographical 
location), even if individual wards have high infection rates because of certain characteristics 
(staff relations, infection-control procedures, medical specialty) at the ward-level. 
Aggregating data to the hospital level could sacrifice a great deal of information on the 
degree of variation in infection rates within the hospitals and lead to inappropriate inferences. 
A two-level model could be used in this instance to examine hospital-level (level-two or 
cluster-level) and ward-level (level-one) infection rates.  
Turning to a more general discussion, we might want to know (i) the degree to which 
the clusters’ means vary around the overall (or population) mean of the response variable; 
and also (ii) to what extent the units within clusters vary around the cluster means. I have 
drawn on the work of Bartholomew, Steele et al. (2008) and Rabe-Hesketh and Skrondal 
(2012) in the following illustration. A simple linear regression model with no covariates, 
ignoring clustering, might be: 
where 𝑦𝑖 is the response of unit i, 𝛽0 is the population mean, and 𝑒𝑖 is the distance 
between the population mean and the value of y for unit i (otherwise known as the 
‘residual’or ‘error’). Extending this to consider cluster membership, we could instead write 
where 𝑦𝑖𝑗 is the response of unit i in cluster j and the overall mean is 𝛽. We have 
modelled the two-level structure by partitioning the residual, or variance, into two 
components. The departure of cluster j from 𝛽 is known as its ‘random effect’, 𝑢𝑗 , which has 
between-cluster variance 𝜎𝑢
2, uncorrelated across clusters; the departure of unit i from the 
cluster mean, 𝑒𝑖𝑗 , has a constant within-cluster variance 𝜎𝑒
2. Residuals follow normal 
distributions: 
𝑢𝑗 ∼ 𝑁(0, 𝜎𝑢
2) 
𝑒𝑗 ∼ 𝑁(0, 𝜎𝑒
2) 
 
 𝑦𝑖 = 𝛽0 + 𝑒𝑖 ,  (4.1) 
 𝑦𝑖𝑗 = 𝛽 + 𝑢𝑗 + 𝑒𝑖𝑗  , (4.2) 
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This ‘mixed effects’ model has a fixed part containing the covariates (𝛽 in this case) 
and a random part (𝑢𝑗  and 𝑒𝑖𝑗here). The fixed part (or mean structure) describes the 
population-averaged relationship between the response and predictor variables (Rabe-
Hesketh and Skrondal 2012). 
 
 Extending the constant-only model above, the response of a normally distributed 
outcome variable to a single covariate 𝑥𝑖𝑗 is  
In this case, the relationship between the response variable and the covariate is 
described by a straight line with constant 𝛽1 and slope 𝛽2. The cluster j intercept 𝛽1 + 𝑢𝑗 
represents the deviation from the overall mean by 𝑢𝑗  (Bartholomew et al. 2008). In this linear 
case, the mean of the response variable, 𝑦𝑖𝑗  , is a linear function of the covariate. Equations 
(4.2) and (4.3) describe linear multilevel models.  
Adopting now a multilevel generalised linear modelling approach, there are three 
model components to be described (Rodrıguez 2008, Hox 2010):  
1. an outcome variable y with a specific error distribution and mean 𝜇 and 
variance 𝜎2 
2. a linear equation producing a latent predictor 𝜂 for the expected value 𝜇 of 
outcome variable y  
3. a link function g describing the relationship between this expectation, 𝜇, and 
predicted values or transformed mean 𝜂, where 𝜂 = 𝑔(𝜇). 
 
Equation (4.3) can thus be re-written as a multilevel generalised linear model: 
  
𝑔 (𝜇𝑖𝑗) = 𝜂𝑖𝑗 = 𝛽1 + 𝛽2𝑥𝑖𝑗 + 𝑢𝑗 , 
 
where the conditional mean 𝜇 depends on the random effect 𝑢𝑗and a covariate 𝑥𝑖𝑗 so 
that the outcome is independent and follows the linear equation (Rodrıguez 2008).  
In this multilevel generalised linear framework, the conditional outcome distribution 
is now assumed to be exponential, rather than linear (Rodrıguez 2008), as would be the case 
in the general linear multilevel model. If the errors are normally distributed and the link 
function is identity, we have 𝜇𝑖𝑗 = 𝜂𝑖𝑗 , as in the general linear case (Hox 2010). In this case, 
the mean of the response is modelled on the same scale as the covariates (Baldwin, 
 𝑦𝑖𝑗 = 𝛽1 + 𝛽2𝑥𝑖𝑗 + 𝑢𝑗 + 𝑒𝑖𝑗 . 
(4.3) 
  
99 
 
Fellingham, and Baldwin 2016). Where the outcome variable is not expected to be normally 
distributed, non-linear approaches are required to appropriately model the relationship 
between the conditional mean of response variable and covariates. Non-linear models are 
discussed in the following section. 
The multilevel models so far described explicitly partition the residual variation of the 
response variable from the population mean according to the source (level 1 or level 2). The 
approach can be useful in examining variability in the costs of a particular participant 
receiving telehealth, given that person’s characteristics. These hierarchical models have come 
into more common use within health economics in recent years in studies examining costs 
across regions, countries and centres (Thompson, Nixon, and Grieve 2006, Vazquez-Polo et 
al. 2005, Manca, Hawkins, and Sculpher 2005). On the other hand, if we are only interested 
in the response at the ‘population’ level – for instance to examine how participants differ in 
response to particular factors, such as allocation to a telehealth intervention, we might choose 
a ‘marginal’ or ‘population-averaged’ approach.  While population-averaged and subject-
specific (or conditional) coefficients will be similar in the linear model, even if the 
interpretation is different (Baldwin, Fellingham, and Baldwin 2016), they will not be the 
same in the non-linear case, as discussed in section 4.19.5.  
 
4.19.3 Three-level Model Specification 
Three-level ‘null’ linear model with Gaussian distribution and identity link: In the 
simplest case, we consider a linear, multilevel random-intercept cost model: 𝑦𝑖𝑗𝑘 denotes cost 
at occasion 𝑖 (𝑖 = 1,2) for person 𝑗 (𝑗 = 1, … . , 𝑛) in general practice cluster (𝑘 = 1, … , 𝑛). A 
random intercept model without covariates can be written as: 
 
where 𝛽 represents the overall mean, 𝜇𝑗𝑘
(2)
 is random intercept for subject 𝑗 and cluster 
𝑘 and 𝜇𝑘
(3) is the random intercept for cluster 𝑘. The GP-level and participant-level random 
intercepts are assumed to have means of zero and variances of 𝜎𝜇
2(3) and 𝜎𝜇
2(2) respectively, 
and the time-level error term, a mean of zero and variance 𝜀𝑖𝑗𝑘 (Rabe-Hesketh and Skrondal 
2012). In this model, participants in each allocation group (practice-level clusters allocated to 
either intervention or control) have the same trajectory of costs over the two time points.  
 𝑦𝑖𝑗𝑘 = 𝛽 + 𝑢𝑗𝑘
(2)
+ 𝑢𝑘
(3)
+ 𝑒𝑖𝑗𝑘 (4.4) 
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 Three-level ‘null’ linear model with gamma distribution and log-link: Health and 
social expenditure data might be expected to follow a non-normal distribution. Some people 
receiving services may have very low (or no) costs but a few will have very considerable 
costs. To accommodate the zero-truncated and right skewed data, we can modify the model to 
fit these to a gamma distribution with mean 𝜇 and variance 𝜎2, and log-link (Thompson, 
Nixon, and Grieve 2006, Rabe-Hesketh, Toulopoulou, and Murray 2001, Manning, Basu, and 
Mullahy 2005, Liu et al. 2010) and write the model as: 
  
where 𝜇𝑖𝑗𝑘, = 𝐸(𝑦𝑖𝑗𝑘| x𝑖𝑗𝑘, 𝑢𝑗𝑘
(2), 𝑢𝑘
(3)
).  
Three-level linear model with covariates: The aim of the analyses was to examine the 
difference in baseline and 12-month follow-up costs between treatment groups in terms of the 
subgroups (e.g. living arrangements; long-term conditions). This requires an extension to the 
model to allow the calculation of these differences, taking a difference-in-difference-in-
difference (DDD) approach (Das and Smith 2012). The approach is useful for examining 
effects of changes over time between groups, removing the influence of unobserved 
differences between the groups, provided that these do not vary with time (Cameron and 
Trivedi 2005). The approach has been taken in numerous observational and randomised 
controlled studies (Ikenwilo 2013, Bardsley, Steventon, and Doll 2013, Jacobs and Barrenho 
2011). The model is extended to include interaction terms for the subgroup of interest and 
treatment allocation, for time point and subgroup, and for the triple interaction of time point, 
subgroup and treatment allocation, as follows:  
where Subgroup stands for the subgroup of interest, Treat for treatment allocation and 
Time for time point. Also, 
 𝑦𝑖𝑗𝑘| x𝑖𝑗𝑘, 𝑢𝑗𝑘
(2), 𝑢𝑘
(3)~𝐺𝑎𝑚𝑚𝑎(𝜇𝑖𝑗𝑘,𝜎
2),  log (𝜇𝑖𝑗𝑘) = 𝛽 + 𝑢𝑗𝑘
(2) + 𝑢𝑘
(3), (4.5) 
 𝑦𝑖𝑗𝑘| x𝑖𝑗𝑘, 𝑢𝑗𝑘
(2), 𝑢𝑘
(3)~𝐺𝑎𝑚𝑚𝑎(𝜇𝑖𝑗𝑘,𝜎
2),  log (𝜇𝑖𝑗𝑘)
= 𝛽1 + 𝛽2𝑇𝑟𝑒𝑎𝑡𝑘 + 𝛽3𝑇𝑖𝑚𝑒𝑖𝑗𝑘 + 𝛽4𝑇𝑟𝑒𝑎𝑡𝑘𝑇𝑖𝑚𝑒𝑖𝑗𝑘 
+ 𝛽5𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗𝑘 + 𝛽6𝑇𝑟𝑒𝑎𝑡𝑘𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗𝑘
+ 𝛽7𝑇𝑖𝑚𝑒𝑘𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗𝑘 + 𝛽8𝑇𝑟𝑒𝑎𝑡𝑘𝑇𝑖𝑚𝑒𝑖𝑗𝑘𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗𝑘
+ 𝑢𝑗𝑘
(2) + 𝑢𝑘
(3), 
(4.6) 
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 𝑢𝑘
(3)
~𝑁 (0, 𝜎𝑢
2(3)) , 𝑢𝑘
(2)
~𝑁 (0, 𝜎𝑢
2(2)) 
cov(𝑢𝑗𝑘
(2), 𝑢𝑘
(3)) = 0 
 
  
In other words, GP and participant-level random intercepts are assumed to have 
means of zero and variances of 𝜎𝑢
2(3) and 𝜎𝑢
2(2) respectively, given the model covariates. The 
level 2 and 3 random effects are assumed to be independent. 
In this multiplicative model, the exponentiated coefficient on time (exp(𝛽3)) must be 
interpreted as a ratio of costs between the baseline and follow-up points within participants 
(Thompson, Nixon, and Grieve 2006). The coefficient of interest is on the triple interaction 
term 𝛽8 which represents the effect on costs in the intervention period of participants who 
were randomised to the intervention and who were in one of the subgroups. In the case where 
there are two subgroups, this can be understood as (Wooldridge 2008): 
 𝛽8 = [(𝑦𝑇,𝐴,2 − 𝑦𝑇,𝐴,1) − (𝑦𝑇,𝐵,2 − 𝑦𝑇,𝐵,1)] − [(𝑦𝐶,𝐴,2 − 𝑦𝐶,𝐴,1) − (𝑦𝐶,𝐵,2 − 𝑦𝐶,𝐵,1)] 
where 𝑦 denotes conditional mean costs, T denotes intervention group, C control 
group, A is subgroup A, B is subgroup B, 1 denotes time 1 and 2 denotes time 2. The 
response of the outcome is conditional on both the covariate and the random effects for 
participants and general practice cluster.   
 
 Finally, h covariates 𝑧𝑖𝑗𝑘 can be added to the model.  
 
 
4.19.4 Two-level Model Specification 
If the general practice unit has little or no effect on the outcome, there will be little or no 
deviation from the overall mean in response to each model covariate (an ICC for general 
practice cluster of near-zero or zero). If so it would be reasonable to ignore GP-level 
  𝑦𝑖𝑗𝑘| x𝑖𝑗𝑘, 𝑢𝑗𝑘
(2), 𝑢𝑘
(3)~𝐺𝑎𝑚𝑚𝑎(𝜇𝑖𝑗𝑘,𝜎
2),  log (𝜇𝑖𝑗𝑘)
= 𝛽1 + 𝛽2𝑇𝑟𝑒𝑎𝑡𝑘 + 𝛽3𝑇𝑖𝑚𝑒𝑖𝑗𝑘 + 𝛽4𝑇𝑟𝑒𝑎𝑡𝑘𝑇𝑖𝑚𝑒𝑖𝑗𝑘
+ 𝛽5𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗𝑘 + 𝛽6𝑇𝑟𝑒𝑎𝑡𝑘𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗𝑘
+ 𝛽7𝑇𝑖𝑚𝑒𝑘𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗𝑘 
+ 𝛽8𝑇𝑟𝑒𝑎𝑡𝑘𝑇𝑖𝑚𝑒𝑖𝑗𝑘𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗𝑘 + ∑ 𝛽ℎ
ℎ
𝑧𝑖𝑗𝑘 + 𝑢𝑗𝑘
(2)
+ 𝑢𝑘
(3), 
(4.7) 
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clustering in modelling the cost variations data. In this case, the treatment is effectively 
considered to be allocated at the participant level. A two-level random-intercept model with 
covariates is written:  
  
 
4.19.5 Telecare and Telehealth: Population-averaged Model Specification 
So far I have set out costs models that are subject-specific (also known as unit-specific and 
conditional models). However, as discussed in 4.19.2, another approach to clustering can be 
taken. In the ‘marginal’ or ‘population-averaged’ approach, we are interested in the marginal 
expectation of the response variable (Zeger, Liang, and Albert 1988): 𝜇𝑖𝑗, = 𝐸(𝑦𝑖𝑗). The link 
function describes the relationship between 𝜇𝑖𝑗 and covariates 𝑧𝑖𝑗; the variance of 𝑦𝑖𝑗 is a 
variance function g multiplied by a scale parameter 𝜙, or formally 
var(𝑦𝑖𝑗) = 𝑔(𝜇𝑖𝑗) ⋅ 𝜙 . 
Marginal approaches, for instance Generalised Estimating Equations (GEE), account 
for dependency between responses within a cluster (intra-cluster correlation) on covariates by 
specifying an appropriate working correlation matrix (Zorn 2001). This working correlation 
“is assumed to be the same for all subjects, reflecting average dependence among the 
repeated observations over subjects” (Hu et al. 1998, p.695).  
 𝑦𝑖𝑗| x𝑖𝑗, 𝑢𝑗 ~𝐺𝑎𝑚𝑚𝑎(𝜇𝑖𝑗,𝜎
2),  log (𝜇𝑖𝑗)
= 𝛽1 + 𝛽2𝑇𝑟𝑒𝑎𝑡𝑗 + 𝛽3𝑇𝑖𝑚𝑒𝑖𝑗 + 𝛽4𝑇𝑟𝑒𝑎𝑡𝑗𝑇𝑖𝑚𝑒𝑖𝑗
+ 𝛽5𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗 + 𝛽6𝑇𝑟𝑒𝑎𝑡𝑗𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗
+ 𝛽7𝑇𝑖𝑚𝑒𝑖𝑗𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗 + 𝛽8𝑇𝑟𝑒𝑎𝑡𝑗𝑇𝑖𝑚𝑒𝑖𝑗𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗
+ ∑ 𝛽ℎ
ℎ
𝑧𝑖𝑗𝑘 +  𝑢𝑗 , 
(4.8) 
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A population-averaged model with covariates can be written as (the coefficients have 
been subscripted as 𝛽PA to denote that these are parameters of a population averaged model): 
 
In the unit-specific model described in equation (4.3), 𝛽2 can be interpreted as the response in 
outcome 𝑦𝑖𝑗  to a change in covariate 𝑥𝑖𝑗 for a particular individual i, being the effect of 𝑥𝑖𝑗 for 
an observation having the same random effect 𝑢𝑗  . In the population-averaged model, the 
interpretation of 𝛽2PA𝑗  is very different, being the average effect of a change in covariate 𝑥𝑖𝑗 
across the population on the response in outcome 𝑦𝑖𝑗 (Zorn 2001, p. 474). 
Thus the subject-specific approach has the benefit of explicitly modelling how 
clustered observations such as repeated measurements are correlated. However the 
population-average approach is useful for examining how groups differ in response to a 
change in the covariate(s). In linear models, estimates from either approach would be similar; 
however in models where the linear model is estimated through a non-linear link function 
(such as the natural log) this is no longer the case. The random effects and coefficients in 
equation (4.5) are on the log scale. When re-transforming logged expectations of the mean 
response conditional not only on the model covariates but also the random effects, through 
the application of the exponent, then a random effect will have a mean of 1 rather than 0 (see 
assumptions for the distribution of random effects above). Thus it is non-ignorable when 
interpreting the estimate coefficients (Baldwin, Fellingham, and Baldwin 2016, Heagerty and 
Kurland 2001, Rabe-Hesketh and Skrondal 2012). 
 
4.19.6 Marginal Effects  
I explored the marginal effects of treatment allocation on expenditure at baseline and follow-
up by index condition (telehealth) or living arrangement (telecare) in the models (which in 
each case included the DDD interaction term for index condition or living arrangement, time 
and allocation). Measuring marginal effects is to measure the change in the conditional mean 
 𝑦𝑖𝑗| x𝑖𝑗~𝐺𝑎𝑚𝑚𝑎(𝜇𝑖𝑗,𝜌𝑗),  log (𝜇𝑖𝑗)
= 𝛽PA1 + 𝛽PA2𝑇𝑟𝑒𝑎𝑡𝑗 + 𝛽PA3𝑇𝑖𝑚𝑒𝑖𝑗 + 𝛽PA4𝑇𝑟𝑒𝑎𝑡𝑗𝑇𝑖𝑚𝑒𝑖𝑗
+ 𝛽PA5𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗 + 𝛽PA6𝑇𝑟𝑒𝑎𝑡𝑗𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗
+ 𝛽PA7𝑇𝑖𝑚𝑒𝑗𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗 + 𝛽PA8𝑇𝑟𝑒𝑎𝑡𝑗𝑇𝑖𝑚𝑒𝑖𝑗𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗
+ ∑ 𝛽𝑃𝐴ℎ
ℎ
𝑧𝑖𝑗 
(4.9) 
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of a dependent variable when an independent variable changes by a unit (Cameron & Trivedi, 
2005). Marginal effects were calculated at the average response of all cases (average 
marginal effects, or AME). As implemented in Stata software, standard errors of the AME 
conditional on covariates were calculated using the delta method (StataCorp 2015b). In the 
two-part population-averaged models (estimated by generalised estimating equations) (see 
below), marginal effects of gamma and logistic regressions were estimated by bootstrapping 
together their recycled predictions, clustering on subject.  
 
4.19.7 Two-part Models 
A two-part approach was employed to substantiate inferences about social and hospital care 
costs, given substantial zero costs for these service categories. Such data can be viewed as 
being semi-continuous or having a mixture of distributions (Liu et al. 2010). Leaving aside 
considerations of clustering for now, the first part of the two-part approach (Cameron and 
Trivedi 2005) consists of a model of binary probability of ‘participation’, so that the outcome 
(d) is observed only for participants, the outcome for non-participants being zero. In the 
second part, the conditional density of the dependent variable for participants (y>0), is 
𝑓(𝑦|𝑑 = 1) for a given density 𝑓(∙). This mixture model can be stated as 
 
𝑓(𝑦|x) = {
Pr[𝑑 = 0|x]                                    if 𝑦 = 0,
Pr[𝑑 = 1|x] 𝑓(𝑦|𝑑 = 1,x)         if 𝑦 > 0.
 
(4.10) 
The two-part model allows the mechanisms driving the zero (first) and non-zero (second) 
parts to differ (Cameron and Trivedi 2005 p.544): in the present case, the reason for receipt or 
non-receipt of a service does not have to be the mechanism driving the quantity of service 
consumed. 
The model is estimated by maximum likelihood. The first part may be modelled as a 
probit or logit regression; the second part fits the data to a positive values-only distribution 
such as the log-normal (Duan et al. 1983) or gamma. Modelling costs with the gamma 
distribution has several useful properties. The response variable does not require 
transformation, as in the log-normal model. Retransformation of the logged response variable 
in the presence of heteroscedastically distributed errors can lead to biased estimates (Mullahy 
1998). Exponentiating the coefficients of a log-normal model also produces geometric mean 
estimates rather than the arithmetic mean estimates of the log-gamma model (Baldwin, 
Fellingham, and Baldwin 2016).  
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While it is possible that the reason for receipt and the quantity consumed if received 
may not be linked, in the context of a within-cluster and within-subject framework, the 
assumption appears strong (Liu et al. 2010). Multilevel two-part models have been proposed 
in more recent years that make use of the generalised gamma distribution in the second part 
that allow for correlation between the random effects of the first and second part, or “cross-
part” correlation (Liu et al. 2010, Lee et al. 2010, Baldwin, Fellingham, and Baldwin 2016). 
If the outcomes of the first and second parts are correlated but their covariance is assumed to 
be zero, this can bias the second part estimates (Lee et al. 2010). While the equation for the 
second-part models has already been described (equation (4.1), the first-part subject-specific 
model of receiving care services can be written as a generalised linear multilevel model 
(GLMM) (in the three-level case) (cf. Rabe-Hesketh and Skrondal 2012): 
 𝑦𝑖𝑗𝑘|𝜋𝑖𝑗𝑘~Binomial(1, 𝜋𝑖𝑗𝑘),  logit (π𝑖𝑗𝑘)
=  𝛽1 + 𝛽2𝑇𝑟𝑒𝑎𝑡𝑘 + 𝛽3𝑇𝑖𝑚𝑒𝑖𝑗𝑘 + 𝛽4𝑇𝑟𝑒𝑎𝑡𝑘𝑇𝑖𝑚𝑒𝑖𝑗𝑘
+ 𝛽5𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗𝑘 + 𝛽6𝑇𝑟𝑒𝑎𝑡𝑘𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗𝑘
+ 𝛽7𝑇𝑖𝑚𝑒𝑘𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗𝑘 + 𝛽8𝑇𝑟𝑒𝑎𝑡𝑘𝑇𝑖𝑚𝑒𝑖𝑗𝑘𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗𝑘
+ 𝑢𝑗𝑘
(2) + 𝑢𝑘
(3)
 
 
(4.11) 
where 𝜋𝑖𝑗𝑘 ≡ Pr (𝑦𝑖𝑗𝑘 = 1|x𝑖𝑗𝑘 , 𝑢𝑗𝑘
(2), 𝑢𝑘
(3)). 
And in the two-level case: 
 𝑦𝑖𝑗|𝜋𝑖𝑗~Binomial(1, 𝜋𝑖𝑗𝑘),  logit (π𝑖𝑗) =  𝛽1 + 𝛽2𝑇𝑟𝑒𝑎𝑡𝑗 + 𝛽3𝑇𝑖𝑚𝑒𝑖𝑗 +
𝛽4𝑇𝑟𝑒𝑎𝑡𝑗𝑇𝑖𝑚𝑒𝑖𝑗 + 𝛽5𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗 + 𝛽6𝑇𝑟𝑒𝑎𝑡𝑗𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗 +
𝛽7𝑇𝑖𝑚𝑒𝑖𝑗𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗 + 𝛽8𝑇𝑟𝑒𝑎𝑡𝑗𝑇𝑖𝑚𝑒𝑖𝑗𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗 + 𝑢𝑗 , 
(4.12) 
where 𝜋𝑖𝑗 ≡ Pr(𝑦𝑖𝑗 = 1|x𝑖𝑗 , 𝑢𝑗 ). 
The random effects are assumed to be independent across clusters, and the responses have a 
Bernoulli distribution.  
The population-averaged case is as equation (4.12) but 𝜋𝑖𝑗 ≡ Pr (𝑦𝑖𝑗 = 1|x𝑖𝑗 ). 
 𝑦𝑖𝑗|𝜋𝑖𝑗~Binomial(1, 𝜋𝑖𝑗𝑘),  logit (π𝑖𝑗) =  𝛽1 + 𝛽2𝑇𝑟𝑒𝑎𝑡𝑗 + 𝛽3𝑇𝑖𝑚𝑒𝑖𝑗 +
𝛽4𝑇𝑟𝑒𝑎𝑡𝑗𝑇𝑖𝑚𝑒𝑖𝑗 + 𝛽5𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗 + 𝛽6𝑇𝑟𝑒𝑎𝑡𝑗𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗 +
𝛽7𝑇𝑖𝑚𝑒𝑖𝑗𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗 + 𝛽8𝑇𝑟𝑒𝑎𝑡𝑗𝑇𝑖𝑚𝑒𝑖𝑗𝑆𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑗, 
(4.13) 
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As previously explained, random-effects logistic models will have a subject-specific 
interpretation, as the log-odds of receipt will be conditional on not only the covariates but 
also the random effects in the model. However for binary response variables, marginal 
probabilities estimated from subject-specific models (by integrating over the random 
intercept distribution) will be similar to those estimated from population-averaged models 
(Hu et al. 1998, Fieberg et al. 2009). In the case of logistic-normal models, it is also possible 
to approximate the population averaged estimate of a coefficient of a conditional model by 
applying the formula (Hu et al. 1998, Zeger, Liang, and Albert 1988): 
𝛽𝑃𝐴 ≃ 𝛽𝑆𝑆/√1 + 0.346𝜎𝑢2 . 
An attractive feature of the subject-specific multilevel two-part model is the ability to 
estimate the correlation between the first and second parts of the model. Thus it is possible to 
examine the extent to which the likelihood of receipt is related to the cost of the services 
consumed. More formally, in the three-level case, the random effects of the first (𝑢1𝑗) and 
second parts (𝑢2𝑗) are assumed to have a multivariate normal distribution with a vector of 
zero means and variance/covariance matrix (Baldwin, Fellingham, and Baldwin 2016, Lee et 
al. 2010): 
[
𝑢1
(3)
𝑢2
(3)] ∼ MVN(0, Σ3) ∑ =
3
[
𝜎
𝑢1
(3)
2
𝜎
𝑢1
(3)𝜎
𝑢2
(2) 𝜎
𝑢2
(3)
2 ] 
 
[
𝑢1
(2)
𝑢2
(2)] ∼ MVN(0, Σ2) ∑ =
2
[
𝜎
𝑢1
(2)
2
𝜎
𝑢1
(2)𝜎
𝑢2
(2) 𝜎
𝑢2
(2)
2 ] 
The vector of random effects of each part (
𝑢1
(3)
𝑢1
(2)) and (
𝑢2
(3)
𝑢2
(2)) are assumed to be 
independent. 
In the two-level case, the random effects are also assumed normally distributed, with 
variance-covariance matrix: 
[
𝑢1
𝑢2
] ∼ MVN(0, Σ) ∑ = [
𝜎
𝑢1
2
𝜎
𝑢1
𝜎
𝑢2
𝜎
𝑢2
2 ] 
The correlation of the random effects, 𝜌12, is the covariance  𝜎𝑢1
𝜎
𝑢2
 , divided by the 
product of the standard deviations of the random effects 𝜎
𝑢1
 and 𝜎
𝑢2
. 
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4.19.8 Methods of Model Testing and Comparison 
It is not possible to employ standard tests of fit such as the log-likelihood ratio test and AIC 
and BIC statistics within the framework of analysing multiply-imputed datasets. Instead, tests 
to evaluate whether the random intercepts for each level were jointly equal to zero were 
carried out using the conditional test of Li et al. (1991), cited by StataCorp (2015b). Whether 
other joint effects (e.g. of living together and intervention allocation, separately and together 
with their interaction term) were equal to zero were similarly tested.  
 
4.19.9 Analyses 
All analyses for this section were carried out in Stata 14 (StataCorp 2015b), using the 
<<meglm>>, <<gsem>> and <<margins>> commands. The <<meglm>> command fits 
generalised linear mixed models by maximum-likelihood, implemented by mean-variance 
adaptive Gauss-Hermite quadrature (StataCorp 2015a). The <<gsem>> command, which 
allows the estimation of systems of equations within a multilevel framework, approximates 
maximum likelihood in the same way. This estimation technique is used to evaluate marginal 
likelihood in GLMM models, necessitated for integrating out random effects in the absence 
of a closed-form solution (Rabe-Hesketh and Skrondal 2012). All results are reported for 
imputed data (see section 4.22).  
 
4.19.10 Dependent Variables Included in the Analyses 
Telehealth and telecare study data were examined separately. In terms of dependent variables, 
I examined first all health and social care costs, with and without the direct costs of the 
intervention (see Table 4.2 for the units contributing costs to the total costs). Second, I 
considered costs to the NHS of primary, secondary and community health care; to secondary 
care only; and social services. Table 4.2 lists the units contributing costs to each care 
category. For the purposes of examining the social care costs (excluding the costs of the 
intervention) in the telecare sample, the costs of community alarms were excluded from the 
calculations: telecare recipients would naturally report having this item as part of their 
telecare package (see Sections 4.2 and 5.16.3), and the receipt of care would be confounded 
with allocation to the intervention. All service costs were assumed to have been incurred by 
public agencies. The analyses focused on data collected at baseline and 12-month follow-up 
(see section 4.11). 
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4.19.11 Telehealth Dataset: Variables Used as Covariates 
It is important, given the multilevel structure of the model, to characterise model covariates 
as belonging to a model level. For instance, in this time-varying model, those variables that 
change over time are characterised as being ‘first level’. As well as the baseline/follow-up 
indicator, there were two first level variables, for self-care and tenure. 
Self-care domain of the EQ5-D: This is an ordinal variable, where 1 is “I have no 
problems with self-care”; 2 is “I have some problems washing or dressing myself” and 3 is “I 
am unable to wash or dress myself”. The variable was used as proxy measure of need for 
social care.  
Tenure category: A categorical variable derived from the original tenure variable. 
Respondents were asked to indicate whether their accommodation was council-rented, 
housing association-rented, privately rented, owner-occupied or they could specify ‘other’ 
accommodation situations. Free-text answers were recoded into one of five categories: (1) 
council rented; (2) rented from housing association, registered social landlord or charitable 
trust; (3) privately rented; (4) owner occupied, shared ownership or equity release; (5) a 
category for all other housing types that could not be classified into the standard categories 
(e.g. family member’s home, mobile home or temporary accommodation). This variable was 
recoded into two categories: (1) all types of rental and other types of accommodation 
(including living with relatives, temporary accommodation); and (2) owner-occupiers 
(including shared ownership and equity release).  
Other demographic covariates are second-level variables, varying only at the person-
level.  
Age: This variable was categorised into 4 age-bands: under 65 or ‘young’ (reference 
category); 65-74 (‘young old’); 75-84 (‘old old’); and 85 years and over (‘oldest old’). 
Another formulation, a continuous variable and its quadratic, was considered but initial 
explorations of model fit indicated that this performed less well. These categorisations have 
been long-established in the sociological literature on ageing (Suzman, Willis, and Manton 
1992) and are useful in terms of formulating policy recommendations for different age 
cohorts.  
Comorbidities: This is a count of chronic conditions sourced from acute hospital 
records (Steventon et al. 2012), treated as a continuous variable, and grand-mean-centred.  
IMD: A continuous variable for Index of Multiple Deprivation 2007 (Noble et al. 
2008), grand-mean-centred. 
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Educational attainment: A three-category variable for education was constructed from 
the existing variable for educational attainment in the dataset. The categories were no formal 
education (reference category); having O levels/GCSE or A levels; degree (undergraduate or 
graduate level).  
Female: A dichotomous variable for female (1) and male (0).  
Ethnicity: A dichotomous variable was constructed, coding ethnicity as White-
British/non-White British.  
Index conditions: The three index long-term conditions – COPD (reference category); 
heart failure; diabetes. 
Two variables could be considered to vary at a higher level of organisation than the person-
level.  
Allocation: Allocation to intervention or control. As the general practices were the 
unit of randomisation, the allocation variable could be considered a level 3 predictor. 
However the variable is not an attribute of general practices as such and could also be 
considered a level 2 predictor.  
Site: identifies the participating local authority (1, 2 or 3). While technically general 
practices are nested within local authority areas, sites have been treated here as a fixed effect. 
 
4.19.12 Telecare Analyses: Variables Used as Covariates 
These analyses focused on the costs for two groups: people living alone and people living 
with others. I outline the reasons for choosing to explore these subgroups’ costs in chapter 6.  
Covariates included in the telecare models were first-level, time-varying variables: 
baseline/follow-up indicator; self-care domain of the EQ-5D-3L, and tenure, as described in 
Section 4.21.11. One additional covariate was also included:  
Living arrangement:  A dichotomous variable for living alone or with others was derived 
from two variables: number of adults in the household and number of children of 16 years or 
younger in the household. All participants reporting one adult and no children in the 
household were assumed to be living in a one-person household and therefore living alone; 
all other living arrangements were classified as living with others. The participant 
questionnaires did not contain an explicit question about the relationship between participants 
and other residents of their household, nor on marital status. There was no way to create a 
variable that expressed both numbers and relationships between residents in the household 
from the available data. Living alone was coded as 0; living together was coded as 1.  
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Several demographic covariates were second-level variables, varying only at the 
person-level. These included age bands, comorbidities, IMD, educational attainment, sex and 
ethnicity (as described in Section 4.21.11).  
Comorbidities: This is a count of chronic conditions sourced from acute hospital 
records (Steventon et al. 2012), treated as a continuous variable, and grand-mean-centred. 
IMD: A continuous variable for Index of Multiple Deprivation 2007 (Noble et al. 
2008), grand-mean-centred. 
Educational attainment: A three-category variable for education: no formal education 
(coded as zero); below degree (having O levels/GCSE or A levels); degree (undergraduate or 
graduate level; the reference category).  
Sex: A dichotomous variable for female/male.  
Ethnicity: A dichotomous variable (White-British/non-White British).  
As in 4.19.11, two variables could be considered to vary at a higher level of organisation than 
the person-level.  
Allocation: Allocation to intervention or control. The allocation variable could be 
considered a level 3 or a level 2 predictor. 
Site: identifies the participating local authority, treated as a fixed effect.  
 
4.20 Cost-effectiveness Analyses 
4.20.1 Decision Rules for Cost-effectiveness 
The relationships between the costs and outcomes of telehealth and telecare were examined 
in terms of the incremental cost-effectiveness and net monetary benefit of the respective 
interventions.  
The incremental cost-effectiveness ratio (ICER) is the difference in the mean costs of 
the intervention and control groups (C) divided by the difference in the mean outcomes 
between the groups (E). The intervention will be seen as cost-effective if the ICER is less 
than some maximum amount (λ) that a societal decision maker/purchaser is willing to pay for 
a gain in outcome. This decision rule can be expressed as  
C/E < λ 
where λ represents willingness to pay (WTP) for the gain in outcome. This equation 
can be re-arranged to give the net monetary benefit (NMB), representing the pecuniary value 
of the additional gain in benefits associated with the intervention, for a given λ, net of the 
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additional cost of providing the intervention (Drummond et al. 2005). If the intervention is to 
be cost-effective, then the NMB must exceed zero:  
 λ x E - C >0 
The National Institute for Health and Care Excellence (NICE) has generally considered that 
for adoption by the NHS, technologies should cost in the region of the £20,000 to £30,000 
per QALY range (National Institute for Health and Clinical Excellence 2008, Cerri, Knapp, 
and Fernandez 2013).  
A range of values, from £0 to £90,000, of willingness to pay for additional benefit 
were considered, including the £20,000 to £30,000 per-QALY range; these results were 
plotted to produce cost-effectiveness acceptability curves (CEACs). CEACs are useful as 
they provide decision makers with a visual representation of the probability that the 
intervention is effective and the error probability associated with that level of WTP 
(Drummond et al. 2005, Drummond et al. 2015).  
 
4.20.2 Cost-effectiveness Analyses 
The regression-based approach allows sampling uncertainty to be taken into account, and 
adjustment for any between-group baseline differences in individual characteristics (e.g. 
socio-demographic differences) (Drummond et al. 2005, Hoch, Rockx, and Krahn 2006).  
It was agreed across the three quantitative themes of the WSD study that a core of 
baseline characteristics would be included in the analyses of the Telecare and Telehealth data, 
namely: age, gender, deprivation as measured by the Index of Multiple Deprivation (IMD), 
ethnicity, index condition (Telehealth participants only), site and presence of comorbidities. 
All covariates included in the cost-effectiveness models for Telecare and Telehealth are listed 
in the following sections. 
Any concerns about the variability of telehealth and telecare interventions are likely to 
be magnified when comparisons are made across localities or centres (Bergmo 2009). Manca, 
Rice et al. (2005) suggest an analytical approach to the variations in costs related to the 
locality, or cluster. In their paper on the subject of generalising cost-effectiveness results 
from multi-centre, cluster-randomised trials, they note that a correlation of costs and 
outcomes may occur because of variations between locations, or clusters. They advocate the 
use of multilevel models (MLM), which can tackle the problem of variability between sites 
simultaneously in terms of resource use and costs and outcomes, and which could allow 
analysts to quantify how generalisable by location the cost-effectiveness results are. There are 
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alternative approaches. Seemingly unrelated regression models were fitted to both telecare 
and telehealth data. This is a system of equations that takes account of the correlation 
between error terms of the cost and outcome equations (Gomes, Ng, et al. 2012).  
 
4.20.3 Telehealth  
Telehealth data were analysed in Stata 14, using gsem. The models adjusted for a number of 
socio-demographic characteristics: site, age, sex, ethnicity, IMD score (Noble et al. 2008) and 
two indicators of health need: a comorbidity count constructed from a range of chronic 
conditions, sourced from acute hospital records (Steventon et al. 2012) and the index long-
term condition (Bower et al. 2011). Baseline costs were also included in cost equations and 
baseline utility or baseline secondary outcome measures (Manca, Hawkins, and Sculpher 
2005) were included in the outcome equations.  
 
4.20.4 Telehealth Sensitivity Analyses 
Decreases in the costs of equipment: Equipment costs might have a considerable 
effect on the overall costs of telehealth, and conclusions about cost-effectiveness could 
depend on the unit cost of equipment use. Equipment prices may fall over time as technology 
evolves. I explored the effect of falling input prices, using data obtained from the Department 
of Health on equipment prices in North American markets in 2010. I applied general price 
decreases of 50 per cent and 80 per cent to equipment costs calculated for the trial. Because 
North American equipment prices were 10-50 per cent of the price for equipment purchased 
in England before the trial, these assumptions were relatively conservative. 
‘At capacity’ scenario: Telehealth teams may have been able to work at a higher 
capacity. The sites had originally expected to have about 1000 users each, at least for a few 
months over the trial period (as those allocated to the telehealth intervention were gradually 
joined by people who had been allocated to the control group). Instead, the monitoring teams 
had somewhere between half and three-fifths of the target number in 2009-10. The sensitivity 
analyses explored costs if each site monitored 1000 people, assuming that the central 
monitoring teams did not increase the number of staff available to handle additional demand, 
and that both service structures and participant outcomes did not change at the larger scale of 
the service.   
  
113 
 
 The equipment costs and telehealth support costs parameters were varied as 
described in the two scenarios above for use in the cost-effectiveness analyses; models and 
covariates remained the same as in the main analyses. 
 
4.20.5 Telecare 
For the telecare data, the SUR models were fitted in Stata 14 (StataCorp 2015b) using the 
gsem command. Covariates used were pre-baseline costs and baseline utility (following 
Manca, Hawkins, and Sculpher 2005)/outcome measure, site, age, sex, ethnicity, Index of 
Multiple Deprivation (IMD) 2007 quintiles (Noble et al. 2008), a one-person household 
indicator, a count of chronic conditions (Steventon et al. 2013), level of dependency (baseline 
EQ5-D self-care domain score) and whether the participant had a 'personal/community alarm' 
at baseline. The self-care domain score was included as a covariate as much of the variation 
in receipt of social care is linked to the degree of difficulty individuals experience in tasks 
such as washing and dressing; self-care is highly correlated with the need for support in 
activities of daily living (ADL) (Forder and Caiels 2011). The presence of a 
personal/community alarm was included as an indicator that the local authority, the family or 
the individual considered the individual to be at risk. Cluster-robust standard errors were used 
in estimating regression coefficients (observations were clustered by general practice). 
Estimates from the results were used to calculate the ICER and the net monetary benefit 
(NMB) using Fieller’s rules (Fieller 1954, O'Brien and Briggs 2002, Glick 2007). The 
formula for calculating the ICER point estimate and confidence intervals and the NMB point 
estimates and confidence intervals at different levels of willingness to pay employed the 
model estimates of the covariance between costs and outcomes, and the coefficients on the 
intervention variable in the cost and outcomes equations and their variances.  
 
4.20.6 Telecare Sensitivity Analyses 
The assumptions of the analyses of the primary outcome were subjected to further testing. 
One analysis explored the robustness of the base case to variations in the costs of the 
intervention by using a lower cost of telecare monitoring support, if telecare could be 
delivered for the cost of a service operating at scale (a ‘mainstream’ service). A study by 
Bayer and Barlow (2010) provided a figure of £5 per week. A second analysis examined the 
input prices for telecare equipment if that equipment had been purchased at half the price 
paid within the trial, given that with advances in technology, telecare equipment prices might 
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fall substantially. A third analysis examined the impact of assuming that costs and outcomes 
were normally distributed in the base case analysis. This involved performing the SUR 
analyses on 3000 bootstrapped replications generated using a two-stage bootstrap procedure 
in R, as described in Gomes, Ng et al (2012). SUR was carried out in R using the 
systemfit package (Henningsen and Hamann 2007). The procedure and analyses were 
performed separately on each complete dataset generated by the multiple imputation process 
(see 4.24) and estimates combined in NORM (NORM: Multiple imputation of incomplete 
multivariate data under a normal model (Version 2) [Software] 1999). 
 
4.21 Missing Data 
There were inevitably data missing at all assessment points. CSRIs that were not returned 
because the participant did not complete the assessment were considered to be missing and 
were not included in any imputations or analyses. When the CSRI section of the 
questionnaire pack was not filled out at all or just one or two answers given, data for the 
whole case was also considered as entirely missing. Apart from these cases, service costs 
were calculated for each participant. If the use of a particular service was indicated on the 
CSRI, but not the frequency of use of that service, then a per-contact unit cost was used to 
value that item (rather than a duration-based unit cost). Where no such unit cost was 
available, the mean duration of users who reported frequency of use was calculated and the 
mean duration applied to those missing information on duration of use; a mean cost of users 
was calculated, attaching duration-based unit costs to frequency, and this mean cost was 
allocated to cases where only use of the service was indicated. Service use costs were 
aggregated up to cost categories (see Table 4.2) which were in turn added together to produce 
the total cost. Where all individual costs making up a cost category were missing, the total for 
the cost category was calculated as missing whereas if only some of the costs were missing, 
then these were assumed to be zero costs and the total cost represented as the sum of the 
available costs.17 If the case was not entirely missing, but category-level costs were missing, 
these costs were derived through multiple imputation.  
 
                                                          
17 In Stata, the command used was: egen newvar=rowtotal (var1, var2,…varx), m 
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4.22 Multiple Imputation 
The imputation models used for the costs and cost-effectiveness analyses drew on a number 
of predictors. In the case of telehealth, predictors included socio-demographics (age, sex, 
education, ethnicity, number of comorbidities, site, Index of Multiple Deprivation score, 
long-term condition indicator, general practice, household size, housing tenure), outcome and 
process measures (EQ-5D-3L, ICECAP-O, SF-12, depression symptoms, state-trait anxiety, 
self-efficacy) and category-level and total costs at all assessment points, as well as variables 
related to the trial itself (allocation, reasons for withdrawal). For telecare, predictors included: 
socio-demographics (as for telehealth), outcome and process measures (EQ-5D-3L, SF-12, 
ICECAP-O, state-trait anxiety, self-efficacy) and category-level and total costs at all 
assessment points, and variables related to the trial (allocation, reasons for withdrawal, 
function/classification of telecare equipment).  
 For both telehealth and telecare datasets, missing data were imputed using the data 
available from cases that had completed an assessment at that time point. Thus no data was 
imputed where the case was fully missing because the assessment had not been completed 
(for any reason) at that time point.  
Data were assumed to be missing at random, which means that missingness is 
dependent on the observed values of the data and not on the unobserved values of the data 
(Little and Rubin 2002). Multiple imputations of costs and outcomes data for the telecare 
analyses in chapters 6 and 8 was carried out via predictive mean matching (PMM) using the 
MCMC procedure in SPSS v.21 (SPSS Inc., Chicago, Illinois).  
Imputation of data for the telehealth analyses (work carried out in 2017) presented in 
chapters 6 and 7 was conducted within a multilevel framework. Multiple imputation by PMM 
(with 5 nearest neighbours) was implemented using the mice (Van Buuren and Groothuis-
Oudshoorn, 2011) v. 2.25 and miceadds (v2.7-19) packages in R {R Core Team, 2016 
#1195}. The process generated 10 completed datasets with a maximum of 15 iterations for 
the convergence of the MICE (Multivariate Imputation by Chained Equations) algorithm. In 
this approach, a linear mixed model (implemented using the mice.impute.2l.lmer function, 
itself dependent on the lme4 R package) (Bates et al. 2015) serves as the basis of the 
imputation model; values predicted by the model are matched to the nearest observed value in 
the data. The multilevel approach explicitly accounts for the relationship between a predictor 
and an outcome at both the individual and at the cluster level (Ludtke, Robitzsch, and Grund 
2017). The approach also recognises the possibility that missingness in an outcome may be 
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linked to the clustering unit, for instance because cluster members share common 
characteristics or because of specific attributes of that cluster (Gomes et al. 2013). Missing 
data were also imputed separately by experimental group, following Diaz-Ordaz, Kenward, 
and Grieve (2014) and Gomes et al. (2013). In each case, the procedure was followed to 
create ten datasets (Schafer 1999), to be analysed and then combined, taking the stochastic 
nature of the imputations into account (Carpenter and Kenward 2007, Rubin 1987). 
  
4.23 Ethics  
The study was given approval by the Liverpool NHS Research Ethics Committee (ref: 
08/H1005/4). 
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Chapter 5  
 
 
Telehealth and Telecare Samples: Characteristics, Service Use Patterns and 
Costs 
 
5.1 Introduction 
In this chapter I present results in terms of the availability of data from each trial at the three 
study assessment points. I give an overview of the baseline characteristics of the two trial 
populations and compare the samples completing the final assessment point with those who 
did not complete. I also present a comparison of the resource use and costs of the 
experimental groups at the three trial assessment points. Costs of self-reported service use 
over the last three months before each assessment point are reported by category; mean 
values summarise the (imputed) costs of the available cases, while the standard errors are 
adjusted for cluster. The discussions throughout this chapter focus primarily on the baseline 
and 12-month follow-up results. Issues with 4-month data were discussed in section 4.11; 
baseline characteristics of participants completing/not completing at 4 months are discussed 
in the chapter, and 4-months service use and costs results from the 4-months data are 
presented in Appendix 2. 
 
5.2 Telehealth 
There were 3230 participants from 238 general practices in the WSD telehealth trial. Of these 
individuals, 1573 (patients of 154 general practices) participated in the WSD telehealth 
questionnaire study: 845 (81 practices) were allocated to the intervention and 728 (73 
practices) to usual care. Seventeen participants allocated to usual care received the 
intervention, and six allocated to the intervention did not receive any equipment.  
Baseline data from the questionnaire study on services used were available for 841 
telehealth and 728 usual care participants. At the 4-month follow-up, service use data were 
available for 972 participants (547 intervention and 425 control participants). At the 12-
month follow-up, 969 (538 telehealth, 431 control) had service use data available. By 12-
month follow-up, 599 (38 per cent) participants had dropped out of the questionnaire study, 
leaving outcomes data from 974 participants. Service use data from both baseline and 12-
month follow-up were available for 965 participants (534 intervention; 431 control). Service 
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use data was available at all three assessment points for 743 participants (418 intervention; 
325 control). 
 
5.3 Socio-demographic Characteristics 
Participants’ characteristics at baseline assessment are presented in terms of completion of 
the baseline assessment and completion and non-completion of study instruments at the 12-
month assessment (Table 5.1). The majority of the sample was male (59 per cent). While the 
mean age was 70.4, just under a third of participants were under 65 years of age. A large 
proportion (68 per cent) of the sample had at least one comorbidity. The sample was quite 
evenly distributed between the three participating local authorities, although a larger 
proportion (40 per cent) resided in site 2. 
The experimental groups were broadly similar at the outset of the study, although a 
larger percentage of participants with heart failure were in the usual care group (38 per cent) 
than in the telehealth group (31 per cent). A larger percentage of patients with chronic 
obstructive pulmonary disease (40 per cent) were in the telehealth group than in usual care 
(34 per cent).  
There were differences between telehealth and usual care participants in relation to the 
groups in the first and second IMD quintiles (the least deprived groups), although mean 
scores did not differ greatly. Within each experimental group, the baseline and 12-month 
follow-up samples were broadly similar in age, number of comorbidities, the proportion of 
females and proportions of participants with chronic obstructive pulmonary disease and heart 
failure. At baseline and follow-up, telehealth participants with an index condition of chronic 
obstructive pulmonary disease formed the largest group; in the usual care group, participants 
with an index condition of heart failure constituted the largest group.  
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Table 5.1 Baseline characteristics of participants with economic data available at baseline and 12-month follow-up across Telehealth sample 
 Total baseline sample  
Participants completing 12-
month follow-up study 
instruments* 
 
Participants not completing 12-
month follow-up study 
instruments† 
 
UC 
(n=728) 
TH 
(n=841) 
Raw  
UC 
(n=431) 
TH 
(n=534) 
Raw  
UC 
(n=297) 
TH 
(n=302) 
Raw 
Mean years of age 
(SD) 
70.6 
(20.7) 
70.1 
(21.6) 
-0.5  70.1 
(16.1) 
70.0 
(17.0) 
-0.1  71.3 
(16.9) 
70.5 (16.8) -0.8 
 Under 65  
   (young) 
215 
(30%) 
242 
(29%) 
-1%  131 
(30%) 
150 
(28%) 
-2%  84  
(28%) 
90 
(30%) 
2% 
 65-74 
 (young old)‡ 
214 
(29%) 
288 
(34%) 
5%  137 
(32%) 
199 
(37%) 
5%  77 
(26%) 
86 
(28%) 
3% 
 75-84 
   (old old) 
239 
(33%) 
243 
(29%) 
-4%  130 
(30%) 
156 
(29%) 
-1%  109 (37%) 87 
(29%) 
-8% 
 85+ 
 (oldest old)§ 
60 
(8%) 
68 
(8%) 
0%  33 
(8%) 
29 
(5%) 
2%  727 
(9%) 
39 
(13%) 
4% 
Women  290 
(40%) 
347 
(41%)  
1%  162 
(38%) 
222 
(42%) 
4%  128 
(43%)  
124 
(41%) 
-2% 
Mean IMD score 
(SD) || 
28.6 
(52.2) 
27.7 
(55.3) 
0.9  27.7 
(40.1) 
26.0 
(43.8) 
-1.7  29.8 
(36.3) 
30.6 (36.2) 0.7 
1st quintile||  130 
(18%) 
215 
(26%)  
8%  81 
(19%) 
151 
(28%) 
9%  49 
(16%)  
64 
(21%)  
5% 
2nd quintile|| 164 
(23%) 
140 
(17%)  
-6%  105 
(24%)  
93 
(17%) 
-7%  59 
(20%)  
46 
(15%) 
-5% 
3rd quintile|| 124 
(17%) 
155 
(18%) 
1%  79 
(18%)  
101 
(19%) 
1%  45 
(15%) 
53 
(18%) 
2% 
4th quintile|| 168 
(23%) 
165 
(20%) 
-3%  87 
(20%) 
110 
(21%) 
0%  81 
(27%) 
54 
(18%)  
-9% 
5th quintile|| 142 
(20%) 
166 
(20%) 
0%  79 
(18%) 
79 
(15%) 
-4%  63 
(21%)  
85 
(28%)  
7% 
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 Total baseline sample  
Participants completing 12-
month follow-up study 
instruments* 
 
Participants not completing 12-
month follow-up study 
instruments† 
 
UC 
(n=728) 
TH 
(n=841) 
Raw  
UC 
(n=431) 
TH 
(n=534) 
Raw  
UC 
(n=297) 
TH 
(n=302) 
Raw 
Index condition            
COPD 244 
(34%) 
334  
(40%) 
6%  140 
(33%) 
232 
(43%) 
11%  104 
(35%)  
99 
(33%) 
-2% 
Heart failure 275 
(38%) 
263 (31%)  7%  175 
(41%) 
177 
(33%) 
8%  100 
(34%)  
86 
(29%) 
5% 
Diabetes 209 
(29%)  
244 (29%)  0%  116 
(27%) 
125 
(23%) 
3%  93 
(31%)  
117 
(39%) 
7% 
1+ comorbidities 511 
(70%)  
560  
(67%)  
-4%  297 
(69%)  
345  
(65%)  
-4%  214 
(72%)  
211  
(70%)  
-2% 
Mean no. 
comorbidities (SD) 
2 
(2.8) 
1.8 
(2.9) 
0.2  2 
(2.7) 
1.8 
(2.9) 
0.2  2.1 
(2.1) 
2 
(2.1) 
0.1 
WSD site            
Site 1 234 
(32%)  
256 
(30%)  
2%  132 
(31%) 
174 
(33%)  
2%  102 
(34%)  
81 
(27%)  
8% 
Site 2 ¶ 283 
(39%)  
342 
(41%)  
2%  184 
(43%) 
236 
(44%) 
1%  99 
(33%) 
105 
(35%) 
1% 
Site 3** 211 
(29%)  
243 
(29%)  
0%  115 
(27%) 
124 
(23%) 
3%  96 
(32%) 
116 
(38%) 
6% 
White British 
ethnicity|| 
630 
(87%)  
735 
(87%)  
1%  377 
(87%) 
478 
(90%) 
2%  253 
(85%) 
255 
(84%)  
1% 
Living alone||†† 195 
(27%)  
229 
(27%)  
0%  119 
(28%) 
132 
(25%) 
-3%  76 
(26%) 
95 
(31%)  
6% 
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 Total baseline sample  
Participants completing 12-
month follow-up study 
instruments* 
 
Participants not completing 12-
month follow-up study 
instruments† 
 
UC 
(n=728) 
TH 
(n=841) 
Raw  
UC 
(n=431) 
TH 
(n=534) 
Raw  
UC 
(n=297) 
TH 
(n=302) 
Raw 
Owns|| 497 
(68%) 
569 (68%) -1%  299 (69%) 373 (70%) 0%  198 (67%) 193 (64%) -3% 
Education            
No formal 
education|| 
423 
(58%) 
501 
(60%) 
2%  235 (55%) 301 
(56%) 
2%  187 
(63%) 
198 (66%) 3% 
GCSE/O/ 
A- level ||‡‡ 
222 
(31%) 
247 
(29%)  
-1%  144 (33%) 169 (32%) -2%  78  
(26%) 
75  
(25%) 
-1% 
 Degree|| 83 (11%) 93 
(11%) 
0%  51 
(12%) 
64  
(12%) 
0%  32  
(11%) 
29  
(10%) 
-1% 
UC=usual care; TH=telehealth; COPD=chronic obstructive pulmonary disease; SD=standard deviation. 
*cases where costs and outcomes data were available 
† Outcomes instruments not completed and/or CSRI not completed 
‡ Difference within TH: differences between completion/non-completion clustered 𝜒2= 4.591 and p<0.05 
§ Difference within TH: differences between completion/non-completion clustered 𝜒2=14.456 and p<0.001 
|| Imputed data 
¶ Difference within TH: differences between completion/non-completion z=-2.6641, p<0.01; difference within UC: differences between 
completion/non-completion: z=-2.5456, p<0.05 
**Difference within TH: differences between completion/non-completion z=4.6633, p<0.001 
†† Difference within TH: differences between completion/non-completion clustered 𝜒2= 4.464, p<0.05  
‡ ‡ Difference within UC: differences between completion/non-completion clustered 𝜒2= 4.1405, p<0.05  
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While participants were recruited into the trial on the basis of having one of three 
‘index’ conditions (COPD, diabetes or heart failure), some had more than one of these 
conditions. The proportion of the total questionnaire study sample at baseline with each long-
term condition and the overlap between those conditions is illustrated for each experimental 
group in a proportional Venn diagram (Figure 5.1). It can be seen that in both groups about 
three-quarters of the sample had just one long-term condition. A slightly smaller proportion 
of participants with diabetes or with heart failure had only the one condition relative to 
participants with COPD. Very few had all three conditions. 
 
Figure 5.1 Proportions of the Telehealth sample with a long-term condition, by experimental 
group 
 
 
5.3.1 Characteristics of the Sample Completing and Not Completing the 12-month Follow-up 
Comparing the characteristics of cases with data available at baseline and at 12-month 
follow-up within their ITT allocation-groups (Table 5.1), and taking clustering into account, 
there were no significant differences between most demographic characteristics at baseline 
and at follow-up within the control or intervention groups. There were, however, differences 
within the groups in the proportions from sites 2 and 3. Within each experimental group, the 
participants completing at 12 months had a significantly higher proportion of people living in 
site 2 than those not completing. Within the intervention group, the non-completing sample 
had a significantly higher proportion of participants living in site 3 than the completing 
COPD
3%
10%
Diabetes
5%
Heart Failure
7%
24%
24%
27%
Usual care
COPD
4%
7%
Diabetes
7%
Heart Failure
7%
22%
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sample. Of participants allocated to the intervention, in the completing sample there was a 
lower proportion of participants living alone, a higher proportion in the young-old age band, a 
lower proportion in the oldest-old age band and a higher proportion of people with 
secondary-school qualifications (GCSE/O/A-levels) than in the non-completing sample.   
The characteristics of the whole sample completing at both time points were mostly similar to 
those not completing. A greater proportion of participants who completed the questionnaire 
study were in site 2 than was the case in the non-completers (43 per cent vs. 33 per cent; z=-
3.716, P<0.001); conversely a smaller proportion of participants who completed the study 
were in site 3 than was the case in the non-completers (25 per cent vs. 35 per cent; z=4.509, 
P<0.001).  
 
5.4 Cluster Numbers and Sizes  
The clusters diminished in size between assessments and were slightly less well-balanced at 
the 12-month follow-up relative to baseline. Cluster size decreased from approximately 10 
participants on average in both experimental groups at baseline, to 6 and 7 participants in the 
usual care and telehealth groups respectively (Table 5.2 and Table 5.3). 
 
Table 5.2 Number and size of clusters, participants with economic data available in 
Telehealth sample 
 Total baseline sample  Participants completing 12-month 
follow-up study instruments* 
 
 
UC 
(N=73) 
TH 
(N=81) 
 UC 
(N=69) 
TH 
(N=76) 
Cluster size 
 
10 [1-44] 10.4 [1-48]  6.2 [1-26] 7 [1-32] 
Note: Data are mean [min – max] 
UC=Usual care; TH=Telehealth; COPD=chronic obstructive pulmonary disease. 
*where costs and outcomes data were available 
 
 
5.5 Characteristics of the Sample Completing and Not Completing the 4-month Follow-
up 
The characteristics of cases with data available at baseline and at 4-month follow-up are 
compared within their ITT allocation-groups in Appendix 2, Table A2.1. As with the 12-
month follow-up, in each experimental group, the participants completing at 4 months had a 
significantly higher proportion living in site 2 than those not completing; also the participants 
in the usual care group completing at 4-months had a significantly lower proportion living in 
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site 3 than those not completing. In addition, telehealth group participants completing at 4 
months had a significantly higher proportion living in site 1 than those not completing. The 
completing samples of telehealth participants differed significantly from the non-completing 
telehealth sample in terms of having lower proportions in the young-old, higher proportions 
in the oldest-old age bands (the completing telehealth sample was non-significantly older 
than the non-completing telehealth group). A smaller proportion of telehealth participants that 
completed had diabetes than telehealth participants not completing; the same pattern was 
observable in the usual care completing/non-completing samples. The completing/non-
completing samples of telehealth participants also differed in terms of ethnicity, numbers in 
IMD and mean IMD score. Across the sample, a greater proportion of participants 
completing the questionnaire study were in site 2 than in the case of the non-completers (44 
per cent vs. 33 per cent; z=4.412, p<0.001); and a smaller proportion of participants who 
completed the study were in site 3 than in the case of the non-completers (21 per cent vs. 41 
per cent; z=8.357, p<0.001).  
 
5.6 Telehealth Service Use: Descriptive statistics 
Examining the data from 1569 cases that were available at the baseline (Table 5.3) and 965 
cases at the 12-month follow-up time points (Table 5.4), mean reported service use was 
broadly similar between the telehealth and usual care groups. Due to the potentially large 
number of comparisons, between-group differences were not subjected to tests of 
significance. Proportions of the sample using services were generally greater in the follow-up 
sample. There was a broad pattern of slightly fewer reported mean contacts with hospital 
services for the telehealth group than for the usual care group at both assessment points, and 
these differences were generally larger at follow-up. In each group, the proportions using and 
the mean use of community matron and specialist nurse contacts was somewhat higher at 
follow-up, as were proportions and mean use of primary care (visiting the GP surgery and 
practice nurse contacts). The use of community care services was not negligible, particularly 
in terms of home care and home help, 15 and 14 percent using these services in control and 
intervention respectively; and 17 and 12 percent in control and intervention respectively at 
follow-up. 14 (16) per cent of the control and 13 (15) per cent of the intervention group used 
a community alarm at baseline (12-month follow-up). 
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Table 5.3 Number and percentage of groups using services and mean numbers of units (standard errors) used over previous 3 months across 
Telehealth sample, available cases at baseline 
Resource item Control  
(n=728) 
  Telehealth  
(n=841) 
  Difference  
 % using* N using Mean (SE) % using* N using Mean (SE) Mean 
Hospital use        
A&E attendance 13 93 0.21 (0.03) 13 111 0.17 (0.02) -0.04 
Inpatient services  11 81 0.66 (0.11) 10 83 0.57 (0.10) -0.09 
Day Hospital attendances 6 42 0.24 (0.15) 7 61 0.22 (0.07) -0.03 
Outpatient attendances 50 359 1.56 (0.13) 49 410 1.25 (0.09) -0.31 
Community health services/primary care        
Paramedic contact 11 82 0.27 (0.06) 9 77 0.19 (0.04) -0.08 
Community matron visit 11 77 0.52 (0.08) 8 68 0.36 (0.06) -0.16 
Community matron telephone contact 3 22 0.11 (0.03) 2 13 0.06 (0.02) -0.05 
Community or district nurse visit 14 99 0.94 (0.22) 10 86 0.88 (0.28) -0.05 
Community or district nurse telephone contact 2 17 0.14 (0.09) 1 12 0.02 (0.01) -0.11 
Practice nurse visit 26 190 0.87 (0.11) 29 242 0.82 (0.08) -0.05 
Night nurse visit 0 2 0.00 (0.00) 0 2 0.00 (0.00) 0 
Specialist nurse contacts 18 132 0.56 (0.26) 17 142 0.32 (0.05) -0.24 
Physiotherapist or occupational therapist visit 9 62 0.39 (0.08) 9 73 0.28 (0.04) -0.11 
GP (home) visit 13 95 0.27 (0.03) 11 95 0.26 (0.04) -0.01 
GP (surgery) visit 58 419 1.43 (0.08) 57 480 1.37 (0.07) -0.06 
GP (telephone) visit 11 83 0.25 (0.03) 12 101 0.25 (0.03) 0 
Dentist visit  23 168 0.33 (0.03) 23 196 0.35 (0.03) 0.02 
Chiropodist visit 23 166 0.43 (0.09) 23 196 0.35 (0.03) -0.08 
Optician visit 19 139 0.22 (0.02) 21 175 0.24 (0.02) 0.01 
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Resource item Control  
(n=728) 
  Telehealth  
(n=841) 
  Difference  
 % using* N using Mean (SE) % using* N using Mean (SE) Mean 
Community mental health        
Psychiatrist visit 1 6 0.01 (0.00) 1 8 0.04 (0.02) 0.03 
Mental health nurse visit 1 6 0.02 (0.01) 1 5 0.01 (0.01) -0.01 
Community care services        
Social worker visit 3 19 0.07 (0.02) 4 31 0.07 (0.02) 0 
All daytime home care/home help visit 15 112 7.42 (1.18) 14 115 5.17 (0.78) -2.25 
Council home help visit 6 45 5.38 (1.06) 5 42 3.47 (0.73) -1.91 
Private/independent home care/home help visit 11 77 2.05 (0.32) 10 80 1.71 (0.27) -0.34 
Paid night carer visit 1 4 0.39 (0.28) 1 8 0.46 (0.21) 0.07 
Meals on Wheels meal 1 6 0.44 (0.23) 1 11 0.79 (0.28) 0.35 
Laundry (incontinence) service 0 2 0.02 (0.02) 0 4 0.04 (0.02) 0.01 
Community alarm 14 104  13 112   
Equipment inc. mobility aids, ADL NHS 1 8 0.02 (0.01) 0 3 0.01 (0.00) -0.01 
Major and minor adaptations NHS 1 6 0.01 (0.00) 0 3 0.00 (0.00) -0.01 
Equipment inc. mobility aids, ADL LA 2 15 0.03 (0.01) 1 12 0.02 (0.01) -0.01 
Major and minor adaptations LA 7 46 0.09 (0.01) 4 34 0.06 (0.01) -0.03 
Care home respite        
Days 0 1 0.03 (0.03) 0 0 0.00 (0.00) -0.03 
Day services 4 728 0.47 (0.12) 4 841 0.69 (0.18) 0.22 
Day care and other day attendances - LA 3 25 0.44 (0.11) 3 29 0.59 (0.16) 0.16 
Day care and other day attendances - NHS 0 3 0.03 (0.02) 1 6 0.10 (0.07) 0.07 
Medications        
Number of medications 99 726 7.86 (0.13) 99 839 7.94 (0.13) 0.08 
*Proportion of non-missing cases who reported using a service  
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Table 5.4 Number and percentage of groups using services and mean numbers of units (standard errors) used over previous 3 months across 
Telehealth sample, available cases at 12-month follow-up 
Resource item Control  
(n=431) 
  Telehealth  
(n=534) 
  Difference 
 % using* N using Mean (SE) % using* N using Mean (SE) Mean 
Hospital use        
A&E attendance 20 85 0.38 (0.07) 14 73 0.23 (0.04) -0.15 
Inpatient services  15 63 1.23 (0.24) 11 56 0.98 (0.22) -0.25 
Day Hospital attendances 21 84 0.51 (0.12) 16 79 0.39 (0.10) -0.13 
Outpatient attendances 48 196 1.31 (0.13) 50 260 1.11 (0.08) -0.19 
Community health services/primary care        
Paramedic contact 12 46 0.18 (0.04) 10 47 0.13 (0.02) -0.05 
Community matron visit 13 51 0.76 (0.15) 14 67 0.70 (0.14) -0.06 
Community matron telephone contact 6 22 0.20 (0.04) 10 45 0.38 (0.10) 0.18 
Community or district nurse visit 14 56 0.73 (0.25) 10 49 1.26 (0.74) 0.53 
Community or district nurse telephone contact 5 19 0.14 (0.06) 7 34 0.24 (0.07) 0.1 
Practice nurse visit 57 200 1.50 (0.15) 53 227 1.26 (0.11) -0.24 
Night nurse visit 0 1 0.00 (0.00) 0 1 0.01 (0.01) 0.01 
Specialist nurse contacts 27 118 0.69 (0.10) 27 143 0.64 (0.08) -0.05 
Physiotherapist or occupational therapist visit 10 32 0.70 (0.30) 8 36 0.29 (0.08) -0.41 
GP (home) visit 16 48 0.37 (0.07) 10 35 0.23 (0.07) -0.13 
GP (surgery) visit 73 292 1.69 (0.08) 71 349 1.70 (0.10) 0.01 
GP (telephone) visit 28 83 0.52 (0.06) 27 102 0.42 (0.04) -0.1 
Dentist visit 27 104 0.42 (0.06) 29 141 0.45 (0.04) 0.03 
Chiropodist visit 28 106 0.61 (0.13) 28 133 0.60 (0.11) -0.01 
Optician visit 31 115 0.48 (0.09) 26 121 0.37 (0.04) -0.11 
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Resource item Control  
(n=431) 
  Telehealth  
(n=534) 
  Difference 
 % using* N using Mean (SE) % using* N using Mean (SE) Mean 
Community mental health        
Psychiatrist visit 2 6 0.02 (0.01) 1 7 0.02 (0.01) 0 
Mental health nurse visit 1 4 0.02 (0.01) 1 7 0.03 (0.02) 0.01 
Community care services        
Social worker visit 6 22 0.35 (0.23) 5 26 0.16 (0.05) -0.19 
All daytime home care/home help visit 17 74 6.36 (1.40) 12 65 4.98 (1.50) -1.38 
Council home help visit 6 23 4.26 (1.29) 4 18 3.63 (1.57) -0.62 
Private/independent home care/home help visit 15 59 2.90 (0.81) 11 53 1.77 (0.36) -1.13 
Paid night carer visit 1 3 0.19 (0.11) 1 6 0.40 (0.24) 0.21 
Meals on Wheels meal 2 6 0.45 (0.26) 1 5 0.65 (0.46) 0.2 
Laundry (incontinence) service 0 0 0.00 (0.00) 1 5 0.05 (0.03) 0.05 
Community alarm 16 65  15 79   
Equipment inc. mobility aids, ADL NHS 4 17 0.09 (0.03) 5 24 0.11 (0.03) 0.02 
Major and minor adaptations NHS 1 3 0.01 (0.00) 1 4 0.01 (0.00) 0 
Equipment inc. mobility aids, ADL LA 3 12 0.05 (0.01) 3 15 0.04 (0.01) -0.01 
Major and minor adaptations LA 3 10 0.04 (0.01) 4 21 0.06 (0.01) 0.02 
Care home respite        
Days 0 1 0.02 (0.02) 0 1 0.03 (0.03) 0 
Day services        
Day care and other day attendances - LA 5 23 0.58 (0.18) 2 13 0.41 (0.16) -0.17 
Day care and other day attendances - NHS 0 1 0.00 (0.00) 0 2 0.03 (0.02) 0.03 
Medications        
Number of medications 100 315 8.57 (0.23) 100 411 8.64 (0.20) 0.07 
*Proportion of non-missing cases who reported using a service 
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5.7 Telehealth Intervention 
In each site, participants received telehealth equipment that consisted of a freestanding base 
unit or a television set-top box and ‘peripherals’ (monitors such as pulse oximeters, blood 
pressure cuff, glucometers and weigh scales). Sites provided monitors based on condition, 
their local protocols and clinical assessment. Three of the peripherals were considered 
‘critical’ to a particular index condition (glucometer to diabetes; pulse oximeter to COPD; 
weighing scales to heart failure) and thus would be routinely provided for that condition. 
However clinicians could over-ride provision of the peripheral if they judged it to be 
clinically inappropriate for a particular patient (Cartwright et al. 2013). The peripherals sent 
vital signs data to the base unit/set-top box wirelessly or by cable. In each site, patient data 
thus collected was uploaded to a server. Computer algorithms then compared patients’ 
readings to their baseline clinical parameters and classed them according to a risk-rating 
system. Each weekday, the readings would be reviewed by nursing staff who could then 
respond in various ways: for instance by further monitoring with no immediate action, 
contacting the patient for further discussion, contacting the patient’s GP, or contacting the 
emergency services. The configurations of services in place to manage and respond to the 
received and processed vital signs data (or ‘alerts’) varied considerably between sites. The 
interventions, although varying between sites, could be classified as second-generation 
telehealth (Cartwright et al. 2013). 
 
5.7.1 Description of Telehealth Support Services 
Telehealth service configurations have been described in Table 5.5 in terms of equipment 
supply; installation, server and equipment maintenance, asset management and training; and 
monitoring and responses to alarm and sensor alerts. All sites had equipment supplied by 
private companies but only site 2 followed a rental model. The structures and processes in 
place for project management varied across sites. The local authority in site 2 provided both 
installation technicians and back-office support staff for non-clinical problems (e.g. 
troubleshooting for equipment malfunction), whereas these aspects were entirely managed 
within the NHS in site 1. In all cases there was a call centre staffed by nurses and support 
workers; in two sites, other community-based nurses had access to telehealth data. While the 
trial objective was to examine the impact of ‘telehealth’ per se rather than specific models, 
the variations in service configurations were reflected in the site-specific service costs.  
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Table 5.5 Features of delivery systems in the WSD Telehealth pilot sites, 2009/10 
Producers  
   Roles 
Site 1 Site 2 Site 3 
Equipment supply 
 
Equipment was procured from 
several suppliers. 
Most telehealth equipment was 
procured from one supplier. 
The base telehealth units were 
rented along with combinations of 
peripherals as a monthly package. 
Installation, server and 
equipment 
maintenance, asset 
management, training 
 
Installations, maintenance and asset 
management were the responsibility 
of local engineers employed by the 
primary care organisation; during 
installation engineers were 
accompanied by support staff from 
the central team who demonstrated 
how to use the equipment.  
Technicians from the local authority 
carried out installations, maintenance 
and asset management, and provided 
users with an initial tutorial on use of 
the equipment. 
Equipment was supplied, installed 
and configured by a private 
company that also trained patients 
in its use. 
Monitoring and 
responses to 
alarms/sensors alerts 
Telehealth data were reviewed by a 
central clinical team of nursing and 
support staff, and also by community 
matrons or specialist nurses based in 
community health settings. The 
central team also followed up non-
clinical issues, e.g. where no data 
had been transferred by the user for 
some days, or in case of equipment 
or software problems. 
Arrangements for clinical monitoring 
differed across the two Primary Care 
Trust areas within the participating 
local authority. Telehealth data in both 
areas could be monitored by call centre 
teams of qualified and unqualified 
nursing personnel. Data was also be 
monitored by specialist community 
nurses (specialist community matrons, 
community matrons or specialist 
nurses in one Trust; community 
matrons, but not specialist nurses, in 
the other). The telehealth core team 
(run by the local authority social 
services department) followed up non-
clinical issues with users. 
Telehealth data were reviewed by 
a central clinical team with nursing 
and support staff; also the team 
followed up non-clinical issues.  
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5.8 Telehealth Equipment 
Telehealth participants received 2.8 (SD 0.6) items of telehealth ‘peripheral’ equipment on 
average (Table 5.6). Combinations of peripherals were common: for instance, 43 per cent 
received a combination of blood pressure monitor, pulse oximeter and weighing scales. Thus 
most participants (87 per cent (745/856)) received more than one item. There were striking 
variations in the distribution of the monitors between sites (Figure 5.2). The proportion of 
patients receiving equipment in Site 1 varied more distinctly depending on the index 
condition than in the other two sites: for instance, very small proportions of patients with 
COPD and heart failure received a glucometer. In all sites and across the conditions, almost 
all those in receipt of telehealth devices had blood pressure monitors; in Sites 2 and 3 and 
across the conditions, substantial majorities of telehealth device recipients received weighing 
scales.  
 
Table 5.6 Telehealth equipment used by Telehealth study sample (N=856) 
Items of Equipment N* % using 
BP monitor  831 97% 
Glucometer  300 35% 
Pulse oximeter  581 68% 
Weighing scales  
681 80% 
Combinations of items†    
BP monitor + weighing scales 68 8% 
BP monitor + glucometer 44 5% 
BP monitor + oximeter 99 12% 
BP monitor + pulse oximeter + weighing scales 364 43% 
BP monitor + glucometer+ weighing scales 149 17% 
Notes: BP monitor=Blood pressure monitor 
*Number of questionnaire participants at baseline with equipment data available, including those not 
completing CSRIs. 
† Combinations of equipment used by more than 1% of the questionnaire study sample. 
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Figure 5.2 Distribution of peripheral monitors by index condition and site 
 
 
0
2
0
4
0
6
0
8
0
1
0
0
P
e
rc
e
n
ta
g
e
 r
e
c
e
iv
in
g
 t
e
le
h
e
a
lt
h
 m
o
n
it
o
r
Site 1 Site 2 Site 3
COPD
0
2
0
4
0
6
0
8
0
1
0
0
P
e
rc
e
n
ta
g
e
 r
e
c
e
iv
in
g
 t
e
le
h
e
a
lt
h
 m
o
n
it
o
r
Site 1 Site 2 Site 3
Heart Failure
0
2
0
4
0
6
0
8
0
1
0
0
P
e
rc
e
n
ta
g
e
 r
e
c
e
iv
in
g
 t
e
le
h
e
a
lt
h
 m
o
n
it
o
r
Site 1 Site 2 Site 3
Diabetes
BP m on itor Gl uco m eter
Pu lse  o xi m ete r Wei ghi ng  s cal es
  
133 
 
5.9 Unit Costs of the Telehealth Services 
Annual telehealth intervention delivery and equipment unit costs, and intervention unit costs, 
are presented in terms of the range of costs across the three sites (Table 5.7). Some additional 
unit costs are presented here: the costs excluding project management costs, costs excluding 
equipment costs and costs had the sites been able to recruit their maximum planned number 
of participants and run at a higher capacity during the trial.  
 
Table 5.7 Telehealth intervention costs in the three WSD sites 
Cost category Range (£ per year, 2009-10) 
In-house staff* 338,598 – 540,381 
Computer hardware and peripherals 188,249 – 490,748 
Computer software 86,064 – 39,678 
Installation 17,914 – 69,185 
Contract costs/fees to other organisations 8,623 – 261,588 
TOTAL DIRECT COST 840,464 – 1,168,671 
DIRECT SUPPORT COST PER PARTICIPANT  1,487 – 2,042 
 Less total equipment cost† 1,134 – 1,241 
 Less posts/contracts specific to project management 804 – 1,199 
 Assuming 1000 participants recruited per site‡ 580 – 733 
Equipment costs per participant† 334 – 852 
Costs rounded to the nearest £1. 
*Excludes costs of installation staff, which were reported separately. 
†Total equipment costs=costs of base units and peripherals-specific costs. 
‡The monitoring costs of the service, assuming that it was functioning “at capacity” (for 
sensitivity analyses). 
 
Per-site level unit costs of support, excluding equipment costs, were allocated to each 
participant on the basis of their receipt of telehealth equipment (the per-protocol rather than 
intention-to treat-allocation). The mean annual cost for telehealth equipment and support was 
£1847 (standard error £11.3) for participants in receipt of telehealth equipment with 12-
month follow-up costs data. 
 
5.10 Costs of Health and Social Care 
Categories of costs of self-reported service use (imputed data) over the last three months 
before the baseline and the 12-month follow-ups are reported in Table 5.8 and .Table 5.9 
Costs in the three months prior to baseline were similar in the intervention and control 
groups. Examining costs in the three months prior to the 12-month follow-up (excluding the 
direct costs of the intervention), hospital costs made up about half the total costs (47 per cent) 
for all participants, followed by primary care costs (18 per cent); medications (18 per cent); 
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and combined costs of social care (including community care, local authority-provided day 
care and equipment) (16 per cent). Costs in the telehealth group, excluding intervention 
specific costs, were not significantly lower than those in the usual care group, with a 
difference in costs of £243 (95% CI (-£565, £79)) between groups. The costs, including 
intervention-specific costs, in the telehealth group were higher than in the usual care group. 
For the telehealth group, three-month costs for equipment averaged £168 per person, about a 
tenth of the total. Total costs for health and social care, for the three months prior to the 12-
month interview, were £1150 and £1394 for the telehealth and usual care groups, 
respectively, excluding the direct costs of the intervention; if direct costs were included, these 
costs were £1608 and £1403, respectively.  
In terms of missing data, baseline costs at the category level were generally near-
complete (less than 2 per cent missing) (LA and NHS equipment having the highest 
proportion of missingness at 2 per cent and 5 per cent of cases in both groups respectively). 
At follow-up, there were more missing in certain categories: care home costs (5 per cent of 
telehealth and 6 per cent of usual care cases), NHS day care costs (7 per cent of telehealth 
and 11 per cent of usual care cases), NHS adaptations and equipment (4 per cent of telehealth 
and 8 per cent of usual care cases), LA adaptations and equipment (4 per cent of telehealth 
and 9 per cent of usual care cases), and medications costs (23 per cent of telehealth and 27 
per cent of usual care cases).  
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Table 5.8 Mean service costs (standard errors) over previous 3 months across Telehealth sample, available cases at 
baseline 
Resource item 
Control  
(n=728) 
Telehealth 
(n=841) 
Difference (units) 
 Mean (SE) Mean (SE) Mean (95% CI) 
Hospital use 461 (46) 432 (43) -29 (-153, 95) 
Community health services/primary care 235 (16) 195 (16) -40 (-84, 5) 
Community mental health 3 (5) 14 ( 5) 11 ( -3, 24) 
Community care services 131 (43) 138 (42) 7 (-111, 126) 
Care home respite 2 (1) 0 (1) -2 (-5, 2) 
Day services LA 11 (5) 16 (4) 5 (-8, 17) 
Day services NHS 3 (9) 12 (8) 9 (-15, 33) 
Medications 440 (20) 464 (19) 24 (-30, 78) 
Equipment/Adaptations LA 3 (1) 2 ( 0) -1 (-3, 0) 
Equipment LA/Adaptations NHS 1 (0) 0 ( 0) -0 (-1, 0) 
Total costs excl. TH delivery & equipment 1289 (71) 1273 (66) -16 (-206, 174) 
Note: Imputed data (10 completed datasets). 
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Table 5.9 Mean service costs (standard errors) over previous 3 months across Telehealth sample, available cases at 12-
month follow-up 
Resource item 
Control  
(n=431) 
Telehealth 
(n=538) 
Difference (units) 
 Mean (SE) Mean (SE) Mean (95% CI) 
Hospital use 670 (90) 520 (83) -149 (-389, 90) 
Community health services/primary care 244 (20) 211 (20) -33 (-86, 20) 
Community mental health 8 (9) 6 (9) -3 (-12, 7) 
Community care services 197 (28) 149 (28) -48 (-144, 48) 
Care home respite 1 (8) 2 (9) 0 (-9, 9) 
Day services LA 43 (14) 21 (13) -22 (-59, 16) 
Day services NHS 2 (5) 8 (4) 6 (-7, 20) 
Medications 227 (8) 232 (7) 5 (-16, 25) 
Equipment/Adaptations LA 1 (1) 1 (1) 1 (-2, 4) 
Equipment LA/Adaptations NHS 0 (0) 0 (0) 0 (0, 1) 
Total costs exc. telehealth delivery & equipment 1 394 (119) 1 150 (110) -243 (-562, 75) 
Telehealth intervention 6 (4) 289 (4) 284 (272, 296)** 
Telehealth equipment 4 (8) 168 (8) 165 (141, 188)** 
Total costs inc. telehealth delivery & equipment 1403 (120) 1608 (110) 205 (-114, 524) 
Note: Includes cases where baseline cost data are missing. Imputed data (10 completed datasets). 
*p<0.001 on clustered t-test
  
137 
 
5.11 Clustering Effects 
The clustering of costs (excluding the intervention) for telehealth participants is examined in 
Table 5.10. The ICCs presented for the general practice level are examined separately by time 
point. The estimated ICC values at each time point are higher in the intervention group than 
in controls; however the confidence intervals of the estimates overlap, suggesting that 
practice-level clustering is similar within the allocation groups at each time point. The 
variation in total costs (excluding intervention costs) between clusters at baseline and at 12-
month follow-up is illustrated in Figure 5.3 and Figure 5.4. 
 
Table 5.10 Health and social care service costs, Telehealth sample, prior three months: intra-
cluster correlation coefficients (ICC) for general practice, per time point, ITT allocation 
 Baseline ICCa No. 
Practices 
N Follow-up ICCa No. 
Practices 
N 
Control  -0.002 (-0.037, 0.032) 73 728 0.007 (-0.054, 
0.069) 
69 431 
TH 0.022 (-0.016, 0.060) 81 841 0.061 (-0.005, 
0.127) 
76 538 
Note: costs exclude costs of the intervention. Imputed data (10 completed datasets). 
a from one-way analysis of variance, Searle’s Confidence intervals (Ukoumunne 2002). 
 
Figure 5.3 Caterpillar plot of health and social care costs per cluster, Telehealth sample, 
three months prior to baseline, by experimental group 
 
Note: graph of data from the first complete dataset generated by the multiple imputation process 
(graphs from other complete datasets are similar). The error bars represent the standard errors of the 
cluster means (including clusters of one). 
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Figure 5.4 Caterpillar plot of health and social care costs per cluster, Telehealth sample, 
three months prior to 12-month follow-up, by experimental group 
 
Note: graph of data from the first complete dataset generated by the multiple imputation process 
(graphs from other complete datasets are similar). The error bars represent the standard errors of the 
cluster means (including clusters of one). 
5.11.1 Telecare 
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participants, to usual care. At the baseline assessment point, service use data were available 
for 1,182 participants; these were available for 531 (269 telecare and 262 usual care) 
participants from 174 practices at the 4-month assessment, and for 757 participants from 191 
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were participants under 65 years of age. Almost half of the people participating had at least 
one comorbidity. The samples with data available at baseline and 12-month follow-up were 
generally well-balanced in terms of age, sex and mean IMD score. At both time points there 
was a larger percentage of the telecare group in the second IMD quintile. There was little 
difference between groups in the proportions living alone.  
 
5.13 Characteristics of the Samples Completing and Not Completing the 12-month 
Follow-up 
A comparison of baseline characteristics of participants who did and did not complete study 
instruments at 12-month follow-up is presented in Table 5.11. Of participants allocated to the 
usual care intervention, participants completing were older (75.9 years) than participants who 
did not complete (73.2 years). Compared to the sample of usual care participants not 
completing study instruments, the usual care sample completing study instruments had a 
higher proportion of cases in the secondary-school education level group (GCSE/A/O-level), 
lower proportions of cases in site 2 and higher proportions of cases in site 3.  
 
5.13.1 Cluster Numbers and Sizes  
The clusters slightly diminished in size but became more balanced at the 12-month follow-up, 
from approximately 6 cases on average in the usual care group and 5 cases in the telecare 
group at baseline, to approximately 4 in both treatment groups. 
 
5.14 Characteristics of the Sample Completing and Not Completing the 4-month 
Follow-up 
At the 4-month follow-up, the majority of Telecare study participants did not complete 
questionnaires. However, there were few differences between the samples completing and not 
completing, within experimental groups (Appendix 2, Table A2.). The proportion of 
intervention participants from site 2 was greater in the completers group than in the non-
completers (56 per cent vs. 44 per cent, z=-2.7860, p=.0053). Conversely the proportions of 
usual care participants from site 3 was lower in the completers than in the non-completers 
group (22 per cent vs. 33 per cent, z=0.6740, p=0.0075). These differences were apparent 
across experimental groups, with higher proportions of completers than non-completers 
residing in site 2 and lower proportions of completers than non-completers residing in site 3. 
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Table 5.11 Baseline characteristics of participants with economic data available at baseline and 12-month follow-up across Telecare sample  
 Total baseline sample   
Participants completing 12-
month follow-up study 
instruments*  
Participants not completing 12-
month follow-up study 
instruments† 
 
UC 
(n=634) 
TC 
(n=548) 
Raw  
UC 
(n=378) 
TC 
(n=375) 
Raw  
UC 
(n=253) 
TC 
(n=170) 
Raw 
Mean years of age 
(SD)‡ 
74.3 
(17.5) 
74 
(17.1) 
-0.3  
73.1 
(17.6) 
73.2 
(17.4) 
0.1  
75.9 
(14.5) 
75.8 
(14.4) 
-0.1 
 Under 65 (young) 138 
(22%) 
129 
(24%) 
2%  
91 
(24%) 
91 
(24%) 
0%  47 (19%) 
36 
(21%) 
3% 
 65-74 (young old) 139 
(22%) 
116 
(21%) 
-1%  
94 
(25%) 
89 
(24%) 
-1%  45 (18%) 
27 
(16%) 
-2% 
 75-84 (old old) 208 
(33%) 
168 
(31%) 
-2%  
118 
(31%) 
112 
(30%) 
-1%  88 (35%) 
55 
(32%) 
-2% 
 85+ (oldest old) 149 
(24%) 
135 
(25%) 
-1%  
75 
(20%) 
83 
(22%) 
2%  73 (29%) 
52 
(31%) 
2% 
Female 415 
(65%) 
344 
(63%) 
2%  
250 
(66%) 
241 
(64%) 
-2%  163 (64%) 
102 
(60%) 
-4% 
1+ comorbidities 304 
(48%) 
252 
(46%) 
-2%  
176 
(47%) 
167 
(45%) 
-2%  
125 
(49%) 
84 
(49%) 
0% 
Mean comorbidities 
(SD)§ 
1.1 
(1.6) 
1.1 
(1.6) 
-0.0  
1.1 
(1.5) 
1 
(1.5) 
-0.1  1 (1.6) 
1.2 
(1.6) 
0.2 
White-British‡§ 561 
(89%) 
482 
(88%) 
-1%  
332 
(88%) 
328 
(87%) 
0%  
228 
(90%) 
151 
(89%) 
1% 
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 Total baseline sample   
Participants completing 12-
month follow-up study 
instruments*  
Participants not completing 12-
month follow-up study 
instruments† 
 
UC 
(n=634) 
TC 
(n=548) 
Raw  
UC 
(n=378) 
TC 
(n=375) 
Raw  
UC 
(n=253) 
TC 
(n=170) 
Raw 
WSD site            
 Site 1 137 
(22%) 
125 
(23%) 
1%  
84 
(22%) 
83 
(22%) 
0%  
52 
(21%) 
42 
(25%) 
4% 
 Site 2|| 309 
(49%) 
273 
(50%) 
1%  
169 
(45%) 
187 
(50%) 
5%  
138 
(55%) 
83 
(49%) 
-6% 
 Site 3¶ 188 
(30%) 
150 
(27%) 
-2%  
125 
(33%) 
105 
(28%) 
-5%  
63 
(25%) 
45 
(27%) 
2% 
IMD 28.8 
(40.4) 
27.8 
(38.2) 
-0.7  
29.6 
(32.8) 
27.5 
(32.1) 
-2.1  
27.8 
(28.4) 
28.6 
(25.8) 
0.8 
1st quintile§ 152 
(24%) 
127 
(23%) 
-1%  
87 
(23%) 
89 
(24%) 
1%  
67 
(26%) 
35 
(21%) 
-6% 
2nd quintile§ 82 
(13%) 
109 
(20%) 
7%  
45 
(12%) 
71 
(19%) 
7%  
36 
(14%) 
37 
(22%) 
8% 
3rd quintile§ 133 
(21%) 
100 
(18%) 
-3%  
79 
(21%) 
71 
(19%) 
-2%  
50 
(20%) 
28 
(16%) 
-3% 
4th quintile§ 120 
(19%) 
102 
(19%) 
0%  
72 
(19%) 
70 
(19%) 
0%  
50 
(20%) 
35 
(21%) 
1% 
5th quintile§ 146 
(23%) 
110 
(20%) 
-3%  
95 
(25%) 
74 
(20%) 
-5%  
50 
(20%) 
35 
(21%) 
1% 
Living alone§ 
 
340  
(54%) 
285 
(52%) 
-2%  
202 
(53%) 
188 
(50%) 
-3%  
136  
(54%) 
95  
(56%) 
2% 
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 Total baseline sample   
Participants completing 12-
month follow-up study 
instruments*  
Participants not completing 12-
month follow-up study 
instruments† 
 
UC 
(n=634) 
TC 
(n=548) 
Raw  
UC 
(n=378) 
TC 
(n=375) 
Raw  
UC 
(n=253) 
TC 
(n=170) 
Raw 
Tenure            
Rents/Other§ 242 
(38%)   
192 
(35%)  
-3%  152 
(40%)   
129 
(34%)  
-6%  89 
(35%)  
62 
(36%)   
1% 
Owns§ 392 
(62%)   
356 
(65%) 
3%  226 
(60%) 
246 
(66%)   
6%  164 
(65%)   
108 
(64%) 
-1% 
Education            
No formal 
education§ 
406 
(64%)   
 
349 
(64%)  
 
0%  230 
(61% ) 
235 
(63%)  
 
2%  173 
(68%)   
112 
(66%)   
 
-2% 
GCSE/O/A- 
level§** 
185 
(29%)   
 
129 
(24%) 
) 
-6%  126 
(33%)   
89 
(24%)   
 
-10%  59 
(23%)   
 
39 
(23%)   
 
0% 
Degree 43 
(7%)   
70 
(13%) 
6%  22 
(6%) 
51 
(14%)  
8%  21 
(8%)   
19 
(11%)  
3% 
UC=usual care; TC=telecare; SD=standard deviation 
*costs and outcomes data available 
† Outcomes instruments not completed and/or CSRI not completed 
‡ Age: within UC: differences between completion/completion sample t=1.972, p<0.05 on clustered t-test 
§ Imputed data 
|| Within UC: differences between completion/completion z=2.423, p<0.05 (z-test of proportions)  
¶ Within UC: differences between completion/completion z=-2.198, p<0.05 (z-test of proportions) 
**Within UC: difference between completion/completion clustered 𝜒2= 7.0546, p<0.05 
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Table 5.12 Number and size of clusters corresponding to participants with economic data 
available at baseline and 12-month follow-up across Telecare sample 
 Total baseline sample  Participants completing 12-
month follow-up study 
instruments* 
 
UC TC  UC TC 
 
(N=103) (N=101)  (N=95) (N=96) 
Cluster size 6.2 [1-26] 5.4 [1-21]  4 [1-14] 3.9 [1-14] 
Note: Data are given as mean [min – max] 
UC=Usual care; TC=Telecare 
*where costs and outcomes data were available 
 
5.15 Telecare service Use: Descriptive Statistics 
Differences between experimental groups were small for most categories in the 3 months 
prior to baseline and 12-month follow-up (Table 5.13 and Table 5.14).  The use of social 
services such as home care and social work was greater amongst the telecare participants. 
Telecare participants had 9.6 more daytime home care visits than control participants (42 (SE 
4.3) vs. 33 (SE 3.7)), while telecare participants reported 1.6 more community nursing visits 
at the 12-month follow-up. As in the telehealth sample, there were large differences in the 
proportions reporting seeing a practice nurse at baseline (approximately 21 and 22 per cent in 
control and intervention respectively) and at 12-month follow-up (approximately 42 per cent 
and 41 per cent control and intervention respectively). 
 
5.15.1 Community Alarm Usage 
The percentages of participants who reported having a 'personal/community alarm' (a 
community alarm or a pull-cord) were very similar at baseline (51.5 per cent intervention, 
50.5 per cent usual care). Given the nature of the intervention, we would expect a growth in 
the reporting of some form of personal or community alarm in the intervention group. 
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Table 5.13 Number and percentage of groups using services and mean numbers of units (standard errors) used over previous 3 months across 
Telecare sample, available cases at baseline 
Resource item Usual care 
(n=634) 
  Telecare 
(n=548) 
  Difference  
 
 % using* N using Mean (SE) % using* N using Mean (SE) Mean 
Hospital use        
A&E attendance 15 95 0.18 (0.02) 17 91 0.23 (0.03) 0.04 
Inpatient services  13 83 1.44 (0.26) 12 66 1.65 (0.34) 0.21 
Day Hospital attendances 7 45 0.26 (0.07) 8 42 0.30 (0.10) 0.04 
Outpatient attendances 43 268 1.05 (0.08) 44 240 1.20 (0.12) 0.14 
Community health services/primary care        
Paramedic contact 16 104 0.31 (0.05) 20 111 0.36 (0.05) 0.04 
Community matron visit 4 25 0.41 (0.29) 4 23 0.26 (0.07) -0.15 
Community matron telephone contact 1 7 0.07 (0.03) 1 6 0.06 (0.03) -0.02 
Community or district nurse visit 23 147 2.40 (0.46) 25 136 3.09 (0.62) 0.69 
Community or district nurse telephone contact 5 29 0.11 (0.03) 5 26 0.14 (0.04) 0.03 
Practice nurse visit 21 134 0.75 (0.11) 22 121 0.76 (0.13) 0.01 
Night nurse visit 1 8 0.05 (0.02) 1 5 0.05 (0.04) 0 
Specialist nurse contacts 8 53 0.32 (0.14) 9 48 0.54 (0.29) 0.22 
Physiotherapist or occupational therapist visit 18 117 1.10 (0.17) 23 125 1.54 (0.27) 0.43 
GP (home) visit 22 142 0.46 (0.05) 22 123 0.51 (0.06) 0.05 
GP (surgery) visit 45 287 1.16 (0.08) 45 244 1.08 (0.09) -0.09 
GP (telephone) visit 17 109 0.44 (0.05) 15 82 0.53 (0.11) 0.08 
Dentist visit  21 132 0.35 (0.04) 24 130 0.41 (0.04) 0.06 
Chiropodist visit 34 213 0.56 (0.04) 34 186 0.57 (0.04) 0 
Optician visit 23 145 0.30 (0.03) 20 108 0.26 (0.03) -0.05 
Community mental health        
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Resource item Usual care 
(n=634) 
  Telecare 
(n=548) 
  Difference  
 
 % using* N using Mean (SE) % using* N using Mean (SE) Mean 
Psychiatrist visit 5 29 0.10 (0.03) 4 22 0.20 (0.12) 0.1 
Mental health nurse visit 1 8 0.03 (0.01) 3 14 0.10 (0.04) 0.07 
Community care services        
Social worker visit 16 99 0.49 (0.21) 20 109 0.62 (0.23) 0.13 
All daytime home care/home help visit 50 315 49.67 (3.44) 50 276 47.23 (3.65) -2.44 
Council home help visit 39 245 44.72 (3.29) 35 194 42.17 (3.57) -2.55 
Private/independent home care/home help visit 19 121 5.10 (0.86) 22 121 5.30 (0.83) 0.21 
Paid night carer visit 4 23 1.95 (0.54) 5 28 3.36 (0.92) 1.4 
Meals on Wheels meal 5 34 3.49 (0.68) 5 30 4.20 (1.33) 0.71 
Laundry (incontinence) service 1 7 0.12 (0.05) 1 5 0.07 (0.04) -0.05 
Community alarm 50 320  51 282   
Equipment inc. mobility aids, ADL NHS 4 20 0.06 (0.01) 6 28 0.09 (0.02) 0.04 
Major and minor adaptations NHS 1 3 0.01 (0.01) 2 11 0.03 (0.01) 0.02 
Equipment inc. mobility aids, ADL LA 9 53 0.16 (0.02) 10 50 0.17 (0.03) 0 
Major and minor adaptations LA 14 82 0.20 (0.02) 17 80 0.24 (0.03) 0.04 
Care home respite        
Days 1 8 0.24 (0.11) 2 9 0.31 (0.12) 0.07 
Day services        
Day care and other day attendances - LA 16 103 3.41 (0.42) 17 91 2.77 (0.36) -0.64 
Day care and other day attendances - NHS 2 10 0.21 (0.09) 2 10 0.32 (0.13) 0.11 
Medications        
Number of medications 98 620 6.83 (0.19) 98 534 6.80 (0.21) -0.03 
* Proportion of non-missing cases who reported using a service 
† Reported having a personal/community alarm – means represent number of ‘yes’ responses  
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Table 5.14 Number and percentage of groups using services and mean numbers of units (standard errors) used over previous 3 months across 
Telecare sample, available cases at 12-month follow-up 
Resource item Usual care 
(n=381) 
  Telecare  
(n=376) 
  Difference  
 
 % using* N using Mean (SE) % using* N using Mean (SE) Mean 
Hospital use        
A&E attendance 20 71 0.24 (0.03) 18 64 0.24 (0.04) 0 
Inpatient services  14 51 0.82 (0.17) 16 57 1.05 (0.25) 0.23 
Day Hospital attendances 16 54 0.40 (0.13) 16 58 0.39 (0.10) -0.01 
Outpatient attendances 49 176 1.32 (0.12) 46 162 1.17 (0.11) -0.15 
Community health services/primary care        
Paramedic contact 16 54 0.30 (0.08) 17 60 0.29 (0.05) -0.01 
Community matron visit 5 18 0.32 (0.11) 7 22 0.26 (0.08) -0.06 
Community matron telephone contact 3 9 0.06 (0.02) 4 13 0.18 (0.13) 0.13 
Community or district nurse visit 21 74 1.29 (0.28) 26 93 2.90 (0.66) 1.61 
Community or district nurse telephone contact 8 27 0.15 (0.04) 8 29 0.28 (0.09) 0.12 
Practice nurse visit 42 132 1.43 (0.24) 41 126 1.19 (0.20) -0.24 
Night nurse visit 1 3 0.01 (0.01) 1 3 0.72 (0.56) 0.71 
Specialist nurse contacts 16 59 0.35 (0.06) 14 52 0.49 (0.24) 0.14 
Physiotherapist or occupational therapist visit 14 43 0.50 (0.14) 14 44 0.69 (0.15) 0.19 
GP (home) visit 26 79 0.53 (0.08) 30 92 0.69 (0.08) 0.16 
GP (surgery) visit 64 224 1.66 (0.12) 57 192 1.25 (0.09) -0.41 
GP (telephone) visit 34 100 0.72 (0.11) 32 99 0.89 (0.14) 0.17 
Dentist visit  30 101 0.44 (0.05) 24 81 0.34 (0.04) -0.1 
Chiropodist visit 42 144 0.70 (0.07) 39 136 0.95 (0.18) 0.25 
Optician visit 34 116 0.41 (0.04) 26 85 0.33 (0.03) -0.09 
Community mental health        
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Resource item Usual care 
(n=381) 
  Telecare  
(n=376) 
  Difference  
 
 % using* N using Mean (SE) % using* N using Mean (SE) Mean 
Psychiatrist visit 4 14 0.10 (0.05) 3 10 0.05 (0.03) -0.05 
Mental health nurse visit 1 4 0.02 (0.02) 3 10 0.11 (0.06) 0.09 
Community care services        
Social worker visit 13 43 0.22 (0.05) 16 56 1.19 (0.87) 0.97 
All daytime home care/home help visit 45 170 32.50 
(3.68) 
54 202 42.23 
(4.28) 
9.74 
Council home help visit 29 101 29.29 
(3.88) 
33 114 36.33 
(4.20) 
7.05 
Private/independent home care/home help visit 29 99 7.94 (1.38) 36 125 11.86 
(2.24) 
3.92 
Paid night carer visit 2 8 0.42 (0.29) 3 10 0.79 (0.41) 0.37 
Meals on Wheels meal 6 19 2.34 (0.69) 6 20 3.68 (0.91) 1.34 
Laundry (incontinence) service 2 8 0.21 (0.08) 2 6 0.35 (0.29) 0.14 
Community alarm 64 232  89 320   
Equipment inc. mobility aids, ADL NHS 11 39 0.30 (0.06) 14 47 0.34 (0.06) 0.04 
Major and minor adaptations NHS 2 8 0.04 (0.01) 4 14 0.07 (0.02) 0.03 
Equipment inc. mobility aids, ADL LA 7 24 0.11 (0.03) 8 28 0.19 (0.04) 0.08 
Major and minor adaptations LA 12 40 0.22 (0.04) 10 32 0.13 (0.02) -0.09 
Care home respite        
Days 1 4 0.12 (0.08) 2 4 0.27 (0.18) 0.15 
Day services        
Day care and other day attendances -LA 13 50 2.32 (0.42) 14 53 2.35 (0.40) 0.03 
Day care and other day attendances - NHS 1 4 0.10 (0.06) 1 5 0.09 (0.05) -0.01 
Medications        
Number of medications 99 303 7.42 (0.23) 99 277 7.10 (0.24) -0.32 
*Proportion of non-missing cases who reported using a service 
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By the 12-month follow-up, 64 per cent of the usual care group reported using a 
community alarm, a relative increase of 26 per cent from baseline and an absolute difference 
in baseline and follow-up proportions of 13 (clustered 𝜒2= 105.8396, p=.0000). The 
proportion of the usual care group using a community alarm at the 4-month follow-up (61 per 
cent) showed a similar trend from baseline (clustered 𝜒2= 107.3696, p=.0000). 
It is possible that community alarms being installed in the control group participants’ 
homes during the trial period could have attenuated differences in outcomes related to the 
intervention between the experimental groups, if the telecare provided as part of the 
intervention did not vary substantially from the telecare provided through other routes. 
Participants were not asked to give details on the types of community alarms/telecare devices 
that were in their homes at the baseline assessment or (for non-WSD devices) during the 
follow-up period. No further information was available on the type of telecare packages 
(obtained through other routes than WSD) used by the control participants.  
 
5.16 Intervention Costs 
5.16.1 Telecare intervention 
The WSD telecare intervention most closely resembled a second-generation telecare system, 
whereby the participant received a base unit and pendant/bracelet that could be used to alert 
call centre monitoring operators, and sensors were monitored remotely and automatically (see 
5.16.3 for further details on the equipment). 
 
5.16.2 Description of the Telecare Services 
The configuration of telecare services varied considerably. Not surprisingly given the mixed 
market in social care, some aspects of WSD Telecare services were contracted out, to 
differing extents, to other public and private organisations (Table 5.15). All sites had call 
centre contracts with long-standing providers of telecare in their local areas, either district 
councils or arm’s-length management organisations. One private company supplied the 
majority of telecare equipment across the sites. Installation and response arrangements in 
particular varied between and also within the sites. For instance one site did not organise a 
dedicated response to any telecare sensor alerts, whereas the other sites had the option to 
organise a visit to the service user in certain circumstances. 
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Table 5.15 Features of delivery systems in the WSD Telecare pilot sites, 2009/10 
  
Producers  
   Roles 
Site 1 
 
Site 2 Site 3 
 
Equipment supply 
 
Equipment purchased by the local 
authority for the project from private 
provider.  
Equipment purchased for the project 
through private provider.  
 
Equipment purchased by the local 
authority for the project from private 
providers.  
Installation, server 
and equipment 
maintenance, asset 
management, 
training 
 
Most services provided by local 
authority-based project team: 
installations, responsible for asset 
management, routine maintenance and 
callouts for equipment-related 
problems such as battery 
replacements. Installations also 
provided 1 day/week by one of the 2 
monitoring services. 
 
District council call centres hosted the 
servers. 
Services provided by combination of 
local authority-based units. Local 
authority business unit carried out 
installations, handled warehousing, 
inventory control and equipment 
configuration; provided routine 
maintenance, maintenance callouts. 
Local authority project team provided 
project/contract management; 
assessment for equipment; point of 
contact for service users with 
equipment-related/technical problems. 
 
District council call centre hosted the 
server.  
Services provided by combination of 
local authority-based unit and private 
providers.  
 
Private company responsible for 
transporting the equipment to the 
person’s home, installing cabling, 
installing and configuring the 
equipment; also for asset 
management, scheduled maintenance 
visits and maintenance callouts. 
 
Local authority managed server. 
Arm’s-length local authority call 
centre assessed for equipment, follow-
up equipment testing visit. 
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Producers  
   Roles 
Site 1 
 
Site 2 Site 3 
 
Monitoring and 
responses to 
alarms/sensors 
alerts 
Monitoring: provided by call centres 
in 2 districts, later merged into single 
service, 24/7 service. 
 
Responses: via call centre staff, either 
to contact nominated carer to request 
response, or contact emergency 
services.  
 
Two types of responses to sensor 
alerts/activations: operator contacts 
the service user, if the user reports a 
problem, operator contacts a 
nominated carer to visit the service 
user; if no carer is available to respond 
but a response of some kind is 
required, operator contacts the 
emergency services. 
 
No dedicated WSD response service. 
Monitoring: provided by a district 
local authority call centre, providing 
24/7 service.  
 
Responses: initial response via call 
centre operators. Three types of 
responses to sensor alerts/activations:  
Operator contacts nominated carer to 
request response; if no carer available 
to respond, operator calls dedicated 
WSD response team; or contacts the 
emergency services.  
 
Dedicated WSD telecare response 
teams were organised on a district 
basis: in one PCT area, intermediate 
care and out-of-hours nursing teams; 
in the other, private providers of out-
of-hours primary care services and a 
provider of health and domiciliary 
care.  
Monitoring: provided by arm’s-length 
local authority call centre, providing 
24/7 service.  
 
Responses: initial response via call 
centre telecare officers. Three types of 
responses to sensor alerts/activations: 
telecare officer contacts the service 
user to investigate the nature of the 
problem. If necessary, telecare officer 
contacts the emergency services; the 
officer contacts named carers 
(relatives or friends) to ask carer to 
visit the service user; if nominated 
carers are not available, officer visits 
the service user. 
 
The call centre offers a dedicated 
response visiting service to people 
using telecare from the local authority. 
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5.16.3 Telecare Equipment 
The number of items of telecare equipment provided to participants ranged between 1 and 11 
items (Table 5.16). On average, participants had a mean of 4.7 items (a mode of 4). Of the 
available sensors, smoke detectors, carbon monoxide monitors, fall detectors, flood detectors 
and temperature extremes sensors were most frequently provided.  
The WSD evaluation team developed a categorisation of telecare devices by assessing 
the function of devices and mapping these against groupings from the telecare literature 
(Bower et al. 2011, Brownsell, Blackburn, and Hawley 2008, Demiris and Hensel 2008, 
Doughty et al. 2008). For the purposes of the trial, the evaluation team also added a category 
for ‘standalone’ devices. These are devices that are not monitored but that can facilitate 
telecare (e.g. key safes, which allow authorised staff responding to a telecare alert to enter the 
person’s home) (Hirani et al. 2013). The telecare equipment was mapped to one of the four 
functions:  monitoring functional status; monitoring home security; monitoring the home 
environment; and standalone devices. The following list shows which devices were mapped 
to each function. 
Functional monitoring: Lifeline base unit + pendant, Minuet watch, Pull Cord, Bed 
Occupancy, Chair Occupancy, Enuresis Sensor, Epilepsy sensor, Fall Detector, Medication 
dispenser 
Security monitoring: Bogus caller button, PIR Movement Sensor, Property Exit 
Sensor 
Environmental monitoring: Natural Gas Detector, Carbon Monoxide Detector, Smoke 
Detector, Heat Sensor, Temperature Extremes Sensor, Flood Detector 
Standalone: Motion Light, Picture Phone, Timex USB Watch, Memo Minder, 
Dummy Bell Box, Key Safe, Magiplug, DDA Pager, Big Button Phone 
 
Relatively few participants received safety and security monitoring sensors; in 
contrast, all participants had at least one "functional monitoring" sensor. More than half of 
the telecare participants had stand-alone devices. The most frequently used telecare packages 
combined functional, environmental and stand-alone devices. 
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Table 5.16 Telecare equipment used by Telecare study sample by function  
 N* mean 
(SD) 
[[Range ] % 
using 
All items of equipment 553 4.7 (1.77) [1 - 11] 100% 
Functional monitoring 553 1.8 (0.83) [1 - 5] 100% 
Environmental monitoring 522 2.1 (1.15) [0 - 5] 94% 
Stand-alone devices 302 0.6 (0.63) [0 - 3] 55% 
Security monitoring 79 0.2 (0.42) [0 - 3] 14% 
Participants with items from a single function 
category 
17 1.7 (0.59) [1 - 3] 3.1% 
Combinations of function†      
Functional, environmental and stand-alone  240 5.2 (0.09) [3 - 10] 43.4% 
Functional and environmental 207 3.7 (0.09) [2 - 7] 37.4% 
Functional, environmental, safety/security and 
stand-alone  
50 7.1 (1.64) [4 - 11] 9.0% 
Functional, environmental and safety/security 25 5.4 (0.25) [4 - 8] 4.5% 
Functional and stand-alone 10 3.4 (0.27) [2 - 5] 1.8% 
* Number of questionnaire participants at baseline, including those not completing CSRIs 
†combinations of equipment used by more than 1% of the questionnaire study sample 
 
5.16.4 Unit costs of the Telecare Services 
The ranges of unit costs of telecare support across the sites are given in Table 5.17, along 
with the costs of the service excluding project-related posts and contracts from calculations, 
and excluding costs of dedicated WSD telecare responders. As I have noted, sites had quite 
different project management structures and local arrangements for monitoring and 
responding to telecare sensor activations; as might be expected, the unit costs of telecare 
support also varied substantially between the sites. The mean annual per-person cost of 
telecare equipment was £81 (SE £1.9) for participants who had completed baseline 
assessments and £82 (SE £2.3) for those who had also completed the 12-month follow-up. 
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Table 5.17 Unit costs, Telecare intervention in the three WSD sites 
Cost category Range (£ per year, 2009-10) 
In-house staff  26,999 – 213,465  
Monitoring base unit  6,951 – 12,228  
Sensors and other peripherals 17,019 – 28,148  
Maintenance 24,891 – 34,217  
Installation 13,694 – 17,224  
Contract costs/fees to other organisations 52,000 – 191,112  
DIRECT NON-EQUIPMENT COST OF SUPPORT 170,432 – 456,019  
DIRECT SUPPORT COST PER PARTICIPANT* 437 – 1004 
Less project management-specific posts and contracts 423 - 870  
Less response-related contract costs 408 - 908  
“Mainstream” telecare support package of £5 per week †   261  
Equipment costs   
Unit costs‡  1.05 - 93.20 
Equipment costs per participant 73 - 93 
* Excludes cost of equipment 
† For sensitivity analysis 
‡ Annual equivalent 
 
5.16.5 Costs of Health and Social Care 
At baseline, hospital services constituted about a quarter of health and social care costs 
(imputed and excluding intervention costs), with community primary and mental health care 
costs contributing 14 per cent and community social care 37 per cent (Table 5.18). At 12-
month follow-up (Table 5.19), the composition of costs was largely unchanged, although 
medications accounted for less of the total (8 per cent vs. 15 per cent). The mean annual cost 
of a telecare support and equipment package (for those in receipt of equipment) was £791. 
Intervention group costs were somewhat higher than control group costs at the end of the 
trial.  
In terms of missing data, most costs at the category level were near-complete (<2% 
missing) at baseline (however NHS equipment and adaptations were missing for 14 per cent 
of telecare and 12 per cent of usual care cases; LA equipment and adaptations missing for 6 
per cent telecare and 3 per cent usual care cases). At follow-up, there were more missing data 
in certain categories: care home costs (6 per cent of telecare, 3 per cent of usual care cases), 
NHS day care costs (19 per cent of telecare and 18 per cent of usual care cases), NHS 
adaptations and equipment (7 per cent of telecare, 6 per cent of usual care cases), LA 
adaptations and equipment (7 per cent of telecare, 5 per cent of usual care cases), and 
medications costs (25 per cent of telecare cases, 20 per cent of usual care cases).  
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Table 5.18 Mean service costs (standard errors) over previous 3 months across Telecare sample, available cases at 
baseline 
Resource item 
Usual care 
(n=634) 
Telecare 
(n=548) 
Difference (units) 
 Mean (SE) Mean (SE) Mean (95% CI) 
Hospital use 662 (84) 660 (89) -3 (-243,237) 
Community health services/primary care 299 (36) 354 (37) 55 (-47,156) 
Community mental health 21 (7) 25 (7) 4 (-16,24) 
Community care services 880 (113) 913 (117) 32 (-286, 351) 
Care home respite 16 (14) 22 (15) 6 (-35,46) 
Day services LA 112 (13) 86 (14) -26 (-63,12) 
Day services NHS 33 (23) 51 (24) 17 (-49,83) 
Medications 379 (24) 364 (25) -15 (-83, 53) 
Equipment/Adaptations LA 7 (1) 8 (1) 0 (-4, 4) 
Equipment LA/Adaptations NHS 1 (0) 2 (0) 1 (0, 2) 
Total costs exc. telecare delivery and equipment 2411 (166) 2484 (174) 73 (-398, 544) 
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Table 5.19 Mean service costs (standard errors) over previous 3 months across Telecare sample, available cases at 12-month 
follow-up 
Resource item 
Usual care 
(n=381) 
Telecare 
(n=376) 
Difference (units) 
 Mean (SE) Mean (SE) Mean (95% CI) 
Hospital use 466 (69) 512 (69) 45 (-147, 237) 
Community health services/primary care 230 (21) 269 (21) 38 (-19, 96) 
Community mental health 12 (9) 18 (9) 5 (-19, 30) 
Community care services 724 (109) 855 (109) 131 (-172, 434) 
Care home respite 8 (9) 19 (9) 11 (-13, 36) 
Day services LA 175 (30) 184 (30) 8 (-75, 92) 
Day services NHS 12 (7) 13 (7) 0 (-18, 19) 
Medications 164 (10) 147 (9) -17 (-44, 9) 
Equipment/Adaptations LA 7 (2) 3 (2) -4 (-9, 2) 
Equipment LA/Adaptations NHS 2 (1) 3 (1) 1 (0, 3) 
Total costs exc. telecare delivery and equipment 1801 (167) 2021 (166) 220 (-242, 681) 
Telecare intervention 9 (7) 177 (6) 169 (151, 187)** 
Telecare equipment 1 (1) 20 (1) 19 (18, 21)** 
Total costs inc. TC delivery & equipment 1811 (169) 2218 (168) 408 (-59, 875) 
Note: Includes cases where baseline cost data are missing. 
*p<0.001 on clustered t-test 
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5.16.6 Clustering Effects 
The clustering of costs (excluding the intervention) is examined in Table 5.20. The ICCs 
presented for the general practice level are examined separately by time point. The estimated 
ICC values at each time point are higher in the intervention group than in controls (in 
particular, the baseline ICC is much higher in the intervention group than in the control group 
and the confidence intervals of the ICC do not overlap). The confidence intervals of the 12-
month follow-up ICC estimates overlap, suggesting that practice-level clustering is similar 
within the allocation groups at that time point.  
 A caterpillar plot of these costs ranked in ascending order illustrates this point, as 
well as highlighting the variability in costs between general practice clusters.  
 
Table 5.20 Health and social care service costs, Telecare sample, prior three months: intra-
cluster correlation coefficients (ICC) for general practice, per time point, ITT allocation 
 Baseline ICCa No. 
Practices 
N Follow-up ICCa No. 
Practices 
N 
Usual care -0.008 (-0.056,0.039) 103 634 0.087(-0.010,0.183) 95 381 
Telecare 0.196 (0.104,0.289) 101 548 0.094 (-0.005,0.193) 96 376 
Note: imputed data; costs exclude costs of the intervention  
a. From one-way analysis of variance, Searle’s Confidence intervals (Ukoumunne 2002) 
Figure 5.5 Caterpillar plot of costs per cluster, Telecare sample, three months prior to 
baseline, by experimental group 
 
Note: graph of data from the first complete dataset generated by the multiple imputation process 
(graphs from other complete datasets are similar). The error bars represent the standard errors of the 
cluster means (including clusters of one). 
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Figure 5.6 Caterpillar plot of costs per cluster, Telecare sample, three months prior to 12-
month follow-up, by experimental group 
 
Note: graph of data from the first complete dataset generated by the multiple imputation process 
(graphs from other complete datasets are similar). The error bars represent the standard errors of the 
cluster means (including clusters of one). 
 
5.17 Discussion 
The trial participant samples were distinctly different, as would be expected given the 
different trial eligibility criteria. There was a preponderance of women in the telecare study 
sample, whereas there were more men than women in the telehealth study sample. Compared 
to the telehealth sample, more of the telecare sample resided in site 2. Compared to the 
resource-use profile of telehealth trial participants at baseline, the telecare trial participants 
were heavier users of hospital, mental health, social care and GP services (especially home 
visits and rehabilitation). Fewer telecare than telehealth study participants used community 
matron services.  
Demographic and costs data from both studies exhibited considerable heterogeneity, 
attributable to a number of factors. Sites contributed participants in unequal proportions in 
both studies. Site 2 provided about 50 per cent of participants at baseline in telecare, with Site 
1 providing about 23 per cent of the sample; Site 2 provided about 40 per cent in telehealth, 
with the other two sites contributing roughly equal numbers to the sample at baseline. These 
imbalances were somewhat exacerbated by attrition over the 12-month study period. There 
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was considerable between-site variation in the production processes of both the telehealth and 
telecare interventions. 
In both of the questionnaire studies, there was a substantial loss to follow-up at both 
4-month and 12-month assessment points. In the following chapters, analyses focus on the 
data from the 12-month follow-up. In neither case was there much evidence that, within 
experimental groups, the participants that completed the 12-month follow-up differed from 
those that did not, nor between groups apart from variations in the proportions of people with 
COPD in the telehealth sample. 
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Chapter 6  
 
 
Cost Variations in the Telehealth and Telecare Samples 
 
In this chapter I address  research question 3 in each of the telehealth and telecare samples. In 
each case I examine key participant characteristics associated with variations in health and 
social care costs. I first present a subgroup analysis, examining whether the three-month costs 
of participants allocated to telehealth or usual care differ between baseline and long-term 
follow-up time points, depending on their index long-term condition (diabetes, COPD or 
heart failure). I next examine whether the costs of participants allocated to telecare or usual 
care differ between baseline and follow-up depending on their living arrangements (living 
alone or with others).  
 
6.1 Telehealth  
There is a small body of evidence on drivers of health and social care costs of recipients of 
telehealth with long-term conditions. The bulk of this literature is based on Medicare data on 
heart failure patients in the United States. A study of 168 Medicare heart failure patients 
using telehealth examined the association of key medical events (where action is taken by the 
monitoring practitioner in response to the telehealth alert) and use of emergency department 
(ED) and hospitalisations, finding that cancer comorbidity, anxiety comorbidity and the 
number of weekly alerts were significant predictors of all-cause emergency department visits 
and hospital admissions (Radhakrishnan et al. 2013b). A study of 403 Medicare heart failure 
patients discharged from hospital to the care of a home-health care agency found that 29 per 
cent of the sample had a re-hospitalisation within 60 days, and that the number of prescribed 
medications and non-use of certain cardiac medications prescribed (Angiotensin Converting 
Enzyme Inhibitor/ Angiotensin II Receptor Blockers) were predictors of increased risk of 
these events (Radhakrishnan et al. 2013a). A study of a similar population of telehomecare 
users with heart failure found that a higher risk of re-hospitalisation over 60 days was related 
to living arrangements (living with others), overall health status, severe pain and skin 
problems, and lower rates with independence in dressing the lower body (Kang et al. 2016). 
One small UK study (Biddiss, Brownsell, and Hawley 2009) of 45 community-dwelling heart 
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failure patients receiving telemonitoring found associations between key medical events and 
the number of alerts per week, self-rated mobility, self-rated health and self-rated anxiety.  
Two studies noted possible problems with false alarms and many “non-events”. 
Radhakrishnan, Jacelon et al. (2013b) remark on the low numbers of “meaningful” alerts 
recorded (less than 5 per cent of all alerts resulted in a key medical event; false alarms were 
frequent). Biddiss, Brownsell et al. (2009) likewise report that only 6 per cent of alerts 
resulted in a key medical event and also suggests that self-reported health and symptom alerts 
were better predictors of key events than physiological indicators (vital signs measurements 
such as blood pressure), 86 per cent of which did not result in a key medical event. 
In terms of predictors of health care use and costs in the wider population with these 
chronic conditions, a number of studies have examined these using survey or administrative 
data. A variety of personal characteristics, area-level and organisational factors have been 
examined. Several studies have identified drivers of higher health care use in the COPD 
population. Personal characteristics can predict health care utilisation: older age (Hutchinson 
et al. 2010), being female (Menn et al. 2012, Hetlevik, Melbye, and Gjesdal 2016), having 
any comorbidities (Hetlevik, Melbye, and Gjesdal 2016), having particular comorbidities 
such as arthritis, cancer, diabetes, CVD and stroke (Menn et al. 2012), heart failure 
(Hutchinson et al. 2010), having more advanced stages of the disease (Menn et al. 2012), 
ADL difficulties (Garcia-Polo et al. 2012) and lower educational attainment (Hetlevik, 
Melbye, and Gjesdal 2016). Clinical measures constitute another set of health care utilisation 
predictors: FEV1 and BMI (Garcia-Polo et al. 2012, Darnell et al. 2013), higher peripheral 
blood leukocytes and fibrinogen and lower SPO2 (blood oxygen saturation) (Garcia-Polo et 
al. 2012). In addition, increased health care usage is associated with management by 
particular medical specialties (Darnell et al. 2013) and with characteristics of general 
practitioners and practices (Hetlevik, Melbye, and Gjesdal 2016). Lastly, use of 
pharmaceuticals such as the number of prescriptions and use of prescriptions such as inhaled 
corticosteroid and short acting anticholinergics (Darnell et al. 2013) and use of home oxygen 
(Hutchinson et al. 2010) are associated with increased utilisation in COPD. A study of 
patients with COPD, diabetes or at cardiovascular risk in the care of Dutch disease 
management providers found that having cardiovascular disease as a comorbidity, higher 
comorbidity on the Charlson index and lower EQ-5D-3L scores were associated with higher 
health care costs; also in patients with COPD, being in employment was associated with 
decreased costs (Tsiachristas and Rutten-van Mölken 2014). 
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I examined the impact of telehealth on subgroup costs by exploring the effect of the 
intervention at baseline and 12-month follow-up on the costs of participants with the three 
index conditions (COPD, diabetes and heart failure), as well as that of participants’ socio-
demographic and needs-related characteristics. Given that the approach taken was to examine 
the impact of the index conditions across the sample rather than separately examine costs of 
each condition, covariates in the models were necessarily generic to the whole telehealth 
sample, rather than condition-specific (e.g. severity of disease). The questionnaire dataset did 
not include any clinical measures or physician-level personal characteristics. 
The analysis addressed the question: does the impact of telehealth on costs differ 
between the different index conditions, COPD, HF and diabetes? And does the answer 
change depending on the sector for which costs are measured – secondary (hospital) NHS 
care, primary and community NHS care, or social care? 
 
6.2 Methods Used in the Telehealth Cost Subgroup Analyses 
In this section I provide an overview of models employed to examine subgroup difference in 
costs related to receipt of telehealth. I constructed models of total health and social care costs 
(including and excluding intervention costs) and agency-specific costs (NHS and social care, 
hospital care). The composition of cost categories are given in Chapter 4, Table 4.2. 
 
6.2.1 Models 
Multilevel models were fitted to the costs data. Multilevel and population-averaged models of 
the relationship between a continuous response variable and a set of covariates were 
presented in the methods chapter (4.19.2). A three-level difference-in-difference-in-
difference (DDD) approach was described in equation (4.6). The costs of telehealth 
participants can be described as a function that includes a set of covariates:  
𝐶𝑂𝑆𝑇𝑆
= 𝑓[𝑇𝐻, 𝐿𝑇𝐶, 𝐹𝑜𝑙𝑙𝑜𝑤𝑢𝑝, 𝐴𝑔𝑒, 𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛, 𝐹𝑒𝑚𝑎𝑙𝑒, 𝐸𝑡ℎ𝑛, 𝐶𝑜𝑚𝑜𝑟𝑏, 𝑂𝑤𝑛𝑠, S𝑖𝑡𝑒, 𝐼𝑀𝐷, 𝑆𝑒𝑙𝑓𝑐𝑎𝑟𝑒], 
where f(.) is any function described in the models given in Chapter 4, 4.19.2. Here, TH is the 
treatment allocation. LTC is a categorical variable for index long-term conditions. Dummy 
variables were created from the LTC variable to indicate which long-term conditions the 
participant had (these are labelled COPD, HF and Diab). Followup is an indicator for the 12-
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month follow-up vs. the baseline time point. Age is a categorical variable18, Education is a 
three-category variable (no formal, GCSE/O/A-level or degree-level qualifications), Female 
identifies women and men in the sample, Comorb is a count of chronic conditions sourced 
from acute hospital records (Steventon et al. 2012), Ethn is a binary indicator of white-
British/non-white British ethnicity, IMD is a continuous measure of deprivation based on the 
Index of Multiple Deprivation 2007 (Noble et al. 2008), Site identifies the participating local 
authority, Selfcare is an indicator of ADL need based on the self-care domain of the EQ-5D-
3L(no problems, some problems, unable to wash or dress) and Owns is an indicator of owner-
occupation vs. renting and other forms of tenure.  
As discussed in Chapter 4, Section 4.19.5, subject-specific and population-averaged 
models are underpinned by different assumptions and therefore have different interpretations. 
While the former are invaluable for exploring how a participant’s costs changed in response 
to having telehealth, they are less useful in answering policy questions such as ‘how did the 
costs in the intervention group differ from the costs of the controls?’ An important, if self-
evident point should be made, that marginal models can only estimate the average impact of 
one random effect, not the impact over multiple levels of nesting. Predicted probabilities 
generated by subject-specific regressions of dichotomous variables should match those 
produced by population-averaged models (Heagerty and Kurland 2001, Rabe-Hesketh and 
Skrondal 2012); however where non-linear transformations of continuous response variables 
are concerned this does not apply (see section 4.19.4). 
Returning to the models described by equations (4.6) to (4.9), the coefficients on each 
triple-interaction term in the equations (the difference-in-difference-in-difference estimator), 
here called 𝐻𝐹 and 𝐷𝑖𝑎𝑏 (the reference category being COPD) can be understood as (see 
Section 994.19.3):  
𝐻𝐹 = [(𝑦
𝑇,𝐶𝑂𝑃𝐷,2
− 𝑦
𝑇,𝐶𝑂𝑃𝐷,1
) − (𝑦
𝑇,𝐻𝐹,2
− 𝑦
𝑇,𝐻𝐹,1
)] − [(𝑦
𝐶,𝐶𝑂𝑃𝐷,2
− 𝑦
𝐶,𝐶𝑂𝑃𝐷,1
) − (𝑦
𝐶,𝐻𝐹,2
− 𝑦
𝐶,𝐻𝐹,1
)]  
𝐷𝑖𝑎𝑏 = [(𝑦
𝑇,𝐶𝑂𝑃𝐷,2
− 𝑦
𝑇,𝐶𝑂𝑃𝐷,1
) − (𝑦
𝑇,𝐷𝐼𝐴𝐵,2
− 𝑦
𝑇,𝐷𝐼𝐴𝐵,1
)] − [(𝑦
𝐶,𝐶𝑂𝑃𝐷,2
− 𝑦
𝐶,𝐶𝑂𝑃𝐷,1
) − (𝑦
𝐶,𝐷𝐼𝐴𝐵,2
−
𝑦
𝐶,𝐷𝐼𝐴𝐵,1
)]  
 
In the marginal model, 𝐻𝐹 can be interpreted as the ratio of follow-up to baseline costs in 
intervention participants with COPD (the reference category) vs. this ratio in HF participants; 
𝐷𝑖𝑎𝑏 can be interpreted as the ratio of follow-up to baseline costs in intervention participants 
with COPD vs. this ratio in diabetes participants. It is less straightforward to interpret the 
                                                          
18Ages were categorised into 4 bands: 1 "under 65 (young)"; 2 "65-74 (young old)"; 3 "75-84 (old old)"; and 4 
"85+ (oldest old)". 
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subject-specific model: the costs ratio for a given participant with COPD in the intervention 
group can be compared to the costs ratio of a participant with HF in the intervention group 
with the same values of the random intercept (Rabe-Hesketh and Skrondal 2012).  
  
6.3 Distributions of Telehealth Costs and Clustering Effects 
The costs of health and social care (excluding the intervention) for study participants were 
right-skewed, as can be seen in Figure 6.1. The figure depicts their frequency distribution and 
also the corresponding density functions of the gamma and normal distributions over both 
time points. Examining the density probability plots for these distributions, it is evident that 
these data fit the gamma better than the normal distribution.  
 
Figure 6.1 Frequency and theoretical distributions of service costs 
 
 
The clustering of costs for the 965 participants included in this analysis is examined in 
Table 6.3 at both participant and general practice level. The cost data (pooled across 
participants) were clustered within 145 general practices, with practices allocated to the 
intervention (76) outnumbering those allocated to control (69), where cluster sizes were 
smaller in the control (12.5) than in the intervention group (14.5). Costs pooled across 
baseline and follow-up points varied somewhat more within than between GP clusters in the 
intervention; the difference in the amount of variation within and between clusters was more 
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pronounced in the control group. At level 1, the pattern is reversed, with more variation 
between participants than within participants in both groups, not surprising given the limited 
time points under observation. This pattern can also be summarised by the intra-cluster 
correlation (ICC) (calculated by one-way analysis of variance (Ukoumunne 2002)). Pooling 
observations over time, the ICC for general practice is lower in the control than in the 
intervention group. The ICC at level two is slightly higher in the control than in the 
intervention group, but the ICCs are broadly similar between groups. These statistics suggest 
that costs vary somewhat by the cluster-randomisation unit (and more so in the intervention 
clusters), and to a greater extent within-person over time; however they do not take into 
account the influence of important confounders such as age and sex. The ICC of costs for 
general practice, examined by time point, is higher in the intervention than in the control 
clusters, particularly at follow-up; the ICC is higher and negative in the controls at baseline 
compared to the smaller and positive ICC at follow-up. This suggests that there is more 
variability within the control than the intervention GP clusters (one reason being that the 
average number of participants per control cluster is smaller).  
 
6.4 Costs of Participant Subgroups with COPD, Heart Failure and Diabetes 
The population of the Telehealth questionnaire study (see Section 5.2) was predominantly 
male; while many participants were in their older years, just under a third were less than 65 
years of age. Around a quarter of the sample lived alone. Most people (67 per cent) had one 
or more comorbid conditions. The raw costs of participants with index conditions of COPD 
and heart failure (Table 6.2) were in general similar in both experimental groups at baseline; 
however costs were somewhat higher for the people with diabetes allocated to telehealth.  
At follow-up, between-group differences in total costs (excluding those of the 
intervention) were slightly greater than at baseline for participants with COPD and heart 
failure but less for those with diabetes (6 per cent less in TH than in UC). With the addition 
of the cost of the TH intervention, the differences between experimental groups were 
uniformly somewhat higher. 
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Table 6.1 Health and social care service costs (£): cluster means, counts and intra-cluster 
correlation coefficients (ICC) 
Note: costs at baseline and follow-up, excludes costs of intervention. Imputed data. 
a. Intra-cluster correlation, calculated by one-way analysis of variance; Searle’s Confidence intervals 
report arithmetic mean cluster size for unbalanced data (Ukoumunne 2002) 
b. Average number of units under observation 
c. Participant costs pooled across time points 
Time point (level 1)    
Usual care Mean SD Count ICCa 
 1,251 1,798 862 0.204 (0.113,0.295) 
  between subject n  
  1,395 431  
  within subject Mean nb  
  1,135 2  
TH Mean SD Count ICCa 
 1,167 1,861 1,068 0. 204 (0.123, 0.285) 
  between subject n  
  1,444 534  
  within subject Mean nb  
  1,175 2  
Participant unit (level 2)    
 Mean SD Count ICCa 
Usual care 1,251c 1,394 862 0.021 (-1.014,0.057) 
  between practice n  
  750 69  
  within practice Mean nb  
  1,275 12.49  
TH Mean SD Count ICCa 
 1167c 1443 1068 0.062 (0.017, 0.107) 
  between practice n  
  1001 76  
  within practice Mean nb  
  1282 14.05  
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Table 6.2 Mean costs (clustered standard errors) at baseline and 12 months, by ITT allocation and index condition, participants with 
complete data 
 
COPD    Heart 
Failure 
   Diabetes   
  
Usual care 
(SE) 
Telehealth 
(SE) 
Diff.   Usual care 
(SE) 
Telehealth 
(SE) 
Diff.   Usual care 
(SE) 
Telehealth 
(SE) 
Diff.  
  (n=140) (n=232) 
 
 (n=175) (n=177) 
 
 (n=116) (n=125)   
Total costs exc.  
delivery and 
equipment     
 
   
 
   
Baseline 1179 (117) 1119 (92) -60  1112 (117) 1134 (117) 22  1015 (214) 1371 (218) 356 
Follow-up 1387 (191) 1125 (148) -262  1348 (137) 1065 (134) -283  1471 (298) 1320 (302) -152 
Total costs inc.  
delivery and 
equipment     
 
   
 
   
Baseline - - -  - - -  - - - 
Follow-up 1391 (191) 1581 (148) 192  1357 (137) 1516 (134) 160  1489 (301) 1785 (306) 296 
 NHSa            
Baseline 1045 (116) 1030 (93) -15  988 (110) 1016 (110) 28  948 (184) 1228 (184) 281 
Follow-up 1105 (164) 931 (131) -173  1142 (123) 903 (119) -239  1224 (253) 1166 (255) -58 
Hospital only            
Baseline 367 (118) 308 (100) -60  381 (79) 422 (79) 41  304 (158) 536 (157) 232 
Follow-up 620 (133) 455 (107) -164  687 (113) 483 (112) -204  705 (246) 694 (253) -10 
Community care 
(LA)    
 
   
 
   
Baseline 134 (40) 89 (31) -45  124 (51) 118 (52) -6  67 (64) 142 (66) 75 
Follow-up 282 (89) 193 (69) -89  206 (54) 163 (54) -43  248 (66) 154 (66) -93 
Note: Imputed data (10 completed datasets).  
a. Hospital, primary and community mental health services. 
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6.5 Model Results of Telehealth Subgroup Analyses: Total Costs 
Several subject-specific models were fitted to the data in order to examine the impact of 
clustering at general practice and person levels. To begin with, three-level constant-only 
models were fitted to total costs and sub-cost categories (Appendix 3, A3.1, Table A3.1). For 
total costs, the level 3 variance (𝜎𝜇2 
(3), representing the ratio of the mean of the practice to the 
overall mean) was 1.041 and less than the level 2 variance (𝜎𝜇2 
(2), representing the ratio of the 
mean of person to the GP cluster mean), which was 1.366 and thus contributing less (33% vs. 
43%) to the total variation in costs (A3.1, Table A3.1, model (1)). Approximately 25 per cent 
of the total cost variation in this model (coefficient of 0.781, representing the ratio of costs at 
each time point to the person’s overall mean) is attributable to level 1. The inclusion of a 
0
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Figure 6.2 Total, hospital, NHS and social care costs by index condition at baseline and 
follow-up 
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random intercept for general practice and DDD model with no other covariates was 
significantly different from zero (p=0.037) (Appendix 3, A3.1, Table A3.1, model (2)). The 
addition of the DDD variables reduced the amount of variation in costs due to practice-level 
factors and increased the amount of variation in costs due to participant characteristics. The 
inclusion of further covariates for needs-related and other personal characteristics (A3.1, 
Table A3.1, model (3)) greatly reduced the level 3 variance, suggesting that the full set of 
independent variables accounted for much of the variation at that level. A two-level constant-
only model (Appendix 3, Table A3.1, model (4)) unsurprisingly had a higher level 2 variance, 
of 1.414 (95 per cent CI 1.319, 1.516), but a very similar scale parameter of 0.782 (95 per 
cent CI 0.716, 0.854). With the addition of other covariates, variation between participants 
was little different than in the three-level model (A3.1, Table A3.1, model (6)). In the two-
level case, the estimated random intercept was 1.237, and the confidence limits of the 
estimate indicated that 95 per cent of participants can be expected to have an intercept 
between 1.169 and 1.309. In the three-level case, the random intercept estimate was slightly 
higher (1.234) but as 95 per cent of participants can be expected to have an intercept between 
1.158 and 1.315, there is no evidence that the three-level model fits better than the two-level 
version.  
Results of models fitted on the costs of health and social care (excluding intervention 
costs), NHS, hospital and social care were similar. In each case, F-tests of the level three 
random intercept indicated that the general practice level variance was not significantly 
different from zero at the 5 per cent level; although in some cases the level 3 intercept could 
not be estimated and models could not converge with the inclusion of the full set of 
covariates. 
In summary, the inclusion of the third (general practice) level did not improve the fit 
of the cost models. I focus on the two-level model results hereon. 
 
6.5.1 Two-level Subject-specific and Population-averaged Analyses: Total Costs 
The interaction effects of allocation, time point and condition were jointly significantly 
different from zero, whether including or excluding intervention costs (Table 6.3). Looking at 
the time-by-allocation interaction term, total costs were greater in the last three months of the 
trial (by 53 per cent, p=0.001) for a given participant in the TH group relative to controls at 
the baseline. In the model excluding intervention costs, the time-by-allocation interaction 
term was not significantly different from zero (p=0.3). 
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The education dummy variables were jointly associated with costs (including or 
excluding intervention costs, p=0.003 and p=0.002 respectively), as were the age and ADL 
function dummies (p=0.000, including or excluding intervention costs). Having difficulty 
with self-care increased costs by 56 per cent and 64 per cent, including or excluding 
intervention costs, respectively. Being female was associated with increased total costs 
excluding those of the intervention (19 per cent higher). Each additional comorbid condition 
was associated with an increase in costs (including or excluding those of the intervention) in 
the order of 14 per cent to 16 per cent.  
The population-averaged model results for health and social care costs differed 
somewhat from those of the subject-specific model. The interaction effects of allocation, time 
point and condition were not jointly significantly different from zero at the 5 per cent level, 
including intervention costs or excluding intervention costs (Table 6.3). Being female did not 
increase costs (excluding intervention costs) in this model.  
In other respects, results were similar across subject-specific and population-averaged 
models in terms of association of costs with a number of characteristics. Tenure did not 
appear to influence the total costs of care and small-area level deprivation score was also not 
associated with costs at the 5 per cent level in any model. Costs of participants having 
difficulty with ADLs were estimated to be more than one and a half times as great as the 
costs of participants without ADL difficulty; being unable to self-care increased costs more 
than two-fold. Education, age and ADL function dummies were jointly significant as in the 
subject-specific models (at the 5 per cent, 1 per cent and 0.1 per cent level respectively). 
 
6.6 Model Results of Telehealth Subgroup Analyses - Marginal Effects 
To explore the implications of the models, the partial effect of treatment allocation on total 
costs (excluding/including intervention costs) was decomposed by time and index long-term 
condition (Table 6.4 to Table 6.7). In the subject-specific model results (Table 6.4), at the 12-
month follow-up, the costs (including intervention costs) of intervention group participants 
were higher than in controls across the three conditions. For COPD participants, the 
difference in the differences between intervention and control costs at follow-up and baseline 
(DD) was significant (p=0.000). The pattern of results in the heart failure (HF) group were 
somewhat similar but the estimate was not significant at the 5 per cent level (p=0.059). There 
was little indication of difference in the cost differences between time points in the diabetic 
group.  
  
170 
 
Table 6.3 Parameter estimates, subject specific (random intercept) and population-averaged 
(GEE) models of costs (£) in 3 months prior to baseline and 12-month follow-up 
 Subject-specific Population average 
 Excluding  
intervention costs 
Including  
intervention 
costs 
Excluding 
intervention 
costs 
Including 
intervention costs 
Parameter Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
TH 1.028 1.027 1.003 1.004 
 (0.106) (0.106) (0.134) (0.131) 
Follow-up 0.955 0.965 0.995 1.017 
 (0.105) (0.107) (0.133) (0.136) 
TH*Follow-up 0.865 1.534** 0.899 1.353+ 
 (0.121) (0.207) (0.159) (0.221) 
HF 0.881 0.887 0.859 0.868 
 (0.098) (0.099) (0.130) (0.129) 
Diab 0.874 0.863 0.830 0.823 
 (0.106) (0.103) (0.132) (0.126) 
TH*HF 1.057 1.048 1.097 1.080 
 (0.158) (0.156) (0.210) (0.203) 
TH*Diab 1.249 1.247 1.351 1.353 
 (0.202) (0.202) (0.281) (0.275) 
HF*Follow-up 1.255 1.252 1.356 1.319 
 (0.191) (0.193) (0.292) (0.281) 
Diab*Follow-up 1.355* 1.375* 1.338 1.341+ 
 (0.206) (0.210) (0.240) (0.238) 
TH*Follow-up*HF 0.816 0.794 0.698 0.728 
 (0.164) (0.151) (0.192) (0.185) 
TH*Follow-
up*Diab 
0.787 0.718 0.755 0.712 
 (0.169) (0.145) (0.209) (0.179) 
Young old 1.161* 1.108+ 1.131 1.085 
 (0.078) (0.067) (0.088) (0.077) 
Old old 1.176* 1.115 1.205* 1.146 
 (0.087) (0.076) (0.111) (0.097) 
Oldest old 1.823*** 1.653*** 1.616*** 1.515*** 
 (0.173) (0.149) (0.171) (0.154) 
GCSE/O/A-level 1.230*** 1.192*** 1.211** 1.180* 
 (0.072) (0.062) (0.087) (0.076) 
Degree-level 1.136+ 1.121+ 1.067 1.066 
 (0.087) (0.077) (0.095) (0.085) 
Female 1.119* 1.099* 1.068 1.056 
 (0.058) (0.051) (0.067) (0.059) 
White-British 1.212+ 1.186+ 1.198 1.172 
 (0.132) (0.119) (0.170) (0.152) 
Comorbidities 1.162*** 1.144*** 1.160*** 1.145*** 
 (0.017) (0.015) (0.020) (0.018) 
Owns 0.876* 0.888* 0.838* 0.853* 
 (0.057) (0.053) (0.073) (0.068) 
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 Subject-specific Population average 
 Excluding  
intervention costs 
Including  
intervention 
costs 
Excluding 
intervention 
costs 
Including 
intervention costs 
Parameter Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Site 2 1.034 1.074 1.039 1.073  
 (0.065) (0.061) (0.082) (0.075) 
Site 3 1.006 1.078 1.065 1.124 
 (0.099) (0.098) (0.134) (0.133) 
IMD 1.005+ 1.003 1.004 1.002 
 (0.003) (0.003) (0.003) (0.003) 
Some problems 1.636*** 1.556*** 1.657*** 1.578*** 
 (0.090) (0.078) (0.106) (0.091) 
Unable wash/dress 2.722*** 2.460*** 3.022*** 2.675*** 
 (0.462) (0.381) (0.549) (0.432) 
Level 1 constant 549.929*** 577.705*** 675.255*** 705.170*** 
 (86.246) (84.578) (126.057) (120.005) 
𝜎  0.798*** 0.746***   
 (0.044) (0.035)   
 𝜎2[𝑢]  1.321*** 1.237***   
 (0.049) (0.036)   
Ni 1930 1930  1930  
Interaction effects F(7.000, 
7951772)=2.701 
p=0.008 
F(7.000, 
14186249)=2.0
55 p=0.045 
F(7.000, 
43309927)=1.9
13 
p=0.063 
F(7.000, 
51257609)=0.877 
p=0.523 
+  p<0.1 *,  p<0.05  **,  p<0.01, ***p<0.001 
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Table 6.4 Two-level subject-specific model: Partial effect/discrete difference in costs (£) between TH and UC, (ITT allocation) between baseline 
and follow-up, by index condition 
 Excluding intervention costs  Including intervention costs 
 COPD  HF  Diab   COPD  HF  Diab  
Intervention vs. 
control 
Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p  Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p 
Baseline 32 0.790 96 0.437 304 0.052  29 0.798 79 0.493 281 0.055 
(122)  (124)  (156)   (115)  (115)  (146)  
Follow-up -126 0.335 -325* 0.028 -182 0.308  623*** 0.000 409** 0.006 566 ** 0.002 
(131)  (148)  (178)   (135)  (149)  (184)  
Follow-up-
Baseline 
-159 
(158) 
0.315 -421 
(177) 
0.017 -486 
(213) 
0.023  593 
(160) 
0.000 330  
(174) 
0.059 285 
(213) 
0.18 
 
Table 6.5 Two-level subject-specific model: difference-in-difference-in-difference (DDD)  
 Excluding intervention costs   Including intervention costs  
 Exp (𝛽) 
(95% CI) 
p  Exp (𝛽) 
(95% CI) 
p 
DDD HF- COPD -262 
(-725,200) 
0.267  -264 
(-720, 193) 
0.258 
DDD Diab - COPD -327  
(-847,193) 
0.218  -308 
(-826, 210) 
0.244 
DDD Diab - HF -64.377 
(-606, 477) 
0.816  -44 
(-579, 490) 
0.871 
Total costs  
(sum of DD) 
-1065 
(-1691,-440) 
0.001  1208 
(573,1843) 
0 
Ni 1930   1930  
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Table 6.6 Population-averaged model: Partial effect/discrete changes in costs (£), baseline to follow-up of ITT allocation, by index condition 
 Excluding intervention costs  Including intervention costs 
 COPD  HF   Diabetes     COPD   HF   Diabetes    
Intervention 
vs. control 
Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p  Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p 
Baseline 4 0.980 109 0.466 370 0.074  4 0.978 90 0.534 361 0.067 
(158)  (150)   (207)   (150)  (144)  (197)  
Follow-up -117 0.476 -476*  0.044 -116 0.619  426* 0.011 102 0.655 440 0.055 
(164)  (237)  (233)   (166)  (229)  (230)  
Follow-up-
Baseline 
-121 
(204) 
0.553 -585 
(274) 
0.032 -486 
(286) 
0.09  422 
(202) 
0.037 12 
(265) 
0.963 79 
(278) 
0.776 
 
Table 6.7 Population-averaged model: difference-in-difference-in-difference (DDD) costs estimates (£) 
 Excluding intervention costs   Including intervention costs  
 Exp (𝛽) 
(95% CI) 
p  Exp (𝛽) 
(95% CI) 
p 
DDD HF- COPD -464 
(-1132, 204) 
0.173  -409  
(-1059, 240) 
0.217 
DDD Diab - 
COPD 
-364.817 
(-1056, 326) 
0.302  -342  
(-1020, 335) 
0.322 
DDD Diab - HF 99.485 
(-677, 876) 
0.802  67 
(-684, 818) 
0.862 
Total costs -1192.29  
(-2065, 319) 
0.007  513 
(-339, 1366) 
0.238 
Ni 1930   1930  
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The marginal effects (the DDD), whether comparing the cost differences over time between 
COPD and HF, HF and diabetes, or COPD and diabetes, were not significant at the 5 per cent 
level. Adding together the effects of the intervention over the last three months of the 
intervention period on all three condition groups gave an adjusted estimate of £1208 
(p=0.000) greater than in the control group. Table 6.4 also presents the marginal effects 
results for health and social care costs excluding direct intervention costs. The cost 
differences between intervention and control were significantly lower (p<0.05) at 12-month 
follow-up (that is, the DD) in the case of HF and diabetic participants. However the results do 
not suggest that there were substantial differences between subgroups. Adjusting for 
demographic and needs-related characteristics, total estimated costs excluding those of the 
intervention of participants allocated to telehealth were significantly lower at the 1 per cent 
level, by £1065.  
The population-averaged approach (Table 6.6) produced somewhat different marginal 
effects estimates of total cost differences. The DD for the COPD group was about two-thirds 
of the size predicted by the subject-specific model. The DDs for heart failure and diabetic 
groups were small and not significantly different from zero. The DDD estimates, as with the 
subject-specific estimates, were not significantly different from zero at the 5 per cent level. 
The impact of the intervention on costs across the conditions was not significant. The 
marginal effects estimates for health and social care costs excluding the intervention were on 
the other hand broadly similar to those produced by the subject-specific model. There were 
no differences in the DD between conditions; however the overall impact across conditions 
was to decrease three-month costs significantly at the 1 per cent level, by £1192. 
 
6.7 Telehealth Subgroup Costs by Sector 
6.7.1 NHS Costs 
Use of NHS services was near universal, between 99 per cent and 100 per cent of participants 
in the subgroups having NHS costs at either time point. The results of the random intercept 
model of NHS costs are given in Table 6.8. The interaction terms for time, allocation and 
condition were significantly different from zero. Having some difficulty with self-care 
increased costs by 51 per cent; being unable to self-care increased costs by 88 per cent. Costs 
were 25 per cent higher for a given participant attaining secondary school qualifications 
(GCSE/O- or A-levels) compared to a participant with no formal education. The education 
dummy variables were jointly significantly different from zero (F(2.000,151080)=6.937, 
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p=0.001). The coefficients for age categories were significantly different from zero 
(F(3.000,550208)=3.912, p=0.008). White British ethnicity was associated with 25 per cent 
higher costs than for other ethnicities. Each additional comorbidity was associated with 
increased costs, as in the total costs models. The coefficient on the interaction of time point 
and diabetes was significantly greater than zero (p=0.030), suggesting that costs at follow-up 
diverged for the participants with similar values of random intercept who had COPD and 
diabetic conditions.  
In the population-averaged model (Table 6.8), the triple interaction terms were not 
jointly significant at the 5 per cent level. The coefficient on the interaction of time point and 
diabetes was not significantly greater than zero (p=0.091). Overall, higher levels of education 
was significantly associated with increased costs (F(2.000,864443)=4.179, p=0.015). For 
other covariates, coefficients were similar to the subject-specific model, but standard errors 
were larger.  
Marginal effects: Results of the subject-specific model (Table 6.9 and Table 6.10) 
were similar to those for health and social care costs excluding intervention costs. The end-
of-trial cost difference, net of the baseline cost difference, in heart failure participants 
indicates that intervention participants’ NHS costs were significantly lower than controls. A 
similar result is found for the diabetic participants. None of the differences in the difference-
in-differences between subgroups (DDD) was significant (Table 6.10). The estimated total 
cost savings across conditions, adjusted for subgroup differences and other covariates, 
suggests a substantial decrease in NHS costs (not including direct costs of the telehealth 
intervention) of £804 between time points.  
The results of the population averaged model (Table 6.11) suggested larger DD 
estimates in the heart failure and diabetes groups than predicted by the subject-specific 
model; the DD estimate in the heart failure group was significant. As with the subject-
specific model, there were no significant differences in the difference-in-differences between 
subgroups (DDD) (Table 6.12). The estimated three-month savings across conditions on the 
other hand remained large (£990, p=0.014). 
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Table 6.8 Parameter estimates, subject specific (random intercept) and population-averaged 
(GEE) models of NHS costs (£) in the 3 months prior to baseline and 12-month follow-up 
 Subject-specific Population average 
Parameter Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
TH 1.045 1.029 
 (0.108) (0.135) 
Follow-up 0.854 0.916 
 (0.094) (0.123) 
TH*Follow-up 0.906 0.912 
 (0.126) (0.164) 
HF 0.868 0.864 
 (0.098) (0.131) 
Diab 0.894 0.852 
 (0.108) (0.131) 
TH*HF 1.057 1.065 
 (0.159) (0.206) 
TH*Diab 1.191 1.303 
 (0.194) (0.275) 
HF*Follow-up 1.333+ 1.430 
 (0.207) (0.324) 
Diab*Follow-up 1.392* 1.363+ 
 (0.212) (0.250) 
TH*Follow-up*HF 0.789 0.688 
 (0.161) (0.198) 
TH*Follow-up*Diab 0.795 0.764 
 (0.172) (0.219) 
Young old 1.082 1.058 
 (0.074) (0.083) 
Old old 1.063 1.102 
 (0.080) (0.105) 
Oldest old 1.391*** 1.255* 
 (0.137) (0.135) 
GCSE/O/A-level 1.246*** 1.231** 
 (0.074) (0.091) 
Degree-level 1.107 1.042 
 (0.085) (0.096) 
Female 1.054 1.013 
 (0.055) (0.065) 
White-British 1.253* 1.260 
 (0.138) (0.178) 
Comorb 1.164*** 1.162*** 
 (0.017) (0.021) 
Owns 0.872* 0.831* 
 (0.058) (0.075) 
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 Subject-specific Population average 
Parameter Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Site 2 1.009 1.024 
 (0.064) (0.083) 
Site 3 1.006 1.079 
 (0.101) (0.137) 
IMD 1.002 1.001 
 (0.003) (0.003) 
Some problems 1.512*** 1.547*** 
 (0.084) (0.103) 
Unable wash/dress 1.876*** 1.976*** 
 (0.279) (0.356) 
Level 1 constant 562.191*** 666.723*** 
 (90.052) (125.926) 
𝜎 0.797***  
 (0.044)  
 𝜎2[𝑢]  1.343***  
 (0.048)  
Ni 1930 1930 
Interaction effects F(7.000,3742241)=2.414 
p=0.018 
F(7.000,27278471)=1.727 
p=0.098 
+ p<0.1 *,  p<0.05  **,  p<0.01, ***p<0.001 
 
Table 6.9 Two-level subject-specific model of NHS costs: Partial effect/discrete changes in 
costs (£), baseline to follow-up of ITT allocation, by condition  
 COPD  HF  Diabetes   
Intervention 
vs. control 
Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p  
Baseline 47 0.669 101 0.359 241 0.090  
(110)  (110)  (142)   
Follow-up -48 0.654 -240 0.058 -125 0.416  
(108)  (127)  (154)   
Follow-up-
Baseline 
-95  
(134) 
0.478 -342  
(155) 
0.028 -367  
(186) 
0.034  
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Table 6.10 Two-level subject-specific model of NHS costs: difference-in-difference-in-
difference (DDD) costs (£) estimates and total costs  
 Exp (𝛽) 
(95% CI) 
p 
DDD HF- COPD -246  
(-648,155) 
0.229 
DDD Diab - COPD -271.11  
(-723,181) 
0.24 
DDD Diab - HF -24.691  
(-500,451) 
0.919 
Total costs (sum of DD)  -804  
(-1347,-261) 
0.004 
Ni 1930  
 
Table 6.11 Population-averaged model of NHS costs: Partial effect/discrete changes in costs 
(£), baseline to follow-up of ITT allocation, by condition  
 COPD  HF  Diabetes  
Intervention 
vs. control 
Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p 
Baseline 30  0.827 92 0.501 322 0.098 
(138)  (137)  (195)  
Follow-up -60 0.674 -406 0.058 -81 0.690 
(142)  (214)  (202)  
Follow-up-
Baseline 
-90 
(178) 
0.614 -498 
(250) 
0.047 -403 
(260) 
0.056 
 
Table 6.12 Population-averaged model of NHS costs: difference-in-difference-in-difference 
(DDD) costs (£) estimates and total costs 
 Exp (𝛽) 
(95% CI) 
p 
DDD HF - COPD -407.665 
(-1009,193) 
0.184 
DDD Diab - COPD -313 
(-932,306) 
0.322 
DDD Diab - HF 95 
(-614, 803) 
0.793 
Sum of DD -990 
(-1778, -203) 
0.014  
Ni 1930  
 
6.8 Numbers and Proportions Using Hospital and Social Care Services 
55 per cent of participants (n=528) at baseline and 56 percent (n=545) at 12-month follow-up 
had used some hospital service. There were some variations in proportions having used these 
services in the prior three months at baseline and 12 months (Table 6.15). In particular, fewer 
participants with COPD in the TH group had any social care than in the UC group at 12-
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months. Use of hospital services by people with diabetes was particularly high across time 
points and experimental groups. Social care was less used than hospital care across the 
subgroups. The imputed datasets differed slightly in the number using any social care service, 
given that missing category costs were estimated. The numbers using social care were 243 at 
baseline; complete datasets at follow-up varied between 335 and 336.  
 
6.9 Hospital Costs: Two-part Models 
Results are given in Table 6.14 and Table 6.15. In the first (logistic) part of the subject-
specific two-part model of receipt of any hospital care and all hospital costs, the interaction 
effects of time, condition and time point were not jointly significant. The interaction of time 
point and diabetes was significantly different from zero. Educational level was strongly 
associated with an increase in receipt of any hospital care (Table 6.14). The odds of receipt 
were about 1.6 times greater for those with a secondary school education than no formal 
education. The education dummies were jointly significant at 1 per cent 
(F(2.000,931645)=5.872, p=0.003). White British ethnic background nearly doubled the odds 
of receipt of care compared to other ethnicities. Each additional comorbidity increased the 
likelihood of receipt by 27 per cent. The ADL need dummies were jointly significant 
(F(3.000, 2.836e+10)=5.05, p=0.002). Neither age nor tenure was significantly associated 
with receipt of hospital care. The exponentiated covariance between the random effects for 
receipt and costs was significantly greater than zero (1.365, 95 per cent CI 1.07, 1.743, 
p=0.012), indicating that receipt of and costs of hospital care were positively correlated. In 
the second (gamma regression) part (Table 6.15), each extra comorbidity increased the costs 
of hospital care by 19 per cent. ADL needs dummies were jointly significant 
(F(2.000,3.075e+11)=5.969, p=0.003). The interaction effects were not jointly significant. 
Site was associated with neither receipt nor costs of hospital care.  
In the population-averaged logistic regression of receipt, the interaction terms of the 
DDD estimator were jointly significantly different from zero. Estimates for most covariates 
were similar to those of the subject-specific model, although the size of the estimates and 
their standard errors were somewhat smaller. As with the subject-specific model, the 
interaction of time point and diabetes was significantly different from zero at the 5 per cent 
level; also ADL need and education were significant at the 1 per cent level 
(F(2.000,3.983e+09)=6.958, p=0.001; and F(2.000,830650)=6.040, p=0.002 respectively).  
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Table 6.13 Use of hospital and social care in the prior 3 months at baseline and 12-month follow-up: percentage (number) using service  
COPD 
  
 Heart 
Failure 
  
 Diabetes   
 Usual care 
(SE) 
Telehealth 
(SE) 
Raw   Usual care 
(SE) 
Telehealth 
(SE) 
Raw   Usual care 
(SE) 
Telehealth 
(SE) 
Raw  
  (n=140) (n=232) 
 
 (n=175) (n=177) 
 
 (n=116) (n=125)   
Hospital only            
Baseline 48% (67) 47% (109) -1%  56% (98) 62% (110) 6%  53% (61) 66% (83) 14% 
Follow-up 48% (67) 46% (107) -2%  62% (108) 56% (99) -16%  71% (82) 66% (82) -5% 
Community care (LA)*           
Baseline 29% (41) 24% (56) -5%  31% (54) 27% (47) -7%  18% (21) 19% (24) 1% 
Follow-up 42% (59) 30% (69) -12%**  41% (71) 34% (61) -6%  30% (35) 32% (40) 2% 
Note: the number of cases of social care use vary between multiply imputed datasets 1 to 10 (numbers per dataset: 335 in 8 and 336 in 2 
complete datasets) 
*Imputed data.  
**Difference between usual care and telehealth 𝜒2=4.048 and p=0.044 
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The population-averaged gamma regression of costs for those in receipt of any 
hospital services yielded estimates that were somewhat larger and standard errors were in 
general substantially larger than the two-part subject-specific model; the constant was almost 
twice as large as the subject-specific estimate. Each extra comorbidity increased the costs of 
hospital care by 15 per cent. ADL needs dummies were jointly significant 
(F(2.000,3.075e+11)=5.969, p=0.003). Age was not significantly associated with costs 
(F(3.000,1.484e+11)=1.266, p=0.284). 
Marginal effects: Examining the predictions generated by the subject-specific model 
(Table 6.16), there were no significant differences in costs of hospital care between 
intervention and control at baseline or at follow-up in any of the condition subgroups. 
Likewise there was little indication of difference in the DD between conditions. While the 
predictions generated by the two-part population-averaged model (Table 6.18 and Table 6.19) 
were derived from separate models, the standard errors are drawn from a bootstrapped 
distribution of estimates from these models. These predictions differed quite markedly from 
the subject-specific-derived results (in which standard errors are adjusted for the correlation 
between random effects of the receipt and costs models), particularly for the difference-in-
difference estimates for groups with heart failure and diabetes. For the most part, the overall 
interpretation of the effects does not change: the differences between intervention and control 
at each time point are not significantly different nor are the DDD between conditions. The 
total savings across conditions due to telehealth estimated from either model are not 
significant. 
 
6.10 Social Service Costs: Two-part Models 
In the logistic part of the subject-specific model (Table 6.14), the interaction and main effects 
of time, condition and time point were not jointly significant. The odds of receipt over the 
three months prior to the 12-month follow-up point were 3.2 times higher than at baseline; 
being female increased the odds of receipt almost four-fold. Being unable to wash or dress 
increased the odds of social care receipt enormously over having no difficulties with ADLs 
(by 28 times). Each additional comorbid condition increased the odds of receipt by 18. Being 
an owner-occupier decreased the odds of receipt by 72 per cent.  
The exponentiated covariance between receipt and cost models’ random effects was 
greater than one, denoting a (non-significantly) positive relationship between these (𝜌 =2.007 
(95 per cent CI 0.953, 4.225, p=0.067). In terms of costs of participants in receipt of some 
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form of social care (Table 6.15), cost in the three months prior to follow-up (Table 6.15) were 
88 per cent higher than at in the three months prior to baseline. Higher costs were 
significantly associated with age (F(5.000,27061166)=14.999, p=0.000). The education 
dummies were not jointly significant (F(2.000,11441499)=0.891, p=0.410). Costs increased 
slightly (1.8 per cent) with higher (more deprived) IMD scores. Having moderate ADL 
difficulties increased the costs of care by 67 per cent and being unable to wash or dress 
increased costs by 279 per cent. Site was not a significant predictor of receipt or costs of 
social care in the Telehealth sample.  
In the population-averaged logistic regression of receipt (Table 6.14), the estimates 
and standard errors were quite similar to the subject-specific model. Being at the follow-up 
time point and being female doubled the odds of receipt. Comorbidities were associated with 
higher odds of receipt. ADL need increased the odds of receipt so that the most severely ADL 
impaired were 7.6 times more likely to receive than those without problems washing and 
dressing. Home ownership decreased the odds by 54 per cent. Age dummies were jointly 
significant (F(3.000,2.278e+08)=35.058, p=0.000). The population-averaged gamma 
regression results (Table 6.15) did not suggest a significant difference in costs between 
baseline and follow-up, or between owners and other forms of tenure. The interaction effects 
of the DDD estimator were not significantly different from zero. The standard errors of the 
estimates were in general slightly smaller. Levels of ADL need (F(2.000,8.870e+09)=19.886, 
p=0.000) and mean IMD score remained significant at the 5 per cent level as did the age 
dummies (jointly) (F(3.000,7.416e+08)=4.247, p=0.005). The intercept was more than four 
times larger than the subject-specific estimate. 
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Table 6.14 Two-level model estimates of receipt from two-part subject-specific and population averaged models in 3 months prior to baseline 
and 12-month follow-up 
 Subject-specific Population average 
 Social care 
Random intercept 
Hospital care 
Random intercept 
Social care Hospital care 
 
Parameter 𝛽  Exp (𝛽) 
(SE) 
𝛽  Exp (𝛽) 
(SE) 
𝛽  Exp (𝛽) 
(SE) 
𝛽  Exp (𝛽) 
(SE) 
TH -0.047 0.954 0.039 1.040 -0.055 0.947 0.036 1.037 
 (0.421) (0.402) (0.254) (0.264) (0.269) (0.255) (0.218) (0.227) 
Follow-up 1.158** 3.183** 0.024 1.024 0.722** 2.058** 0.020 1.021 
 (0.367) (1.167) (0.262) (0.269) (0.228) (0.469) (0.226) (0.230) 
TH*Follow-up -0.782+ 0.457+ -0.085 0.918 -0.472 0.624 -0.074 0.929 
 (0.467) (0.214) (0.337) (0.309) (0.293) (0.183) (0.289) (0.269) 
HF 0.228 1.256 0.304 1.356 0.155 1.168 0.265 1.304 
 (0.440) (0.552) (0.269) (0.365) (0.283) (0.330) (0.233) (0.303) 
Diab -0.501 0.606 0.198 1.219 -0.352 0.703 0.174 1.190 
 (0.526) (0.319) (0.305) (0.372) (0.337) (0.237) (0.263) (0.313) 
TH*HF -0.255 0.775 0.371 1.449 -0.185 0.831 0.318 1.375 
 (0.587) (0.455) (0.359) (0.520) (0.380) (0.316) (0.310) (0.426) 
TH*Diab 0.093 1.098 0.671+ 1.955+ 0.100 1.106 0.575 1.778 
 (0.679) (0.746) (0.406) (0.795) (0.440) (0.486) (0.350) (0.623) 
HF*Follow-up -0.307 0.736 0.371 1.297 -0.186 0.831 0.226 1.254 
 (0.476) (0.350) (0.359) (0.454) (0.300) (0.249) (0.302) (0.379) 
Diab*Follow-up 0.023 1.024 0.671+ 2.422* 0.035 1.036 0.762* 2.142* 
 (0.567) (0.581) (0.406) (0.918) (0.359) (0.372) (0.327) (0.699) 
TH*Follow-up*HF 0.519 1.681 -0.543 0.581 0.308 1.361 -0.471 0.625 
 (0.653) (1.098) (0.479) (0.278) (0.415) (0.565) (0.414) (0.258) 
TH*Follow-up*Diab 0.832 2.298 -0.862 0.422 0.516 1.675 -0.741 0.476 
 (0.767) (1.763) (0.535) (0.226) (0.485) (0.812) (0.462) (0.220) 
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 Subject-specific Population average 
 Social care 
Random intercept 
Hospital care 
Random intercept 
Social care Hospital care 
Parameter 𝛽  Exp (𝛽) 
(SE) 
𝛽  Exp (𝛽) 
(SE) 
𝛽  Exp (𝛽) 
(SE) 
𝛽  Exp (𝛽) 
(SE) 
Young old 1.097*** 2.994*** 0.116 1.123 -2.104*** 2.059*** 0.102 1.107 
 (0.290) (0.867) (0.158) (0.177) (0.400) (0.393) (0.136) (0.151) 
Old old 2.104*** 8.200*** -0.017 0.983 0.722*** 3.918*** -0.008 0.992 
 (0.311) (2.547) (0.165) (0.162) (0.191) (0.761) (0.143) (0.142) 
Oldest old 4.209*** 67.322*** 0.313 1.368 1.366*** 14.399*** 0.270 1.310 
 (0.496) (33.395) (0.261) (0.357) (0.194) (4.056) (0.227) (0.298) 
GCSE/O/A-level -0.175 0.839 0.449*** 1.567*** 2.667*** 0.908 0.389*** 1.475*** 
 (0.229) (0.192) (0.134) (0.209) (0.282) (0.135) (0.114) (0.168) 
Degree-level 0.272 1.313 0.317 1.373 -0.097 1.194 0.278 1.321 
 (0.340) (0.446) (0.200) (0.274) (0.148) (0.262) (0.174) (0.229) 
Female 1.382*** 3.982*** 0.071 1.073 0.177 2.487*** 0.064 1.066 
 (0.221) (0.880) (0.122) (0.131) (0.220) (0.332) (0.106) (0.113) 
White-British -0.025 0.975 0.665* 1.944* 0.911*** 0.967 0.569* 1.766* 
 (0.416) (0.405) (0.264) (0.514) (0.134) (0.265) (0.228) (0.403) 
Comorb 0.167** 1.182** 0.240*** 1.272*** -0.033 1.114** 0.207*** 1.230*** 
 (0.059) (0.070) (0.035) (0.045) (0.274) (0.041) (0.030) (0.037) 
Owns -1.258*** 0.284*** 0.176 1.192 0.108** 0.463*** 0.152 1.164 
 (0.236) (0.067) (0.137) (0.163) (0.037) (0.068) (0.119) (0.138) 
Site 2 -0.007 0.993 0.075 1.078 -0.770*** 1.016 0.065 1.067 
 (0.247) (0.245) (0.143) (0.154) (0.147) (0.162) (0.123) (0.132) 
Site 3 -0.241 0.786 0.275 1.317 0.016 0.863 0.229 1.257 
 (0.371) (0.291) (0.229) (0.302) (0.160) (0.212) (0.198) (0.249) 
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 Subject-specific Population average 
 Social care 
Random intercept 
Hospital care 
Random intercept 
Social care Hospital care 
Parameter 𝛽  Exp (𝛽) 
(SE) 
𝛽  Exp (𝛽) 
(SE) 
𝛽  Exp (𝛽) 
(SE) 
𝛽  Exp (𝛽) 
(SE) 
IMD 0.006 1.006 0.007 1.007 -0.147 1.005 0.006 1.006 
 (0.010) (0.010) (0.006) (0.006) (0.245) (0.007) (0.006) (0.006) 
Some problems 1.220*** 3.387*** 0.452*** 1.572*** 0.005 2.123*** 0.406*** 1.501*** 
 (0.200) (0.678) (0.130) (0.204) (0.007) (0.269) (0.112) (0.168) 
Unable wash/dress 3.243*** 25.600*** 0.487 1.627 0.753*** 7.626*** 0.450 1.569 
 (0.603) (15.441) (0.345) (0.561) (0.127) (2.732) (0.301) (0.472) 
Level 1 constant -3.280*** 0.038*** -1.326*** 0.265*** 2.032*** 0.122*** -1.149*** 0.317*** 
 (0.640) (0.024) (0.386) (0.102) (0.358) (0.049) (0.332) (0.105) 
 𝜎2[𝑢]  1.125+ 46.509*** 0.858*** 2.140**  -  - 
 (0.646) (35.693) (0.070) (0.504)  -  - 
Ni 1930 1930 1930 1930 
Interaction effects F(7.000,3.339e+08)=0.659 
p=0.707 
F(7.000,7.489e+11)=2.004 
p=0.051 
F(7.000,57602794.181)=
1.018 
p=0.416 
F(7.000,6.947e+11)=2.
019 
p=0.049 
Note: the number of cases of social care use vary between multiply imputed datasets 1 to 10 (numbers per dataset: 335 in 8 and 336 in 2 complete 
datasets)  
+ p<0.1 *, p<0.05 **, p<0.01, ***p<0.001 
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Table 6.15 Two-level model estimates of costs from two-part subject-specific and population 
averaged models in 3 months prior to baseline and 12-month follow-up 
 Subject-specific Population average 
 Social care Hospital care Social care Hospital care 
 Random 
intercept 
Random 
intercept 
  
Parameter Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
TH 0.851 0.840 0.981 0.869 
 (0.357) (0.166) (0.433) (0.228) 
Follow-up 1.859* 1.371 1.267 1.475+ 
 (0.573) (0.287) (0.409) (0.333) 
TH*Follow-up 0.855 0.909 0.920 0.988 
 (0.361) (0.248) (0.461) (0.323) 
HF 0.888 0.865 0.669 0.790 
 (0.350) (0.175) (0.247) (0.220) 
Diab 0.730 0.733 0.652 0.701 
 (0.379) (0.165) (0.339) (0.192) 
TH*HF 1.207 1.105 1.030 1.177 
 (0.648) (0.297) (0.550) (0.416) 
TH*Diab 2.507 1.108 1.743 1.569 
 (1.687) (0.347) (1.173) (0.649) 
HF*Follow-up 0.752 1.014 0.935 1.365 
 (0.295) (0.304) (0.373) (0.490) 
Diab*Follow-up 1.590 1.139 1.574 1.107 
 (0.897) (0.342) (0.928) (0.356) 
TH*Follow-up*HF 1.052 0.939 1.058 0.613 
 (0.606) (0.362) (0.656) (0.298) 
TH*Follow-up*Diab 0.395 1.009 0.496 0.731 
 (0.291) (0.420) (0.383) (0.392) 
Young old 1.333 1.121 1.373 1.098 
 (0.364) (0.133) (0.294) (0.154) 
Old old 1.314 0.997 1.182 1.117 
 (0.373) (0.131) (0.253) (0.190) 
Oldest old 3.195** 1.608* 2.245** 1.464+ 
 (1.181) (0.314) (0.612) (0.289) 
GCSE/O/A-level 1.171 1.245* 1.202 1.155 
 (0.221) (0.129) (0.183) (0.141) 
Degree-level 1.399 1.105 1.204 0.861 
 (0.334) (0.144) (0.219) (0.118) 
Female 1.055 1.001 0.895 0.927 
 (0.203) (0.095) (0.120) (0.105) 
White-British 0.722 1.003 0.620 0.935 
 (0.261) (0.182) (0.180) (0.214) 
Comorb 1.064 1.194*** 1.080+ 1.152*** 
 (0.048) (0.030) (0.050) (0.034) 
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 Subject-specific Population average 
 Social care Hospital care Social care Hospital care 
Parameter Random 
intercept 
Random 
intercept 
  
Owns 1.629* 0.853 1.264 0.807 
 (0.318) (0.099) (0.212) (0.124) 
Site 2 1.316 1.074 1.193 1.099 
 (0.256) (0.128) (0.209) (0.154) 
Site 3 0.857 0.971 0.839 1.070 
 (0.265) (0.166) (0.247) (0.236) 
IMD 1.019* 1.005 1.019* 1.004 
 (0.008) (0.006) (0.008) (0.006) 
Some problems 1.672** 1.389** 1.616*** 1.424*** 
 (0.266) (0.140) (0.217) (0.152) 
Unable wash/dress 3.794** 1.444 5.685*** 1.667 
 (1.823) (0.367) (1.718) (0.572) 
Level 1 constant 67.258*** 361.030*** 289.364*** 657.763*** 
 (50.311) (103.730) (134.110) (198.042) 
𝜎 1.208* 0.879*** - - 
 (0.090) (0.022) - - 
 𝜎2[𝑢]  3.080+ 2.359*** - - 
 (1.989) (0.165) - - 
𝜌12  2.212
+ 1.365* - - 
 (1.049) (0.170) - - 
Ni 335-336 1073 335-336 1073 
Interaction effects F(7.000,3.339e
+08)=0.659 
p=0.707 
F(7.000,2.138e
+12)=0.216 
p=0.982 
F(7.000,1.197e
+09)=0.238 
p=0.976 
F(7.000,1.242e
+12)=0.558 
p=0.791 
Note: the number of cases of social care use vary between multiply imputed datasets 1 to 10 
(numbers per dataset: 335 in 8 and 336 in 2 complete datasets)  
+ p<0.1 *, p<0.05 **, p<0.01, ***p<0.001 
 
Marginal effects: As with hospital costs, there were no significant differences in the 
three-month costs of social care between intervention and control at baseline or 12-month 
follow-up in any condition subgroup (Table 6.16). The results of the population-averaged 
model show similarly that there were no differences between intervention and control 
between conditions. The estimate of total savings due to telehealth was not significantly 
different from zero.  
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Table 6.16 Two-level subject-specific model: Partial effect/discrete changes in costs (£), baseline to follow-up of ITT allocation, by living 
arrangement  
Intervention vs. 
control 
Social care  
 
 Hospital care 
 
 COPD  HF  Diab   COPD  HF  Diab  
 Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p  Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p 
Baseline -14 0.692 -6 0.871 62 0.208  -52 0.489 18 0.819 46 0.620 
(36)  (37)  (49)   (74)  (80)  (93)  
Follow-up -102 0.159 -38 0.484 -66 0.497  -123 0.274 -158 0.237 -128 0.387 
(72)  (54)  (96)   (112)  (134)  (148)  
Follow-up-Baseline -87.71  
(67) 
0.192 -32  
(55) 
0.562 -127 
(101) 
0.206  -71 
(121) 
0.555 -177 
(148) 
0.233  -174 
(159) 
0.272 
 
Table 6.17 Two-level subject-specific model: difference-in-difference-in-difference 
(DDD) costs (£) estimates and total costs  
 Social care    Hospital care  
 Exp (𝛽) 
(95% CI) 
p  Exp (𝛽) 
(95% CI) 
p 
DDD HF - COPD -32 
(-140, 76) 
0.562  -105 
(-479, 268) 
0.581 
DDD DIAB - COPD -40  
(-273, 193) 
0.739  -103 
(-495, 290) 
0.608 
DDD DIAB - HF -95 
(-320, 129) 
0.404  2  
(-422, 427) 
0.991 
Total costs 
(sum of DD) 
 -247  
(-511, 17) 
0.067  -423 
(-911, 66) 
0.09 
Ni 1930   1930  
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Table 6.18 Population-averaged model: Partial effect/discrete changes in costs (£), baseline to follow-up of ITT allocation, by living 
arrangement  
 Social care   Hospital care 
 COPD  HF  Diab   COPD  HF  Diab  
Intervention vs. 
control 
Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p  Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p 
Baseline -7 0.920 -11 0.787 64 0.345  -47 0.635 56 0.545 207 0.194 
(68)  (39)  (68)   (99)  (93)  (159)  
Follow-up -73 0.342 -27 0.476 -46 0.581  -93 0.534 -327 0.080 -44 0.804 
(77)  (39)  (83)   (149)  (187)  (177)  
Follow-up-
Baseline 
-67 
(87) 
0.446 -17 
(46) 
0.716 -110 
(104) 
0.289  -46 
(161) 
0.774 -384 
(212) 
0.07 -251 
(230) 
0.275 
 
Table 6.19 Population-averaged model: difference-in-difference-in-difference (DDD) costs (£) estimates 
and total costs  
 Social care    Hospital care  
 Exp (𝛽) 
(95% CI) 
p  Exp (𝛽) 
(95% CI) 
p 
DDD HF - COPD 50  
(-148, 248) 0.622 
 -337  
(-854, 179) 
0.200 
DDD DIAB - 
COPD 
 -43 
(-312, 225) 0.752 
 -205  
(-747, 337) 
0.459 
DDD DIAB - HF  -93 
(-320, 133) 
0.421   133 
(-458, 723) 
0.660 
Total costs 
(sum of DD) 
 -193 
(-464, 77) 0.162 
 -680 
(-1397, 36) 
0.063 
Ni 1930   1930  
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6.11 Discussion of Telehealth Subgroup Analyses Results 
It appears that, controlling for socio-demographic and needs-related variables, there is little 
clear evidence of a difference in the impact of telehealth on the total, NHS, hospital or social 
care costs of Telehealth questionnaire study participants on the basis of their index long-term 
condition. The evidence from the subject-specific and population-averaged models of total 
costs (not including intervention costs) and the marginal effects (of treatment allocation by 
time point and index long-term condition group) suggests that people with diabetes and with 
heart failure in the intervention group had lower total costs than in the control in the last three 
months of their participation in the trial, taking the difference in baseline costs into account. 
However the between-group differences were not significantly different between conditions. 
A similar conclusion could be reached about the between-group cost differences for 
participants with diabetes and heart failure based on the subject-specific model of NHS costs 
(but these differences were not found in the population-averaged estimates). Across the 
conditions, the total costs (including intervention costs) at the end of the study were greater in 
the intervention than in the control group. On the other hand, across conditions, those in the 
intervention group had on average lower 3-month NHS, and overall costs at 12-month 
follow-up, if excluding the costs of the intervention. This is clearly important. While the high 
costs of the intervention at the time meant that there could be no overall cost savings if these 
were taken into account, there is substantial evidence here that telehealth did decrease 
participants’ other health costs across the board. Interestingly, social care receipt was higher 
at the follow-up, across the sample. Several covariates were consistently associated with 
higher costs across sectors: ADL need, older age, number of comorbid conditions. These are 
all characteristics related to chronic disability and ill-health. Being female increased total 
costs in the subject specific model of total costs, and increased social care costs in both 
modelling approaches. Higher level of education was associated with increased total costs 
and costs of NHS and hospital care and odds of receipt of hospital care. Owner-occupation 
was associated with lower total, NHS and social care costs. 
 
6.12 Limitations 
The observations available for each participant were limited to three-month cost snapshots at 
baseline and follow-up. This limited the amount of information available on within-
participant variation in costs over time. Making inferences about change over time must be 
considered in this light. Differences in ADL need may not have been fully reflected by the 
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EQ-5D-3L self-care subscale that was used as a proxy for this characteristic. Details of 
comorbid conditions other than COPD, diabetes and heart failure were not available in the 
dataset.  
 
6.13 Telecare Subgroup Analyses 
In chapter 5, I set out an overview of the costs of people with social care needs who had been 
allocated to either telecare or usual care. This descriptive summary suggested that there were 
no statistically significant cost differences between experimental groups at the 12-month 
follow-up, whether or not the direct costs of the intervention were included. While the focus 
of the WSD Telecare study was to examine the costs (and outcomes) of all participants 
allocated to the telecare or usual care programmes, there may well be subgroups of 
participants that have quite distinct costs that vary in response to the introduction of telecare. 
Policymakers and commissioners may want to know where to target telecare resources to 
make savings, nationally or locally, by implementing this intervention. In this section, I 
examine whether telecare has an impact on expenditure depending on the living arrangements 
of the user.  
As I have set out in Chapter 2, there are a few reasons given in the policy and industry 
literature for advocating telecare as a ‘good thing’. There is a strong emphasis on the 
promotion of ‘independence’, suggesting that telecare is useful in cases where people are at 
risk of becoming dependent. Thus telecare could be particularly useful for those ‘at risk’ 
because of age-related disability, and for people living alone (Lloyd 2012a) who might 
otherwise need more hands-on care or a move to more supportive accommodation. 
Particularly in the case of people living alone, a motivation for providing this group with 
telecare might be to ensure their safety and protect them from serious injuries or even prevent 
falls (Department of Health 2005a). People living alone may be at risk of more serious 
injuries after a fall than those living with others (Elliott, Painter, and Hudson 2009). This 
could be because an individual who cannot summon help after a fall may have a ‘long lie’ on 
the floor, with adverse consequences; equipped with a remotely monitored falls-detector, that 
person could benefit from a rapid response to the activation of the detector. Indeed, in 
England the proportions using a pendant alarm is much higher in people who live alone than 
in people who live with others (12 per cent versus 2 per cent) (Nyman and Victor 2014). For 
such reasons, it is worth asking whether expenditure on people living alone differs from 
expenditure on those living with others, because of the presence of telecare. The question is 
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of considerable policy relevance, given the intersection of old age, living alone and 
morbidity, all trends that will accelerate in future years. The majority of people aged 85 years 
and over, or ‘oldest old’ in England and Wales live alone (59 per cent) (compared to 38 per 
cent of the ‘old old’); their number has grown rapidly in recent years (Tomassini 2006). 
Finding ways to support and protect this group, a sizeable proportion of which may be 
expected to experience morbidity, will be of increasing importance as the population ages 
(Office for National Statistics 2011). 
 In the next sections, I explore relationships between individual characteristics and 
patterns of health and social care expenditure and ask whether living arrangement (living 
alone or with others) has a differential impact on these patterns.  
 
6.14 Methods Used in the Telecare Cost Subgroup Analyses 
I presented generic models of participants’ costs in Chapter 4, Section 4.19.2. The health and 
social care costs of telecare participants can be described as a function including covariates: 
𝐶𝑂𝑆𝑇𝑆
= 𝑓[𝑇𝐶, 𝐴𝑔𝑒, 𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛, 𝐹𝑒𝑚𝑎𝑙𝑒, 𝐶𝑜𝑚𝑜𝑟𝑏, 𝐸𝑡ℎ𝑛, 𝐼𝑀𝐷, 𝑆𝑖𝑡𝑒, 𝑆𝑒𝑙𝑓𝑐𝑎𝑟𝑒, 𝑂𝑤𝑛𝑠, 𝐿𝑖𝑣𝑒𝑤𝑖𝑡ℎ, 𝐹𝑜𝑙𝑙𝑜𝑤𝑢𝑝 ], 
where f(.) is a function as described in the models laid out in Section 4.19.2 . TC is the 
treatment allocation, Age is a categorical variable19, Female identifies women and men in the 
sample, Comorb is a count of chronic conditions sourced from acute hospital records 
(Steventon et al. 2012), Ethn is a binary indicator of white-British/non-white British 
ethnicity, IMD is a continuous measure of deprivation based on the Index of Multiple 
Deprivation 2007 (Noble et al. 2008), Site identifies the participating local authority, Selfcare 
is an indicator of ADL need based on the self-care domain of the EQ5-D, Owns is an 
indicator of owner-occupation vs. renting and other forms of tenure and Livewith is an 
indicator for multi-person households (living with others) and Followup is an indicator for 
the 12-month follow-up vs. the baseline time point..  
The discussion of population and subject-specific models in section 6.2 holds equally 
for the telecare costs analysis. The general approach to modelling the costs data was the same 
as taken in analysing the costs of telehealth participants. The investigation in this case centred 
on the impact of living arrangement on the costs of care for participants. I used a difference-
in-difference-in-difference method to explore differences between experimental groups over 
                                                          
19 Ages were categorised into 4 bands : 1 "under 65 (young)"; 2 "65-74 (young old)"; 3 "75-84 (old old)"; and 4 
"85+ (oldest old)". 
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the two time points by living arrangement. I first considered total costs, with and without the 
direct costs of the intervention, then costs by sector (to the NHS, to secondary health/hospital 
services and to Social Services). Hospital and social care services were used by some but not 
all of the sample and therefore models were initially fitted only to the users of services. I 
examined the probability of use of hospital and of social care also through multilevel logistic 
models and applied these predicted probabilities to estimate the costs in the full sample. The 
average marginal effects of allocation, time and living arrangement were estimated in order to 
compare the differences between experimental groups over the two time points in those living 
with others and those living alone. All analyses reported in this chapter are based on imputed 
data (see Chapter 4, Section 4.22) and include all participants who had costs data available at 
both baseline and 12-month follow-up, 753 cases (375 intervention and 378 control). 
Participants’ data were analysed by their ITT allocation.  
As these analyses focus on the participants’ living arrangements, the availability of 
data on living arrangements is important. The variable for living arrangement was derived 
from two variables: adults living in the household (including the respondent) and children 
under 16 years of age living permanently in the household. At baseline, there was one 
missing observation for numbers of adults in the household, but for children in the household, 
there were missing data in both groups (25 (7 per cent) controls; 33 (8 per cent) intervention). 
At follow-up, almost half of the responses to the number of children in the household were 
missing (212 (44 per cent) controls; 197 (47 per cent) intervention) (in contrast to 3 per cent 
and 4 per cent missing data for adults in the household). Perhaps this question seemed 
irrelevant to many respondents, which in combination with large proportion of the sample 
completing the questionnaire by post resulted in many missing observations (see   for box-
and-whisker plots displaying the missingness of this variable plotted against age, grouped by 
age band). These household composition variables were included in the multiple imputation 
model (see Chapter 4, Section 4.22); the variables for living alone and with others were then 
derived from the imputed data.  
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Figure 6.3 Box-and-whisker plots: missing data in the children 16 years of age in the 
household, by age of respondent grouped by age band  
 
 
6.15 Characteristics of the Telecare Participants: Participants’ Living Arrangements 
As I have described in Chapter 5, the population completing the Telecare study was 
predominantly female. While approximately half of the participants were aged 75 years and 
over (the ‘old-old’ and ‘oldest-old’), just under a quarter were under 65 years of age. Half of 
the sample lived alone.  
The proportion of the sample living with others at baseline was roughly equal in both 
groups although slightly greater in the intervention group (47 per cent control vs. 50 per cent 
intervention); proportions at 12-month follow-up were similar (46 per cent control vs. 49 per 
cent intervention). Transitions from living with others at baseline to living alone at follow-up 
were rare in both experimental and control groups (3 per cent (n=12) in control vs. 4 per cent 
(n=14) in the intervention, respectively). Transitions from living alone at baseline to living 
with others at follow-up were equally rare (2 per cent (n=8) in control vs. 3 per cent (n=10) in 
the intervention, respectively).  
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6.16 Costs  
The total costs of the telecare sample were calculated (see Chapter 4, section 4.17) including 
and excluding the cost of the intervention. In this chapter, costs have been further 
disaggregated by agency (NHS, local authority social care) and by health sector (secondary 
care; primary, community and mental health care).  
Total unadjusted health and social care expenditure on people living alone and living 
with others in the three months prior to baseline and 12-month follow-up is summarised in 
Table 6.20 (by ITT allocation). At follow-up, total spend on those living alone who received 
the intervention was significantly greater than on those receiving usual care (£634, cluster-
adjusted t=-2.757, p=0.006); corresponding spend on those living with others in receipt of 
telecare was somewhat (£111) higher than controls. The pre-baseline costs, in contrast, were 
somewhat greater in the intervention group regardless of living arrangement. People living 
with others and allocated to the intervention had much higher pre-baseline costs than 
controls, a difference rather more marked than in the corresponding groups who lived alone.  
At follow-up, people living alone allocated to the intervention group had somewhat 
higher secondary care costs on average than those in the control group (difference of £237, 
t=-1.803, p=0.071), while those living with others in the intervention group had somewhat 
lower costs than those in the control group (£170, t=0.903, p=0.367). At follow-up and 
looking at health and social care expenditure separately, the difference between experimental 
groups was somewhat greater in those living alone than in those living with others; however 
only NHS expenditure on those living alone differed significantly at the 5 per cent level 
between experimental groups.  
Looking at the sample as a whole (not shown in the table), people living alone at 12-
month follow-up had lower unadjusted total costs than those living with others (£1702 vs. 
£2154), a difference of £452 (t=-1.9, p=0.057) and lower unadjusted social care costs than 
those living with others (£799 vs. £1,198), a difference of £399 (t=-2.244, p=0.026). In 
contrast, there was little difference in hospital costs between those living alone (£476) and 
with others (£500) across the sample at the 12-month follow-up.  
  
  
196 
 
Table 6.20 Costs at baseline and 12 months, by ITT allocation and living arrangement, participants with complete data 
 Living alonea    Living with othersb    
 Usual care (SE) Telecare (SE)  Difference  Usual care (SE) Telecare (SE) Difference 
Total costs exc. delivery and 
equipment  
       
Baseline 1892 (220) 2135 (223)  243  2206 (247) 2693 (245) 487  
Follow-up 1480 (159) 1939 (163)  460* 2201 (314) 2109 (316) -92  
Total costs inc. delivery and 
equipment  
       
Baseline - -  - - - - 
Follow-up 1492 (161) 2126 (165)  634** 2207 (314) 2319 (316) 111  
Hospital, primary and community 
mental health (NHS) 
       
Baseline 1191 (167) 1234 (170)  43  1333 (148) 1640 (144) 307  
Follow-up 764 (101) 1041 (104)  276* 1036 (186) 875 (189) -161  
Hospital only        
Baseline 541 (156) 611 (158)  70  541 (118) 689 (115) 147  
Follow-up 362 (91) 599 (94)  237  588 (132) 417 (134) -170  
Community care (LA)        
Baseline 692 (112) 892 (114)  199  868 (162) 1047 (161) 179  
Follow-up 706 (115) 899 (118)  192  1160 (207) 1234 (205) 74  
a. Numbers living alone at baseline: UC N=202, TC N=188. Numbers living alone at follow-up: UC N=206, TC N=192. 
b. Numbers living with others at baseline: UC N=176,TC=187. Numbers living with others at follow-up: UC N=172, TC N=183.  
* p<0.05 on clustered t-test  
** p<0.01 on clustered t-test  
 
  
197 
 
6.16.1 Distribution of Costs  
The costs of health and social care (excluding the intervention) for study participants were 
right-skewed, as can be seen in Figure 6.4. The figure depicts their frequency distribution and 
also the corresponding density functions of the gamma and normal distributions over both 
time points. Examining the density probability plots for these distributions, it is evident that 
these data fit the gamma better than the normal distribution.  
 
Figure 6.4 Frequency and theoretical distributions of service costs 
 
 
6.16.2 Clustering Effects 
Participants’ mean health and social care costs (excluding the intervention) over the baseline 
and follow-up points, aggregated at participant and at general practice level, are presented in 
Table 6.21. The table also shows the overall, between- and within-cluster standard deviations 
of the means. Costs data are clustered within 191 general practices, almost equally divided 
between allocation groups (95 control and 96 intervention participants, with similar sizes of 
clusters (7.96 control vs. 7.81 intervention). Participants’ costs (pooled across baseline and 
follow-up points) vary somewhat more within- than between-GP clusters, particularly in the 
control group. At participant level, there is more variation between- than within-participants 
in both groups (not surprising given that there are only two time points under observation).  
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The degree of between-cluster variation can be summarised by the intra-cluster 
correlation, or ICC (calculated here by one-way analysis of variance (Ukoumunne 2002)), 
also given in Table 6.21. Pooling observations over time, the ICC for general practice is 
slightly lower in the control than in the intervention group. The ICC at the participant level 
(with observations for two time points per cluster) is slightly higher in the control than in the 
intervention group, but the ICCs are broadly similar between groups. These statistics suggest 
that the extent of between-general practices variation in costs (excluding the intervention) and 
therefore homogeneity within practices is quite high (between 0.108 and 0.11) (see also 
Section 5.16.6). They do not, on the other hand, take into account the influence of 
participants’ socio-demographic characteristics.  
 
Table 6.21 Health and social care service costs: cluster means, counts and intra-cluster 
correlation coefficients (ICC) 
Over time points     
Control Mean SD Count ICCa 
 1,923 2,485 756 0.274 (0.181,0.368) 
  between subject n  
  1984 378  
  within subject Mean nb  
  1498 2  
TC Mean SD Count ICCa 
 2217 2854 750 0. 229 (0.133, 0.325) 
  between subject n  
  2237 375  
  within subject Mean nb  
  1774 2  
Over participants     
 Mean SD Count ICCa 
Control 1,923c 1982 756 0.108 (0.044,0.172) 
  between practice n  
  1344 95  
     within practice Mean nb  
  1608 7.96  
TC Mean SD Count ICCa 
 2,217c 2236 750 0.110 (0.045, 0.174) 
  between practice n  
  1697 96  
  within practice Mean nb  
  1788 7.81  
Note: imputed data; costs at baseline and follow-up, excludes costs of intervention  
a Intra-cluster correlation, calculated by one-way analysis of variance; Searle’s Confidence intervals 
report arithmetic mean cluster size for unbalanced data (Ukoumunne 2002) 
b average number of units under observation 
c participant costs pooled across time points 
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6.17 Model Results of Telecare Subgroup Analyses: Total Costs 
I followed similar methods to those employed in examining the costs of telehealth 
participants (section 6.2.1). Results of models run can be found in Appendix 3, A3.2, Table 
3.2). A three-level constant-only model (model (1)) of costs data demonstrates the proportion 
of variability in costs (including intervention costs) due to participant- and general practice-
level factors. Between-participant variation (𝜎𝜇2 
(2)
= 1.429; 95 per cent CI 1.294, 1.578) was 
greater than the variation between general practice clusters (𝜎𝜇2 
(3)
= 1.222; 95 per cent CI 
1.136, 1.315) (or 41 per cent vs. 35 per cent of the total variance). The within-participant 
standard deviation was 0.797 (95 per cent CI 0.734, 0.866) times the average cost. However 
on adding the DDD terms and other socio-demographic covariates into the random intercept 
model (Table 3.2, model (3)), the amount of unexplained third-level variation in costs 
decreased substantially so that the variance was no longer significantly different from zero 
(𝜎𝜇2 
(3) =1.017; 95 per cent CI 0.980, 1.056; p=0.371). The between-participant variance was 
higher and its standard error lower in the two- than the three-level model (𝜎𝜇2 
(2)
= 1.256 (SE 
0.047) vs. 𝜎𝜇2 
(3)
= 1.237 (SE 0.050) ), while there was no difference in the within-participant 
variances estimated, as could be expected (Van den Noortgate, Opdenakker, and Onghena 
2005). Most (not all) fixed effect coefficients became slightly larger. Nonetheless the impact 
of ignoring the third level appears to be small. Appendix 3 presents the results of the two-
level model (with DDD terms and other socio-demographic covariates) of costs, both 
including and excluding intervention costs. Including direct intervention costs in the total 
costs, the coefficient for allocation to telecare (under ITT) was not significantly associated 
with increased spend. The coefficients on time, age bands, comorbidities, having ADL needs 
and site 2 dummy variable were significantly different from zero at either the 5 per cent or 1 
per cent level. Age, and the passage of 9 months’ time (follow-up) are associated with 
decreased costs; number of comorbidities, living in site 2 and having ADL needs are 
associated with increased costs. For instance, being in the “young old” category was 
associated with a 24 per cent decrease in costs relative to being under 65 years. Being unable 
to complete basic activities of daily living was associated with costs 170 per cent higher than 
those of being independent in such activities. As might be expected, given the substantial 
additional cost associated with the intervention, the interaction of time point and allocation 
was significantly different from zero at the 10 per cent level. The size and significance of the 
triple interaction term (DDD) was not much affected by the inclusion or exclusion of 
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intervention costs. The main effects of allocation and living arrangements and their 
interaction term were significantly greater than zero on joint conditional tests (p=0.001).  
Excluding direct intervention costs produced similar results. The coefficient on the 
triple interaction term (DDD) was not significantly different from zero at the 5 per cent level 
(p=0.187). Joint conditional tests indicated that the coefficients on variables for allocation, 
time and living with others (the main effects) were significantly different from zero (p=0.01) 
and that coefficients on these variables and on the interaction terms (the main and interaction 
effects) were significantly different from zero (p=0.000), but the interaction effects were not 
(p=0.375).  
The results of the random intercept model do not provide strong evidence of a 
telecare-related decrease in total health and social care expenditure at follow-up on those 
living with others. Results obtained from the population-averged models showed a pattern of 
similar results for total costs, including or excluding the intervention cost. As with the subject 
specific models, the main effects of allocation and living arrangements and their interaction 
term were significantly greater than zero at the 5 per cent level on joint conditional tests.  
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Table 6.22 Parameter estimates, subject specific (random intercept) and population-averaged (GEE) models of total and NHS costs in 3 months 
prior to baseline and 12-month follow-up 
 Subject-specific Population average 
 Excluding 
intervention costs 
Including  
intervention costs 
NHS  Excluding 
intervention costs 
Including  
intervention costs 
NHS  
Parameter Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
TC 1.106 1.111 0.956 1.155 1.157 0.991 
 (0.122) (0.123) (0.121) (0.152) (0.152) (0.163) 
Followup 0.804* 0.813* 0.711*** 0.774** 0.780* 0.655*** 
 (0.071) (0.071) (0.073) (0.076) (0.077) (0.084) 
Followup*TC 1.106 1.274+ 1.201 1.126 1.244 1.301 
 (0.149) (0.165) (0.190) (0.179) (0.193) (0.278) 
Lives w/others 0.976 0.984 1.032 0.916 0.922 0.949 
 (0.102) (0.103) (0.123) (0.098) (0.098) (0.128) 
TC*Lives w/ 0.985 0.986 1.188 1.032 1.031 1.241 
 (0.148) (0.148) (0.203) (0.175) (0.175) (0.260) 
Followup*Lives w/ 1.033 1.030 1.002 1.190 1.186 1.161 
 (0.142) (0.141) (0.154) (0.178) (0.177) (0.205) 
TC*Followup*Lives w/ 0.773 0.790 0.600* 0.690+ 0.702 0.519* 
 (0.151) (0.149) (0.133) (0.154) (0.153) (0.147) 
Young old 0.760** 0.763*** 0.900 0.731*** 0.734*** 0.827+ 
 (0.065) (0.063) (0.086) (0.062) (0.061) (0.085) 
Old old 0.799** 0.791** 0.895 0.781** 0.775** 0.846 
 (0.069) (0.065) (0.088) (0.065) (0.063) (0.092) 
Oldest old 0.784* 0.780** 0.737** 0.789* 0.788* 0.724** 
 (0.076) (0.072) (0.082) (0.076) (0.074) (0.090) 
Below-degree 0.994 0.996 0.942 1.004 1.002 0.928 
 (0.070) (0.066) (0.073) (0.070) (0.068) (0.079) 
 
  
202 
 
 Subject-specific   Population average   
 Excluding 
intervention costs 
Including  
intervention costs 
NHS  Excluding 
intervention costs 
Including  
intervention costs 
NHS  
Parameter Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Degree 1.070 1.062 1.134 1.037 1.030 1.136 
 (0.111) (0.104) (0.142) (0.101) (0.096) (0.154) 
Female 1.026 1.027 1.015 0.996 0.998 0.961 
 (0.066) (0.063) (0.072) (0.064) (0.063) (0.077) 
White-British 1.073 1.077 1.080 1.183 1.180 1.163 
 (0.125) (0.119) (0.132) (0.141) (0.136) (0.154) 
Comorb 1.146*** 1.142*** 1.197*** 1.129*** 1.128*** 1.184*** 
 (0.021) (0.020) (0.026) (0.020) (0.020) (0.028) 
Owns 0.958 0.964 1.010 0.996 0.996 1.019 
 (0.066) (0.063) (0.078) (0.072) (0.070) (0.087) 
IMD  0.997 0.997 0.994 0.998 0.998 0.994 
 (0.003) (0.003) (0.004) (0.003) (0.003) (0.004) 
Some ADL problems 1.478*** 1.456*** 1.406*** 1.466*** 1.453*** 1.384*** 
 (0.099) (0.093) (0.100) (0.111) (0.106) (0.123) 
Unable to wash/dress 2.829*** 2.695*** 1.761*** 2.847*** 2.755*** 1.840*** 
 (0.258) (0.237) (0.184) (0.271) (0.255) (0.232) 
Constant 1148.150*** 1130.463*** 798.314*** 1158.410*** 1158.095*** 984.800*** 
 (219.421) (206.922) (173.842) (228.635) (222.116) (239.812) 
𝜎  0.822*** 0.791*** 0.861***    
 (0.031) (0.031) (0.034)    
𝜎[𝑢]  1.284*** 1.256*** 1.433***    
 (0.055) (0.047) (0.063)    
Ni 1506 1506 1506 1506 1506 1506 
Interaction effects F(4.000,3752233)
=1.058 p=0.375 
F(4.000,4230982)
=1.584 p=0.175 
F(4.000,3.087e+0
8)=2.976 p=0.018 
F(4.000,342929)=1
.191 p=0.313 
F(4.000,377335)=
1.268 p=0.280 
F(4.000,2056192
2)=1.864 p=0.114 
Note: lives w/= lives with others; comorb=number of comorbidities 
+ p<0.1 *, p<0.05 **, p<0.01, ***p<0.001 
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Marginal Effects: Marginal effects of the interaction predicted on the basis of the subject-
specific and population-averaged model were investigated to explore the average cost 
implications. I examined the partial effect of treatment allocation (Table 6.23) on total costs, 
decomposed by time and living arrangements, from the subject-specific model. At follow-up, 
expenditure on people in the intervention group who live alone was significantly higher than 
in controls; the expenditure on people in this group who live with others was also somewhat 
but not significantly higher than in controls at the 5 per cent level. The marginal effect of 
interest (the DDD) - the effect of telecare on three month-costs for participants living with 
others - was substantial; however the confidence intervals of the estimate were very wide and 
crossed zero (-£465; 95 per cent CI -£1275, £346). We also would need to consider the 
implications for expenditure on all participants allocated to the intervention. Adding together 
the partial effects of the intervention on both subgroups during the intervention phase, 
expenditure in the intervention period is non-significantly increased from baseline by £437 
(95 per cent CI -£358, £1232).  
I also examined total health and social care costs, after excluding direct costs of the 
intervention. The difference between baseline and follow-up costs for intervention 
participants living alone were somewhat higher than controls (£156; 95 per cent CI -£359, 
£671), while the (non-significant) difference between time points between intervention and 
control participants living with others is in the opposite direction (-£367; 95 per cent CI -
£1002, £267). The total estimated expenditure on all intervention participants, across living 
arrangements, is a modest and non-significant decrease from baseline of £211 (95 per cent CI 
-£1022, £600).  
The population average derived marginal effects results (Table 6.24) diverge 
somewhat from those derived from the subject-specific model. Differences in total costs 
between allocation groups at baseline for participants living with others are double that of the 
estimates from the SS model (and at follow-up are half that of the SS model), but are not 
significantly different from zero. The difference between allocation groups in costs, 
excluding intervention costs, of those living alone at follow-up is larger than in the SS model 
and significant (£362 SS p=0.057 vs. £457 PA p=0.015). However in other respects while the 
PA model estimates are larger and standard errors smaller, the conclusions remain the same 
as would be drawn from the SS model.  
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Table 6.23 Two-level subject-specific model: Partial effect/discrete changes in costs (£), baseline to follow-up of ITT allocation, by living 
arrangement  
 Excluding intervention costs  Including intervention costs 
 Live alone  Live with others   Live alone  Live with others  
Intervention 
vs. control 
Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p  Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p 
Baseline 206 0.365 223 0.399  209 0.345 230 0.369 
(227)  (263)   (222)  (256)  
Follow-up 362 0.057 -146 0.547  660*** 0.000 217 0.361 
(190)  (242)   (188)  (237)  
Follow-up- 
Baseline 
156 
(-359, 671) 
0.553 
 
-367 
(-1002, 267) 
0.257  450.852 
(-55, 957) 
0.081 -14 
(-637, 609) 
0.966 
 Excluding intervention costs    Including intervention costs   
 Exp (𝛽) 
(95% CI) 
p   Exp (𝛽) 
(95% CI) 
p  
DDD -523  
(-1348, 301) 
0.213   -465 
(-1275,346) 
0.261  
Total costs -211 
(-1022, 600) 
0.609   437 
(-358, 1232) 
0.281  
Ni 1506  1506 
+ p<0.1 *, p<0.05 **,  p<0.01, ***p<0.001 
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Table 6.24 Population-averaged model: Partial effect/discrete changes in costs (£), baseline to follow-up of ITT allocation, by living 
arrangement  
 Excluding intervention costs  Including intervention costs 
 Live alone  Live with others   Live alone  Live with others  
Intervention 
vs. control 
Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p  Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p 
Baseline 294.002 0.281 435.286 0.104  295.697 0.275 432.921 0.104 
(273)  (267.728)   (271.029)  (266.046)  
Follow-up 457.015* 0.015 -158.416 0.544  667.164*** 0.000 89.871 0.730 
(187.099)  (261.171)   (187.142)  (260.203)  
Follow-up- 
Baseline 
163.013 
(314.862) 
0.605 
 
-593.702 
(356.335) 
0.096 
 
 371.467 
(313.58) 
0.236 
 
-343.05 
(354.495) 
0.333 
 
 Excluding intervention costs    Including intervention costs   
 Exp (𝛽) 
(95% CI) 
p   Exp (𝛽) 
(95% CI) 
p  
DDD -756.715 
(-1695.63,182.2) 
0.114 
 
  -714.517 
(-1648.7, 219.666)  
0.134 
 
 
Total costs -430.689 
(-1355.71, 494.333) 
0.361 
 
  28.418 
(-892.61,949.445) 
0.952 
 
 
Ni 1506  1506 
+ p<0.1 *, p<0.05 **, p<0.01, ***p<0.001 
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These results suggest that while telecare increased total spending (including 
intervention costs) on all intervention participants, the magnitude of expenditure at follow-up 
was much greater in the case of those living alone than in those living with others, controlling 
for characteristics such as social care need. Also, setting aside the direct cost of the 
intervention, the results suggest that telecare substantially increased health and social care 
spending on those living alone, while the intervention had a weaker and opposite effect on the 
spend on those living with others. However, taking into account the differences between 
groups, and subgroups, over time, from model estimates, it would be difficult to conclude 
from the results that the intervention had any impact on total health and social care costs.  
 
6.17.1 Costs by Sector 
Health and social care costs were investigated separately to understand better the source of 
the variation in the costs of trial participants. At both time points, virtually all participants 
had received some form of NHS service in the prior three months; slightly over half (55 per 
cent at baseline, 54 per cent at follow-up) used some form of hospital service. Despite the 
trial taking place in a population with social care need, not all participants reported receipt of 
social care services (as some trial eligibility criteria were not related to existing receipt of 
care). At follow-up (baseline), 66 per cent (61 per cent) received some form of social care (as 
previously defined, see Table 4.2.  
 
6.17.2 NHS Costs 
In the random-intercept model, the interaction effects were significant at the 1 per cent level. 
Oldest-age and needs-related characteristics were significantly associated with decreased and 
increased costs respectively, as with the total costs. Age categories and ADL needs categories 
were also jointly significant on F-tests (age: F(3.000,25598553.804)=2.670, p=0. 046; ADLs: 
F(2.000,69366.118)=17.911, p=0.000). The coefficient on the DDD interaction term for 
living with others and allocation was significantly different from zero at the 5 per cent level. 
NHS costs at follow-up across the sample also decreased by 29 per cent. The results of the 
population-averaged (PA) model were broadly similar to those of the subject-specific (SS) 
model. 
Marginal effects: While control participants living alone had higher costs than 
intervention participants in the pre-baseline period, the reverse occurred in those living with 
others (although in neither case were differences significant at the 5 per cent level) (see Table 
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6.25). Conversely, at follow-up, intervention group participants living alone had higher NHS 
costs, while the reverse occurred in those living with others (again in neither case were 
differences significant at the 5 per cent level). As a result, the change in the cost difference 
between experimental groups from the pre-baseline to the follow-up period was significantly 
lower in the living with others subgroup (at the 5 per cent level). In other words, for those 
living with others, the difference in NHS costs did vary depending on the allocation. This 
pattern was reversed in the living alone subgroup. The effect of telecare in the intervention 
period for participants living with others (the DDD), a savings of £560 (95 per cent CI -
£1068, -£52), was significant at the 5 per cent level (Table 6.26). However, adding the partial 
effects of the intervention on both subgroups, while NHS spending in the last three months of 
the intervention period appears to be decreased compared to baseline by £201 (95 per cent CI 
-£696, £293), the total saving was not significantly different from zero at the 5 per cent level. 
Results of the population-averaged model (Table 6.27 and Table 6.28) were in line with those 
of the SS model, although the estimated DD in the group living with others was larger (-£481 
PA vs. -£381); the DDD was also larger (-£725 PA vs. -£560). 
 
Table 6.25 Two-level subject-specific model: Partial effect/discrete changes in costs (£), 
baseline to follow-up of ITT allocation, by living arrangement  
+ p<0.1 *, p<0.05 **, p<0.01, ***p<0.001 
 NHS costs    
 Live alone  Live with others  
Intervention vs. 
control 
Exp (𝛽)  
(SE) 
p Exp (𝛽)  
(SE) 
p 
Baseline -51.297 0.722 193.155 0.272 
 (144.442)  (175.794)  
Follow-up 128.145 0.248 -187.437 0.108 
 (111.029)  (116.619)  
Follow-up-Baseline 179.441  
(-150.321,509.204) 
0.286 -380.592 
 (-758.071,-3.113) 
0.048 
Ni 1506   
 NHS costs    
 Live alone  Live with others  
Intervention vs. 
control 
Exp (𝛽)  
(SE) 
p Exp (𝛽)  
(SE) 
p 
Baseline -51.297 0.722 193.155 0.272 
(144.442)  (175.794)  
Follow-up 128 0.248 -187.437 0.108 
(111.029)  (116.619)  
Follow-up-Baseline 179.441  
(-150.321,509.204) 
0.286 -380.592 
 (-758.071,-3.113) 
0.048 
Ni 1506   
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Table 6.26 Two-level subject-specific model: difference-in-difference-in-difference (DDD) 
costs (£) estimates and total costs  
 NHS costs   
 Exp (𝛽) 
(95% CI) 
p  
DDD -560 
(-1068,-52) 
0.031  
Total costs -201 
(-696,293) 
0.425  
Ni 1506   
 
Table 6.27 Population-averaged model: Partial effect/discrete changes in costs (£), baseline 
to follow-up of ITT allocation, by living arrangement  
 NHS costs     
 Live alone  Live with others   
Intervention vs. control Exp (𝛽) 
(SE) 
p Exp (𝛽) 
(SE) 
p  
Baseline -11 0.955 305 0.108  
(195)  (190)   
Follow-up 233 0.078 -176.071 0.203  
(132)  (138.247)   
Follow-up-Baseline 244 
(235) 
0.299 
 
-481.238 
(220.231) 
0.029 
 
 
Ni 1506 1506   
 
Table 6.28 Population-averaged model: difference-in-difference-in-difference (DDD) costs 
(£) estimates and total costs  
 
6.17.3 Hospital Costs: Two-part Models 
A two-level model of participants’ observations at baseline and follow-up was fitted. In the 
‘first’ part of the model (a logistic model) (Table 6.29) the conditional odds of receipt of any 
kind of hospital care were nearly halved for the oldest-old compared to those under 65 years 
of age; the overall effect of age was significant at the 10 per cent level (F(3, 
39706591)=2.291, p=0.076). Each additional chronic condition increased the odds of receipt 
of hospital care (by 29 per cent); having high ADL needs increased the odds of using hospital 
services by 65 per cent. Having a degree-level qualification increased the odds of receipt by 
 NHS costs   
 Exp (𝛽) 
(95% CI) 
p  
DDD -725.3 
(-1366,-85) 
0.026 
 
 
Total costs -237.176 
(-860,385) 
0.455 
 
 
Ni 1506   
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65 per cent (significant at the 10 per cent level). The estimate of the effect of the DDD 
interaction term was not significantly different from zero (p=0.168). Joint tests of interaction 
effects were not significantly different from zero. 
Hospital care costs from the ‘second’ part of the model (those in receipt of any 
hospital care) are displayed in Table 6.30. The young-old had lower hospital costs compared 
to the under-65 group (p=0.014); the age band variables were jointly significantly different 
from zero at the 1 per cent level (F(3,6.577e+08)=4.586, p=0.003). High (but not moderate) 
ADL need was significantly associated with increased cost at the 10 per cent level. Each 
additional comorbid condition was associated with a 17 per cent increase in costs. The DDD 
interaction term was significantly different from zero at the 10 per cent level (p=0.085). 
However, as with the first part of the model, F-tests of the interaction effects indicated that 
these variables were not jointly significantly different from zero.  
The exponentiated estimate of the covariance between random effects for subject in 
the two parts of the model was 0.933 (95 per cent CI 0.663,1.312); as the 95 per cent 
confidence limits cross one, it appears that the odds of receipt do not co-vary with the size of 
hospital costs. 
Marginal effects: The marginal probability of receipt of hospital services was applied 
to the marginal mean hospital costs predicted by the subject-specific two-part model. For 
people living with others, the difference between time points in the difference between 
experimental groups’ hospital costs was £389 (p=0.023). The difference in between-group 
differences (the DDD) was substantial (£494; 95 per cent CI -£953, -£36, p=0.035). The total 
saving made across those living alone and those living with others (£283; 95 per cent CI -
£731, £165) was not significant at the 5 per cent level (p=0.215). The marginal effects 
derived from the two-parts of the population-averaged model were broadly similar but while 
the estimate of the DDD was larger, the 95 per cent confidence intervals of this estimate 
crossed zero.  
 
6.17.4 Social Service Costs: Two-part Models 
In the random-intercept two-part model (Table 6.29), the conditional odds of receipt of social 
care in site 2 were 4.7 times higher than those in site 1, while the odds of receipt in site 3 
were about a third of those in site 1. Those with high ADL needs were 6.4 times more likely 
to receive care. The conditional odds of receipt increased by 79 per cent between baseline and 
follow-up periods (p=0.033), controlling for other factors. The main effects of time point, 
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allocation and living arrangement were not significantly greater than zero at the 5 per cent 
level, nor were their interaction effects. The DDD interaction effects were not jointly 
significantly greater than zero at the 5 per cent level. 
Social care costs of those in receipt of social care were examined (Table 6.30). Costs 
were lower at the 5 per cent level in the young-old and old-old age-bands compared to the 
under-65s. The age band variables were jointly significantly different from zero 
(F(3,858852)=2.619, p=0.049). The effect of moderate ADL-need was to increase costs by a 
factor of 1.4 and the effect of severe need was to more than triple costs. Costs in site 2 were 
also significantly higher at the 5 per cent level than in site 1. The main effects, the DDD 
interaction terms and the interaction and main effects were not significant at the 5 per cent 
level.  
The exponentiated covariance of the random effects of the first and second parts of the 
model was 1.966 (95 per cent CI 1.895, 2.040); the results suggest that receipt of social care 
and the costliness of social care are highly and positively related.  
The population-averaged logistic and gamma regression models yielded comparable 
results to those of the subject-specific model.  
 Marginal effects: The results of the subject-specific and population-averaged 
models were similar (Table 6.31 and Table 6.32). In the case of people living alone, the 
intervention participants’ marginal mean costs were somewhat higher than those of controls 
at both time points. There was little difference in costs between experimental groups in the 
case of people living with others. The estimated difference between the baseline and follow-
up differences in the differences between intervention and control costs (the DDD) had wide 
confidence intervals that crossed zero. There was little evidence that the intervention had an 
impact on social care costs at follow-up either within or across living arrangements.  
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Table 6.29 Two-level model estimates of receipt of social care and hospital care from two-part subject-specific and population averaged models 
in prior 3 months, 12-month follow-up 
 Subject-specific Population average 
 Social 
care 
Social 
care 
Hospital 
care 
Hospital 
care 
Social 
care 
Social 
care 
Hospital 
care 
Hospital 
care 
Parameter  𝛽 
(SE) 
Exp (𝛽) 
(SE) 
 𝛽 
(SE) 
Exp (𝛽) 
(SE) 
 𝛽 
(SE) 
Exp (𝛽) 
(SE) 
 𝛽 
(SE) 
Exp (𝛽) 
(SE) 
TC 0.545+ 1.724+ -0.352 0.703 0.432+ 1.540+ -0.267 0.765 
 (0.314) (0.542) (0.272) (0.191) (0.230) (0.354) (0.210) (0.161) 
Follow-up 0.584* 1.793* -0.291 0.747 0.426* 1.531* -0.225 0.799 
 (0.274) (0.491) (0.239) (0.178) (0.200) (0.306) (0.184) (0.147) 
Follow-up*TC -0.084 0.919 0.487 1.627 -0.058 0.944 0.378 1.459 
 (0.405) (0.373) (0.341) (0.555) (0.296) (0.279) (0.264) (0.386) 
Lives w/ others -0.016 0.984 -0.071 0.931 0.004 1.004 -0.052 0.950 
 (0.331) (0.326) (0.278) (0.259) (0.242) (0.243) (0.215) (0.205) 
TC*Lives w/ others -0.291 0.748 0.214 1.239 -0.242 0.785 0.164 1.178 
 (0.467) (0.350) (0.389) (0.481) (0.345) (0.271) (0.301) (0.355) 
Follow-up*Lives w/ others -0.398 0.672 0.294 1.342 -0.307 0.736 0.227 1.255 
 (0.403) (0.271) (0.350) (0.470) (0.296) (0.218) (0.272) (0.341) 
TC* Follow-up*Lives w/ others -0.473 0.623 -0.687 0.503 -0.349 0.705 -0.534 0.586 
 (0.583) (0.363) (0.492) (0.248) (0.430) (0.303) (0.381) (0.223) 
Young old -0.467+ 0.627+ 0.187 1.205 -0.342+ 0.710+ 0.143 1.154 
 (0.269) (0.169) (0.228) (0.275) (0.200) (0.142) (0.175) (0.202) 
Old old 0.203 1.225 -0.058 0.944 0.133 1.142 -0.037 0.963 
 (0.269) (0.330) (0.222) (0.209) (0.201) (0.230) (0.171) (0.165) 
Oldest old 0.412 1.510 -0.667** 0.513** 0.313 1.367 -0.514** 0.598** 
 (0.310) (0.468) (0.240) (0.123) (0.230) (0.315) (0.183) (0.110) 
Below-degree -0.021 0.980 -0.187 0.829 -0.016 0.984 -0.143 0.867 
 (0.215) (0.210) (0.182) (0.151) (0.161) (0.159) (0.140) (0.121) 
Degree 0.430 1.538 0.500+ 1.648+ 0.272 1.313 0.382 1.465 
 (0.354) (0.544) (0.304) (0.501) (0.257) (0.338) (0.235) (0.344) 
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 Subject-specific Population average 
 Social 
care  
Social 
care 
Hospital 
care 
Hospital 
care 
Social 
care  
Social 
care 
Hospital 
care 
Hospital 
care 
Parameter  𝛽 
(SE) 
Exp (𝛽) 
(SE) 
 𝛽 
(SE) 
Exp (𝛽) 
(SE) 
 𝛽 
(SE) 
Exp (𝛽) 
(SE) 
 𝛽 
(SE) 
Exp (𝛽) 
(SE) 
Female 0.305 1.357 0.235 1.265 0.225 1.253 0.182 1.200 
 (0.194) (0.264) (0.162) (0.205) (0.144) (0.181) (0.125) (0.150) 
White-British 0.050 1.051 -0.094 0.910 0.019 1.019 -0.069 0.933 
 (0.313) (0.330) (0.288) (0.262) (0.232) (0.236) (0.222) (0.208) 
Number of comorbidities 0.096 1.101 0.253*** 1.288*** 0.070 1.073 0.198*** 1.219*** 
 (0.060) (0.066) (0.058) (0.074) (0.045) (0.048) (0.045) (0.054) 
Owner -0.082 0.921 0.160 1.174 -0.081 0.923 0.123 1.131 
 (0.221) (0.203) (0.175) (0.205) (0.166) (0.153) (0.135) (0.153) 
Site 2 1.546*** 4.693*** -0.174 0.840 1.149*** 3.155*** -0.135 0.873 
 (0.244) (1.144) (0.208) (0.175) (0.179) (0.564) (0.161) (0.141) 
Site 3 -1.132*** 0.322*** -0.005 0.995 -0.827*** 0.437*** -0.001 0.999 
 (0.326) (0.105) (0.286) (0.285) (0.238) (0.104) (0.221) (0.220) 
Mean IMD score -0.003 0.997 -0.012 0.988 -0.002 0.998 -0.009 0.991 
 (0.010) (0.010) (0.009) (0.009) (0.008) (0.008) (0.007) (0.007) 
Some ADL problems 0.673*** 1.961*** 0.280+ 1.323+ 0.502*** 1.652*** 0.215+ 1.240+ 
 (0.186) (0.365) (0.167) (0.221) (0.137) (0.227) (0.129) (0.160) 
Unable to wash/dress 1.856*** 6.401*** 0.501* 1.650* 1.475*** 4.371*** 0.383* 1.466* 
 (0.309) (1.981) (0.226) (0.374) (0.230) (1.007) (0.173) (0.254) 
Level 1 constant -0.595 0.552 0.261 1.298 -0.442 0.643 0.194 1.214 
 (0.520) (0.287) (0.470) (0.610) (0.383) (0.246) (0.363) (0.440) 
𝜎2[𝑢]  2.180*** 8.850*** 1.523*** 4.587***     
 (0.059) (0.520) (0.375) (1.721)     
Ni 1506 1506 1506 1506 1506 1506 1506 1506 
Interaction effects F(4.000,79039527)=2.2
59 p=0.060 
F(4.000,3.729e+09)=0.
643 p=0.632 
F(4.000,516419)=2.341 
p=0.053 
F(4.000,3.984e+09)=0.
652 p=0.626 
+ p<0.1 *, p<0.05 **,  p<0.01, ***p<0.001 
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Table 6.30 Two-level model estimates of costs from two-part subject-specific and population 
averaged models in prior 3 months, 12-month follow-up 
 Subject-specific Population average 
 Social Care Hospital  Social Care Hospital  
Parameter Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
TC 1.271 1.121 1.273 1.197 
 (0.193) (0.249) (0.202) (0.362) 
Follow-up 0.916 1.032 0.861 0.826 
 (0.108) (0.194) (0.091) (0.180) 
Follow-up*TC 0.957 1.039 0.959 1.133 
 (0.157) (0.286) (0.168) (0.408) 
Lives w/ others 0.904 0.819 0.927 0.848 
 (0.152) (0.185) (0.144) (0.218) 
TC*Lives w/ others 0.741 1.315 0.757 1.227 
 (0.166) (0.413) (0.170) (0.489) 
Follow-up*Lives w/ others 1.231 1.254 1.321 1.403 
 (0.255) (0.341) (0.281) (0.433) 
TC* Follow-up*Lives w/ others 1.222 0.511+ 1.192 0.446+ 
 (0.336) (0.200) (0.349) (0.219) 
Young old 0.725* 0.703* 0.730** 0.614** 
 (0.098) (0.101) (0.089) (0.098) 
Old old 0.719* 0.824 0.702** 0.826 
 (0.095) (0.126) (0.086) (0.133) 
Oldest old 0.817 0.707+ 0.794+ 0.824 
 (0.110) (0.136) (0.104) (0.168) 
Below-degree 1.079 1.042 1.076 0.904 
 (0.115) (0.135) (0.107) (0.125) 
Degree 0.915 0.946 0.859 0.929 
 (0.117) (0.178) (0.104) (0.192) 
Female 1.060 0.850 1.041 0.857 
 (0.100) (0.101) (0.093) (0.110) 
White-British 1.168 1.051 1.191 1.229 
 (0.271) (0.186) (0.248) (0.269) 
Number of comorbidities 1.039 1.173*** 1.023 1.165*** 
 (0.030) (0.043) (0.027) (0.041) 
Owner 0.988 0.960 1.006 0.991 
 (0.101) (0.123) (0.105) (0.137) 
Site 2 2.290*** 0.937 2.089*** 0.865 
 (0.249) (0.142) (0.223) (0.139) 
Site 3 1.243 0.945 1.500+ 0.941 
 (0.282) (0.199) (0.326) (0.251) 
Mean IMD score 1.000 0.994 0.999 0.994 
 (0.005) (0.006) (0.005) (0.007) 
Some ADL problems 1.365** 1.162 1.292* 1.249 
 (0.143) (0.139) (0.146) (0.176) 
Unable to wash/dress 3.536*** 1.371+ 2.892*** 1.922*** 
 (0.424) (0.243) (0.360) (0.378) 
Level 1 constant 359.401*** 703.520*** 487.307*** 921.535*** 
 (111.958) (239.374) (133.252) (400.093) 
  
214 
 
 
 
Table 6.31 Two-level subject-specific model: Partial effect/discrete changes in costs, 
baseline to follow-up of ITT allocation, by living arrangement  
 Hospital care  Social care  
 Live alone  Live with 
others 
 Live alone  Live with 
others 
 
Intervention 
vs. control 
Exp (𝛽) 
(SE) 
p  p Exp (𝛽) 
(SE) 
p  p 
Baseline -0.196 0.999 199 0.147 250 0.056 -23 0.885 
 (119)  (138)  (131)  (159)  
Follow-up 105 0.359 -189 0.112 191 0.093 58 0.776 
 (115)  (119)  (114)  (205)  
Follow-up-
Baseline 
105 
(-201,411) 
0.499 -389 
(-723, -54) 
0.023 -58 
(-321, 204) 
0.662 
 
81  
(-361, 524) 
0.719 
 
 
Table 6.32 Two-level subject-specific model: difference-in-difference-in-difference (DDD) 
estimates 
 Hospital care   Social care  
 Exp (𝛽) 
(95% CI) 
p  Exp (𝛽) 
(95% CI) 
p 
DDD -494 
(-953,-36) 
0.035  140 
(-375,655) 
0.595 
 
Across living 
arrangements 
-283 
(-732, 165) 
0.215  22.882 
(-491, 536) 
0.87 
Ni 1506   1506  
Note: partial effects calculated using estimates from two-level costs and receipt models 
  
 Subject-specific Population average 
 Social Care Hospital  Social Care Hospital  
Parameter Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
𝜎  1.159*** 0.917** 963 822 
 (0.029) (0.028)   
𝜎2[𝑢]  1.233*** 2.328***   
 (0.011) (0.183)   
𝜌12  1.966
*** 0.933   
 (0.032) (0.162)   
Ni 963 822   
Interaction effects F(4.000,465
216.906)=1.
763 
p=0.133 
F(4.000,5.5
98e+09)=1.
493 
p=0.201 
F(4.000,269
831.871)=2.
101 
p=0.078 
F(4.000,682
09401.489)
=1.464 
p=0.210 
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Table 6.33 Population-averaged model: Partial effect/discrete changes in costs, baseline to 
follow-up of ITT allocation, by living arrangement  
Intervention 
vs. control 
Hospital care  
Exp (𝛽) 
(SE) 
Social care 
Exp (𝛽) 
(SE) 
 Live alone p Live with 
others 
p Live alone p Live with 
others 
p 
Baseline 44 
(178) 
0.807 198  
(152) 
0.190 
 
331 
(176) 
0.061 
 
3  
(138) 
0.981 
 
Follow-up 184  
(131) 
0.159 
 
-187  
(113) 
0.098 
 
238 
 (138) 
0.084 
 
46 
(182) 
0.801 
 
Follow-up-
Baseline 
141 
(-279,560) 
0.511 
 
-386 
(-752,-20) 
0.039 
 
-93 
(-428,242) 
0.588 
 
42.565 
(-348,433) 
0.831 
 
 
Table 6.34 Population-averaged model: difference-in-difference-in-difference (DDD) 
estimates 
 Hospital care  
Exp (𝛽) 
(SE) 
p  Social care 
Exp (𝛽) 
(SE) 
p 
DDD -526.580  
(-1097.735,44.576) 
0.071 
 
 135.202 
(-370.582,640.986) 
0.600 
 
Across living 
arrangements 
-245.204 
 (-787.059,296.651) 
0.375 
 
 -50.072  
(-573.359,473.216) 
0.851 
 
Ni 1506   1506  
Note: partial effects derived from two-part population-averaged model estimates   
6.18 Discussion of Telecare Subgroup Analyses Results 
The treatment effect at follow-up in people living with others was to reduce combined health 
and social care expenditure, but this effect was not significantly different from zero at the 5 
per cent level. The direction of the effect of treatment on expenditure did not vary depending 
on the inclusion or exclusion of direct intervention costs, nor on whether a subject-specific or 
population-averaged approach was taken. Controlling for other factors, health and social care 
costs were lower at follow-up regardless of allocation. 
In a separate model of social care expenditure on those in receipt of care, the effect of 
trial allocation to the intervention was not associated with any trend in spending in terms of 
either living arrangements or time points. In separate models of NHS costs and costs of those 
using hospital services, the results indicate that the impact of the intervention on the costs of 
a given participant living with others differed from the impact on a given participant living 
alone. Any apparent reductions in expenditure related to telecare occurred in the NHS rather 
than in social care.  
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An examination of the marginal effects of telecare at baseline and follow-up by type 
of living arrangement yielded some interesting findings. It appears that there were savings to 
the NHS in the group of telecare participants living with others at the follow-up. However 
once the lack of savings made in providing services for telecare recipients living alone was 
taken into account, we cannot be certain of making savings, given the lack of statistical 
significance even at the 10 per cent level. A similar pattern was seen in the two-part model of 
hospital costs. In contrast, the results of the two-part model of social care expenditure suggest 
that costs were not greatly affected by the introduction of telecare, whether participants lived 
alone or with others.  
Subject-specific and population-averaged modelling approaches were taken in order 
to examine the impact of telecare on individuals in the sample and also to be able to make 
inferences about the impact of telecare over the groups under comparison (experimental 
groups in different living arrangements) that would be useful in a policy context. The results 
of the two approaches yielded generally comparable findings.  
Across sectors, time points and models, number of comorbidities and higher levels of 
ADL need were found to be associated consistently with higher costs. There were also 
associations between higher costs and site:  higher total costs and higher odds of receipt and 
costs of social care were associated with site 2, relative to site 1. Site 3 was associated with 
lower odds of social care receipt than site 1. While older age was associated with lower total 
and NHS costs and lower odds of receipt of hospital care, this covariate was associated with 
higher hospital and social care costs. 
The results presented here require careful interpretation. Telecare is advocated as a 
technology that promotes independence and thereby reduces costs associated with the care 
and support of its users. People living alone may be expected to particularly benefit from the 
technology because it is thought to reduce the risks of falling or other accidents. The results 
suggest that people in receipt of telecare who live alone are the subject of more health care 
expenditure than those in receipt of telecare who are living with others. This could be for a 
number of reasons. The need for care may not have been completely captured, for instance in 
that the level of cognitive impairment was not measured by any study instrument, so that the 
groups did actually differ in terms of related needs. Alternatively, responders and also 
responses to telecare activations could differ. People living alone might be more likely to 
receive a formal (paid) service response that might raise further concerns about unmet needs, 
which would prompt health investigations. Those living with others might get an unpaid 
response from their co-resident carer so that formal services are not activated, or 
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professionals involved might be less concerned given the availability of informal carers. In 
other words, health professionals' responses might differ because they perceive clients living 
alone to be at more risk than those living with others, for the same assessed level of need.  
There is some evidence from the UK and elsewhere to support this suggestion. Living 
alone has been estimated to increase the hospital costs of elective surgery (Turner, Nikolova, 
and Sutton 2016). One US study found that older people living alone were 60 per cent more 
likely to visit an emergency department over a 12-month period than people living with a 
spouse (Hastings et al. 2008). Another found that a population of older veterans living alone 
used more outpatient visits than those living with others (Guzman, Sohn, and Harada 2004).  
Two Finnish studies provide evidence in the opposite direction. An analysis of older people 
participating in a trial of rehabilitation suggested that living alone was a strong predictor of 
social care use, as were indicators of availability of informal care, older age, mood, self-
reported health, ADL-related need and cognition (Kehusmaa et al. 2012). Also, functional 
ability and living in the community were related to lower health care costs, controlling for 
other needs and socio-demographic characteristics. Older people living alone in Finland are 
more likely to receive health and social care services, and be the subject of higher health and 
social care expenditure, than those living with others (Noro, Häkkinen, and Laitinen 1999). In 
the UK, such allocation decisions may depend on implicit assumptions that unpaid co-
resident carers can substitute for paid carers, particularly in times of cuts to councils’ budgets 
(Milne et al. 2013). It is possible that while professionals are not comfortable with adjusting 
services to those living alone and relying on telecare to 'manage the risks of independent 
living' (Bower et al. 2011), they are more comfortable with adjusting services for those living 
with others. There is some evidence here that NHS and particularly hospital services were 
directed towards individuals living alone in receipt of telecare rather than those in receipt of 
telecare living with others; in contrast there is no evidence for this pattern of response by 
social services. Perhaps social care assessors are less risk-averse than health professionals 
(Cameron 2006). It is also possible that co-resident carers’ behaviour was changed by 
telecare so that they did not seek health care for the participant where they otherwise would 
have done. It is also possible that telecare does more to address health-related rather than 
social care-related need than we might assume. Agboola et al. (2014) found that people 
admitted after activating their personal emergency response system were more likely to be 
admitted for chronic illness or infection reasons than for falls. 
Another possibility is that the telecare sensors of people living alone were more likely 
to be activated for some reason. There is some evidence also that those living alone both are 
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more likely to use an alarm and to have more, and more serious, injuries if they have a fall 
(Elliott, Painter, and Hudson 2009). Although one rationale for advocating the use of 
personal/pendant alarms (not necessarily telecare) is to mitigate the consequences of falls, 
those falling do not necessarily use their alarms (Fleming and Brayne 2008) and false alarm-
related call-outs to the emergency services can occur (Johnston et al. 2010). Other studies 
have found that personal alarms may not decrease anxiety, fear of falling or use of health 
services (Lee et al. 2008). Whether a similar phenomenon occurs with telecare (where sensor 
activations may create additional false alarms and additional visits and therefore more input 
and more expenditure) would require further research. Data on alarm activations was not 
available for analysis and so could not be controlled for in the analyses.  
 
6.19 Limitations 
The analysis does not adjust for the characteristics of others in the household, who may also 
have social care needs and be benefiting in some way from the telecare service, including less 
reliance on care and support services. Data was not collected on the relationship between the 
other members of the household and the participant so different caring relationships could not 
be controlled for. If the respondents differed in their likeliness to recall service use by living 
arrangement – for instance in that a co-resident carer could prompt a participant to recall an 
appointment that would have been otherwise forgotten by someone living alone – the 
difference between groups in terms of living arrangements could be exaggerated. However 
the relationship of the differences between allocation groups within these subgroups would 
not be affected.  
The observations available for each participant were limited to three-month cost 
snapshots at baseline and follow-up. This limited the amount of information available on 
within-participant variation in costs over time. Making inferences about change over time 
must be considered in this light.  
 
6.20 Implications for Policy and Research 
The research presented here raises some questions that would benefit from further research. 
More work is needed to understand the decision-making that takes place when telecare 
systems bring people living alone into contact with health professionals. Perhaps a different 
approach to managing risk is needed, for instance to allow health professionals to ‘live with’ 
the perceived risks run by people living alone. If risk-aversion results in bad and expensive 
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outcomes for people living alone using telecare, then reducing risk-averse decision-making 
could shift resources into more effective activities. For example, the system could redistribute 
some funds towards those living with others who are perhaps benefiting from the reassurance 
provided to their carers to be able to go out and leave the person unaccompanied. 
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Chapter 7  
 
 
Cost-effectiveness of Telehealth 
 
There is enormous policy interest in technologies that help people with long-term conditions 
to manage disease and the symptoms of disease effectively and cost-effectively. Whether 
technologies such as telehealth can make a difference to the lives of the population with 
chronic disease has been the focus of much research since the 2000s. The relationship 
between health and social care expenditure and quality of life and psychosocial outcomes 
requires careful investigation. Further research is needed to allow policymakers to make an 
informed decision when considering whether telehealth represents a useful and effective 
route for delivering health care and equally whether it represents the best use of available 
public funds. This chapter focuses on the question: is telehealth in addition to standard 
support and treatment cost-effective compared to standard support and treatment alone?  
In this chapter I present the findings of an analysis of data from the WSD cluster-
randomised controlled trial, designed to address the question of cost-effectiveness of a 
telehealth intervention. I begin with a recapitulation of the context of the study and statistical 
methods employed in the economic evaluation. I present the results and discuss the 
implications of the findings for policymakers and address the limitations and strengths of the 
analysis. 
 
7.1 Context 
Telehealth was defined in the WSD trial as “the remote exchange of data between a patient 
and health care professional to assist in the diagnosis and management of a health care 
condition” (Bower et al. 2011). Participants used telemonitoring equipment to collect and 
transmit vital signs data. These data were classified into risk-related alerts (for example, 
using a traffic light system), according to parameters that would be set initially on the basis of 
clinical guidelines or by a clinician responsible for that patient’s care. The parameters were 
reset by a clinician (general practitioner, telehealth nurse, or community matron) as required, 
after an initial settling-in period. The exact response to the alert depended on the risk level 
associated with the readings, clinical judgment and local protocols that were usually based on 
clinical guidelines (Bower et al. 2011). 
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Monitoring staff were also able to transmit health-related questions, messages, or 
videos to educate patients on their conditions, using the telehealth base unit or set-top box. 
Participants in the telehealth group were not charged for using telehealth services (for 
instance, freephone numbers were provided for calls to central monitoring teams or for 
transmitting vital signs data). On the other hand, participants were expected to have or to 
arrange for a telephone line, power points and electricity, and in one site they were expected 
to have a television available. 
The telehealth systems employed within the trial included elements of both 
telemonitoring and telephone support. The trial was not designed to investigate the effect of 
individual service configurations or technologies (Bower et al. 2011). Rather, the evaluation 
examined whether “telehealth” as a class of technologies added to standard support and 
treatment, is cost-effective compared with standard care alone. As discussed in Chapter 4, 
each study site had different suppliers and service models, which evolved over the course of 
the trial. 
 
7.2 Methods 
The primary outcome of interest in the cost-effectiveness analysis was the total cost to health 
and social care per QALY gained by implementing the telehealth intervention. The 
evaluation also explored several secondary outcomes (state anxiety, depression, well-being 
and QALY derived from SF-6D utilities). As data were missing in variables to be used in the 
analysis (see Chapter 4), ten complete datasets were imputed as has been described in 
Chapter 4, Section 4.22. Seemingly unrelated regressions (SUR) were then applied, adjusting 
standard errors for cluster (general practice). Outcome equations adjusted for baseline 
outcome, site, demographic and individual characteristics (age, sex, ethnicity, IMD, index 
condition, number of chronic conditions). Cost equations adjusted for baseline costs, site, 
demographic and individual characteristics (age, sex, ethnicity, IMD, index condition, 
number of chronic conditions). This modelling approach allowed the estimation of the impact 
of the intervention while controlling for clustering and accounting for the correlation between 
the cost and outcome variables.  
Sensitivity analyses explored the robustness of results to variations in the costs of the 
intervention in terms of lower input prices for equipment and lower costs of telehealth 
monitoring support.  
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The results from the SUR regressions were used to estimate incremental cost-
effectiveness ratios (ICERs) – the additional cost per unit of outcome from the addition of 
telehealth to standard care – and net monetary benefit. Cost-effectiveness acceptability curves 
were plotted, depicting the likelihood that telehealth is cost-effective given different 
assumptions about willingness to pay for outcomes. 
 
7.3 Results  
At baseline, service use and costs data were available for 841 intervention and 728 control 
participants. At the 12-month follow-up, outcomes data were available for 974 participants, 
of whom 969 had costs data available (538 intervention, 431 control). Costs and outcomes 
data at baseline and 12-month follow-up were available for 965 participants (534 
intervention, 431 control). 
 
7.3.1 Costs 
Total annual equivalent costs are given in Table 7.1 for the 965 cases available at baseline 
and follow-up (consisting of 431 control and 534 intervention participants). Annual 
equivalent costs prior to baseline were similar between experimental groups but rather higher 
in the usual care group in the study year, if intervention costs are not included in the total. In 
contrast, the usual care group had rather lower costs, if intervention costs are taken into 
account. Nonetheless, the cluster-adjusted 95 per cent confidence intervals of the total cost 
differences at baseline and at 12-month follow-up were wide and crossed zero.  
 
7.3.2 Outcomes 
Descriptive statistics on outcome data at baseline and 12-month follow-up are summarised in 
Table 7.2. Controls had slightly higher scores at baseline on a number of measures, although 
on formal testing (using a clustered t-test) the differences between groups were not 
significantly different from zero at the 5 per cent level. The difference in mean EQ-5D-3L-
derived QALY (non-significant at the 5 per cent level) was quite small. Comparing results 
from the two generic preference-based measures of health, EQ-5D-3L and SF-12, baseline 
utilities derived from EQ-5D-3L were lower than those derived from the SF-6D; however 
either instrument yielded a very small between-group difference in mean utility scores (-
0.001 and -0.007 respectively). The difference between experimental groups at 12-month 
follow-up in mean EQ-5D-3L-derived utilities (non-significant at the 5 per cent level) was 
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much larger than the difference in utilities derived from the SF-6D (0.031 vs. 0.007). The 
(non-significant) difference in EQ-5D-3L-derived QALY was also small but larger than the 
SF-6D derived QALY (0.031 vs 0.000). The Brief STAI was the only outcome measure 
where the difference between the groups was significant at the 5 per cent level; the difference 
was nonetheless small (less than one point, on a 24-point scale). 
 
Table 7.1  Mean service costs (£) across Telehealth sample, annual equivalent 
 
Resource item Usual care 
(SE) 
Telehealth  
(SE) 
Raw difference 
  (n=431) (n=534) (95% CI) 
Pre-baseline period    
Total costs 4431 (325) 4731 (298) 300 (-572, 1173) 
Intervention period    
Total costs excluding Telehealth 
delivery and equipment 
5575 (480) 4603 (445) -973 (-2266, 320) 
Telehealth equipment costs 15 (34) 673 (33) 658 (563, 752)** 
Telehealth intervention costs  
22 (17) 1156 (17) 
1134 (1086, 
1182)** 
Total costs including Telehealth 
delivery and equipment 
5613 (480) 6431 (445) 819 (-476, 2113) 
- project management costs  5609 (480) 6240 (446) 631 (-664, 1926) 
Sensitivity analyses    
50% reduction in equipment 
prices 
5605 (479) 6095 (445) 490 (-803, 1782) 
80% reduction in equipment 
prices 
5601 (479) 5893 (444) 292 (-1000, 1585) 
Operating at increased capacity  5596 (478) 5960 (444) 364 (-926, 1654) 
Operating at increased capacity 
and 50% reduction in equipment 
prices 
5595 (479) 5621 (444) 25 (-1267, 1317) 
Operating at increased capacity 
and 80% reduction in equipment 
prices 
5591 (479) 5419 (444) -172 (-1464, 1120) 
Note: Table reports the annual equivalent costs for 965 cases with baseline cost data available,  (10 
complete datasets) (10 complete datasets). Standard errors are cluster-adjusted. 
*p<0.01 on clustered t-test 
**p<0.05 on clustered t-test 
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Table 7.2  Outcomes at baseline and 12-month follow-up, Telehealth sample  
 
Outcome measure Usual care  
(SE) 
Telehealth  
(SE) 
Difference 
  
(n=431) (n=534) 
(95% CI) 
Baseline    
Utility (EQ-5D-3L) 0.556 (0.021) 0.554 (0.02) -0.001 (-0.059, 0.056) 
STAI 10.019 (0.249) 9.803 (0.235) -0.216 (-0.891, 0.46) 
CESD-10 9.377 (0.331) 9.405 (0.304) 0.028 (-0.862, 0.917) 
ICECAP-O 0.786 (0.011) 0.797 (0.01) 0.011 (-0.019, 0.041) 
Utility (SF-6D) 0.648 (0.009) 0.641 (0.009) -0.007 (-0.032, 0.018) 
12-month follow-up    
 Utility (EQ-5D-3L) 0.537 (0.02) 0.568 (0.019) 0.031 (-0.024, 0.086) 
STAI 11.528 (0.201) 10.692 (0.18) -0.836 (-1.369, -0.303)** 
CESD-10 10.491 (0.36) 9.735 (0.331) -0.757 (-1.723, 0.21) 
ICECAP-O 0.753 (0.009) 0.767 (0.009) 0.014 (-0.011, 0.039) 
QALY - EQ-5D-3L 0.546 (0.019) 0.561 (0.018) 0.015 (-0.038, 0.068) 
Utility (SF-6D) 0.629 (0.009) 0.636 (0.009) 0.007 (-0.018, 0.032) 
QALY - SF-6D 0.638 (0.009) 0.638 (0.008) 0 (-0.023, 0.024) 
Note: Table reports results for 965 cases with baseline cost and outcome data available,  (10 
complete datasets). Standard errors are cluster-adjusted. 
*p<0.01 on clustered t-test 
**p<0.05 on clustered t-test 
 
7.4 Cost-effectiveness Analyses  
In the SUR model, there was a small but significant difference between the groups in the 
primary outcome (Table 7.3), QALY over the period to the 12-month follow-up (a mean 
difference 0.014). In terms of secondary outcomes, most differences were small and not 
significant at the 5 per cent level, except for the CESD-10 (the difference being small, at less 
than one point) (Steffens et al. 2002); and the STAI, again with less than one-point 
difference. Base case costs including intervention costs were non-significantly higher among 
the telehealth group than the usual care group.  
The SUR model estimates yielded an ICER of £67,000 per QALY (Table 7.3). 
Excluding project management costs, the ratio fell to £54,200. Looking at the secondary 
outcome measures, the ratio for an improvement from highest to lowest levels of anxiety on 
the Brief STAI scale was £22,600; for the CESD-10 scale, the ICER was £6,900 for 
achieving a five-point reduction; the ICER for an improvement from no capability to full 
capability on the ICECAP-O scale was £233,700.  
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Whether telehealth can be considered to be cost-effective depends on the willingness 
to pay for the outcomes generated. Figure 7.1 presents the probability that telehealth would 
be seen as cost-effective as an addition to usual care, using an acceptability curve for 
different values of willingness to pay. At the £30,000 threshold (associated with NICE 
recommendations (National Institute for Health and Clinical Excellence 2008)), the 
probability of cost-effectiveness was 20 per cent. This probability only exceeded 50 per cent 
at threshold values of willingness to pay above £67,000. Figure 7.1 also shows the probability 
of cost-effectiveness if costs related to project management were excluded: at the £30,000 
threshold, the probability of cost-effectiveness was 29 per cent. Excluding project 
management costs, the probability exceeded 50 per cent only at values above about £57,000.  
 
7.4.1 Secondary Outcomes 
There were significant but very modest differences between intervention and control groups 
in state anxiety and depression symptoms (Table 7.3). The probability of cost-effectiveness 
for a 100 per cent improvement from highest to lowest levels of anxiety on the Brief STAI 
only exceeded 50 per cent at willingness to pay levels above about £22,600 (Figure 7.2). The 
probability that the treatment was cost-effective in achieving a five-point reduction on the 
CESD-10 scale exceeded 50 per cent at levels of willingness to pay above about £7000, and 
reached 90 per cent at about £22,000 (Figure 7.3). In relation to an improvement from no 
capability to full capability on the ICECAP-O index, the probability of cost-effectiveness of 
telehealth was 15 per cent at a willingness to pay of £50,000 (Figure 7.4). On the QALY 
derived from the SF-12, the difference between groups was 0.005 (in favour of the 
intervention); the ICER was 178,600. The probability of cost-effectiveness at £30,000 was 9 
per cent.  
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Table 7.3  Differences in cost (£) and effect between Telehealth and UC groups (12 months), annual equivalent 
Values in means (CI) unless otherwise 
stated 
Outcomes / total costs 
Control=431 
Outcomes / total costs 
Telehealth=534 
Difference in outcomes / total 
costs or ICER 
(Control=431; Telehealth=534) 
QALY (adjusted mean, SUR model†) 0.547 (0.537 , 0.557) 0.561 (0.552, 0.570)  0.014 (0.001, 0.028)* 
Cost (adjusted mean, SUR model‡) 5 530 (4 601,6 460) 6 498 (5 924, 7 072)  968 (-145, 2080)  
ICER (£ per QALY) (SUR model§ ) - - 67 000 (-8 600, 1 406 900)  
excluding project management costs    
Cost (adjusted mean, SUR model‡) 5525 (4594, 6456) 6308 (5731, 6885) 783 (-332, 1 898) 
ICER (£ per QALY) (SUR model§) - - 54 200 (-21 100, 1 202 400) 
Secondary outcomes analyses    
Brief STAI (adjusted mean, SUR model†) 11.49 (11.814 , 11.184) 10.72 (11.022 , 10.428) -0.774 (-0.342 , -1.206) ||  
Brief STAI ICER (£) (SUR model‡§)   22 600 (-3 200, 74 600)  
CESD-10 (adjusted mean, SUR model†) 10.46 (10.91 , 10.02) 9.76 (10.17 , 9.35) -0.705 (-0.095 , -1.315) ¶  
CESD-10 ICER (£) (SUR model‡§)   6 900 (-900, 72 000)  
ICECAP-O (adjusted mean, SUR model†) 0.759 (0.746, 0.771) 0.763 (0.753, 0.772) 0.004 (-0.012, 0.020) 
ICECAP-O ICER (£) (adjusted mean, SUR 
model†) 
  233 700 (unbounded,unbounded) 
QALY SF-6D (adjusted mean, SUR 
model†) 
0.635 (0.629, 0.641) 0.641 (0.636, 0.646) 0.005 (-0.003, 0.014) 
QALY SF-6D ICER (£) (SUR model§)   178 600 (-21 000, 378 800) 
Note: Table reports results for 965 cases with baseline cost and outcome data available,  (10 complete datasets). Standard errors are robust 
cluster-adjusted. 
† From SUR analyses (outcome equation), adjusted for allocation, baseline outcome, site, age, sex, ethnicity, IMD, index condition, 
number of chronic conditions 
‡ From SUR analyses (cost equation), adjusted for allocation, baseline costs, baseline outcome, site, age, sex, ethnicity, IMD, index 
condition, number of chronic conditions 
§ rounded to nearest hundred 
|| Retransformed to original scale to enable comparison with raw mean difference; transformed mean=0.043 (0.19, 0.067) 
¶ Retransformed to original scale to enable comparison with raw mean difference; transformed mean=0.141 (0.019, 0.263) 
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Table 7.4  Sensitivity analyses: differences in cost (£) and effect between Telehealth and UC groups (12 months), annual equivalent 
Values in means (CI) unless otherwise 
stated 
Outcomes / total costs 
Control=431 
Outcomes / total 
costs 
Telehealth=534 
Difference in outcomes / total 
costs or ICER 
(Control=431; Telehealth=534) 
Variations in intervention costs:    
Equipment prices reduced by 50%    
Cost (adjusted mean, SUR model‡) 5 524 (4 593, 6 455) 6160 (5 585, 6 735) 636 (-478, 1750) 
ICER (£ per QALY) (SUR model§) - - 44 100 (-32 300, 1 045 500) 
Equipment prices reduced by 80%    
Cost (adjusted mean, SUR model‡) 5 520 (4 588, 6 453) 5958 (5 381, 6 534) 437 (-678, 1 553) 
ICER (£ per QALY) (SUR model§) - - 30 300 (-51 000, 833 000) 
Operating at increased capacity    
Cost (adjusted mean, SUR model‡) 5 516 (4 588, 6 445) 6 024 (5 451, 6 598) 508 (-600, 1 600) 
ICER (£ per QALY) (SUR model†‡) - - 35 167 (-43 500, 905 400) 
Equipment prices reduced by 50% & operating at increased capacity  
Cost (adjusted mean, SUR model†) 5 464 (4 572 , 6 356) 5771 (5 183 , 6 359) 167 (-946, 1 280) 
ICER (£ per QALY) (SUR model§) - - 11 600 (-87 500, 557 700) 
Equipment prices reduced by 80% & operating at increased capacity  
Cost (adjusted mean, SUR model†) 5 517 (4 586, 6 448) 5684 (5 111, 6 257) -32 (-1 100, 1 100) 
ICER (£ per QALY) (SUR model§) - - -2 200 (-134 100, 373 000) 
Note: Table reports results for 965 cases with baseline cost and outcome data available,  (10 complete datasets). Standard errors are robust 
cluster-adjusted. 
† From SUR analyses (outcome equation), adjusted for baseline outcome, site, age, sex, ethnicity, IMD, index condition, number of 
chronic conditions 
‡ From SUR analyses (cost equation), adjusted for baseline costs, baseline outcome, site, age, sex, ethnicity, IMD, index condition, number 
of chronic conditions 
§ rounded to nearest hundred 
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Figure 7.1 Cost-effectiveness acceptability curve: QALY 
 
Figure 7.2 Cost-effectiveness acceptability curve: Brief STAI 
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Figure 7.3 Cost-effectiveness acceptability curve: CESD 
 
Figure 7.4 Cost-effectiveness acceptability curve: ICECAP-O 
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Figure 7.5 Cost-effectiveness acceptability curve: QALY (SF-6D) 
 
 
7.4.2 Sensitivity Analyses 
Equipment costs contributed a sizeable proportion of direct costs per person for the telehealth 
group (Table 7.1). Table 7.1presents the three-month costs estimated for the sensitivity 
analyses (presented here multiplied by 4 to give the yearly equivalent). If equipment prices 
fell by 80 per cent, estimated mean costs per year (unadjusted) for the telehealth group fell 
from £6431 (SE £445) to £5893 (SE £444). However, total costs of the telehealth group 
remained slightly higher than those of the usual care group (difference £292 (-£1000, 
£1585)). If equipment prices decreased by 50 per cent, total costs for the telehealth group 
were also higher than for the usual care group (£490, 95 per cent CI -£803, £1782)) Under the 
80 per cent reduction in equipment costs scenario, the ICER fell to £30,300 per QALY (Table 
7.4). In the scenario (Table 7.1) where the service was working ‘at increased capacity,’ the 
raw annual mean costs of the telehealth group fell to £5960 (standard error £444). 
 
7.4.3 Reduction in Equipment Costs and Full Utilisation Combined Scenario 
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difference between groups decreased (Table 7.1). Total mean costs of telehealth per year 
(unadjusted) per participant were non-significantly less for telehealth (-£172 (95% CI-£1464, 
£1120) than for usual care (Table 7.1). At a 50 per cent reduction in equipment costs with the 
same decreased labour costs, the corresponding cost was non-significantly more (£25, 95% 
CI -£1267, £1317) for the telehealth group than for the usual care group. In the adjusted 
model of costs derived from the SUR analyses (Table 7.4), the cost differences were not 
significant, being a little higher for the telehealth group than for the usual care group, 
assuming 50 per cent reductions in input price and higher working capacity (increase of £167, 
95% CI -946, 1280); and a little lower assuming 80 per cent reductions in input price and 
higher working capacity (decrease of £32, 95% CI -1100, 1100). With an 80 per cent 
reduction in equipment costs and operating at the higher capacity, the cost-effectiveness ratio 
was negative (-£2,200 per QALY), with ICER confidence intervals that crossed zero. Figure 
7.6 shows cost-effectiveness acceptability curves for all sensitivity analyses. No substantial 
changes to the results were seen: assuming an 80 per cent reduction in equipment costs, the 
probability that telehealth was cost-effective was 50 per cent at a willingness to pay level of 
£30,000 per QALY. Results from the sensitivity analyses based on operating at full capacity 
were similar. However, combining the two scenarios (at an 80 percent reduction in equipment 
costs) increased the likelihood that telehealth was cost-effective, to 76 per cent for a 
willingness to pay of £30,000 per QALY. 
  
232 
 
 
Figure 7.6 Cost-effectiveness acceptability curve: QALY, sensitivity to input prices 
 
 
7.5 Discussion  
The WSD telehealth questionnaire study was nested in a large-scale pragmatic, randomised 
controlled trial of telehealth in England. Costs and outcomes data at 12 months were 
available for 969 participants. The mean costs of self-reported service use, combined with 
telehealth intervention costs, were somewhat greater for the group randomised to telehealth in 
addition to standard care than for the group randomised to usual care alone. In a model 
adjusting for demographic characteristics and level of need, this difference in costs was also 
somewhat greater. For the primary outcome measure, the probability that telehealth was cost-
effective was relatively low, only exceeding 50 per cent at willingness-to-pay values above 
£67,000 per QALY. The probability of cost-effectiveness measured in terms of anxiety and 
depression symptoms rose above 50 per cent at willingness to pay values in excess of 
£22,600 and £7,000, respectively. 
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7.5.1 Strengths and Limitations 
One limitation of self-reported data on service use is that respondents may under-report 
services that they frequently use (Bhandari and Wagner 2006, Richards, Coast, and Peters 
2003). Notwithstanding, relying on self-reported service use remains an important method of 
collecting data for a wide range of health and social care services, since administrative data 
are agency- or service-specific. Furthermore, some administrative data may under-report the 
patient’s receipt of services not directly provided by the data owner (for instance GP records 
on patients’ use of social care or other community health services) (Byford et al. 2007, Mistry 
et al. 2005). It has been recommended that a shorter period of recall is used for frequently 
used services in order to minimise this issue (Bhandari and Wagner 2006) and a three-month 
time-frame was used in this study.  
An assumption was made that participants’ costs between nine and 12 months could 
be multiplied up to a yearly cost. This method of estimation may have made the findings of 
this analysis more conservative; longitudinal hospital data have shown that initial differences 
between groups in bed days narrowed over the period of the intervention (Steventon et al. 
2012). However, the pattern associated with acute hospital services cannot be assumed to 
hold with services that are more frequently used and less episodic, such as community 
nursing or home care. 
The extent to which the costs and outcomes differed between those participants who 
completed the 12-month follow-up and those who did not is unknown. The analysis adjusted 
for demographic and cost covariates at baseline that might influence the decision to complete 
long-term follow-up, and so went some way towards addressing imbalances caused by 
dropout between intervention and control groups. The analyses took account of both 
clustering and the correlation between the cost and outcome variables.   
The telehealth interventions under study were complex (Craig et al. 2008), involving 
both human services and advanced assistive technologies. A number of issues are likely to 
arise in the economic evaluation of complex interventions: users might be a heterogeneous 
group; users could be highly involved in the production of care; the more active the user 
involvement, the more complicated the association is between inputs and outputs; and 
multiple agencies could be involved in delivering the intervention (Byford et al. 2007). The 
intervention also involved coproduction by teams that varied in composition from site to site. 
As a consequence of the pragmatic nature of the trial, heterogeneity arose from 
differences in the way that the interventions were delivered. Pragmatic trials, if they are to be 
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useful in directing policy and practice, must be representative of the real-world clinical 
population to which new interventions will be applied (Roland and Torgerson 1998).  
 There might have been variations in the mix and balance of mainstream services 
within and between the health and social care providers in the sites. While introducing the 
telehealth intervention into multiple sites improved generalisability, it was correspondingly 
more difficult to specify the exact nature of the intervention to be used and identify which 
features might have been more helpful in improving health-related quality of life. The study 
was neither intended nor powered to examine differences in outcomes between specific 
service delivery models. On the other hand, certain core features of the telehealth intervention 
were in evidence across the sites: store and forward systems, patient education protocols, 
computerised risk-based classification of vital signs data and central monitoring teams. 
Whether implementation of this “disruptive” technology (Coye, Haselkorn, and DeMello 
2009) at these sites caused any system-wide change in the delivery of local health and social 
care services was beyond the scope of the economic evaluation. 
Other research in the WSD research programme has examined the effects of telehealth 
on organisations and professionals (Bower et al. 2011). Unsurprisingly the impacts of the trial 
from these perspectives were ambiguous. The demands of the RCT itself may have hindered 
more organic processes of adopting remote care within organisations. After the trial, the sites 
began to review the population that had been recruited in order to satisfy the sample size 
requirements of the trial, seeking to target patients according to their own local service 
objectives (Hendy et al. 2012). Nursing professionals were largely supportive of the benefits 
of telehealth to empower patients to manage their conditions whereas GPs had more guarded 
attitudes towards the usefulness of the technology (MacNeill et al. 2014).  
The economic evaluation focused on self-reported outcomes and service use, and did 
not include surrogate measures of outcome such as levels of glycated haemoglobin (HbA1c) 
(Park et al. 2008), blood pressure readings or mortality (although mortality was examined 
elsewhere in the WSD evaluation (Steventon et al. 2012)). Recent reviews and studies have 
identified promising results from trials of telehealth in a variety of long-term conditions 
including diabetes, heart failure, chronic obstructive pulmonary disease and asthma (Barlow 
et al. 2007, Clark et al. 2010, Inglis et al. 2010, Pare, Janna, and Sicotte 2007, Polisena, 
Coyle, et al. 2009, Polisena, Tran, et al. 2009). The bulk of this evidence concerns results 
measured by surrogate and mortality outcomes, rather than by self-reported data on health-
related quality of life. Systematic reviews have reported rather mixed evidence in favour of 
telehealth in terms of outcomes of health-related quality of life for people with diabetes 
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(Polisena, Tran, et al. 2009) and respiratory conditions (Pare, Janna, and Sicotte 2007, 
Polisena, Coyle, et al. 2009). Evidence has also favoured telemonitoring for people with 
coronary heart failure (Inglis et al. 2010), not least because of the diversity of generic and 
condition-specific measures reported. 
It is also important to consider the country context when comparing these results with 
previous studies, many of which were US-based. That health care is free at the point of use in 
the UK may mean that participants had better access to appropriate primary care services than 
a comparable population of users in the US; thus, there is less potential to reduce the use of 
the more expensive services in secondary care here. It should be noted that in this evaluation, 
there was a non-significant reduction in secondary care costs in the telehealth group. Another 
way in which the population might have had less room to show improvement was in terms of 
the level of need, or severity, of the index condition.  
One question arising from these results would be that the timeframe of the evaluation 
may have been too short to show improvements in health-related quality of life, a potential 
weakness shared with many published economic evaluations of telemedicine (Mistry 2012). 
By the same token there is no evidence base to show that a longer time horizon leads to 
improved outcomes.  
This study raises some questions for further research. The extent to which telehealth 
should be targeted towards specific patient populations and subpopulations should be further 
investigated in future studies. Also, specific models of TH delivery should be investigated to 
understand their relationship with variations in outcomes and costs (McLean et al. 2013). It 
would be helpful to understand variations in frequency and intensity of response to 
“breaches” of vital signs protocols (data that were not collected within the telehealth trial) 
and their relationship with quality of life outcomes.   
 
7.5.2 Comparison with Other Studies 
Few telehealth evaluations have examined the association between outcomes and costs 
(Bensink, Hailey, and Wootton 2006, Whitten et al. 2002). Recent reviews have found 
telehealth to be cost saving; however, the quality of the evaluations reviewed has generally 
been described as poor (Bergmo 2009, Polisena, Coyle, et al. 2009, Vergara Rojas and 
Gagnon 2008). Some reviews have found telehealth to decrease use of acute hospital services 
(Inglis et al. 2010, Polisena, Tran, et al. 2009, Polisena et al. 2010a), but there is less 
evidence in terms of use of primary care (Polisena, Tran, et al. 2009). In this analysis there 
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was a pattern of reduced use of health and social care services by the telehealth group, if 
intervention specific costs were excluded, although the differences were small. 
Information on the costs of providing telehealth in the form of telemonitoring has 
been scarce. Direct intervention costs of telehealth (whether by telephone support or 
telemonitoring) reported in the literature range widely, and come from a variety of health 
systems and countries. Inglis and colleagues (Inglis et al. 2010) identified a small number of 
studies of telemonitoring for heart failure that gave such details. One (Balk et al. 2007) noted 
that the costs of telemonitoring increased the total costs for the intervention group, but did not 
give the actual intervention cost; another (Giordano et al. 2009) provided a mean annual cost 
per patient for telemonitoring of €185 (Inglis et al. 2010). Barlow and colleagues (Barlow et 
al. 2007) provided UK-based estimates of telehealth equipment costs of about £700-900 and 
monitoring costs of £260-520 per year (2007 prices). The estimated annual costs of telehealth 
monitoring, support, and equipment in our study varied between sites (about £1500-2000), 
reflecting the heterogeneity in models of telehealth delivery. 
Because there are no societal thresholds for ICERs involving ICECAP-O, Brief STAI 
or CESD-10, we can only interpret any positive findings related to these instruments with 
caution. ICECAP-O is a relatively new instrument and little empirical information currently 
exists on the average values expected in a population with long-term conditions, or on its use 
in economic evaluations (Davis et al. 2012, Petrou and Gray 2011). 
 
7.5.3 Implications for Clinicians and Policymakers 
These results suggest that the QALY gain by people using telehealth in addition to standard 
support and treatment was similar to those receiving usual care, and that total costs for the 
telehealth group were higher than for the usual care group. The probability of cost-
effectiveness judged by reference to this QALY measure was relatively low over a range of 
values of willingness to pay. Total costs were sensitive to the costs of the intervention, 
reducing the point estimate of the cost per QALY substantially such that it became negative 
(assuming that returns to scale could be achieved without altering outcomes). However, 
because the difference in total costs between treatment groups was not significant even with 
these assumed reductions, the probability of cost-effectiveness was only about 76 per cent at 
the £30,000 threshold of willingness to pay, used as a reference by NICE. These results take 
into account costs to both health and social care systems, to give a picture of the 
consequences to costs and quality of life from investment in telehealth across the health and 
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social care agencies. If investment in telehealth falls mainly to primary and social care 
purchasers, while most savings accrue to the acute sector - for which there is some weak 
evidence here - then reinvestment into community health and social care services would be 
vital. 
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Chapter 8  
 
 
Cost-effectiveness of Telecare 
 
Literature on the outcomes of telecare (as distinct from telehealth and telemedicine) is scarce 
(Barlow, Bayer, and Curry 2006) and cost-effectiveness studies nearly non-existent (Graybill, 
McMeekin, and Wildman 2014). In this chapter, I present the results of a cost-effectiveness 
analysis of the WSD telecare intervention, drawing on the WSD Telecare questionnaire study 
dataset. I first review the analytic methods employed, then review the results, and end with a 
discussion of the implications, strengths and limitations of the analysis, and future directions 
for research.  
 
8.1 Methods 
In this section I briefly summarise the analytic methods described in Chapter 4, Section 4.20. 
The primary outcome of interest in the cost-effectiveness analysis was total cost to health and 
social care to gain a QALY by implementing the telecare intervention. I also explored a 
number of other outcomes (state anxiety, SF-12 components, ICECAP and QALY derived 
from SF-6D utilities). Multiple imputation of missing variables was carried out (Chapter 4, 
Section 4.22). Seemingly unrelated regressions (SUR) were then applied, adjusting standard 
errors for cluster (general practice). Outcome equations adjusted for baseline utility (or 
baseline outcome in the case of other measures), site, demographic and individual 
characteristics (age, sex, ethnicity, IMD, number of chronic conditions, EQ5-D self-care 
score, previous community alarm, one-person household); cost equations adjusted for 
baseline costs, baseline outcome, site, demographic and individual characteristics (age, sex, 
ethnicity, IMD, number of chronic conditions, EQ5-D self-care score, previous community 
alarm, one-person household). This modelling approach allowed the estimation of the impact 
of the intervention while controlling for clustering and accounting for the correlation between 
the cost and outcome variables. Sensitivity analyses explored the robustness of results to (i) 
variations in the costs of the intervention (lower input prices for equipment and telecare 
monitoring support), and (ii) to the non-normality of the data. In the latter sensitivity analysis, 
the data were two-stage bootstrapped in R and the SUR model fitted; results from each 
imputation were combined in NORM (Schafer 1999) . Lastly, an interaction term for 
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allocation and living-arrangement subgroup (living alone or living with others) was included 
in the SUR models, in order to explore the cost-effectiveness of telecare within these 
subgroups. 
 
8.2 Results  
At 12-month follow-up, outcomes data were available for 379 telecare and 384 control 
participants (69 per cent vs. 60 per cent of the baseline sample respectively). Costs data were 
available at 12-month follow-up for 381 telecare and 376 control participants (69 per cent vs. 
59 per cent of the baseline sample, respectively). Cost and outcome data across baseline and 
12-month follow-up were available for 375 intervention and 378 control participants. 
 
8.2.1 Costs 
All costs considered in the main cost-effectiveness analyses and in the sensitivity analyses are 
summarised in Table 8.1, in terms of mean costs over the three months prior to baseline and 
12-month follow-up, with cluster-adjusted standard errors. The annual-equivalent costs for 
the pre-baseline period were rather higher in the telecare group (£1499, 95% CI -£563, 
£3561).  Total annual-equivalent costs over the intervention period were rather higher in the 
intervention than in the control group but  not significantly different between groups on 
cluster-adjusted t-tests, whether including or excluding intervention costs, and under 
alternative assumptions about the intervention costs (excluding project-management posts 
and contracts or dedicated responder service costs from the intervention costs). 
 
8.2.2 Outcomes 
Raw mean outcome scores at both time points are summarised in similar fashion in Table 8.2. 
Outcomes did not differ greatly between groups at baseline with the exception of MCS-12 
scores, where the telecare group had lower scores at baseline than controls. Differences 
between groups at the 12-month follow-up were small and not significantly different. The 
direction of effect was in favour of the intervention group in the STAI and the PCS-12 
measures, and in favour of the control group in the EQ-5D-3L-generated utility and -derived 
QALY, ICECAP-O, MCS-12 and SF-6D-derived QALY measures (there was no difference 
between groups in SF-6D-generated utility scores). Utility scores derived from the SF-6D 
were substantially higher than those derived from the EQ-5D-3L at both baseline and follow-
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up; the standard errors of the EQ-5D-3L mean utilities were three times larger than those of 
the SF-6D mean utilities.  
 
Table 8.1  Mean service costs (£) across Telecare sample, annual equivalent 
Resource item Usual care 
(SE) 
Telecare  
(SE) 
Raw difference 
  (n=378) (n=375) (95% CI) 
Pre-baseline period    
Total costs 8152 (742) 9651 (736) 1499 (-563, 3561) 
Intervention period    
Total costs excluding telecare 
delivery and equipment 
7232 (667) 8088 (664) 856 (-1001, 2713) 
Telecare equipment costs 4 (2) 82 (2) 78 (72, 84)** 
Telecare intervention costs  35 (26) 710 (26) 676 (603, 748)** 
Total costs including telecare 
delivery and equipment 
7271 (676) 8880 (672) 1610 (-270, 3490) 
-less project management posts 
& contracts 
7266 (675) 8778 (671) 1512 (-366, 3389) 
-less dedicated responder costs 7266 (675) 8809 (672) 1543 (-336, 3422) 
Sensitivity analyses    
-at 50% reduction in equipment 
prices 
7269 (676) 8839 (672) 1571 (-309, 3450) 
-£5 cost per week 7248 (668) 8421 (664) 1173 (-685, 3032) 
-£5 cost per week + 50% 
reduction in equipment prices 
7246 (668) 8380 (664) 1134 (-723, 2992) 
Note: Table reports the annual equivalent costs for 753 cases with baseline cost data available,  (10 
complete datasets). Standard errors are cluster-adjusted. 
*p<0.01 on t-test 
**p<0.05 on t-test 
  
 
 
Table 8.2 Outcomes at baseline and 12-month follow-up, Telecare sample 
 
Resource item Usual care (SE) Telecare (SE) Difference 
  (n=378) (n=375) (95% CI) 
Baseline    
Utility (EQ-5D-3L) 0.338 (0.022) 0.317 (0.022) -0.021 (-0.083, 0.041) 
MCS 12 43.754 (0.75) 41.613 (0.746) -2.141 (-4.227, -0.055)* 
PCS 12 30.257 (0.537) 30.864 (0.535) 0.607 (-0.888, 2.101) 
STAI 10.758 (0.274) 11.091 (0.272) 0.332 (-0.429, 1.094) 
ICECAP-O 0.686 (0.012) 0.674 (0.012) -0.012 (-0.045, 0.021) 
Utility (SF-6D) 0.568 (0.007) 0.558 (0.007) -0.011 (-0.03, 0.008) 
12-month follow-up    
 Utility (EQ-5D-3L) 0.333 (0.02) 0.321 (0.02) -0.013 (-0.068, 0.042) 
MCS 12 42.279 (0.658) 42.3 (0.658) 0.02 (-1.816, 1.856) 
PCS 12 28.691 (0.546) 29.08 (0.543) 0.388 (-1.131, 1.907) 
STAI 12.344 (0.256) 12.138 (0.256) -0.206 (-0.919, 0.507) 
ICECAP-O 0.649 (0.011) 0.638 (0.011) -0.011 (-0.042, 0.02) 
QALY - EQ-5D-
3L 0.336 (0.019) 0.319 (0.019) -0.017 (-0.07, 0.036) 
Utility (SF-6D) 0.551 (0.007) 0.551 (0.007) 0 (-0.018, 0.019) 
QALY - SF-6D 0.559 (0.006) 0.554 (0.006) -0.005 (-0.023, 0.012) 
Note: Table reports results for 753 cases with baseline cost and outcome data available,  (10 complete 
datasets). Standard errors are cluster-adjusted. 
*p<0.01 on t-test **p<0.05 on t-test 
 
8.3 Cost-effectiveness Results  
Examining the results of the SUR model, QALYs were very slightly higher in the telecare 
group (by 0.003 (95% CI -0.018, 0.024)) (Table 8.3). Adjusted annual costs of telecare 
participants were £1,000 (CIs -535, 2536) higher than those of control participants. The ICER 
was £368,000, with undefined confidence intervals. Considering costs excluding project 
management and excluding dedicated telecare responder costs, the ICERs were slightly lower 
(£332,000 and £343,000 respectively). The probability of cost-effectiveness at the higher end 
of the NICE willingness-to-pay threshold range, £30,000, was 16 per cent (Figure 8.1). 
Examining higher willingness-to-pay thresholds made little difference to the probability that 
telecare could be found to be cost-effective, reaching just under 30 per cent at a threshold of 
£90,000 per QALY. Varying the costs of the intervention by excluding the costs of (a) project 
management-specific posts and contracts or (b) dedicated response services in sites 2 and 3 
produced relatively similar results, with probabilities of cost-effectiveness respectively 3 per 
cent and 2 per cent higher at a willingness-to-pay of £30,000 per QALY than that produced 
by the main estimate.  
  
 
 
Table 8.3 Differences in cost and effect between Telecare and usual care groups (12 months), annual equivalent 
Values in means (CI) unless otherwise 
stated 
Outcomes / total costs 
Control=378 
Outcomes / total costs 
Telecare=375 
Difference in outcomes / total 
costs 
(Usual care=378; Telecare=375) 
QALY (adjusted mean, SUR model†) 0.326 (0.312 , 0.340) 0.329 (0.313, 0.344)  0.003 (-0.018 , 0.024)  
Cost (adjusted mean, SUR model‡) 7574 (6 535, 8612) 8574 (7 490, 9 658)  1000 (-535, 2536)  
ICER (£ per QALY) (SUR model§ ) - - 368 000 (undefined, undefined)  
Excluding project management costs    
Cost (adjusted mean, SUR model‡) 7568 (6 530, 8 607) 8472 (7 388, 9 557) 904 (-632, 2 440) 
ICER (£ per QALY) (SUR model§) - - 332 000 (undefined, undefined) 
Excluding dedicated response costs    
Cost (adjusted mean, SUR model‡) 7570 (6 531,8609) 8503 (7 419, 9 588)  933 (-603, 2470)  
ICER (£ per QALY) (SUR model§) - - 343 00 (undefined, undefined) 
Secondary outcomes analyses    
ICECAP-O (adjusted mean, SUR model†) 0.644 (0.629, 0.660) 0.642 (0.625, 0.659) -0.002 (-0.026, 0.021) 
STAI (adjusted mean, SUR model†) 12.426 (12.822 , 12.012) 12.066 (12.444 , 11.67) -0.36 (0.198 , -0.918) || 
STAI ICER (£) (SUR model‡§)   50000 (undefined , undefined)  
MCS-12 (adjusted mean, SUR model†) 41.796 (40.78 , 42.81) 42.788 (41.81 , 43.76) 0.992 (-0.42, 2.4) 
MCS-12 ICER (£) (SUR model§)   4 000 (undefined , undefined)  
PCS-12 (adjusted mean, SUR model†) 28.731 (28.02 , 29.44) 29.04 (28.28 , 29.81) 0.312 (-0.741 , 1.362) 
PCS-12 ICER (£) (SUR model§)   10 000 (undefined, undefined)  
QALY SF-6D (adjusted mean, SUR 
model†) 0.555 (0.551, 0.559) 0.559 (0.554, 0.564) 0.004 (-0.002, 0.011) 
QALY SF-6D ICER (£) (SUR model§)   240 000 
Note: Table reports results for 753 cases with baseline cost and outcome data available (10 complete datasets). Standard errors are robust cluster-adjusted. 
†from SUR analyses (outcome equation), adjusted for baseline utility, site, age, sex, ethnicity, IMD, number of chronic conditions, EQ5-D self-care score, 
previous community alarm, one-person household 
‡ from SUR analyses (cost equation), adjusted for baseline costs, baseline outcome, site, age, sex, ethnicity, IMD, number of chronic conditions, EQ5-D self-
care score, previous community alarm, one-person household 
§ rounded to nearest thousand 
|| re-transformed to original scale to enable comparison with raw mean difference; transformed mean= 0.020 (-0.011, 0.051) 
  
  
 
 
 Table 8.4 Sensitivity analyses: differences in cost and effect between Telecare and usual care groups (12 months), annual equivalent 
Values in means (CI) unless otherwise stated Outcomes / total costs 
Control=378 
Outcomes / total 
costs 
Telecare=375 
Difference in total costs 
(Usual care=378; Telecare=375) 
Variations in intervention costs:    
Equipment prices reduced by 50%    
Cost (adjusted mean, SUR model‡) 7572 (6533,8611) 8534 (7450,9618) 962 (-574, 2497)  
ICER (£ per QALY) (SUR model§) - - 353 000 (undefined, undefined) 
Mainstream support package of £5 per week    
Cost (adjusted mean, SUR model‡) 7545 (6504 , 8586) 8121 (7032 , 9211)  576 (-964, 2117)  
ICER (£ per QALY) (SUR model†‡) - -  212 000 (undefined, undefined) 
Equipment prices reduced by 50% &  
mainstream support package of £5 per week  
Cost (adjusted mean, SUR model†) 7543 (6 502 , 8584) 8081 (6 993 , 9170)  538 (-1003, 2079)  
ICER (£ per QALY) (SUR model§) - -  197 000 (undefined, undefined)  
Two-stage bootstrapped  
estimates+ SUR:    
QALY (unadjusted group means||, adjusted 
mean difference, SUR model‡¶) 0.336 (0.295, 0.377) 0.319 (0.278, 0.360) -0.001 (-0.038, 0.036) 
Cost (unadjusted group means, adjusted 
mean difference||, SUR model‡¶) 7 285 (5965, 8605) 8 859 (7444, 10274) 911 (-942 , 2764) 
Note: Table reports results for 753 cases with baseline cost and outcome data available,  (10 complete datasets). Standard errors are robust cluster-adjusted. 
†from SUR analyses (outcome equation), adjusted for baseline utility, site, age, sex, ethnicity, IMD, number of chronic conditions, EQ5-D self-care score, 
previous community alarm, one-person household 
‡ from SUR analyses (cost equation), adjusted for baseline costs, baseline outcome, site, age, sex, ethnicity, IMD, number of chronic conditions, EQ5-D self-
care score, previous community alarm, one-person household 
§ rounded to nearest thousand 
|| from two-stage bootstrapped estimates of group means, 3000 replications 
¶ two-stage bootstrapped estimates of SUR coefficient on allocation, 3000 replications 
  
  
 
 
Table 8.5 Subgroup analyses: Differences in cost and effect between Telecare and usual care groups (12 months), participants living together or 
alone, annual equivalent 
Values in means (CI) unless otherwise stated Outcomes / total costs 
Control=378 
Outcomes / total costs 
Telecare=375 
Difference in outcomes / total costs 
(Usual care=378; Telecare=375) 
Living with others    
QALY (adjusted mean, SUR model†) 0.312 (0.292 , 0.332) 0.315 (0.295 , 0.335) 0.003 (-0.025 , 0.031) 
Cost (adjusted mean, SUR model‡) 8582 (6 879 , 10 284) 8309 (6 801 , 9818)  -272 (-2 716 , 2 171) 
ICER (£ per QALY) (SUR model§ ) - - -91 000 (undefined, undefined)  
excluding project management costs    
Cost (adjusted mean, SUR model‡) 8579 (6 876 , 10 282) 8 206 (6697 , 9715) -373 (-2818 , 2071) 
ICER (£ per QALY) (SUR model§) - - -125 000 (undefined, undefined) 
excluding dedicated response costs    
Cost (adjusted mean, SUR model‡) 8579 (6 876 , 10281) 8237 (6728 , 9745) -342 (-2786 , 2102) 
ICER (£ per QALY) (SUR model§) - - -114 000 (undefined, undefined) 
Living alone    
QALY (adjusted mean, SUR model†) 0.339 (0.318 , 0.36) 0.341 (0.319 , 0.363) 0.002 (-0.027 , 0.032) 
Cost (adjusted mean, SUR model‡) 6 674 (5 531 ,7 816) 8 862 (7 580 , 10 144) 2 188 (568, 3 809) 
ICER (£ per QALY) (SUR model§ ) - - 884 000 (33 000 , -77 000) 
Excluding project management costs    
Cost (adjusted mean, SUR model‡) 6666 (5 524 , 7807) 8761 (7 479 , 10 044) 2 096 (476 , 3716) 
ICER (£ per QALY) (SUR model§) - - 847 000 (29 000, -72 000) 
Excluding dedicated response costs    
Cost (adjusted mean, SUR model‡) 6668 (5 526 , 7811) 8792 (7 509 , 10 075) 2124 (503 , 3 744) 
ICER (£ per QALY) (SUR model§) - - 858 000 (30 000, -73 000) 
Note: Table reports results for 753 cases with baseline cost and outcome data available (10 complete datasets). Standard errors are robust cluster-adjusted. 
†from SUR analyses (outcome equation), adjusted for baseline utility, site, age, sex, ethnicity, IMD, number of chronic conditions, EQ5-D self-care score, 
previous community alarm, one-person household 
‡ from SUR analyses (cost equation), adjusted for baseline costs, baseline outcome, site, age, sex, ethnicity, IMD, number of chronic conditions, EQ5-D self-
care score, previous community alarm, one-person household 
§ rounded to nearest thousand 
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Figure 8.1 Cost-effectiveness acceptability curve: QALY 
 
 
8.3.1 Secondary Outcomes 
There was a small difference in mean adjusted ICECAP-O scores in favour of the control 
group (-0.002) and small differences in Brief STAI, MCS-12, PCS-12 and SF-6D in favour of 
the telecare group. The ICER for a movement from worst to best on the STAI scale was 
£50,000, for a 3-point increase in the PCS-12 was £10,000 and for a 4-point increase in the 
MCS-12 was £4,00020. The difference between groups on ICECAP-O favoured the control 
group. In terms of this outcome, telecare was dominated by the usual care alternative, being 
both (marginally) less effective and more expensive (Table 8.3). The cost per QALY gained 
(where QALYs were derived from SF-6D utilities) was £240,000. The probability of 
achieving a reduction from maximum to lowest level of state anxiety, as measured by the 
STAI, at levels of WTP of £10,000 to £20,000, ranged between 16 per cent and 24 per cent 
(Figure 8.2). The probability of achieving a 3-point increase in PCS-12 ranged between 51 
per cent and 61 per cent (Figure 8.3), and the probability of achieving a 4-point increase in 
MCS-12, between 77 per cent and 86 per cent, at the same WTP levels (Figure 8.4). While 
                                                          
20 The choice of effect size is explained in Chapter 4, Section 4.8.1. 
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the ICER produced by the SF-6D QALY was lower, the probability of cost-effectiveness was 
very similar to that produced by the EQ-5D-3L at the £30,000 range (13 per cent); the shape 
of the CEAC produced using the two instruments were similar at lower values but using 
QALY derived from the SF-6D (Figure 8.5) produced a somewhat flatter curve at higher 
WTP values. 
 
Figure 8.2 Cost-effectiveness acceptability curve: Brief STAI 
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Figure 8.3 Cost-effectiveness acceptability curve: PCS-12 
 
Figure 8.4 Cost-effectiveness acceptability curve: MCS-12 
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Figure 8.5 Cost-effectiveness acceptability curve: QALY (SF-6D) 
 
 
8.3.2 Sensitivity Analyses 
The first set of sensitivity analyses explored the robustness of results to different assumptions 
about the costs of the intervention. One possibility explored was that the cost of telecare 
support could be lower than estimated. A 'mainstream' cost of £5 per week was taken from a 
published report on telecare costs in Welsh councils by Bayer and Barlow (2010). Using this 
estimate for the cost of telecare support, the probability of telecare being cost-effective was 
30 per cent at the £30,000 WTP threshold (Figure 8.6). The cost per QALY gained was 
£212,000 (Table 8.4). Assumptions about the input prices for telecare equipment were also 
tested by substituting the cost of equipment if purchased at half the price paid in the trial. The 
probability of cost-effectiveness was 17 per cent assuming the same threshold WTP. The two 
assumptions were combined in a further scenario, which increased the probability that 
telecare was cost-effective to 31 per cent, again assuming a WTP of £30,000, and the ICER 
was £197,000. 
In addition, a two-stage bootstrap procedure was performed, running the SUR on 
3000 bootstrapped replications. The QALY difference was very small and negative (-0.001) 
(suggesting that telecare was slightly less effective than usual care) and the cost difference a 
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little lower than the main estimate (£911); neither the cost nor the outcome difference was 
significant at the 5 per cent level (p=0.954 and p=0.335 respectively).  
Figure 8.6 Cost-effectiveness acceptability curve: QALY, sensitivity to input prices 
 
 
8.3.3 Subgroup Analysis 
In Chapter 6, I explored differences in the costs of telecare between living-arrangement 
subgroups (participants living alone and with others). Here I examine the cost-effectiveness 
of telecare within these subgroups. People living alone had very different costs and outcomes 
from those living with others. Mean QALY was 0.027 (95% CI 0.005, 0.049) higher for those 
living alone than for those living with others. As discussed in Chapter 6, the costs of those 
living with others in receipt of telecare had lower costs than in controls, whereas participants 
living alone in receipt of telecare had slightly higher costs. The results of the SUR model 
interacting the allocation and living arrangement variables (Table 8.5) indicate that there was 
a small difference in costs at follow-up between the experimental groups in participants 
living with others (with wide 95 per cent confidence intervals, crossing zero). There was a 
large and statistically significant difference in costs at follow-up between experimental 
groups in participants living alone (about £2180 higher in the intervention than in the control 
group). The intervention participants, whether living alone or with others, had very slightly 
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higher mean QALY than controls (0.003 and 0.002, respectively). The results were similar if 
excluding costs of project management or of dedicated response services. The cost per QALY 
was very large in the group living alone (£884,000) and smaller and negative (-91,000) in the 
group living with others. The probability of cost-effectiveness at the £30,000 NICE threshold 
was much lower in the living alone subgroup (2 per cent) than in the living with others group 
(60 per cent) (Figure 8.7). A 95 per cent cost-effectiveness ellipse plot drawing on the SUR 
results estimates (Figure 8.8) is useful in demonstrating that the costs and QALY for each 
subgroup overlap substantially. The difference in costs of those living alone are higher than 
those living with others so that all the points on the ellipse lie above the x-axis; the difference 
in costs of those living with others straddle the x-axis. The intervention is more costly than 
usual care; it is possible but not at all certain that the intervention is more effective. From the 
confidence intervals of the ICER for those living alone it can be seen that the intervention is 
less cost effective than usual care below £33 000 and that above that WTP, there is no 
certainty that telecare is more cost-effective than usual care (or the other way around). For 
people living with others, at a WTP of £30,000, while the probability of cost-effectiveness is 
60 per cent, it is evident that there is sufficient uncertainty around the point estimate that no 
95 per cent confidence intervals can be constructed. 
Figure 8.7 Cost-effectiveness acceptability curve: QALY, subgroup analyses 
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Figure 8.8 Cost-effectiveness ellipse: QALY, subgroup analyses 
 
 
8.4 Discussion  
The WSD telecare study involved a much larger number of participants than any previous 
study of its kind. The randomised-controlled trial design enabled a formal evaluation of the 
impact of telecare on costs and outcomes in a population with social care need. In these ways, 
the research reported here has been important in contributing to the very limited international 
evidence base on the cost-effectiveness of telecare.  
The size and RCT design of the study constitute a major strength of this analysis. The 
use of cost-per-QALY as an outcome enables the technical efficiency of the WSD telecare 
intervention to be compared to future telecare interventions, and to that of other health and 
social care interventions. However a number of limitations must be acknowledged.  
The numbers of participants who decided to take part in the questionnaire study were 
not entirely balanced, so that 48 per cent of participants in the telecare arm opted in, while a 
smaller proportion, 43 per cent of participants in the usual care arm opted in (Hirani et al. 
2013). Also, there were more controls at baseline than intervention participants (634 vs. 548 
respectively, or 16 per cent more) and the possibility that there was some self-selection after 
cluster-randomisation cannot be discounted. Such issues are well-known in cluster-
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randomised trials (Puffer, Torgerson, and Watson 2003). There was substantial loss to 
follow-up at 12 months, of 40 per cent in the control group, and 32 per cent in the 
intervention group. That the attrition rates differed between the allocation groups opens up 
the possibility of bias, for instance in retaining a larger portion of the intervention group with 
more favourable outcomes relative to controls. On the other hand, baseline characteristics did 
not differ substantially within allocation groups for the cases with data available at baseline 
and 12-month follow-up. The analyses did adjust for confounders that could have influenced 
attrition, compensating to some extent for imbalances between the groups at follow-up. This 
does not rule out the possibility that other, unmeasured characteristics could have differed 
between groups at baseline or follow-up, or between those who did and did not complete the 
study.  
The analysis did not take into account costs that might have arisen after participants 
dropped out from the trial because they were admitted to residential or nursing care, and did 
not treat dropout due to death differently from other sources of loss to 12-month follow-up. 
Also, I estimated the costs of health and social care over the study period by multiplying the 
3-month costs prior to the 12-month follow-up by four. This relied on the assumption that 
costs were relatively constant over the year across the categories of service use. It is useful 
here to refer to another stream of work within the WSD research programme, which 
examined longitudinal administrative data on mortality, along with long-term residential or 
nursing care admissions and a (restricted) range of health and social care costs of the trial 
population over the 12-month study period (Steventon et al. 2013). In that research the 
mortality rates were similar (being 8.9 per cent in the control group and 8.7 per cent in the 
intervention group). Proportions admitted permanently to care homes were also similar in 
both groups (3.2 per cent usual care vs. 3.1 per cent telecare). 
In the trial, given that the design was pragmatic, there was no prescription or 
standardisation of the processes for assessing potential participants’ need for telecare. This 
flexibility had implications for external validity and reproducibility. The way that telecare 
services in other parts of the country assess potential clients’ need for telecare could differ 
from the assessment practices in the trial sites. The scale of the trial precluded the collection 
and detailed examination of (largely qualitative) assessment documentation, to understand 
what variations might have existed in assessment practices in the trial sites. It should also be 
said that if a range of assessment models existed within the sites, then some of those models 
are likely to have existed in other places. A related point is that the variety of telecare 
equipment combinations and functions and of potential responses to sensor activations may 
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have increased the complexity of the relationships between trial inputs, outputs and outcomes 
(Byford and Sefton 2003). If different types and intensities of package have distinctly 
different impacts on outcomes and costs, the overall outcome-cost relationship may be 
difficult to interpret without in some way delineating the purpose of the package.  
Lastly, data were not available on the number of sensor alerts or false alarms 
associated with individual participants or on participant-specific call centre responses to 
sensor alerts. In addition, there were no data on numbers of visits made by dedicated response 
teams to individual participants. The need to cost the telecare support element of the 
intervention at a site level narrowed the amount of potential variability in intervention costs 
between participants; this may have diminished the sensitivity of the analysis to detecting the 
impact of the intervention.  
 
8.4.1 How Does Telecare Create Benefits for Service Users? Were These Adequately 
Measured? And Who Benefits? 
The intervention appears to have had a minimal impact on a range of quality of life and 
psychosocial outcomes. A question arises: by what means would telecare systems act to 
improve outcomes? The assumptions underlying the expected impact need to be unpacked. 
This is a difficult task given that delivery systems of telecare support are variable; also 
telecare technology is ever-evolving. The scope of the technology evaluated here 
encompassed remote, automatic and passive monitoring systems that went beyond older and 
more basic forms of telecare largely focused on summoning assistance (which in this trial 
could also form an element of standard support and care). One reason given for telecare 
systems improving quality of life for their users is that it creates a sense of reassurance (Beale 
et al. 2010, Hirani et al. 2013, Roush and Teasdale 2011). How much more reassurance is 
provided by additional sensors, over and above that provided by the ability to summon help, 
is not easy to quantify.  
A further issue is that the primary outcome measure was derived from the EQ-5D-3L, 
yet EQ-5D-3L may not be able to capture entirely the improvements brought about by 
telecare. The EQ-5D-3L was chosen because it is a generic measure of health-related quality 
of life that can be used as a basis for comparing alternative technologies (National Institute 
for Health and Clinical Excellence 2008); also, it is suitable for use with older people (cf. 
Haywood, Garratt, and Fitzpatrick 2005, Hawton et al. 2011). The EQ-5D-3L dimensions of 
health (self-care, anxiety/depression, usual activities, pain/discomfort and mobility) are 
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certainly relevant to the sorts of benefits that are expected of telecare. On the other hand, the 
EQ-5D-3L focuses on health and restoration of function rather than achievement of benefit 
through the more compensatory mechanisms provided by much of social care (Forder and 
Caiels 2011), including telecare. Thus it is possible that while EQ-5D-3L is sensitive to 
change in situations where changes in health are expected to be substantial (Haywood, 
Garratt, and Fitzpatrick 2005), this may not be the case with telecare. 
Lastly there is a question as to where the benefits of telecare primarily lie. They may 
accrue mainly to telecare users’ families and carers rather than the users themselves. It must 
be said that evidence on the impact on quality of life for carers of people using telecare is 
scarce; however the use of telecare may reduce carer strain (Davies, Rixon, and Newman 
2013). Nevertheless, if there were beneficial impacts on carers as a result of the introduction 
of the intervention, these would not have been captured in the analysis presented here. It is 
worth considering that there can be dis-benefits associated with telecare; potential and actual 
telecare users’ concerns about threats to privacy or to identity may impinge upon their 
willingness to use or continue to use telecare (Sanders et al. 2012). Benefits may accrue to 
telecare users with certain characteristics. As I have explored in the Chapter 6, higher costs 
may be associated with telecare users with particular characteristics such as living 
arrangements; the result of closer monitoring may have prompted additional service 
responses for some people.  
The sub-group analysis of cost-effectiveness by participants living alone or with 
others proved equivocal but it seems that telecare would not be recommended for people with 
social care need who are living alone. More research is needed to examine this issue, given 
that outcomes were not powered to investigate sub-group effects.  
 
8.5 Conclusion 
There is great deal of interest amongst policy-makers in the potential of telecare to improve 
quality of life while containing or perhaps decreasing the use and costs of health and social 
care and support. However in this study a package of second-generation telecare equipment 
and associated monitoring service combined with (in two sites) a dedicated response service 
did not constitute a cost-effective alternative to usual care, assuming a commonly accepted 
willingness to pay for QALYs. The evidence in favour of telecare remains underwhelming 
from the cost-effectiveness perspective and so policy-makers should for now avoid 
characterising the technology as a 'magic bullet' (Poole 2006).   
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Chapter 9  
 
 
Conclusion 
 
In this thesis I have examined the costs and outcomes of implementing telehealth and telecare 
in England, in the context of the Department of Health-funded Whole Systems Demonstrator 
evaluation. Two large-scale cluster-randomised controlled trials of telehealth and telecare 
formed the core of the WSD programme. In each trial, the research team recruited General 
Practices within three English local-authority areas, to be randomised to either intervention or 
control. The analyses presented here drew on person-level data from the WSD Telehealth and 
Telecare Questionnaire Studies. The WSD Questionnaire studies collected self-report data 
from individuals participating in the respective WSD telehealth and telecare trials. In 
addition, during the period of the study, I collected information from each site about the 
production of the telehealth and telecare interventions, in order to calculate intervention 
specific-costs. My original contribution was to plan and conduct the costs and cost-
effectiveness analyses of the WSD Questionnaire Studies data.  
 The overall objective was to examine the costs and benefits of introducing 
telehealth and telecare in England. The question was broken into four sub-questions.  
 
9.1 What are the Patterns of Service Use for People with and without Telecare or 
Telehealth Support?  
Data from the WSD Telehealth Questionnaire study was analysed to examine patterns of 
service use and costs by telehealth and usual care participants at baseline and follow-up 
assessments. Because of issues of quality in the 4-month data, comparisons presented were 
between baseline and 12-month follow-up. There were small differences between groups 
across the individual items of health and social care service use at both baseline and 12-
months. The telehealth group had somewhat lower mean use of hospital services relative to 
usual care, particularly at the follow-up. Use of primary care services and community and 
specialist nurses was higher within both groups (but not different between groups) at follow-
up. Both groups used some community care services such as home care and home help. In 
terms of the intervention, sites offered different configurations of telemonitoring services, but 
all involved a central monitoring call-centre, and two also offered access to monitoring data 
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by community-based nurses. Data on telehealth monitor alerts and responses to alerts by 
monitoring personnel were not available. Participants used 2.8 (SD 0.6) items of telehealth 
peripheral equipment. The most common combination of items was a BP monitor, pulse 
oximeter and weighing scales. The proportions of participants in receipt of different types of 
monitors varied more distinctly by index condition in site 1 compared to the other two sites 
(e.g. low proportions of patients with COPD and heart failure received glucometers). 
In the WSD Telecare sample, differences between individual service use items 
(including community alarms) were small at baseline. Both groups’ resource use at 12 
months was also similar, apart from certain community-based health and care categories:  
home care, social work and community nursing visits, all greater in the telecare group. While 
use of community alarms was very high in the telecare group at the 12-month follow-up, as 
would be expected given the nature of the intervention, there were substantial rises in the use 
of pendant alarms between baseline and 12-month (and also 4-month) follow-up in the usual 
care group. In terms of the intervention, telecare services across the sites offered a call-centre 
monitoring service for any sensor and user-initiated alerts. There were differences between 
delivery models between sites, for instance in installation and response arrangements. Two of 
three sites offered a dedicated service to respond to alerts, which could include home visits. 
The average number of telecare equipment items used in the telecare group was 4.7 (SD 
1.77). Most participants had ‘functional monitoring’ items (e.g. bed occupancy alarms), 
whereas few had sensors with security functions (e.g. bogus caller button). There were many 
possible combinations of equipment: the most frequent combination of devices observed 
involved those with functional (e.g. bed and chair occupancy sensors), stand-alone (e.g. key 
safes) and environmental (e.g. carbon monoxide detectors) functions. 
 
9.2 What are the Total and Component (Service-specific) Costs per Person of the 
Support/Treatment Received?  
In the WSD Telehealth Questionnaire sample, the costs of health and social care in the three 
month period prior to baseline were similar between allocation groups (£1289 (SE £71) 
intervention vs. £1273 (SE £66) control). At 12-month follow-up, costs of care, excluding 
intervention costs, between allocation groups also did not differ significantly (£1150 (SE 
£110) intervention vs. £1394 (SE £119) control). Hospital costs comprised nearly half (47 per 
cent) of the total costs (excluding intervention costs), with primary care and medication costs 
making up 18 per cent of costs each; social care costs comprised 16 per cent of the total. For 
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participants completing the 12-month assessment point, the mean three-month cost (in 
2009/10 prices) of a package of telehealth support was £289 (SE £4) and for equipment, £168 
(SE £8). Equipment costs made up a tenth of the overall costs of intervention participant 
costs. Counting in the costs of the intervention, three-month total costs in the intervention 
group were slightly higher than in the control group ((£1608 (SE £110) vs. £1403 (SE £120); 
a difference of £205 (95 per cent CI -£114, £524)). Practice-level clustering of total costs was 
similar within the allocation groups at each time point. 
In the WSD Telecare sample, costs at baseline were similar (£2411 (SE £166) vs. 
£2484 (SE £174)). At the 12-month follow-up, costs (excluding intervention costs) of both 
groups were lower than at baseline; costs were somewhat but not significantly higher in the 
telecare group compared in the control group (£1801 (SE £167) vs. £2021 (SE £166)). 
Hospital costs comprised about a quarter of the total costs (excluding intervention costs), and 
community-based social care costs comprised slightly more than a third of the total. The cost 
per quarter of telecare support for intervention participants was £177 (SE £6) and the cost of 
telecare equipment only £20 (SE £1). The extent of clustering of total costs in the total 
baseline sample was much higher in the intervention than the control group, but not in the 12-
month follow-up sample.  
 
9.3 What Patient/User Characteristics are Associated with Cost Variations? 
In Chapter 6, I presented two difference-in-difference-in-difference analyses: first, of data 
from the WSD Telehealth Questionnaire study and second of data from the WSD Telecare 
Questionnaire study. Two approaches were taken to working with clustered data: an 
explicitly multilevel approach, exploring how an individual participant’s costs changed in 
response to the intervention; and a population-averaged approach more useful in the policy 
context to examine how costs across the intervention group differed from those of controls. In 
both cases, substantive modelling involved two levels (person at level 2 and time at level 1). 
Because costs were highly skewed, the models were fitted to a gamma distribution with a log-
link. A two-part approach was taken to substantiate inferences about social and hospital care 
costs, given substantial zero costs in these categories. 
 
9.3.1 Telehealth findings 
I examined whether the three-month total, NHS, hospital and social care costs of the TH 
Questionnaire study participants allocated to telehealth or usual care differed between 
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baseline and long-term follow-up time points, depending on their index long-term condition 
(COPD, diabetes, or heart failure).  An examination of raw (unadjusted) costs showed that in 
participants with COPD and heart failure, these were in general similar in both allocation 
groups at baseline; they were noticeably higher in the people with diabetes allocated to 
telehealth. At 12-month follow up, total costs (including intervention costs) were higher in 
the telehealth participants, across index conditions; the differences between allocation groups 
by index condition, including or excluding intervention costs, were not significant.  
I used multilevel modelling to examine between-group cost differences in subgroups 
of participants with COPD, heart failure and diabetes. Controlling for socio-demographic and 
needs-related variables and taking both skewed distribution of the costs and within-person 
clustering effects into account, I found little evidence of variations in total, NHS-wide, 
hospital or social care costs based on long-term index condition. Both subject-specific and 
population-averaged models and marginal effects results suggested that Telehealth 
participants with diabetes and with heart failure had somewhat but not significantly lower 
costs (not including intervention costs) in the last three months of participating in the trial 
than those of usual care participants with those conditions (taking into account differences in 
costs in the three months prior to baseline). Nonetheless, the between-group differences in 
these costs were not significantly different between conditions. On the other hand, across 
conditions, those in the intervention group had on average lower 3-month NHS and overall 
costs than controls- if excluding the costs of the intervention - at 12-month follow-up. It is 
therefore important to consider that the estimate of overall cost savings could change 
considerably if intervention costs were to decrease markedly in response to falls in the price 
of the technology. 
The costs of providing a Telehealth intervention were high, so that across the three 
conditions, total costs (including intervention costs) in the three months at the end of the 
study were greater in the intervention than in the control group. Also marginal effects results 
suggested that the COPD participants had significantly higher costs, including intervention 
costs, in the last three months of participating in the trial than those of usual care participants 
with those conditions after adjusting for the baseline difference.  
Across time points, sectors and models, characteristics associated with chronic 
disability and ill-health - ADL need, older age and number of comorbid conditions - were 
consistently associated with higher costs. Higher levels of education were associated with 
increases in total costs and NHS and hospital costs, and odds of receipt of hospital care. 
Being female was associated with increased total costs (subject-specific model only) and with 
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higher social care costs. Only one socio-economic characteristic, owner-occupation, was 
associated with lower costs (total, NHS-wide, social care). Costs across sectors, time points 
and models did not differ by site. 
 
9.3.2 Telecare findings 
I examined whether the costs of participants allocated to telecare or usual care differed over 
time depending on their living arrangements (living alone or with others). Total unadjusted 
health and social care costs (excluding intervention costs) over the three months prior to 
follow-up of those living alone in receipt of telecare were significantly greater than of those 
receiving usual care (by £460), while costs of those living with others in receipt of telecare 
were somewhat lower (by £92) than of those living with others receiving usual care. Pre-
baseline costs, in contrast, were somewhat greater in the telecare group, regardless of living 
arrangement.  
I then used multilevel modelling to examine this question, controlling for other socio-
demographic characteristics. Looking at the overall costs of health and social care (including 
or excluding the costs of the intervention), there was little evidence that these were affected 
by the telecare intervention, regardless of modelling approach (subject-specific or population-
averaged). Controlling for other factors, health and social care costs were lower at follow-up 
regardless of allocation. Once costs were disaggregated, there were indications of differences 
between groups. Costs of social care, as with total costs, were apparently unaffected by the 
introduction of the telecare intervention. NHS costs and hospital services costs, on the other 
hand, differed depending on allocation and living arrangement. Examining the marginal 
effect of telecare at baseline and follow-up by type of living arrangement, costs to the NHS in 
the group of telecare participants living with others were lower at the follow-up. However, 
taking costs of telecare recipients living alone into account, it was no longer certain that the 
sum of health care costs across living arrangement groups would be lower.  
Number of comorbidities and higher levels of ADL need were consistently associated 
with higher costs. There were some site effects in costs:  higher total costs and higher odds of 
receipt and costs of social care being associated with site 2, relative to site 1, while site 3 was 
associated with lower odds of social care receipt than site 1. Older age was associated with 
lower total and NHS costs and lower odds of receipt of hospital care and lower hospital costs.  
The influence of sites was evident in the general social care costs of participants, 
where site 2 had higher and site 3 had lower costs than site 1. This was in contrast to the 
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absence of site effects seen in the telehealth analyses. In the Telecare study population, with 
social care need and relatively high use of social care services, much greater local variation 
between social care than health care provision is to be expected, reflecting the fundamental 
differences in access (means tested vs. universal) between these services.  
 
9.4 Are Telehealth and Telecare Cost-effective Compared to Standard 
Support/treatment?  
9.4.1 Cost-effectiveness of Telehealth  
In an evaluation using WSD telehealth questionnaire study data, costs and outcomes data at 
baseline and 12 month follow-ups were available for 965 participants (534 intervention, 431 
control). Mean health and social care costs (including intervention costs) were somewhat 
greater in the telehealth group than for the usual care group at follow-up, but the difference 
on a clustered t-test did not reach significance at the 5 per cent level. Findings were similar 
from a SUR model that adjusted for demographic characteristics and level of need.  
Differences in outcomes were small and no differences between groups were 
significant on clustered t-tests apart from the brief STAI where the difference was less than 
one point in favour of telehealth. In SUR models adjusting for baseline characteristics, 
between-group differences were also small. However there was a significant difference of 
0.014 in EQ-5D-3L-derived QALY between groups at 12 month follow-up (in the direction 
of the intervention group). The between-group differences on other outcomes were not 
significant at the 5 per cent level, except for the CESD-10 (small at -0.705, less than one 
point on a 30-point scale) and the STAI (small at -0.774, less than one-point on a 24-point 
scale), in favour of the telehealth group.  
In terms of EQ-5D-3L-derived QALY gain, the probability that telehealth was cost-
effective was relatively low, only exceeding 50 per cent at willingness to pay values above 
£67,000.  
On secondary outcomes, ICERs were: £22,600 for an improvement from highest to 
lowest levels of anxiety on the Brief STAI; £6,900 for achieving a five-point reduction on the 
CESD-10; £233,700 for an improvement from no capability to full capability on the 
ICECAP-O.  The probability of cost-effectiveness in terms of anxiety and depression 
symptoms was 50 per cent at willingness to pay values of over £22,600 and £7,000, 
respectively. The probability of cost-effectiveness of telehealth on the ICECAP-O index was 
15 per cent at a willingness to pay of £50,000. Mean QALY derived from the SF-6D were 
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0.005 higher in the intervention than in the control group; the ICER was £178,600. The 
probability that telehealth was effective was lower than that yielded by EQ-5D-3L and did 
not exceed 35 per cent over a range of willingness to pay from £0 to £90,000. 
 
9.4.2 Cost-effectiveness of Telecare  
In an economic evaluation of WSD telecare questionnaire study data, cost and outcome data 
of 753 participants were available across baseline and 12-month follow-up (375 intervention 
and 378 control). The health and social care cluster-adjusted costs of the intervention group 
were somewhat but not significantly higher than those of the control group (whether 
including or excluding intervention-specific costs). Between-group cluster-adjusted 
differences in outcomes at the 12-month follow-up were small and not significantly different. 
The results of a SUR model adjusting for baseline characteristics, ADL needs and previous 
use of community alarms in the intervention group showed that the telecare group had 
slightly higher EQ-5D-3L-3L-derived QALY than the control group. Differences between 
groups on other outcomes from the SUR models were small. Differences in brief STAI, 
MCS-12, PCS-12 and SF-6D were in favour of the telecare group; differences in ICECAP-O 
scores were in favour of the usual care group. Cost per EQ-5D-3L-derived QALY was 
£368,000. Cost-effectiveness at the willingness to pay threshold of £30,000 per QALY was 
16 per cent. On other measures, ICER were: £50,000 for a movement from worst to best on 
the STAI; £10,000 for a 3-point increase in the PCS-12 and £4,000 for a 4-point increase in 
the MCS-12.  On the ICECAP-O, telecare was dominated by the usual care alternative.  The 
cost per SF-6D-derived QALY gained was £240,000. The probability of cost-effectiveness at 
the higher end of the NICE willingness-to-pay threshold range, £30,000, was 16 per cent. At 
levels of WTP of £10,000 to £20,000, the probability of achieving a reduction from 
maximum to lowest level of state anxiety ranged between 16 per cent and 24 per cent; of 
achieving a 3-point increase in PCS-12 ranged between 51 per cent and 61 per cent; of 
achieving a 4-point increase in MCS-12 ranged between 77 per cent and 86 per cent. The 
probability of cost-effectiveness on QALY derived from the SF-6D at the WTP of £30,000 
was 13 per cent.  
In a sub-group cost-effectiveness analysis, at 12 months, people who used telecare 
and were living with others (at baseline) had similar outcomes to people who used telecare 
and lived alone (at baseline). Total costs were not different between allocation groups in 
people living with others; whereas the costs were higher in the telecare group in people living 
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alone. There was little certainty of cost-effectiveness of telecare for people who were living 
with others at the baseline over a range of WTP from zero to £90,000; telecare for people 
who were living alone at baseline was less cost-effective than usual care at WTP values 
below £33,000 and there was no certainty of telecare being more or less cost-effective than 
usual care above that value.  
Sensitivity analyses examining robustness of the analyses to assumptions about 
intervention-specific costs did not challenge any inferences made from the main analyses. An 
analysis examining robustness of assumptions of normality of distribution of costs and 
outcomes also did not challenge these inferences. The WSD telecare intervention was not a 
cost-effective alternative to usual care, at a commonly accepted willingness to pay for 
QALYs.  
 
9.5 Relating the Findings to the Literature  
I turn to the question of putting these findings in the context of the theoretical and empirical 
literature as reported in chapters 2 and 3. I also discuss relevant recent literature, including 
publications from the WSD research programme.  
 
9.5.1 Telehealth 
As discussed in chapter 7, at the time of the trial, relatively little information on the costs of 
telemonitoring was available in the literature (cf. Inglis et al. 2010). As discussed in chapter 
5, service configurations and costs could vary substantially by site. It was not possible to 
collect data on responses to telehealth alerts, limiting the granularity of intervention support 
costs to site-level, although individual-level costs could vary depending on the device 
provided. These kinds of difficulties may explain why the telehealth intervention costs of 
telephone support or telemonitoring reported in the literature are so variable. With the 
passage of time, falls in prices of telemonitoring devices, and the penetration of smartphone-
based medical applications (Cottrell, Chambers, and O'Connell 2012, NHS Stoke-on-Trent 
2011), will have limited the generalisability of estimates from older studies. Cost estimates 
from the UK-based literature (section 7.5.2) ranged from about £960 to £1,420 per annum 
(2007 prices) (Barlow et al. 2007) and in the telehealth study here, between £1,500 to £2,000 
per annum (2009/10 prices). A study on uncontrolled hypertension (Stoddart et al. 2013), 
contemporaneous with the WSD, used mobile phone technology to transmit readings from 
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blood-pressure monitors to attending physicians, estimating the 6-month cost at only £71 
(2010 prices).  
A cost-effectiveness study by Dixon, Hollinghurst, Edwards, Thomas, Foster, et al. 
(2016) examined a low-cost model of telehealth for raised cardiovascular risk in primary care 
(the NHS Direct Healthlines Service). The cost of the intervention was £129 (SD £56.33) 
(2012/13 prices). This was a web-based model whereby participants with telehealth entered 
blood-pressure readings manually into the Healthlines portal, with telephone-based 
behavioural and educational support from health care advisors (non-qualified clinical 
workers) in the now-defunct NHS Direct service. These intervention costs were much lower 
than those of the WSD, owing to lower labour costs (unqualified clinical support staffing 
based within NHS Direct) and manual inputting of vital signs by patients, using basic blood 
pressure monitors (Thomas et al. 2014)).  
Witt Udsen et al. (2017) report a cost-effectiveness analysis from a Danish pragmatic 
trial of an asynchronous telehealth intervention delivered by municipality health care 
professionals21 to people with COPD (578 in TH and 647 in UC). The intervention cost €704 
(2014 prices). The adjusted total cost of health and social care was €728 (95% CI −€754, 
€2211) higher in the TH group; adjusted QALY were 0.0132 (95% CI −0.0083, 0.0346) 
higher in the TH than UC group. The ICER was €55,327 per QALY. The probability that the 
intervention was cost-effective reached 50 per cent at a WTP value of €55,000. The authors 
concluded that telehealth was not likely to be cost-effective for people with COPD over the 
range of NICE threshold values.   
I examined variations in the costs of participants with COPD, diabetes and heart 
failure related to the introduction of the intervention, adjusting for other personal 
characteristics. Comorbidities, older age and ADL need were drivers of increased costs in all 
models, in line with other research on costs in chronic conditions (Tsiachristas and Rutten-
van Mölken 2014), COPD (Hutchinson et al. 2010), (Hetlevik, Melbye, and Gjesdal 2016) 
and heart failure (in terms of ADL need)(Kang et al. 2016), while being female was a driver 
of overall costs, as has also been reported in the literature on costs of COPD (Menn et al. 
2012, Hetlevik, Melbye, and Gjesdal 2016). It was not possible to capture alerts from the 
                                                          
21 Vital signs data collected by oximeter, BP monitor and scales were communicated to monitoring nurses and 
assistants via computer tablet-based applications. 
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telemonitoring systems in the WSD trial, so there is no way to compare to the literature on 
service use (key events) related to alerts.  
Compared to evidence from the systematic reviews of effectiveness of telehealth for 
long-term conditions presented in Chapter 3, the findings presented in Chapter 6 and Chapter 
7 were less positive than some assessments (Barlow et al. 2007, Clark et al. 2010, Inglis et al. 
2010, Pare, Janna, and Sicotte 2007, Polisena, Coyle, et al. 2009, Polisena, Tran, et al. 2009).  
Results presented in chapter 7 focused on self-reported outcomes. Clinical outcomes and 
reductions in service use rather than person-reported outcome measures are often presented as 
final outcomes in the literature. It is also striking that many reviews lump together several 
disparate outcomes (condition-specific and generic HrQoL, satisfaction with the technology, 
psychological outcome measures) as if they all measured the same concept. There is a need 
for systematic reviews to present outcomes informatively, for instance by considering how 
many studies found improvements in generic HrQoL measures. Where HrQoL outcomes 
were considered separately, systematic reviews reported rather mixed evidence in favour of 
telehealth for people with diabetes (Polisena, Tran, et al. 2009) and respiratory conditions 
(Pare, Janna, and Sicotte 2007, Polisena, Coyle, et al. 2009). A more recent review assessed 
the evidence of the impacts of telephone support and telemonitoring for heart failure on 
health-related quality life as strong (Inglis et al. 2015). The review also found evidence for 
the cost-effectiveness of telephone support but not for telemonitoring. In Bergmo (2009), 
there were surprisingly few economic evaluations giving ICER in terms of cost per QALY 
(only one of which conducted as part of an RCT, for asthma), making comparisons with that 
author’s findings difficult.  
In the planning stages of the WSD Questionnaire studies, EQ-5D-3L was chosen as the 
HrQoL measure to be used in the economic evaluation. However as the SF-12 was collected, 
it was possible to construct the SF-6D for comparative purposes. The evidence on the 
empirical validity of the EQ-5D-3L vs. SF-6D is fairly equivocal (Brazier 2007) and depends 
on the population examined. However, the EQ-5D-3L was chosen as a generic measure of 
health-related quality of life that can be used as a basis for comparing alternative technologies 
(National Institute for Health and Clinical Excellence 2008). Also, EQ-5D-3L can be 
expected to be sensitive to change where changes in health are expected to be substantial 
(Haywood, Garratt, and Fitzpatrick 2005). It is interesting that, compared to the gain in 
QALY derived from the EQ-5D-3L, gain in QALY derived from SF-6D was smaller 
(between-group differences in raw scores: 0.015 vs 0.005 respectively) (but neither difference 
was significant).  
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Grieve, Grishchenko, and Cairns (2009) observe that compared to SF-6D, EQ-5D-3L 
has lower utilities for health states (e.g. pain) that are more severe. The SF-6D descriptive 
system has two dimensions (vitality and social functioning) not found in the EQ-5D-3L. They 
suggest that people in relatively good health may have poorer health states in the SF-6D 
compared to EQ-5D-3L because it has two more levels. In this study, baseline EQ-5D-3L and 
12-month follow up utilities were higher than SF-6D utilities regardless of allocation. If (as 
could reasonably be expected given the WSD telehealth study population) participants were 
not in good health, the results here are in line with this prediction.  
While systematic reviews of telehealth for heart failure have detected decreases in the 
use of secondary care (Inglis et al. 2010, Polisena, Tran, et al. 2009, Polisena et al. 2010a), 
there has been less evidence for COPD and diabetes generally, and less evidence on use of 
primary care services in heart failure (Polisena, Tran, et al. 2009) Some more recent evidence 
from a trial of telemonitoring for Type 2 diabetes (Wild et al. 2016) suggests that telehealth 
does not reduce use of primary care services such as GP and practice nurse contacts  (and see 
also Section 9.5.3 on other findings from the WSD programme).  In the analyses presented in 
Chapter 5, use of some hospital and social care services by the telehealth group were slightly 
lower at the follow-up. In the costs analyses reported in Chapter 6, overall NHS costs 
(intervention specific costs excluded) were somewhat lower but there was no evidence of 
lower costs in the telehealth group, across the conditions, in terms of hospital care.  
According to systematic reviews of economic evaluations of telehealth prior to 2013, 
telehealth studies have generally found that the technology reduces health care costs. 
Nonetheless, reviewers recommended interpreting these results with caution, given that the 
generally poor quality of the evaluations (Bergmo 2009, Polisena, Coyle, et al. 2009, Vergara 
Rojas and Gagnon 2008).   
The Dixon, Hollinghurst, Edwards, Thomas, Foster, et al. (2016) study (N=641) found 
a web-based model of telehealth for raised cardiovascular risk (NHS Direct Healthlines 
Service) to be cost-effective over the NICE WTP threshold range (ICER of £10,859; 
probability of cost-effectiveness of 77% at £20,000 per QALY). Costs in the telehealth group 
were significantly higher at £138 (95 per cent CI £66, £211); QALY gain was 0.012 (95 per 
cent CI −0.001, 0.026). The authors, comparing their results to those of the published WSD 
Telehealth Questionnaire cost-effectiveness, noted the sensitivity of inferences on cost-
effectiveness to costs of technology and the kinds of technology employed.  
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9.5.2 Telecare 
I discuss here how some of the concepts presented in chapter 2 can shed light on the research 
findings in chapters 5, 6 and 8 and the implications of the findings for those concepts. The 
promotion and maintenance of independence in older people is often invoked as a reason for 
telecare provision. Policymakers tend to engage in ‘modernist discourse’, envisaging a 
compliant older population that can get on with technologies such as telecare and telehealth 
technologies, and hoping to reduce wasteful practices such as consuming services provided 
by human carers (Greenhalgh et al. 2012). This ‘better outcomes’ narrative links 
independence, efficiency savings and user quality of life (Glasby, Lynch, and Robinson 
2018) although the chain of causality is never fully specified. Independence from this 
perspective equals not relying on state services (Glasby, Lynch, and Robinson 2018), or 
‘being able to look after yourself’ (Peek, Aarts, and Wouters 2015, Sixsmith and Sixsmith 
2008). The costs and cost-effectiveness analyses presented here examined cost and health-
related quality of life, both elements of the ‘better outcomes’ narrative. On the question of 
total and component service costs, I concluded that telecare had little impact on these (as was 
also concluded in the trial evaluation paper (Steventon et al. 2013)).   
In Chapter 6, I explored differences in costs between the telecare and usual care 
groups in people living alone and people living with others. This exploratory analysis 
suggested that in people living alone, the group ideally placed to benefit from telecare by 
staying ‘independent’, neither health nor social care costs decreased in the presence of 
telecare, whereas some health care costs of those living with others did. I discussed a set of 
possible reasons for these findings. It was possible that need was not adequately controlled 
for in the models by inclusion of the self-care covariate (for instance, other measures of need 
such as cognitive impairment were not measured in the study). Or, telecare exposed unmet 
health needs and thereby caused additional health service use by individuals living alone, 
while telecare for people living with others perhaps gave paid or unpaid carers confidence to 
substitute health care visits with remote monitoring. The results raise the possibility that cost 
savings from social care organisations’ investments in telecare largely accumulate to health 
organisations (cf. Forder 2009). There should be sufficient funding to social care to allow any 
telecare-related reductions in health care spending to be sustained, which would require 
transfers from NHS to social care. A recent paper has identified reductions in hospital length 
of stay related to telecare use from Scottish routine health and social care date (which 
includes data on telecare equipment use) (Momanyi 2017a). 
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The analysis originally published (Henderson et al. 2014) provided a cost-per-QALY 
for telecare that was far in excess of the NICE threshold; the analysis reported here provides 
an even higher ICER (higher by £71,000 per QALY). This does not change any of the 
conclusions originally reported. The results of the subgroup analysis of cost-effectiveness by 
participants living alone or with others proved equivocal but it seems that telecare would not 
be recommended for people with social care need who are living alone. It is however 
important to be mindful of the context. There is a further consideration touched upon in 
chapter 2. Left to their own devices, older people living alone may postpone use of a pendant 
alarm until they see themselves at high risk for falls (Nyman 2014).  In a general population 
of older people with social care need, the situation may be different to that observed in the 
trial population, who were allocated telecare.  
The findings of chapters 6 and 8 taken together were in considerable contrast to the 
policy discourse on telecare, of fostering ‘independence’, decreasing social care service use 
and through some unexplained causal chain, improving quality of life.   
On the question of health-related quality of life, I concluded that telecare had little 
impact on this outcome, although there was some trend to better mental health-related quality 
of life outcomes scores (on the MCS-12). The small improvement in mental health-related 
quality of life outcomes could be related to some sense of ‘reassurance’ (Beale et al. 2010, 
Hirani et al. 2013, Roush and Teasdale 2011).  How much more reassurance was provided by 
additional sensors, over and above that provided by the ability to summon help, was not 
addressed in the trial design. I speculated that if WSD telecare did not vary substantially from 
first-generation telecare, the impact on outcomes for intervention participants might not have 
been much different than for the substantial proportion of controls (64%) reporting 
community alarm use by the end of the trial.   
The study did not address independence as a psychological outcome per se (although 
the concept is captured as one of the five domains of the ICECAP-O). Concepts of 
independence such as not wanting to be dependent on technology or not wanting to be a 
burden on relatives (Peek, Aarts, and Wouters 2015, Sixsmith and Sixsmith 2008) were not 
directly addressed in the trial or study design; however qualitative work within the WSD 
programme examined reasons for declining telecare (Sanders et al. 2012). That research 
found that threats to privacy or to identity did impinge upon individuals’ willingness to use or 
continue to use telecare.   
Compared to the differences in QALY derived from the EQ-5D-3L, between-group 
differences in QALY derived from SF-6D were smaller (-0.017 vs -0.005 respectively). As 
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discussed in chapter 8, the EQ-5D-3L has been found to be suitable for use with older people 
(Haywood, Garratt, and Fitzpatrick 2005, Hawton et al. 2011). Nonetheless, it was not known 
whether EQ-5D-3L would be able fully detect any improvements brought about by telecare, 
given the EQ-5D-3L’s concentration on health and restoration of function.  
Returning to Grieve, Grishchenko, and Cairns (2009), it is interesting to see that 
people in the telecare sample were in apparently poorer health relative to the telehealth 
sample on the EQ-5D-3L. Yet on the SF-6D they had utilities that were, although lower, 
more similar to those of the telehealth sample. This does not appear consistent with the 
pattern suggested in the Grieve paper and observed in the Telehealth study. On the other 
hand, it may be that SF-6D was able to detect more positive aspects of quality of life in the 
vitality and social functioning dimensions, leading to overall higher scores than on EQ-5D-
3L. Perhaps the sensitivity owing to these additional dimensions also led to a smaller 
negative raw difference in QALY between groups at the 12-month follow up. Ultimately, the 
inferences in terms of cost-effectiveness do not change, whichever instrument is used to 
measure HrQoL. 
There are few studies of remotely comparable sample sizes with which to compare the 
findings of this work (except the WSD Telecare trial, see below). Morgenstern et al. (2015) 
reports results of a US-based trial of medical alert devices (first-generation telecare) in 
women with stroke.  Analyses of data from 122 intervention and 112 control participants 
indicated no differences between groups at 90 days in health-related quality of life, 
depression, anxiety or pain, and perceived isolation. 
 
9.5.3 WSD studies 
The WSD research programme included examinations of the effects of telehealth and telecare 
on service use in the larger trial population (Steventon et al. 2012, Steventon et al. 2013), on 
psychosocial outcomes in the questionnaire population (Hirani et al. 2013, Henderson et al. 
2013, Cartwright et al. 2013, Henderson et al. 2014, Rixon et al. 2015, Hirani et al. 2017) and 
from the perspectives of organisations (Hendy et al. 2012), health professionals (Sanders et 
al. 2012) and patients (MacNeill et al. 2014).  
As there were many publications from the WSD programme, I have focused on 
discussing findings from the quantitative research programme that support or are at odds with 
the findings presented in the thesis. Publications of quantitative research on the WSD 
telehealth and telecare trial are summarised in Box 9.1 and Box 9.2 respectively. 
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Telehealth: The results presented in chapters 5, 6 and 7 are broadly in line with the findings 
of the service utilisation analyses conducted as part of the WSD study (Steventon et al. 2012, 
Bardsley, Steventon, and Doll 2013). Despite different approaches, source of data and sample 
sizes, hospital costs were found not to differ between groups over the trial period or three 
months prior to baseline in both the trial analysis and those presented here. In terms of use of 
primary care, despite the differences in the time period (12 months vs 3 months) between the 
trial and questionnaire on GP and practice nurse contacts, in neither that nor the analysis 
presented here were there substantial differences between groups at baseline or over the trial 
period. However practice nurse contacts in the questionnaire data at baseline were far lower 
than at 12 months and much lower than the figures (if divided by four) given in the Bardsley, 
Steventon, and Doll (2013) paper (see Box 9.1), suggesting that there might have been issues 
related to the means of administration of the questionnaires. An exploration of the impact of 
glycaemic control in the WSD trial sample (Steventon et al. 2014) may shed some light on an 
apparent trend in the subject-specific model to lower NHS costs at follow-up in the diabetic 
participants with telehealth. That study found a significant effect of telehealth on glycaemic 
control, albeit a small one, which could, if the trend to better control holds true for the smaller 
sample available in this analysis, have had some impact on reducing use of diabetes-related 
NHS services by this group.  
The results in terms of outcomes presented in chapter 7 are broadly similar to those of 
Cartwright et al. (2013), whose overall conclusion was that while telelehealth did not result in 
better outcomes, there was no evidence of poorer outcomes either. The samples analysed in 
the (Cartwright et al. 2013) paper and the cost-effectiveness paper overlapped but were not 
the same, and analyses in the former included outcome measures at the 4-month follow-up. In 
other publications examining psychosocial outcomes by long-term condition (Hirani et al. 
2017, Rixon et al. 2015, Newman and Whole System Demonstrator Programme Evaluation 
Team 2014), very little difference was found between allocation groups in each case. While I 
did not carry out a cost-effectiveness analysis to investigate the differences between groups 
with COPD, diabetes and heart failure, the results of those studies and the cost analyses in 
chapter 6 suggest that findings would not differ from the overall conclusions of chapter 7.  
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Box 9.1 Publications from the Whole Systems Demonstrator Telehealth studies  
Health-Related Quality Of Life and Psychological Outcomes (WSD Telehealth Questionnaire 
Study) 
Cartwright et al. (2013) examined the effect of second-generation telehealth on 
HrQOL and psychological distress in people with long-term conditions (COPD, diabetes and 
heart failure) over 12 months as part of the WSD Telehealth questionnaire study (1573 
participants), nested in the WSD telehealth pragmatic, cluster-randomised trial (92 general 
practices were randomised to telehealth and 87 to usual care; 1605 telehealth and 1625 usual 
care participants). Outcomes were measured at baseline, four and 12 months. 759 participants 
completed measures at all time points (complete cases) and 1201 completed measures at 
baseline and one other point (available cases). Primary analyses were intention to treat (ITT); 
secondary per-protocol analyses examined efficacy (633 complete cases, 1108 available 
cases). In the ITT and per-protocol analyses, there were no significant differences between 
allocation groups in either complete or available cases samples. The authors concluded that 
the WSD telehealth intervention did not produce improvements in HrQOL or psychological 
distress for participants with long-term conditions; the intervention also did not worsen 
outcomes. Telehealth for the purposes of improving HrQoL or psychological outcomes was 
not recommended. Comparisons of the trial and questionnaire samples suggested there was 
some evidence of potential selection bias into the Questionnaire study, as a higher proportion 
of participants in the trial intervention group than of controls agreed to participate in the 
questionnaire study.  
 
Hirani et al. (2017) examined generic and condition-specific HrQoL, and 
psychological distress (anxiety and depression) in the WSD telehealth questionnaire study 
participants with diabetes ((246 intervention, 209 control). Data from 167 intervention and 
150 control (available cases, those completing baseline and at least one of the follow up 
assessments) were analysed. The groups did not differ significantly on any measure except 
the disinhibited eating scale of the Diabetes Health Profile, where the intervention group had 
higher (worse) scores than the controls; however the effect size on this measure was small 
and confidence intervals were wide and crossed zero. The required sample size to power the 
detection of a small effect was not met due to attrition. The intervention did not improve 
outcomes nor did it worsen outcomes for diabetic participants over 12 months.  
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Box 9.1 (continued) 
Rixon et al. (2015) examine psychological distress (anxiety and depression) and 
generic and condition-specific measures of HrQOL in 447 participant in the WSD telehealth 
questionnaire study with COPD. Small improvements were found in 12-month condition-
specific QOL (emotional functioning and mastery on The Chronic Respiratory Questionnaire 
(CRQ) (Guyatt 1987) in the intervention group compared to controls. The sample size did not 
reach adequate power because of attrition. No differences between in the telehealth and 
control groups were found in generic QOL or in terms of psychological distress. 
 
WSD final report: In an analysis of outcomes in participants of the Telehealth 
Questionnaire trial with heart failure (Newman and Whole System Demonstrator Programme 
Evaluation Team 2014), there were 265 telehealth and 275 usual care participants with heart 
failure at baseline, 146 telehealth and 138 usual care in the complete cases sample and 228 
telehealth and 209 usual care in the available cases sample. The analyses examined generic 
and condition-specific HrQOL and psychological distress outcomes. No robust effects over 
the 12 month period were reported in any outcome measures.  
 
Service Utilisation and Mortality (WSD Telehealth Trial) 
Steventon et al. (2012) reported the results of examining service utilisation and 
mortality in the 1605 telehealth and 1625 control participants recruited via 179 general 
practices into the WSD Telehealth trial. The analyses drew on linked longitudinal 
administrative data (Hospital Episodes Statistics, local commissioning data on emergency 
department visits, and general practice data). Results (using data for 1570 intervention and 
1584 control participants) showed that the (raw) absolute difference in percentages admitted 
was 5.2 (42.9 intervention vs. 48.2 control). The (raw) absolute difference in percentage of 
deaths between groups was 3.7 (4.6 intervention vs. 8.3 control). Results of multilevel 
analyses, adjusting for case mix with predictive risk scores, indicated that the intervention 
group had a significantly lower proportion of hospital admissions over the 12 months from 
baseline, being 18% less likely to have an admission than controls. Unexpectedly, however, 
admissions in the control group rose at beginning of the trial, generating the significant 
overall between-group difference observed at the end. Also, the between-group difference in 
percentage admitted was lower than the 17.5% that the study had been designed to detect.  
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Box 9.1 (continued) 
The analyses showed that the intervention group were 47% less likely to die than 
controls over the same period. There were significant differences between groups on 
secondary outcomes including numbers of bed-days (a reduction in the intervention group of 
0.64 days) and emergency admissions but not on some other measures (outpatient visits and 
costs of hospital service use). Costs were calculated using the Department of Health PBR 
Tariff costs (costs to commissioners of NHS care). The raw costs of hospital care in the three 
months before baseline were £427 in intervention and £506 in the control group; the adjusted 
(geometric mean) difference in tariff costs between groups (not significant) was not large, at 
£188 less in the TH than the control group over the study period. The authors advanced some 
possible reasons for the rise of emergency admissions in the controls: that in the process of 
recruitment professionals detected unmet need in controls that they chose to treat; or that 
control patients were made more aware and concerned about their condition and so were 
more likely to present at hospital for emergency admission; or that there was a selection bias 
so that controls with higher risk, and intervention patients with lower risk, were selected into 
the trial. Comparisons of baseline characteristics between groups made the last of these 
possibilities unlikely.  
 
Steventon et al. (2014) examined glycaemic control in participants in the WSD trial 
sample of patients with type 2 diabetes (N=513). Routine data for Hb A1c was available for 
300 intervention and 213 control participants. Results suggested a modest but not clinically 
significant improvement in glycaemic control in the intervention group.  
 
Steventon, Grieve, and Bardsley (2015) examined the generalisability of the WSD 
telehealth findings to routine clinical practice. Amongst other analyses, they examined the 
unexpected rise in admissions in the control group in the first months of the trial period, 
through a placebo test comparing the trial controls to matched local controls who had not 
participated in the trial. Placebo tests for this outcome and also for mortality failed. 
Furthermore, sensitivity analyses suggested (non-significant) increases in emergency 
admissions and higher mortality in the intervention group, which had important policy 
implications because “reductions in emergency admissions continue to be a major motivation 
to invest in telehealth.” p.1033. The authors concluded that it was not possible to generalise 
the WSD telehealth trial results relating to emergency admissions and mortality to routine  
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Box 9.1 (continued) 
NHS practice. The paper’s authors (Steventon, Grieve, and Newman 2015) also observed that 
it was unlikely that clinical treatment of controls was altered during the trial period; but it was 
possible that the control participants’ health seeking behaviours had been influenced by being 
recruited into the trial (for instance because of disappointment with allocation).  
 
Bardsley, Steventon, and Doll (2013) examined the use of primary care by trial 
participants (1219 intervention, 1098 control). They also examined recorded tests/readings in 
parallel with the kinds of vital signs monitored within telehealth systems (e.g. HbA1C, 
oxygen levels, and weight). In the 12 months prior to the trial, contacts with GPs did not 
differ between experimental groups (TH: 8.8 (SD 6.8) vs. control:  9.0 (SD7.6) and Practice 
nurse: (TH 5.3 (SD 7.8) vs control 6.1 (SD 8.1). Over the 12 months of the trial, there were 
no significant differences in contacts with either GPs (TH 8.99 (7.00): vs. control 8.85 (8.16)) 
or practice nurses (TH 5.92 (9.83) vs control 6.28 (8.98). The authors noted that in the pre-
baseline, across allocation groups, participants had a higher number of GP contacts than 
found in other studies of comparable populations. There was no difference between the 
groups in the numbers of recorded tests/readings over the period of the trial, suggesting that 
there had been no shift of testing out of general practice due to telemonitoring. They noted 
that system-level incentives, for instance payments for taking certain types of clinical 
readings, could mitigate against practices choosing to change how often they took readings. 
The conclusion arrived at was that there was no reason to suspect increased or decreased 
primary care workloads would be associated with telemonitoring.  
 
Telecare: Results of the analyses of service use and costs in the telecare sample (chapters 5 
and 6) are in line with the findings presented in the study of service use and costs in the 
Telecare trial by Steventon et al. (2013) This examined a somewhat more limited range of 
services than presented here. Despite a larger sample size and the use of routine data, 
resource use in the three months prior to baseline reported there was broadly comparable with 
similar items reported here, except in terms of proportions visiting GP surgeries 
(approximately twice the proportion reported here). Here similarly, the between-group 
differences in hospital and social care costs at follow-up were not significant, as was also 
found in the Trial results for the 12-month period, despite differences in overall sample sizes, 
data sources, and different costing approaches.  
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Results of outcomes for telecare and usual care participants presented in chapter 7 
were similar to those presented in Hirani et al. (2013) (see Box 9.2), despite differences in the 
sample sizes examined. The most positive result noted in that paper was on the MCS-12, and 
this was reflected in the cost-effectiveness results for MCS-12 presented here.  
 
Box 9.2 Publications from the Whole Systems Demonstrator Telecare studies  
Health-related quality of life and psychological outcomes (WSD Telecare questionnaire 
study) 
Hirani et al. (2013) assessed the effect of telecare on health-related quality of life and 
psychological outcomes of home-based telecare in people with social care needs over 12 
months, as part of the WSD Telecare questionnaire study, nested in the WSD telecare 
pragmatic, cluster-randomised trial. The unit of randomisation was General Practice. There 
were 550 telecare participants (101 general practices) and 639 usual care participants (103 
general practices) at baseline. Outcomes were measured at baseline, four and 12 months. 873 
cases (430 intervention, 443 control) with data available at baseline and at least one other 
follow-up were available for analysis. Multilevel analyses indicated a significant difference 
between allocation groups on the adjusted SF-12 mental component scores (43.69 (SE 0.83) 
intervention vs. 40.52 (SE 0.88) control). The effect size estimate (Hedge's g of -0.177 (95 
per cent CI –1.364, 1.009) was small. EQ-5D-3L scores declined significantly and depressive 
symptoms increased significantly in both groups from the 4-month to the 12-month follow-
up. The intervention may have mitigated decline in mental health-related quality of life.  
 
Service utilisation and mortality (WSD telecare trial) 
Steventon et al. (2013) examined the impact of telecare on utilisation and costs of 
health and social care services in 1276 telecare and 1324 usual care participants recruited 
through 217 general practices into the WSD Telecare trial. The analyses drew on linked 
longitudinal administrative datasets (Hospital Episodes Statistics, local commissioning data 
on emergency department visits, general practice and local authority data). The primary 
outcome was proportion admitted to hospital over 12 months. Secondary outcomes were: 
mortality, emergency admissions, elective admissions, outpatient attendances, emergency 
department visits, falls admissions, bed days, GP contacts, practice nurses, proportion 
admitted to permanent residential or nursing care, home care weeks, hospital tariff costs, GP 
surgery costs, and social care costs.  
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Box 9.2 (continued) 
Results for 1236 intervention and 1190 control participants with linked data indicated an 
unadjusted absolute difference in percentages admitted of –2.4 per cent (46.8 per cent 
intervention vs. 49.2 per cent control). Mortality rates were 8.7 per cent in the intervention 
group and 8.9 per cent in the control group.  Proportions admitted permanently to care homes 
over the year were similar in both groups (3.1 per cent intervention vs. 3.2 per cent control). 
The unadjusted difference in 12-month hospital tariff costs was £242 (£2,804 intervention vs. 
£2,604 control) and in social care costs –£77 (£4,210 vs. £4,287 control). Multilevel models 
adjusted for baseline covariates and for predictive risk scores. Adjusted proportions admitted 
to hospital was significant in one model (baseline covariate adjustment: Odds ratio=0.83; 
0.69 to 0.99) but not in the other (predictive risk score adjustment: Odds ratio=0.89; 0.74 to 
1.07). There were no significant differences on other outcomes. The authors concluded that 
WSD telecare did not reduce service utilisation or costs over the 12-month study period. 
 
9.6 Strengths and Limitations 
According to systematic reviews of economic evaluations of telehealth prior to 2013, the 
quality of evaluations has left something to be desired in several ways .Recommendations 
have included using more diverse populations to improve external validity; using a 
standardised approach, such as an explicit economic evaluation framework, including all 
relevant costs and being clear about inclusions and exclusions (Bergmo 2009, Polisena, 
Coyle, et al. 2009).  
The economic evaluations of the WSD Telehealth and Telecare Questionnaire studies 
adhered to good practice as defined by economic evaluation guidelines (cf. Husereau et al. 
2013) including stating the research objectives, analytical viewpoint, choice of comparators, 
alternatives compared, outcomes, costs, details of currency and price, stating time horizon, 
giving details of statistical tests and confidence intervals, explaining the approach taken to 
and choice of variables for sensitivity analyses; comparing relevant alternatives, reporting an 
incremental analysis, presenting results for each outcome, answering the study question, and 
drawing conclusions with appropriate caveats. In addition, cost variations analyses took 
account of within-person clustering and the implications of two approaches to clustering. The 
cost-effectiveness analyses took account of both clustering and the correlation between the 
cost and outcome variables (cf. Gomes, Grieve, et al. 2012). 
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The economic evaluation of WSD telecare was important in contributing to the scarce 
evidence base on the cost-effectiveness of this technology.  It differed from other RCTs of 
telecare in the published literature in several important ways. The data was collected from a 
study using a cluster-randomised-controlled trial design. The sample size available for 
analysis was on a much larger scale than other RCTs that are at all comparable (Tomita et al. 
2007, Brownsell, Blackburn, and Hawley 2008, Morgenstern et al. 2015). As with the 
Telehealth trial, the approach conformed to economic evaluation guidelines.  The economic 
evaluation formally assessed the impact of telecare on health and social care costs and on 
HrQoL outcomes.  
These analyses have some limitations. I begin by discussing limitations relating to the 
economic data collection and specific analyses carried out for the dissertation. Some 
limitations are observable in the studies of both technologies: I begin with a discussion of 
these. Limitations specific to one or other evaluation are discussed subsequently, particularly 
in relation to threats to generalisability and uncertainties arising from sampling issues. 
 
9.6.1 Biases and Issues Related to Self-Reported Service Use 
As an evaluator of both the telecare and telehealth questionnaire studies, I faced several 
challenges. The data was to be collected by self-report. Service use can be subject to recall 
bias. It can suffer from ‘telescoping’ forward to take in use occurring prior to the period of 
retrospective recall, or backward, where imperfect recall excludes use within that period  
(Evans & Crawford 2000; Bhandari & Wagner 2006). The CSRIs that I devised for the study 
relied on a three-month retrospective period to try to minimise recall problems as has been 
recommended (Bhandari and Wagner 2006). However the three-month snapshot approach 
posed problems for the analyses of cost variations and cost-effectiveness evaluations in two 
ways. The participants’ annual costs were estimated by multiplying the costs in the three 
months prior to 12-month follow-up by four. The samples completing four- and twelve-
month datasets did not completely overlap. This, in combination with the relatively poor-
quality data yielded by postal-questionnaire only administration led to the decision to 
concentrate on baseline and longer-term follow-up points. This may have been less important 
for less episodic service use such as community nursing than for hospital admissions (see 
Section 7.5.1). In examining the variations in costs, the analyses were limited to comparisons 
of pre-intervention and long-term post-intervention differences between allocation groups 
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and did not permit investigation of changes in costs between the short-term and long-term 
follow-ups.  
In contrast to the self-reporting of service use in the questionnaire studies, the WSD 
trial evaluations (see Box 9.1 and Box 9.2) linked administrative data across health and social 
care organisations. Administrative data has tremendous potential for shedding light on service 
use over long periods of time, and for collecting service use as it would be defined for 
administrative purposes. For instance, a patient’s ability to report that a hospital visit was 
technically an admission and not an A&E episode could be less accurate than data drawn 
from hospital records. However, it is difficult (and costly) to capture the full range of service 
use of relevance to people with relatively high use of health and social care through 
administrative means.  
In the analyses, I limited multiple imputation of data to cases who had completed a 
follow-up assessment, rather than imputing data for non-completers. This decision was in line 
with the strategy across the original evaluations of the questionnaire data. On the other hand, 
improvements were made on the analyses originally reported (Henderson et al. 2014, 
Henderson et al. 2013) in that the missing telecare and telehealth cost data were imputed by 
predictive-mean matching to accommodate the skewness of the cost variables. Missing 
telehealth data was imputed separately by allocation group and used a linear mixed model to 
impute the data as recommended by Diaz-Ordaz, Kenward, and Grieve (2014) and Gomes et 
al. (2013). 
While the telehealth and telecare interventions were in many ways dissimilar, both 
were complex (Craig et al. 2008). Conducting the economic evaluations was challenging for 
reasons enumerated by Byford et al. (2007): user heterogeneity, co-production of care by 
users and professionals, co-production of care by networks of service providers that varied by 
geographical area. Particularly in the case of telehealth, the associations between inputs and 
outcomes were potentially complicated by the degree of patient involvement in producing the 
intervention. The WSD telehealth and telecare trials were pragmatic, seeking to evaluate the 
impact of the interventions per se rather than to examine the impacts of different service 
configurations. While the design enhanced the generalisability of findings to real-world 
service settings, the pragmatic approach also allowed considerable heterogeneity in the 
delivery of telehealth and telecare between sites (see 5.7.1 and 5.16.2).  In the telehealth trial, 
each site had different equipment and software procurement, installation, maintenance and 
monitoring arrangements. Each supplier of equipment and software offered somewhat 
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different options to the user and to the professionals monitoring vital signs data.22 In the 
telecare trial, there were also differences in delivery models, in particular in the availability of 
dedicated telecare response teams. Nonetheless, in each study, the intervention featured 
certain core characteristics across all the sites. In the telehealth trial, all sites offered services 
such as central monitoring teams, patient education protocols and computerised risk-based 
classification of vital signs data. In the telecare trial, all sites featured call-centres that 
monitored sensor data and much of the telecare equipment was supplied by one company. 
The pragmatic design did impose some limitations on interpreting findings. For instance, the 
variability between sites in the ways in which the telehealth/telecare services were delivered 
meant that it was not possible to pinpoint which elements of the intervention were influencing 
outcomes such as HrQOL.  
Other information that might be relevant to an economic evaluation was not available 
– for instance data on sensor alerts and false-alarms from providers’ systems, as well as on 
dedicated response teams’ visits in response to sensor alerts. In the case of telecare, 
information was not available on the telecare assessments that had been conducted and thus 
the goals of the prescribed telecare package were not known. Without having information on 
the intended purpose of the telecare package, there was no way to measure the impact of one 
combination of sensors over another on outcomes and costs. Costing the telehealth and 
telecare support elements of the intervention at a site level limited the granularity of the 
intervention support costs. This narrowed the amount of potential variability in intervention 
costs between participants and could have diminished the sensitivity of the analyses to 
detecting the impact of the intervention.  
Neither evaluation was able to take mortality into account except as one aspect of 
sample attrition. It should be noted that this could be a consideration in the telehealth 
economic evaluation, where mortality in the trial sample was found to be significantly lower 
in the telehealth group (Steventon et al. 2012) (but also see Steventon, Grieve, and Bardsley 
(2015) and Box 9.1). On the other hand, there was little evidence of differential mortality in 
the telecare trial (see section 8.4). Also, whether outcomes, particularly in HrQoL would have 
shown improvements if the telehealth and telecare evaluation periods had been longer, is not 
known.   
                                                          
22 Please note that Cartwright et al. (2013) gathered information on the clinical protocols in place in each site to 
respond to vital signs data from telehealth systems - see section 5.8. 
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 There are several possible limitations to generalisability of these findings. There was 
substantial loss to follow-up between baseline and 12-month follow-up in both studies (in the 
Telehealth study 36 per cent in the intervention and 41 per cent in the control group; in the 
Telecare study, 32 per cent in the intervention and 40 per cent in the control groups). There 
were also imbalances in the size of the allocation groups, the intervention group being 16 per 
cent greater than the control group in both cases. It was possible for self-selection to have 
taken place after cluster-randomisation. There were a few differences within allocation 
groups in the characteristics of participants not completing 12-month follow-up. In both 
Telehealth and Telecare studies there were differences in proportions completing by site, also 
in terms of educational qualifications. Differences in characteristics between completing and 
non-completing samples appeared to be concentrated in the control group in the Telecare 
sample, whereas such differences were more concentrated in the intervention group in the 
Telehealth sample. The cost-effectiveness analyses adjusted for a number of baseline 
demographic and cost covariates that might influence the decision to complete the 12-month 
follow-up, to some extent mitigating imbalances between intervention and control groups 
caused by attrition.  
The generalisabilty of these findings to other health and social care system settings 
and populations should be carefully considered. Much of the telehealth evidence base has 
emerged from the US. Free access to health care in the UK may lead to better access to 
primary care than would be the case for comparable telehealth users in the US, leaving less 
scope here for decreasing use of costlier secondary care.  
Lastly, the costs of the telehealth and telecare interventions estimated in this thesis 
were based on systems in place in 2009/10. Telehealth and, to a lesser extent telecare, 
markets are expanding and prices of systems have been falling. Thus the costs presented here 
will not perfectly reflect current market conditions.  
 
9.7 Implications for Policy and Practice 
9.7.2 Telehealth  
The cost-effectiveness results here suggested that the second-generation form of telehealth 
implemented in the WSD study – a telemonitoring approach with some elements of 
educational and behavioural support in addition to standard support and treatment – was 
slightly more effective and more costly than standard support and treatment. In spite of 
differences in service configurations, the sites all featured monitoring centres staffed by 
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qualified nurses and a range of peripherals that interfaced with some kind of base unit. This 
kind of telehealth was bound to be costlier than some other configurations of telehealth 
(Cottrell, Chambers, and O'Connell 2012, NHS Stoke-on-Trent 2011, Dixon, Hollinghurst, 
Edwards, Thomas, Gaunt, et al. 2016) because of the use of qualified staff and peripherals 
capable of transmitting data automatically. An evident lesson for policy and research would 
be to consider whether this form of telehealth service should be reserved for people with 
more severe conditions, while offering other, simpler forms of telemonitoring for routine use 
by patients’ usual primary care providers. Evidence from other studies also suggests that 
targeting specific chronic health conditions in combination with specific clinical 
characteristics may be needed (e.g. people with very stable or very unstable readings may not 
benefit from monitoring (Vassilev et al. 2015)). 
The evidence of the cost-effectiveness study should be used comparatively by 
commissioners to evaluate the benefits of telehealth for local populations, against other forms 
of disease management, such as self-management interventions. It will be important to keep 
the falling costs of equipment in mind in considering these findings – but that said, device 
costs are not the only costs involved in telemonitoring.  
The wider implications for policy involve recognising that if there are improvements 
to quality of life that result from investments in telehealth across the health and social care 
systems, it is important to deploy mechanisms to re-invest funds from sectors that most 
benefit from telehealth (secondary care) to primary and community health services. 
 
9.7.3 Telecare 
The WSD questionnaire and trial studies provided evidence that second-generation telecare 
does not represent a panacea for the budgetary and demographic challenges facing 
policymakers or commissioners. This assessment is much in line with those of other 
commentators (Poole 2006, Glasby, Lynch, and Robinson 2018, Greenhalgh et al. 2013). 
Nonetheless, this research cannot be interpreted as evidence that first-generation telecare is 
ineffective. Also, patterns of telecare uptake in the general older population (Nyman and 
Victor 2014) suggest that outcomes and costs could be quite different than indicated here. For 
instance, people seeking to take up telecare, despite quite substantial user charges or private 
fees, may derive some benefit not seen in the WSD sample, who accepted the service free of 
charge.  
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9.7.4 Telehealth and Telecare Technologies 
Given the passage of time since the WSD ended, the trajectory of government policy from 
that time is worth pointing out. WSD generated a great deal of evidence, but it took several 
years for that evidence to emerge into the public domain. Ettelt, Mays, and Allen (2015) 
included the WSD in their analysis of English ‘policy experiments’ (alongside the Individual 
Budgets and Partnerships for Older People Pilots). These experiments all in their separate 
ways threw up difficulties for policymakers who had commissioned the research as proof-of-
concept, where the research subsequently did not provide the required proof. The history of 
the policy and press reactions to the findings of the WSD research suggests that “research 
rigour did not translate into policy impact” (Ettelt, Mays, and Allen 2015 p.303) as might 
have been hoped.  
A recent report based on a survey of telecare managers in English local authorities 
gives some insight into the social care policy response to the evidence of the WSD telecare 
trial and questionnaire study (Woolham et al. 2018). Its authors observe that “[…] the WSD 
findings do not seem to have influenced local authorities and policy makers. The WSD 
remains an important study and its neglect is curious” (p.8). They report that 47 per cent of 
respondents asked were aware of the WSD findings. Respondents’ opinions of the WSD 
findings were largely negative for reasons such as: these did not chime with their own local 
experience; that these were undermining good local work; that the study had been flawed or 
was outdated; or that telecare organisations did not trust them.  
 
9.8 Implications for Research  
The outcomes presented across economic evaluation studies of telehealth and (insofar as they 
exist) telecare have been multifarious (Vergara Rojas and Gagnon 2008, Bergmo 2009). The 
ability of future researchers and clinicians to evaluate the impact of telehealth and telecare in 
the light of the available evidence depends on the relevance, appropriateness and consistent 
measurement of outcomes (Gargon et al. 2014, Williamson et al. 2012). The wide variety of 
clinical applications of telehealth pose a challenge to consistency in the choice of trial 
outcomes, as there could be many possible clinical outcomes related to each condition. 
However there are methods for developing consistent sets of outcomes, or ‘core outcome 
sets’, for use in evaluating the effectiveness of interventions. Dodd et al. (2018) have 
proposed a taxonomy of outcomes to assist in consistent reporting of clinical trials and 
improve the efficiency of searching knowledge sources for systematic reviews and clinical 
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research. In this taxonomy, 38 outcome domains cover five core areas: death, 
physiological/clinical, life impacts, resource use and adverse events.  
In the thesis, I focused on the relationship between health and social care costs and 
outcomes of the trial interventions. Core outcome sets related to telehealth or telecare of the 
kind deployed in the WSD trials do not currently appear in the COMET database (COMET 
Initiative 2018).23 The outcomes examined within this thesis, alongside other studies and 
reviews discussed in Chapter 3 and this chapter, can be considered by future developers of 
core outcome sets for telehealth and telecare and thus can inform future economic evaluations 
and systematic reviews. Establishing core outcome sets for telehealth and telecare evaluations 
would extend the usefulness of trial data in this area. The outcome domains to be covered in 
these sets are likely to share some outcome domains in the core areas of death, life impacts, 
resource use and adverse events but to vary between telecare and telehealth in terms of 
outcome domains in the ‘physiological/clinical’ area. It would be important to first determine 
the scope of the outcome set in terms of the condition and population of interest, trial settings 
and intervention (Williamson et al. 2017), given the ambiguities in terminology used to 
describe telehealth and telecare as discussed in Chapter 2. Consideration should be given to 
delineating the type of ‘telehealth’ system to be examined, for instance whether the system 
operates on a store-and-forward and/or real-time basis, the communication technologies used 
(telephone, video, internet) and to the ‘generation’ of telecare systems. Settings should be 
defined: whether the telehealth system is employed primarily in secondary or primary care or 
across clinical settings; whether it is set up exclusively in hospitals/clinics or in the user’s 
home; and whether the telecare system is used in the home, the wider community or in 
communal settings. 
I end with some recommendations for future research specific to telehealth and 
telecare. 
 
9.8.1 Telehealth 
As discussed in chapter 2, there is a developing literature on the role of telehealth in disease 
management and particularly in self-management. Specific models of TH delivery should be 
investigated to understand their relationship with variations in outcomes and costs (McLean 
et al. 2013). I discussed literature (see Chapter 2, Section 2.6.4) suggesting that telehealth can 
                                                          
23 A core outcome set exists for tele-emergency care, a telemedicine intervention operating in emergency 
department settings (Harris et al. 2017). 
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facilitate the complete feedback loop, that a (second-generation) telehealth system makes the 
condition visible to the patient, and that patients may benefit from seeing changes in vital 
signs graphically presented. However the components of telehealth that work to support self-
management are not well described in existing studies (Hanlon et al. 2017). More granular 
information on the components of the telehealth intervention would be useful in order to 
understand which components are related to which kinds of outcomes (for instance self-
monitoring might improve a person’s sense of mastery over the condition, while receiving 
support by telephone might help with managing symptoms (Rixon et al. 2015)). In particular, 
it would be helpful to understand variations in frequency and intensity of response to 
telemonitoring triggers, data that were not collected within the telehealth trial, to investigate 
impacts on quality of life outcomes (Newman and Whole System Demonstrator Programme 
Evaluation Team 2014). An analysis of these data across several long-term conditions would 
shed light on whether there are variations in outcomes and key-event related costs by 
condition.  
 
9.8.2 Telecare 
Research should be conducted to investigate the costs of services used by recipients of 
telecare with different living arrangements (living alone and with others). This could usefully 
be combined with analysis of data from routine care settings rather than from experimental 
studies (Momanyi 2017a, b). The WSD telecare questionnaire and trial studies were not able 
to examine the question of targeting telecare to particular types of social care need or service 
population, nor the question of the intended purpose (at the assessment stage) of the telecare 
package: these should be addressed in future studies. Research into the effectiveness and 
cost-effectiveness of telecare in people with significant cognitive impairment is needed (cf. 
Leroi et al. 2013).  
Lastly, the cost-effectiveness of telecare analysis raised some questions for further 
research. The WSD Telecare Study was not set up to examine by what means telecare 
systems act to improve outcomes. For instance, research could operationalise the concept of 
‘reassurance’ and investigate whether this mediates or moderates the impact of telecare on 
quality of life. Another question that could address the link between telecare, utility and costs 
would be to examine whether targeting of telecare could be improved by assessing 
individuals’ attitude to risk, the extent of risk-aversion and associations with health-related 
quality of life and use of health and social care services. Another question was left 
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unanswered by this study and deserves investigation. What is the additional benefit of remote 
sensors, above and beyond pendant alarms? For instance, future research could compare 
health-related quality of life and well-being provided by additional sensors (second-
generation telecare), to that provided by simpler, first-generation forms of telecare. 
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Table A1. Unit costs  
Resource item  Unit  Unit cost  
(£, 2009-
10) 
 Source/reference  Further description 
Hospital use         
A&E  attendance   3 - 133  Department of 
Health (2011) 
 TPCTAandEMSNA and TPCTAandEMSAD tabs 
 
Inpatient care  bed-day   116 - 1657  Department of 
Health (2011) 
 Weighted average cost of bed-day per HRG 
subchapter code, assigned based on the participant-
reported specialty/reason given for using service 
(TNEIL and TPCTEI tabs) 
 
Inpatient care – 
unknown 
reason/specialty 
 bed-day   505  Department of 
Health (2011) 
 Weighted average cost of bed-day across all adult 
specialties, used when no specialty/reason was given 
for using service (TNEI_L and TPCTEI tabs) 
 Day hospital/day 
case 
 attendance  156 - 1496  Department of 
Health (2011) 
 Weighted average cost of day case per HRG 
subchapter code, based on the participant-reported 
reason given for using service (TPCTDC tab) 
Day hospital/day 
case – unknown 
reason/specialty 
 attendance   660  Department of 
Health (2011) 
 Weighted average of cost of day case across all adult 
specialties when no specialty/reason was given for 
using service (TPCTDC tab) 
Outpatient care 
and procedures 
  attendance   23 - 306  Department of 
Health (2011) 
 Weighted average cost of outpatient visit for the 
specialty (consultant and non-consultant visits), 
excluding first appointments (TPCTCLFUSFF, 
TPCTCLFUMFF,TPCTNCLFUSFF tabs), or 
procedure (TPCTOPROC tab) based on the 
participant-reported specialty/reason given for using 
service 
 
 
 
Outpatient care – 
unknown 
reason/specialty 
 attendance   112  Department of 
Health (2011) 
 Weighted average cost of outpatient visit across 
specialties (consultant and non-consultant visits), 
excluding first appointments 
(TPCTCLFUSFF,TPCTCLFUMFF, 
TPCTNCLFUSFF tabs), used when no 
specialty/reason was given for using service 
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Resource item  Unit  Unit cost  
(£, 2009-
10) 
 Source/reference  Further description 
Outpatient scans  attendance  117  Department of 
Health (2011) 
 Weighted average of cost of diagnostic imaging 
activity (Diagnostic Imaging Procedures, 
TPCTDIAGIM_OP tab) used where scan was 
reported as the reason for using service 
 Community 
health services 
/primary care 
        
Paramedic  per visit   192.00  Curtis (2010)  Average of all paramedic services (categories A, B 
& C) 
Community 
matron 
 minute 
 
visit 
 1.31 
 
38 
 Curtis (2010) 
 
 
 Nurse specialist (community). Excludes qualification 
costs. 
Community 
matron (telephone) 
 minute   1.28  Curtis (2010)  Nurse specialist (community) average cost per 
minute of face to face client contact time. Excludes 
qualification costs. 
 Community or 
district nurse 
 minute  
 
visit  
 1.13 
 
24.00 
 Curtis (2010)  Community nurse average cost per minute of home 
visit. Excludes qualification costs.  
 Community or 
district nurse 
(telephone) 
 minute   0.52  Curtis (2010)  Community nurse average cost per minute of nurse 
time. Excludes qualification costs. 
Practice nurse  minute   0.52  Curtis (2010)  Nurse (General Practice) average cost per minute of 
direct contact time. Excludes qualification costs. 
Night nurse  minute   0.50  Curtis (2010)  Rapid response nurse per delivered hour including 
travel 
Specialist nurse   minute  0.95 
 
 
1.31 
 Curtis (2010)  Nurse (advanced) cost of direct client contact time – 
used for telephone contact time. Excludes 
qualification costs. 
Nurse specialist (community) average cost of face-
to-face client contact time including travel cost – 
used for home visit contact time. Excludes 
qualification costs. 
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Resource item  Unit  Unit cost  
(£, 2009-
10) 
 Source/reference  Further description 
Physiotherapist or 
occupational 
therapist 
 minute   0.65  Curtis (2010)  NHS community occupational 
therapist/physiotherapist, cost per minute of home 
visit. Excludes qualification costs. 
GP (home)  minute  
visit 
 4.00 
94.00 
 Curtis (2010)  GP cost per minute of home visit. Excludes direct 
care staff and qualification costs 
GP home visit lasting 23.4 minutes (including travel 
time). Excludes direct care staff and qualification 
costs 
GP (surgery)  minute 
 
visit  
 2.40 
 
28.00 
 Curtis (2010)  GP surgery/clinic minute. Excludes direct care staff 
and qualification costs. 
GP surgery consultation lasting 11.7 minutes. 
Excludes direct care staff and qualification costs. 
GP (telephone)  consultation   17.00  Curtis (2010)  GP telephone consultation lasting 7.1 minutes 
Dentist  contact   86.85  Department of 
Health (2011) 
 Community Dental Services (CN20) 
Chiropodist  contact   35.37  Department of 
Health (2011) 
 Community Podiatry Services (N910) 
Optician  eye test   20.26  Department of 
Health (2009) 
 NHS sight test 
Community 
mental health 
        
Psychiatrist  minute   4.72  Curtis (2010)  Consultant psychiatrist per minute of patient contact. 
Excludes qualification costs. 
Mental health 
nurse 
 minute   0.83  Curtis (2010)  Nurse (mental health) per hour of face-to-face 
contact including travel. Excludes qualification 
costs. 
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Resource item  Unit  Unit cost  
(£, 2009-
10) 
 Source/reference  Further description 
Community care 
services 
        
Social worker  minute   0.92  Curtis (2010)  Social worker (adult) cost of client-related work. 
Excludes qualification costs. 
Council home help 
visit 
 minute   0.42  Curtis (2010)  Local authority home care worker weekday face-to-
face 
 
Home care/home 
help 
 minute   0.22  Curtis (2010)  Independently provided home care worker weekday, 
face-to-face  
 
Paid night carer  minute   0.50  Curtis (2010)  Local authority home care worker weekday 
evenings, face-to-face 
Meals on Wheels  meal   5.00  Curtis (2010)  Average of cost of a meal from Local Authority 
wheels (£6.00) and from the independent 
sector (£4.00) 
 
 
Personal/ 
community alarm 
 item  13.50  Curtis (2010)  Median annual cost, annuitised over 10 years at 3.5%; 
cost over 3 months 
Major and minor 
adaptations 
 adaptation   1.5 - 455  Curtis (2010)  Kitchen adaptations, stair lift, toilet relocation, low-
level bath, electrical modifications, outdoor railings, 
joinery work, new bathroom. Median annual cost, 
annuitised over 10 years at 3.5%; cost over 3 months 
Equipment 
including mobility 
aids 
and for daily living 
 item   0.1-97.5  Curtis (2010);  
Department of 
Health Care 
Services Efficiency 
Delivery 
Programme (2010); 
NHS Supply Chain 
(2010) 
 
 Manual wheelchair, electric wheelchair, shower 
chair, chair-raise, bedrail, commode, reacher, 
kitchen/perching stool, hoist, trolley, shoehorn, 
raised toilet seat, bath lift, toilet frame 
 
All items annuitised over 10 years at 3.5%, 
following PSSRU unit costing methods; cost over 3 
months 
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Resource item  Unit  Unit cost  
(£, 2009-
10) 
 Source/reference  Further description 
Care home 
respite 
        
Residential care 
home 
 day   63.72  Curtis (2010)  Mean costs, from PSS EX1 2008/09 returns uprated 
using the PSS Pay & Prices inflator 
Nursing home  day  70.57  Curtis (2010)  Mean costs, from PSS EX1 2008/09 returns uprated 
using the PSS Pay & Prices inflator 
Day services         
Day care and other 
day attendances 
 attendance   36.00-
155.82 
 Curtis (2010) ; Older 
People's Inquiry, 
Raynes et al. (2006); 
Rogers, Bower et al. 
(2006); Department 
of Health (2011) 
 
 Local authority day care for older people, from PSS 
EX1, cost per service user per week, assuming 
attendance of three sessions per  
week, Voluntary day care for older people based on 
Age Concern 1999/2000 survey from 10 day centres, 
uprated using PSS Pay & Prices index; Costing the 
bakers' dozen: RISE lunch club;  
National Evaluation of the expert patient 
programme, course; National Schedule of Reference 
Costs 2009-10 weighted average over all services 
(stroke, elderly, other), PCTDCFRAD tab 
Medications         
Medications  Standard 
Quantity 
Units 
 0.01-419.62  Health and Social 
Care Information 
Centre (2011) 
 Price per unit (Nic/Qty (£)) 
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Appendix 2  
 
 
Descriptive Statistics of the 4-month Follow-up Data 
Questionnaires at the short-term follow-up were administered by post only. The 
quality of the CSRI data available was worse than at baseline, when all questionnaires had 
been administered by interviewers; data quality was also worse than that of the 12-month 
follow-up, when the questionnaires had been administered by a mixture of interview and 
postal methods. As an example of the issues arising with the postal-only administration, a 
number of respondents opted to provide details of services they had used in the 'other' boxes 
on the CSRI. As a result, intensive scrutiny of individual forms was needed; where the 
service reported was actually a category of service use given in the questionnaire, these 
responses were re-classified as such.  
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Table A2.1 Baseline characteristics of participants with economic data available at baseline and 4 month follow-up across Telehealth sample 
 Total baseline sample  Participants completing 4-month follow-
up study instruments* 
 Participants not completing 4-month 
follow-up study instruments†  
UC 
(n=728) 
TH 
(n=841) 
Raw  UC 
(n=425) 
TH 
(n=544) 
Raw  UC 
(n=300) 
TH 
(n=286) 
Raw 
Mean years of age 
(SD) 
70.6 
(11.8) 
70.1 
(11.8) 
0.5  71.4 
(15.6) 
70.7 (16.8) 0.6  69.5 (17.7) 68.9 
(17.7) 
0.6 
Under 65 (young) 215 
(30%) 
242 
(29%) 
-1%  113 
(27%) 
141 
(26%) 
-1%  102 (34%) 98 (34%) 0% 
65-74 (young old) ‡ 214 
(29%) 
288 
(34%) 
5%  133 
(31%) 
203 
(37%) 
6%  78 
(26%) 
83 
(29%) 
3% 
75-84 (old old) 239 
(33%) 
243 
(29%) 
-4%  143 
(34%) 
167 
(31%) 
-3%  96 
(32%) 
72 
(25%) 
-7% 
85+ (oldest old) § 60 
(8%) 
68 
(8%) 
0%  36 
(8%) 
33 
(6%) 
-2%  24 
(8%) 
33 
(12%) 
4% 
Women 290 
(40%) 
 
347 
(41%) 
1%  169 
(40%) 
207 
(38%) 
-2%  121 
(40%) 
134 
(47%) 
7% 
 
Mean IMD score 
(SD) ‡|| 
28.6 
(52.2) 
27.7 
(55.3) 
-0.9 
(-6.2, 4.5) 
 26.9 
(38.7) 
24.8 
(43.3) 
-2.1 
(-7.3, 3.1) 
 31.1 
(35.3) 
33.2 
(35.5) 
2.1 
(-3.7, 7.9) 
1st quintile‡ 130 
(18%) 
) 
215 
(26%) 
) 
8%  86 
(20%) 
 
 
163 
(30%) 
 
10%  43 
(14%) 
 
49 
(17%) 
3% 
2nd quintile‡ 164 
(23%) 
) 
140 
(17%) 
) 
-6%  108 
(25%) 
103 
(19%) 
-6%  55 
(18%) 
) 
37 
(13%) 
-5% 
3rd quintile‡ 124 
(17%) 
155 
(18% 
) 
1%  80 
(19%) 
) 
112 
(21%) 
) 
2%  43 
(14%) 
 
41 
(14%) 
0% 
4th quintile‡ 168 
(23%) 
) 
165 
(20%) 
-3%  82 
(19%) 
) 
101 
(19%) 
) 
-1%  86 
(29%) 
 
62 
(22%) 
-7% 
5th quintile‡¶ 142 
(20%) 
) 
166 
(20%) 
) 
0%  69 
(16%) 
) 
65 
(12%) 
) 
-4%  73 
(24%) 
) 
97 
(34%) 
10% 
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Data are mean (cluster-adjusted standard deviation) or number (%) of patients. 
UC=usual care; TH=telehealth; COPD=chronic obstructive pulmonary disease; SD=Standard deviation. 
*cases where costs and outcomes data were available 
† Outcomes instruments not completed and/or CSRI not completed 
‡ Difference within TH: differences between completion/non-completion clustered 𝜒2= 4.591 and p<0.05 
§ Difference within TH: differences between completion/non-completion clustered 𝜒2= 7.333 and p<0.01 
‡ Imputed data 
|| Difference within TH: clustered t= 2.086 p<0.05 
¶ Difference within TH: clustered 𝜒2=5.669 p<0.05 
Index condition            
COPD 
244 
(34%) 
334 
(40%) 
6%  
144 
(34%) 
236 
(43%) 
10%  
98 
(33%) 
94 
(33%) 
0% 
Heart failure 
275 
(38%) 
 
263 
(31%) 
7%  
171 
(40%) 
190 
(3%) 
4%  
103 
(34%) 
70 
(24%) 
-10% 
Diabetes** 
209 
(29%) 
244 
(29%) 
0%  
110 
(26%) 
118 
(22%) 
4%  
99 
(33%) 
122 
(43%) 
10% 
No of 
comorbidities 
2 
(2.8) 
1.8 
(2.9) 
0.2  
2.0 
(2.5) 
1.8 
(2.7) 
0.2  
2.1 
(2.3) 
1.9 
(2.3) 
0.2 
WSD site            
Site 1†† 
234 
(32%) 
256 
(30%) 
2%  
142 
(33%) 
192 
(35%) 
2%  
91 
(30%) 
61 
(21%) 
9% 
Site 2‡‡ 
283 
(39%) 
342 
(41%) 
2%  
183 
(43%) 
244 
(45%) 
2%  
98 
(33%) 
94 
(33%) 
0% 
Site 3*** 
211 
(29%) 
243 
(29%) 
0%  
100 
(24%) 
108 
(20%) 
4%  
111 
(37%) 
131 
(46%) 
9% 
White British 
ethnicity‡ 
630 
(87%) 
735 
(87%) 
1%  
388 
(91%) 
) 
501 
(92%) 
) 
1%  
239 
(80%) 
) 
225 
(79%) 
) 
-1% 
Living alone‡ 
195 
(27%) 
229 
(27%) 
0%  
121 
(28%) 
 
139 
(26%) 
 
-3%  
73 
(24%) 
) 
85 
(30%) 
 
5% 
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**Difference within UC: differences between completion/non-completion: z=2.084, P<0.05. Difference within TH: differences between completion/non-
completion: clustered 𝜒2 6.470, P<0.05 
††Difference within TH: differences between completion/non-completion z=-4.154, P<0.001 
‡‡ Difference within TH: differences between completion/non-completion z=-3.340, P<0.001. Difference within UC: differences between completion/non-
completion: z=-2.829, P<0.01 
*** Difference within TH: differences between completion/non-completion z=7.847, P<0.001. Difference within UC: differences between completion/non-
completion: z=3.933, P<0.001 
 
Table A2.2 Number and size of clusters, participants with economic data available at baseline and 4 month follow-up across Telehealth sample 
 Total baseline sample  Participants completing 4-month 
follow-up study instruments* 
 
UC 
(N=73) 
TH 
(N=81) 
 UC 
(N=64) 
TH 
(N=74) 
Cluster mean  
[min – max] 
10 [1-44] 10.4 [1-48]  6.6 [1-28] 7.4 [1-35] 
Data are mean [min – max] 
UC=usual care; TH=telehealth; COPD=chronic obstructive pulmonary disease. 
*where costs and outcomes data were available 
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Table A2.3 Mean service costs (standard errors) over previous 3 months across Telehealth sample, available cases at 4-
month follow-up (imputed data) 
Resource item 
Control  
(n=425) 
Telehealth 
 (n=547) 
Difference 
 Mean (SE) Mean (SE) Mean (95% CI) 
Hospital use* 552 (56) 467 (50) -85 (-234, 64) 
Community health services/primary care* 166 (21) 140 (18) -27 (-82, 28) 
Community mental health* 2 (1) 2 (1) 1 (-3, 4) 
Community care services*† 118 (26) 94 (23) -24 (-93, 45) 
Care home respite* 7 (3) 8 (3) 2 (-6, 9) 
Day services LA* 29 (8) 14 (7) -14 (-35, 6) 
Day services NHS* 4 (2) 0 (2) -4 (-11, 2) 
Medications* 301 (8) 322 (7) 21 (1, 41)* 
Equipment/Adaptations LA* 3 (1) 2 (1) -1 (-4, 2) 
Equipment LA/Adaptations NHS* 0 (0) 0 (0) 0 (0, 0) 
Total costs exc. telehealth delivery& equipment* 1182 (72) 1050 (63) -132 (-321, 57) 
Telehealth intervention 4 (9) 165 (9) 161 (136, 186)** 
Telehealth equipment 6 (5) 289 (4) 283 (270, 295)** 
Total costs inc. telehealth delivery& equipment* 1193 (72) 1504 (63) 311 (122, 501)** 
Note: Includes cases where baseline cost data were missing. Imputed data (10 completed datasets). 
† Includes community alarms  
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Table A2.4 Baseline characteristics of participants with economic data available at baseline and 4-month follow-up across Telecare sample 
 Total baseline sample   Participants completing 4-
month follow-up study 
instruments* 
 Participants not completing 4-month 
follow-up study instruments† 
 
UC TC Raw  UC TC Raw  UC TC Raw 
  (n=634) (n=548) 
 
 (n=256) (n=261)    (n=371) (n=280)  
Mean years of age 
(SD)‡ 
74.3 
(17.5) 
74 
(17.1) 
-0.3  74.2 
(14.9) 
75.0 
(15.1) 
0.7  69.5 
(17.7) 
68.9 
(17.7) 
-0.6 
 Under 65 
(young) 
138 
(22%) 
129 
(24%) 
2%  59 
(23%) 
60 
(23%) 
0%  78  
(23%) 
69 
(25%) 
4% 
 65-74 (young 
old) 
139 
(22%) 
116 
(21%) 
-1%  51 
(20%) 
47 
(18%) 
-2%  87 
(23%) 
68 
(24%) 
1% 
 75-84 (old old) 208 
(33%) 
168 
(31%) 
-2%  95 
(37%) 
188 
(34%) 
-3%  110  
(30%) 
76 
(27%) 
-3% 
 85+ (oldest old) 149 
(24%) 
135 
(25%) 
-1%  51 
(20%) 
66 
(25%) 
5%  96  
(26%) 
67 
(24%) 
-6% 
Female 415 
(65%) 
344 
(63%) 
2%  173 
(68%) 
167 
(64%) 
-4%  237 
(64%) 
174 
(62%) 
-2% 
Mean comorbidities 
(SD) 
1.1 
(1.6) 
1.1 
(1.6) 
-0.0  1.1 
(1.5) 
1 
(1.5) 
-0.1  1  
(1.7) 
1.1 
(1.7) 
0.0 
White-British‡§ 561 
(89%) 
482 
(88%) 
-1%  233 
(91%) 
243 
(93%) 
0%  324 
(87%) 
232 
(83%) 
-4% 
WSD site            
Site 1 137 
(22%) 
125 
(23%) 
1%  58 
(23%) 
58 
(22%) 
0%  75 
(20%) 
67 
(24%) 
4% 
Site 2|| 309 
(49%) 
273 
(50%) 
1%  169 
(52%) 
145 
(56%) 
4%  176 
(47%) 
122 
(44%) 
-4% 
Site 3¶ 188 
(30%) 
150 
(27%) 
-2%  125 
(25%) 
158 
(22%) 
-3%  120 
(32%) 
91 
(33%) 
0% 
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 Total baseline sample   Participants completing 4-
month follow-up study 
instruments* 
 Participants not completing 4-month 
follow-up study instruments† 
 
UC TC Raw  UC TC Raw  UC TC Raw 
  (n=634) (n=548) 
 
 (n=256) (n=261)    (n=371) (n=280)  
IMD 28.8 
(40.4) 
27.8 
(38.2) 
-0.7  27.5 
(28.0) 
25.3 
(28.9) 
-2.2  29.7 
(32.1) 
30.3 
(28.8) 
0.6 
1st quintile§ 152 
(24%) 
127 
(23%) 
-1%  74 
(29%) 
76 
(29%) 
0%  81 
(22%) 
46 
(16%) 
-5% 
2nd quintile§ 82 
(13%) 
109 
(20%) 
7%  31 
(12%) 
50 
(19%) 
7%  49 
(13%) 
57 
(20%) 
7% 
3rd quintile§ 133 
(21%) 
100 
(18%) 
-3%  52 
(20%) 
51 
(20%) 
-1%  77 
(21%) 
47 
(17%) 
-4% 
4th quintile§ 120 
(19%) 
102 
(19%) 
0%  45 
(18%) 
43 
(16%) 
-1%  74 
(20%) 
62 
(22%) 
2% 
5th quintile§ 146 
(23%) 
110 
(20%) 
-3%  54 
(21%) 
41 
(16%) 
-5%  90 
(24%) 
68 
(24%) 
0% 
Living alone§ 
 
340 
(54%) 
285  
(52%) 
-2%  137  
(54%) 
130 
(50%) 
-4%  196  
(53%) 
149 
 (53%) 
0% 
Data are mean (cluster-adjusted standard deviation) or number (%) of patients. 
UC=usual care; TC=telecare 
*Costs and outcomes data available 
† Outcomes instruments not completed and/or CSRI not completed 
‡ Within UC: differences between completion/completion sample p<0.05 on clustered t-test 
§ Imputed data 
|| Within TC: differences between completion/completion p<0.05 on z-test of proportions 
¶ Within TC: differences between completion/completion p<0.05 on z-test of proportions  
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Table A2.5 Number and size of clusters, participants with economic data available at baseline and 4-month follow-up across Telecare sample 
 Total baseline sample   Participants completing 4-month follow-up study instruments*  
UC TC  UC TC 
 
(N=103) (N=101) 
 
(N=89) (N=85) 
Cluster mean 
[min – max] 
6.2 [1-26] 5.4 [1-21]  2.9 [1-11] 3.1 [1-12] 
Data are mean [min – max] 
UC=usual care; TC=telecare 
*where costs and outcomes data were available 
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Table A2.6 Mean service costs (standard errors) over previous 3 months across Telecare sample, available cases at 4-month 
follow-up (imputed data) 
Resource item 
Control  
(n=259) 
Telecare 
(n=262) 
Difference  
 Mean (SE) Mean (SE) Mean (95% CI) 
Hospital use* 682 (139) 621 (139) -61 (-449, 327) 
Community health services/primary care* 150 (26) 210 (26) 61 (-12, 134) 
Community mental health* 25 (11) 25 (11) 1 (-29, 30) 
Community care services*† 525 (89) 492 (90) -33 (-283, 216) 
Care home respite* 0 (5) 8 (5) 8 (-7, 23) 
Day services LA* 135 (28) 163 (28) 28 (-50, 106) 
Day services NHS* 24 (16) 18 (16) -6 (-50, 38) 
Medications* 190 (11) 188 (11) -1 (-32, 30) 
Equipment/Adaptations LA* 7 (1) 8 (1) 1 (-2, 5) 
Equipment LA/Adaptations NHS* 1 (1) 1 (1) -1 (-2, 1) 
Total costs exc. telecare delivery and equipment* 1737 (208) 1734 (210) -4 (-587, 579) 
Telecare intervention 9 (7) 186 (7) 177 (158, 196)** 
Telecare equipment 1 (1) 20 (1) 20 (18, 21)** 
Total costs incl. TC delivery & equipment 1747 (209) 1940 (211) 193 (-393, 779) 
Note: Includes cases where baseline cost data are missing. Imputed data (10 completed datasets). 
† Includes community alarms 
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Appendix 3  
 
 
Three-level Models of Total Costs: Results 
The tables below present the results of the three-level models investigated and reported in 
Chapter 6, Sections 6.2.1 and 6.17: three-level null models, DDD models without covariates 
(presented here but not discussed in the chapter) and DDD models with covariates.  
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A3.1 Telehealth: Models  
Table 3.1 Estimates, subject specific (random intercept) models of total costs (including intervention) in 3 months prior to baseline and 12-
month follow-up 
 (1) (2) (3) (4) (5) 
Parameter Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
TH  0.923 1.025  0.933 
  (0.103) (0.105)  (0.105) 
Followup  0.965 0.964  0.977 
  (0.115) (0.117)  (0.109) 
TH*Followup  1.595*** 1.537**  1.575*** 
  (0.215) (0.215)  (0.210) 
HF  0.897 0.887  0.913 
  (0.110) (0.102)  (0.110) 
Diab  0.824 0.861  0.857 
  (0.107) (0.096)  (0.109) 
TH*HF  1.124 1.048  1.095 
  (0.197) (0.181)  (0.176) 
TH*Diab  1.355 1.248  1.352+ 
  (0.255) (0.211)  (0.238) 
HF*Followup  1.223 1.254  1.208 
  (0.189) (0.194)  (0.181) 
Diab*Followup  1.433** 1.376*  1.416* 
  (0.191) (0.193)  (0.214) 
TH*Followup*HF  0.824 0.794  0.830 
  (0.158) (0.156)  (0.154) 
TH*Follow*Diab  0.680* 0.718  0.684+ 
  (0.132) (0.146)  (0.135) 
Young old   1.107+   
   (0.067)   
Old-old   1.114   
   (0.075)   
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 (1) (2) (3) (4) (5) 
Parameter Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Oldest old   1.649***   
   (0.158)   
GCSE/O/A-level   1.191***   
   (0.058)   
Degree-level   1.122+   
   (0.074)   
Female   1.099*   
   (0.041)   
White-British   1.185   
   (0.123)   
Comorb   1.144***   
   (0.019)   
Owns   0.889*   
   (0.052)   
Site 2   1.075   
   (0.065)   
Site 3   1.075   
   (0.095)   
IMD   1.003   
   (0.002)   
Some problems   1.555***   
   (0.071)   
Unable wash/dress   2.460***   
   (0.359)   
Level 1 constant 1119.321*** 1006.264*** 580.169*** 1094.552*** 965.521*** 
 (38.810) (88.142) (85.309) (31.568) (85.581) 
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 (1) (2) (3) (4) (5) 
Parameter Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
𝜎  0.781*** 0.749*** 0.746*** 0.782*** 0.749*** 
 (0.035) (0.037) (0.035) (0.035) (0.037) 
𝜎2 [𝑢  ]     1.414
*** 1.467*** 
    (0.050) (0.053) 
𝜎2 [𝑢3 ]  1.041* 1.033* 1.002   
 (0.019) (0.016) (0.005)   
𝜎2 [𝑢2 ]  1.366*** 1.423*** 1.234***   
 (0.053) (0.055) (0.040)   
N 1930 1930 1930 1930 1930 
+ p<0.1 *, p<0.05 **, p<0.01, ***p<0.001 
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A3.2 Telecare: Models 
Table 3.2 Estimates, subject specific (random intercept) models of total costs (including intervention) in 3 months prior to baseline and 12-
month follow-up 
 (1) (2) (3) (4) (5) 
Parameter Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
TC  1.096 1.108  1.125 
  (0.144) (0.114)  (0.135) 
Follow-up  0.836+ 0.812*  0.833* 
  (0.076) (0.076)  (0.070) 
Follow-up*TC  1.304* 1.273+  1.318* 
  (0.172) (0.174)  (0.165) 
Lives w/  1.186+ 0.983  1.234+ 
  (0.118) (0.093)  (0.143) 
TC*Lives w/  1.032 0.992  1.019 
  (0.142) (0.130)  (0.168) 
Follow-up*Lives w/  1.049 1.032  1.047 
  (0.128) (0.135)  (0.137) 
TC* Follow-up*Lives w/  0.766 0.793  0.763 
  (0.128) (0.142)  (0.140) 
Young old   0.766**   
   (0.065)   
Old-old   0.797**   
   (0.062)   
Oldest old   0.785*   
   (0.077)   
Below-degree   0.996   
   (0.059)   
Degree   1.066   
   (0.104)   
Female   1.025   
   (0.066)   
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 (1) (2) (3) (4) (5) 
Parameter Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
Exp (𝛽) 
(SE) 
White-British   1.082   
   (0.112)   
Number of comorbidities   1.141***   
   (0.020)   
Owns   0.967   
   (0.070)   
Site 2   1.513***   
   (0.111)   
Site 3   0.873   
   (0.106)   
Mean IMD score   0.998   
   (0.003)   
Some ADL problems   1.453***   
   (0.090)   
Unable to wash/dress   2.693***   
   (0.224)   
Constant 1688.180*** 1530.968*** 1124.082*** 1638.815*** 1451.222*** 
 (88.426) (147.369) (198.306) (64.533) (124.099) 
 0.797*** 0.794*** 0.790*** 0.800*** 0.797*** 
𝜎  (0.034) (0.034) (0.031) (0.034) (0.034) 
𝜎2 [𝑢  ]     1.728
*** 1.695*** 
    (0.098) (0.093) 
𝜎2 [𝑢3 ]  1.222*** 1.202*** 1.017   
 (0.046) (0.045) (0.019)   
𝜎2 [𝑢2 ]  1.429*** 1.427*** 1.237***   
 (0.072) (0.072) (0.051)   
N 1506 1506 1506 1506 1506 
+ p<0.1 *, p<0.05 **, p<0.01, ***p<0.001 
